Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
26000.0 | 2017-09-08 00:00:00 UTC | Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-glaxosmithkline-plc-2017-09-08 | nan | nan | Big drugmaker. High dividend yield. Promising new products.
All three apply to AbbVie Inc. (NYSE: ABBV) . They also all apply to GlaxoSmithKline plc (NYSE: GSK) . But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. Past performance doesn't necessarily make one stock better than the other, though. Which of these big pharma stocks is the smarter pick for investors now? Here's how AbbVie and GlaxoSmithKline compare.
The case for AbbVie
Since high dividend yield and promising new products were already mentioned, let's first take a look at where AbbVie stands on both. The biotech's dividend currently yields 3.4%. I think AbbVie is the best dividend stock in big pharma , because this great yield combined with the company's excellent track record of dividend increases and its position for future dividend increases.
As for promising new products, AbbVie has an abundance of them. In immunology, the company has great late-stage candidates in upadacitinib and risankizumab. In oncology, Rova-T and veliparib are in phase 3 studies. Potential blockbuster elagolix is being evaluated in late-stage studies for treating endometriosis and uterine fibroids. And that's just the start. AbbVie's pipeline is so loaded that it was ranked third among all big pharma companies by market research firm EvaluatePharma.
We wouldn't want to leave out AbbVie's current products, though. Humira continues to reign as the top-selling drug in the world, raking in more than $16 billion last year. Sales for cancer drug Imbruvica totaled $1.8 billion in 2016 and are on track to top $2.3 billion this year. Recently approved hepatitis C drug Mavyret could be another blockbuster in AbbVie's lineup.
With a great dividend, a fantastic pipeline, and a solid current lineup, what more could you want in a stock? An attractive valuation, of course. AbbVie delivers there also. Shares currently trade at 12 times expected earnings.
The case for GlaxoSmithKline
GlaxoSmithKline's dividend yield of 4.98% ranks as one of the highest yields among healthcare stocks. Although the big drugmaker has cut its dividend somewhat over the past few years, it's hard to complain about that kind of yield.
The company's pipeline includes 16 late-stage candidates. Glaxo's deepest research area is in HIV. The drugmaker has a couple of two-drug combinations featuring dolutegravir that could be winners in addition to other experimental drugs for treating HIV infections and for HIV pre-exposure prophylaxis.
There are quite a few already-approved drugs in GlaxoSmithKline's lineup that are enjoying rapid sales growth. In 2016, the company claimed seven drugs that posted year-over-year growth of at least 100%. HIV drug Triumeq led the way. Glaxo also saw tremendous sales growth for several of its newer respiratory drugs, including Relvar/Breo Ellipta and Anoro Ellipta.
Glaxo stock is also priced attractively. Shares currently trade at 14 times expected earnings. The consensus among Wall Street analysts is that the company will grow earnings by more than 12% annually over the next five years. Factoring in these growth prospects makes GlaxoSmithKline stock's valuation look even better.
Better buy
In my view, the decision between these two stocks isn't a difficult choice. I think the winner is clearly AbbVie.
AbbVie has the stronger slate of current products. It has the better pipeline. And even though its yield is lower than GlaxoSmithKline's, the likelihood of future dividend increases makes it the better choice for dividends as well.
There is one potential fly in the ointment for AbbVie, though: the threat to Humira. AbbVie is tied up in litigation to try to keep biosimilar rivals to Humira off the U.S. market. The company thinks it will be able to fend off rival products through 2022. If it's unsuccessful in doing so, AbbVie stock would suffer. Even with this risk, though, I think AbbVie is the better choice and should continue to reward investors for years to come.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. AbbVie's pipeline is so loaded that it was ranked third among all big pharma companies by market research firm EvaluatePharma. All three apply to AbbVie Inc. (NYSE: ABBV) . | I think AbbVie is the best dividend stock in big pharma , because this great yield combined with the company's excellent track record of dividend increases and its position for future dividend increases. All three apply to AbbVie Inc. (NYSE: ABBV) . But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. | But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. The case for AbbVie Since high dividend yield and promising new products were already mentioned, let's first take a look at where AbbVie stands on both. I think AbbVie is the best dividend stock in big pharma , because this great yield combined with the company's excellent track record of dividend increases and its position for future dividend increases. | But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. I think AbbVie is the best dividend stock in big pharma , because this great yield combined with the company's excellent track record of dividend increases and its position for future dividend increases. All three apply to AbbVie Inc. (NYSE: ABBV) . |
26001.0 | 2017-09-08 00:00:00 UTC | Notable Friday Option Activity: XL, ABBV, COST | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity-xl-abbv-cost-2017-09-08 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in XL Group Ltd (Symbol: XL), where a total of 16,546 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 81.6% of XL's average daily trading volume over the past month of 2.0 million shares. Especially high volume was seen for the $38 strike call option expiring January 19, 2018 , with 5,218 contracts trading so far today, representing approximately 521,800 underlying shares of XL. Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,868 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 68.2% of ABBV's average daily trading volume over the past month, of 5.0 million shares. Particularly high volume was seen for the $87.50 strike call option expiring January 19, 2018 , with 4,154 contracts trading so far today, representing approximately 415,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $87.50 strike highlighted in orange:
And Costco Wholesale Corp (Symbol: COST) options are showing a volume of 15,435 contracts thus far today. That number of contracts represents approximately 1.5 million underlying shares, working out to a sizeable 48.2% of COST's average daily trading volume over the past month, of 3.2 million shares. Particularly high volume was seen for the $155 strike put option expiring September 08, 2017 , with 2,945 contracts trading so far today, representing approximately 294,500 underlying shares of COST. Below is a chart showing COST's trailing twelve month trading history, with the $155 strike highlighted in orange:
For the various different available expirations for XL options , ABBV options , or COST options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $87.50 strike call option expiring January 19, 2018 , with 4,154 contracts trading so far today, representing approximately 415,400 underlying shares of ABBV. Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,868 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 68.2% of ABBV's average daily trading volume over the past month, of 5.0 million shares. | Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,868 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 68.2% of ABBV's average daily trading volume over the past month, of 5.0 million shares. Particularly high volume was seen for the $87.50 strike call option expiring January 19, 2018 , with 4,154 contracts trading so far today, representing approximately 415,400 underlying shares of ABBV. | That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 68.2% of ABBV's average daily trading volume over the past month, of 5.0 million shares. Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,868 contracts thus far today. Particularly high volume was seen for the $87.50 strike call option expiring January 19, 2018 , with 4,154 contracts trading so far today, representing approximately 415,400 underlying shares of ABBV. | Below is a chart showing COST's trailing twelve month trading history, with the $155 strike highlighted in orange: For the various different available expirations for XL options , ABBV options , or COST options , visit StockOptionsChannel.com. Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,868 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 68.2% of ABBV's average daily trading volume over the past month, of 5.0 million shares. |
26002.0 | 2017-09-08 00:00:00 UTC | AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb | ABBV | https://www.nasdaq.com/articles/abbvies-upadacitinib-meets-primary-endpoint-in-phase-iib-2017-09-08 | nan | nan | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. The company plans to advance the candidate into phase III studies next year.
AbbVie's shares have outperformed the industry year to date. The stock has surged 30.6% compared with the industry's 14.5% rally during the period.
The study's primary outcome was the mean percentage change in Eczema Area and Severity Index (EASI) score, a tool used to measure the extent of disease severity. In the trial, upadacitinibshowed greater mean percentage change from baseline in EASI score compared with placebo at 16 weeks. Also, 50% of patients receiving 30 mg once-daily dose of upadacitinib showed almost clear skin. Additionally, the study met secondary endpoints, demonstrating a significant reduction in skin-itching.
Upadacitinib is also being investigated in six phase III studies for rheumatoid arthritis. Other researches are also underway for treatment of Crohn's disease, ulcerative colitis and psoriatic arthritis.
Per National Eczema Association, around 31.6 million people in the United States have some form of atopic dermatitis. Of them, 4.1 million children are affected by the disease. Hence, approval of the drug will provide the company with access to a huge patient population suffering from the disease in the United States.
Notably in March, Regeneron Pharmaceuticals, Inc. REGN along with partner Sanofi SNY had launched Dupixent (dupilumab) Injection for treating atopic dermatitis. Thus, upadacitinib awaits a combat against competitive pressure in the market, once approved.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank & Stocks to Consider
AbbVie currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is Aduro Biotech, Inc. ADRO , carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.26 to $1.24 for 2018 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. AbbVie's shares have outperformed the industry year to date. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. AbbVie's shares have outperformed the industry year to date. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). |
26003.0 | 2017-09-08 00:00:00 UTC | AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-in-focus%3A-stock-moves-6.1-higher-2017-09-08 | nan | nan | AbbVie Inc.ABBV was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 14.4% in the past one-month time frame.
The move came after the company announced solid top-line results from the Phase 2b study of upadacitinib. This covers the latest research on medication for eczema.
The company has not seen any estimate revisions in the past one month, while its Zacks Consensus Estimate for the current quarter has moved lower over the same time period. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
AbbVie currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is ABBV going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV was a big mover last session, as the company saw its shares rise more than 6% on the day. AbbVie currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV was a big mover last session, as the company saw its shares rise more than 6% on the day. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV was a big mover last session, as the company saw its shares rise more than 6% on the day. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV was a big mover last session, as the company saw its shares rise more than 6% on the day. |
26004.0 | 2017-09-08 00:00:00 UTC | Regeneron's Cemiplimab Gains Breakthrough Therapy Status | ABBV | https://www.nasdaq.com/articles/regenerons-cemiplimab-gains-breakthrough-therapy-status-2017-09-08 | nan | nan | Regeneron Pharmaceuticals, Inc.REGN along with partner Sanofi SNY announced that the FDA has granted Breakthrough Therapy status to its experimental candidate, cemiplimab (REGN2810).
Sanofi/Regeneron are looking to get cemiplimab, a checkpoint inhibitor targeting PD-1 (programmed death 1), approved for treating adults with advanced metastatic cutaneous squamous cell carcinoma (CSCC) type of skin cancer. The companies anticipate submitting a biologics license application (BLA) for cemiplimab to the FDA in the first quarter of 2018.
The FDA's Breakthrough Therapy designation aims to expedite the development and review of drugs, intended to treat serious or life-threatening conditions and provide access to patients as soon as possible.
Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. However, shares of the company have outperformed the industry year to date. The stock has surged 28.5% compared with the industry's 15.7% rally during the period.
We remind investors that in June, the companies reported positive, preliminary results from two expansion cohorts of phase I study (n=400), evaluating cemiplimab in patients with advanced CSCC. Data from the study showed that treatment with cemiplimab achieved an overall response rate (ORR) of 46.2% and a disease control rate (DCR) of 69.2%. The data was presented at the 2017 American Society of Clinical Oncology Annual meeting.
Another phase II trial, EMPOWER-CSCC 1, is examining REGN2810 in metastatic CSCC and is currently in the enrolment phase. Additionally, a phase III study evaluating REGN2810 as a first-line treatment for non-small cell lung cancer was initiated in the second quarter of 2017.
Notably, cemiplimab is put under a joint development program by Regeneron and Sanofi, post a global collaboration agreement, entered in July 2015. Regeneron had also inked clinical study agreements with other pharmacy biggies namely, Inovio Pharmaceuticals, Inc. INO and SillaJen, Inc. in the second quarter of 2017 to assess cemiplimab in combination with their respective cancer candidates.
Per the company's press release, CSCC is the second most common and deadliest skin cancer after melanoma in the United States. The disease is also responsible for most deaths among non-melanoma skin cancer patients. Although it is easier to apprehend the condition in early stages, it becomes quite difficult to treat the same once progressed to advanced stages. Hence, the candidate is expected to provide the company with access to a market promising huge potential.
Regeneron Pharmaceuticals, Inc. Price
Regeneron Pharmaceuticals, Inc. Price | Regeneron Pharmaceuticals, Inc. Quote
Zacks Rank
Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi/Regeneron are looking to get cemiplimab, a checkpoint inhibitor targeting PD-1 (programmed death 1), approved for treating adults with advanced metastatic cutaneous squamous cell carcinoma (CSCC) type of skin cancer. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report To read this article on Zacks.com click here. Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. Regeneron Pharmaceuticals, Inc. Price Regeneron Pharmaceuticals, Inc. Price | Regeneron Pharmaceuticals, Inc. Quote Zacks Rank Regeneron currently carries a Zacks Rank #3 (Hold). | Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report To read this article on Zacks.com click here. Regeneron Pharmaceuticals, Inc. Price Regeneron Pharmaceuticals, Inc. Price | Regeneron Pharmaceuticals, Inc. Quote Zacks Rank Regeneron currently carries a Zacks Rank #3 (Hold). | Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report To read this article on Zacks.com click here. Regeneron Pharmaceuticals, Inc.REGN along with partner Sanofi SNY announced that the FDA has granted Breakthrough Therapy status to its experimental candidate, cemiplimab (REGN2810). |
26005.0 | 2017-09-08 00:00:00 UTC | ABBV Crosses Above Average Analyst Target | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-average-analyst-target-2017-09-08 | nan | nan | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 10 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $66.00. And then on the other side of the spectrum one analyst has a target as high as $95.00. The standard deviation is $11.169.
But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABBV crossing above that average target price of $77.90/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $77.90 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover AbbVie Inc:
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on ABBV - FREE .
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABBV crossing above that average target price of $77.90/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $77.90 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. There are 10 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. | There are 10 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. And so with ABBV crossing above that average target price of $77.90/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $77.90 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. | There are 10 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. |
26006.0 | 2017-09-07 00:00:00 UTC | 5 Things Gilead Sciences' Management Just Said That You'll Want to Know | ABBV | https://www.nasdaq.com/articles/5-things-gilead-sciences-management-just-said-youll-want-know-2017-09-07 | nan | nan | Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE) . On Wednesday, several of the company's top executives sat down at the Citi biotech conference to field questions.
Gilead Sciences COO Kevin Young, chief scientific officer Norbert Bischofberger, and CFO Robin Washington participated in what was billed as a "fireside chat." Here are five questions that Gilead's management answered that you'll want to know about.
1. Why buy a company with no current revenue?
It's not surprising that the first question out of the gate for Gilead's executives was related to the Kite acquisition. With Gilead's revenue and earnings falling as a result of slipping hepatitis C virus (HCV) franchise sales, why did Gilead choose to buy a company with no current revenue?
Kevin Young responded that Gilead's primary focus was to "seek innovation." He described cell therapy as the "new vanguard, the new movement in hematological malignancies." Young added that Kite Pharma is "the best company in cell therapy."
With that being said, Young acknowledged that Gilead wanted to "see revenue on the horizon." Kite expects an FDA decision on its lead cell-therapy product, axicabtagene ciloleucel (axi-cel), in November. When Gilead first announced the deal, the company projected the acquisition would be accretive to earnings after year three. Gilead CFO Robin Washington also reiterated that the purchase of Kite would diversify the biotech's revenue, as well as add a new innovative area.
2. Will Gilead price axi-cel using a pay-for-performance model?
Novartis (NYSE: NVS) recently won FDA approval for the first CAR-T cell-therapy product, Kymriah, for treating B-cell precursor acute lymphoblastic leukemia (ALL). The big drugmaker also announced that it will use a pay-for-performance, or outcomes-based approach, for pricing.
Does Novartis' pricing decision mean that Gilead will follow the same path? Kevin Young noted that Gilead closely monitored what Novartis was doing with Kymriah. He said that Kite Pharma has "done a lot of thinking on pricing" for axi-cel, but no final decisions have been made.
Although Young stated that axi-cel and Kymriah target different indications for their first FDA submissions, the reality is that Novartis' pricing approach will likely put tremendous pressure on Gilead to also use some type of pay-for-performance model. Is it possible that one company could use pay-for-performance and another not do so? Young only said that "time will tell."
3. How concerning is potential HIV competition?
Gilead has been the leader in treating HIV for a long time. Norbert Bischofberger, the biotech's chief scientific officer, was asked about his thoughts related to potential competition from GlaxoSmithKline 's (NYSE: GSK) doublet therapies. Bischofberger didn't seem too worried.
He stated that recent data presented at the International AIDS Society conference in Paris by GlaxoSmithKline raised questions about whether or not the company's two-drug regimen would be "enough by themselves." Kevin Young stated that Gilead has spoken with physicians -- and they want triple-combo therapies to avoid resistance and maintain patients into their later years.
Bischofberger added that the zero resistance from studies of its bictegravir/F/TAF combo "resonated" with key opinion leaders. Gilead is optimistic about FDA approval of the HIV combo by February 2018.
4. Will there be more cuts to HCV drug pricing?
Another rival could be shaking things up for Gilead's HCV franchise. AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market.
Kevin Young admitted that Mavyret is "the closest thing we've seen to the profile of our HCV drugs." He also said that Gilead wasn't surprised by AbbVie's pricing. At the same time, though, Young mentioned that Gilead "will think carefully" about the new competition heading into 2018 and was "strongly committed to ensuring that there's always access as a choice to our HCV drugs." That sounds like price cuts for Epclusa and other Gilead HCV drugs could be on the way.
5. What's the outlook for more acquisitions?
Perhaps the most important thing for investors to know from Gilead's management team's comments at the Citi conference was this statement from Kevin Young: The Kite Pharma acquisition "was not necessarily a one-and-done deal." Young said that Gilead continues to look at potential additive partnerships or acquisitions in the area of cell therapy. He also said that if "something interesting" comes along in the broader oncology landscape, Gilead could pursue a deal outside of cell therapy.
Norbert Bischofberger chimed in with more details on what kinds of companies and/or assets might attract Gilead's attention. He ticked off several areas, including gene editing, on/off switches, things that modify cell therapy, and allogeneic approaches.
Robin Washington added that Gilead wants to "maintain financial flexibility for future acquisitions." She stated that while the company plans to use some debt to finance the Kite deal, Gilead's free cash flow will rapidly reduce that debt. She also expressed the hope that any corporate tax reform in the U.S. would include lower tax rates for repatriating cash parked overseas.
After Gilead's announcement of the Kite Pharma deal, I wrote that investors should get ready for more acquisitions . The comments made by its management team on Wednesday hint that it's less a question of if those acquisitions will come than it is of when they'll happen.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. He also said that Gilead wasn't surprised by AbbVie's pricing. | AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. He also said that Gilead wasn't surprised by AbbVie's pricing. | AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. He also said that Gilead wasn't surprised by AbbVie's pricing. | He also said that Gilead wasn't surprised by AbbVie's pricing. AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. |
26007.0 | 2017-09-07 00:00:00 UTC | AbbVie Inc (ABBV) Stock Surges on Positive Eczema Study | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-stock-surges-on-positive-eczema-study-2017-09-07 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema.
The biopharmaceutical company said on Thursday that its experimental drug designed to treat adults with moderate-to-severe eczema reached its main goal in a mid-stage study. Eczema is also known as atopic dermatitis and it's a condition that causes chronic skin inflammation.
Rival Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) saw its stock decline on the news. The company unveiled its own eczema drug Dupixent earlier this year as it garnered approval from the U.S. Food and Drug Administration in March.
AbbVie's mid-stage trial data for its drug was comparable to Dupixent's late-stage data, suggesting it could be stronger than its rival. The medication is called upadacitinib.
However, the sample sizes from the two sizes were considerably different, making such comparisons less than precise. Upadacitinib unveiled a significant improvement in reducing how severe the eczema is in patients, as well as the area of the body affected by the illness.
ABBV shares grew 6.2% Thursday. REGN shares fell 5.6$.
More From InvestorPlace
7 Non-Tech Stocks Using Tech to Win
7 Dividend Aristocrats to Buy for Growth, Too
Amazon.com, Inc. (AMZN) Stock Investors Shouldn't Overlook These Risks
The post AbbVie Inc (ABBV) Stock Surges on Positive Eczema Study appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. AbbVie's mid-stage trial data for its drug was comparable to Dupixent's late-stage data, suggesting it could be stronger than its rival. ABBV shares grew 6.2% Thursday. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie's mid-stage trial data for its drug was comparable to Dupixent's late-stage data, suggesting it could be stronger than its rival. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. More From InvestorPlace 7 Non-Tech Stocks Using Tech to Win 7 Dividend Aristocrats to Buy for Growth, Too Amazon.com, Inc. (AMZN) Stock Investors Shouldn't Overlook These Risks The post AbbVie Inc (ABBV) Stock Surges on Positive Eczema Study appeared first on InvestorPlace . AbbVie's mid-stage trial data for its drug was comparable to Dupixent's late-stage data, suggesting it could be stronger than its rival. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. AbbVie's mid-stage trial data for its drug was comparable to Dupixent's late-stage data, suggesting it could be stronger than its rival. ABBV shares grew 6.2% Thursday. |
26008.0 | 2017-09-07 00:00:00 UTC | Why Cabela's, Fitbit, and AbbVie Jumped Today | ABBV | https://www.nasdaq.com/articles/why-cabelas-fitbit-and-abbvie-jumped-today-2017-09-07 | nan | nan | The stock market was mixed on Thursday, with the major U.S. indexes closing the session almost flat. Concerns about the damage Hurricane Irma will inflict when it hits the Florida coast this weekend continued to weigh on certain sectors, but a moment of bipartisanship in Washington made generated some optimism about the potential for progress on the White House's domestic agenda later this year. Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you what propelled their gains.
Cabela's sale looks like a go
Cabela's stock jumped 14.3% after the retailer got positive news on the regulatory front related to its proposed merger with outdoor gear peer Bass Pro Shops . The Federal Reserve approved the sale of Cabela's credit card division to Synovus Financial (NYSE: SNV) , which was the last obstacle in the way of the larger merger transaction. The stock's move brings its price to within $1 of the proposed $61.50 per share in cash that Cabela's shareholders are slated to receive under the terms of the agreement. Many watchers now expect the deal to get completed before its initial deadline in early October.
Fitbit joins the fight against diabetes
Fitbit shares climbed 9.8% in the wake of the wearables company's announcement that it was forging a new partnership in the fight against diabetes. The fitness-tracking device manufacturer said it will collaborate with glucose-monitoring specialist DexCom (NASDAQ: DXCM) to put important information for those suffering from diabetes on its new Ionic smartwatch. With the holiday shopping season coming up, Fitbit is looking for strategies that can boost its flagging sales; adding a feature that meets the specific needs of a large, well-defined group of potential customers could be just what the doctor ordered for building up sales momentum over the rest of the year.
AbbVie gets some good news
Finally, AbbVie shares gained 6.1%. The drug maker said that its candidate treatment upadacitinib had met its primary endpoint in a phase 2b study in treating atopic dermatitis, showing a greater mean percentage of changes from the baseline in eczema area and severity compared to a placebo. Upadacitinib also helped 50% of patients achieve clear or almost clear skin, and reductions in itching were also positives for the drug. AbbVie management saw the news as good, and with the drug also in phase 3 trials as a treatment for rheumatoid arthritis and psoriatic arthritis, upadacitinib has several potential routes that could lead to it becoming a blockbuster.
Offer from The Motley Fool: The 10 best stocks to buy now
Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor , has tripled the S&P 500!*
Tom and David just revealed their ten top stock picks for investors to buy right now.
Click here to get access to the full list!
*Stock Advisor returns as of September 5, 2017
Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Fitbit. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trials as a treatment for rheumatoid arthritis and psoriatic arthritis, upadacitinib has several potential routes that could lead to it becoming a blockbuster. | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trials as a treatment for rheumatoid arthritis and psoriatic arthritis, upadacitinib has several potential routes that could lead to it becoming a blockbuster. | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trials as a treatment for rheumatoid arthritis and psoriatic arthritis, upadacitinib has several potential routes that could lead to it becoming a blockbuster. | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trials as a treatment for rheumatoid arthritis and psoriatic arthritis, upadacitinib has several potential routes that could lead to it becoming a blockbuster. |
26009.0 | 2017-09-07 00:00:00 UTC | AbbVie Scores 2 Wins: 1 Threatens Regeneron | ABBV | https://www.nasdaq.com/articles/abbvie-scores-2-wins-1-threatens-regeneron-2017-09-07 | nan | nan | AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients.
The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals ' (NASDAQ: REGN) recently launched eczema drug , Dupixent.
Keeping competitors at bay
AbbVie's Humira is complex biologic that's used to treat a variety of autoimmune diseases, including rheumatoid arthritis. Humira is so effective that it is the world's best-selling drug, with $16 billion in sales in 2016 alone.
Humira's success is a good thing, but it also presents AbbVie with a problem. The company's main patent protecting Humira from biosimilar alternatives has already expired, and with Humira accounting for over 60% of AbbVie's sales, management is relying heavily on Humira's remaining patents to hold off competitors as long as possible.
One of these competitors, Coherus Biosciences, is a clinical-stage biosimilar drug developer that's set its sights firmly on challenging Humira as soon as possible.
Coherus had been hoping to secure an inter partes review of AbbVie's U.S. Patent 9,085,619, which is related to Humira's formulation, but the U.S. Patent Office announced today that it has denied Coherus' petition.
The decision doesn't derail Humira biosimilars altogether, but it could push back their launch timelines, and in the process, give AbbVie more time to diversify its revenue away from Humira.
Expanding its portfolio
AbbVie is spending billions of dollars on R&D so it can roll-out new treatments and reduce the impact of Humira biosimilars.
One of the most intriguing of its R&D projects is JAK1 inhibitor upadacitinib, and today, AbbVie reported positive results from a phase 2b study evaluating its use in atopic dermatitis, or eczema.
Specifically, AbbVie says that a once-daily dose of upadacitinib resulted in clear or almost clear skin in 50% of patients with moderate to severe eczema. Also, 69% of patients achieved a 75% improvement in skin clearance or better.
These results are good enough to suggest it could eventually face off against Regeneron Pharmaceutical's recently approved eczema drug, Dupixent, in a billion-dollar marketplace.
In two Dupixent phase 3 trials, 36%, and 38% patients, respectively, achieved clear or near clear skin after receiving a dose of Dupixent every two weeks, and 51% and 44%, respectively, saw a 75% or better reduction in disease severity.
It's bad science to compare results from these two distinct trials to determine which drug is better, but the available data suggests to me that both of these drugs could be effective, and ultimately, that's not good news for Dupixent's market share if phase 3 upadacitinib trials are a success.
More work to do
The patent and trial wins are good news for AbbVie investors, but the company's not out of the woods yet.
Humira biosimilars will eventually launch, and the company has yet to prove that when they do, it will be able to fully replace any lost sales. Additionally, while the phase 2b data is intriguing, investors shouldn't do victory laps until phase 3 data is in hand confirming its efficacy and safety. Until then, there are still question marks longer-term that shouldn't be completely forgotten.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients. One of the most intriguing of its R&D projects is JAK1 inhibitor upadacitinib, and today, AbbVie reported positive results from a phase 2b study evaluating its use in atopic dermatitis, or eczema. The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals ' (NASDAQ: REGN) recently launched eczema drug , Dupixent. | The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals ' (NASDAQ: REGN) recently launched eczema drug , Dupixent. AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients. Keeping competitors at bay AbbVie's Humira is complex biologic that's used to treat a variety of autoimmune diseases, including rheumatoid arthritis. | AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients. The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals ' (NASDAQ: REGN) recently launched eczema drug , Dupixent. The company's main patent protecting Humira from biosimilar alternatives has already expired, and with Humira accounting for over 60% of AbbVie's sales, management is relying heavily on Humira's remaining patents to hold off competitors as long as possible. | The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals ' (NASDAQ: REGN) recently launched eczema drug , Dupixent. AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients. Keeping competitors at bay AbbVie's Humira is complex biologic that's used to treat a variety of autoimmune diseases, including rheumatoid arthritis. |
26010.0 | 2017-09-07 00:00:00 UTC | AbbVie Submits NDA for Endometriosis Candidate to the FDA | ABBV | https://www.nasdaq.com/articles/abbvie-submits-nda-for-endometriosis-candidate-to-the-fda-2017-09-07 | nan | nan | AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis.
The NDA filing is supported by positive results from two replicate pivotal phase III trials evaluating elagolix, a gonadotropin-releasing hormone (GnRH) antagonist, in this indication. The detailed data from the study, presented in October last year, showed that treatment with elagolix resulted in statistically significant reductions in menstrual and non-menstrual pelvic pain associated with endometriosis compared to placebo. Data from the studies also demonstrated superiority compared to placebo in reducing painful intercourse associated with endometriosis.
Endometriosis affects an estimated one in 10 women of reproductive age and is associated with pain symptoms. At present there is no cure for endometriosis. The pain associated with endometriosis is currently managed with oral contraceptives, progestins, danazol, NSAIDS, opioids, and GnRH agonists. Many of these medicines are not specifically indicated for the treatment of endometriosis.
So far this year, AbbVie's share price has increased 23%, comparing favorably with a gain of 11.8% recorded by the industry .
Apart from elagolix, AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche RHHBY , Bristol-Myers BMY and Biogen BIIB .
AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Apart from elagolix, AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche RHHBY , Bristol-Myers BMY and Biogen BIIB . AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis. | Apart from elagolix, AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche RHHBY , Bristol-Myers BMY and Biogen BIIB . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis. | AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis. So far this year, AbbVie's share price has increased 23%, comparing favorably with a gain of 11.8% recorded by the industry . |
26011.0 | 2017-09-07 00:00:00 UTC | Vanguard High Dividend Yield ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/vanguard-high-dividend-yield-etf-experiences-big-inflow-2017-09-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 237,587,161 to 238,389,272). Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average:
Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $79.12. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $79.12. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $79.12. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 237,587,161 to 238,389,272). For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $79.12. | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 237,587,161 to 238,389,272). For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $79.12. |
26012.0 | 2017-09-06 00:00:00 UTC | Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead | ABBV | https://www.nasdaq.com/articles/forget-abbott-buy-these-4-high-growth-medtech-stocks-instead-2017-09-06 | nan | nan | Lately, the MedTech space has been facing the brunt of frequent regulatory changes. While the Trump administration is faced with a socio-economic upheaval, investors are apprehensive about its impact on stocks.
Historic trends suggest that investor sentiments have always been partially inclined toward fancy brand names in a volatile economic backdrop. As a result, companies with a solid brand value and robust fundamentals generally enjoy a smooth sail even during political turbulence.
One such bigwig from the MedTech space is Abbott LaboratoriesABT , which has greatly evolved over the recent years. The company has pursued a slew of mergers and divestments, and has also seen solid growth in its Diabetics business. Among its strategic buyouts, the acquisitions of CFR Pharmaceuticals, Tendyne Holdings, and St. Jude Medical are worth mentioning
After spinning off its proprietary pharmaceutical products division in 2013 to form AbbVie Inc. ABBV , Abbott has gained traction in the Established Pharmaceuticals Division. Since then, revenues have seen a CAGR of 7.6% over the last three years. Over this period, the company has more or less reported strong quarterly numbers, indicating fundamental strength.
Shares Lack Luster
However, the share price performance of Abbott has been disappointing over the same time frame. The company represents a meager return of just 19.2%, lower than the broader industry 's gain of 22.3% and the S&P 500's return of 23.3% over the same time frame.
Of the main issues plaguing Abbott, foreign exchange is a major headwind. The strengthening of the euro and some other developed market currencies have constantly hampered the company's performance in international markets. Abbott currently expects currency exchange to have a negative impact of around 1% on sales in 2017.
Apart from this, the business environment continues to be challenging across the globe. Slow growth in the nutrition business in China and economic problems in Venezuela are expected to remain unresolved for some time, dampening the company's top-line growth.
Bleak Prospects
While Abbott boasts solid fundamentals, the company's prospects are dull. We note that the company promises long-term earnings growth of just 10.7%, lower than the broader industry's estimated growth rate of 13%. Furthermore, Abbott's revenues have declined 10.7% in the last five years compared to the broader industry's revenue growth of 6.1%.
Secondly, Abbott's historical cash-flow growth has been extremely low at -14.3%, comparing unfavorably with the broader industry's positive growth of 5.7%. These unfavorable growth metrics are indicative of the fact that despite a solid brand value, Abbott might not prove to be a lucrative pick for the long haul.
4 Growth Stocks in Focus
The long-term growth parameters are not in favor of Abbott, as it holds a Zacks Rank #3 (Hold) now. So instead of opting for brand values, let's take a look at the following four not-so-fancy MedTech stocks that are expected to gain over the long haul. Apart from flaunting a strong Zacks Rank #1 (Strong Buy) or #2 (Buy), these stocks promise a long-term expected growth rate of 15% or higher, comparing favorably with the broader industry. We also have taken a Growth Style Score of A or B into consideration.
Our Growth Style Score highlights all of the vital metrics of the company's financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with Style Scores of A or B, when combined with a Zacks Rank #1 or #2, offer the best investment opportunities.
Lonza Group LtdLZAGY : Lonza Group sports a Zacks Rank #1 and has a long-term expected earnings growth rate of 15%. The company has a Growth Score of A. You can see the complete list of today's Zacks #1 Rank stocks here .
Lonza Group supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. With an outstanding first half of the year, Lonza Group continues to expect strong performances by its Pharma & Biotech and Specialty Ingredients segments.
The company's strategic initiatives to improve customer relationship management, process innovations, and operational improvement programs in the areas of automation and streamlining instills investor confidence. The stock has gained 115% over the last three years.
OraSure Technologies, Inc.OSUR : This Zacks Rank #2 stock promises long-term expected earnings growth of 16%. Notably, OraSure has a Growth Style Score of B. The company develops, manufactures, markets and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe and internationally.
OraSure banks on solid growth in its infectious disease business unit. Higher sales of the company's molecular products and OraQuick HCV product are the primary growth drivers. The company has also been banking on its flagship Oragene product line.
OraSure has had an impressive run over the last three years. The company has returned 161.2%, significantly higher than the broader industry's 22.09% and the S&P 500's 22.4% over the same time frame.
IDEXX Laboratories, Inc.IDXX
Headquartered in Delaware NJ, IDEXX Laboratories is a developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. A major fraction of IDEXX Laboratories' revenues is derived from its Companion Animal Group segment. Driven by an expanding premium instrument base in the United States and international markets, the company is expected to grow extensively over the long haul.
IDEXX Laboratories boasts a stellar return of 149.4% for the last three years. Furthermore, the estimate revision trend for the next year is promising. Notably, four analysts moved north over the last two months. The Zacks Consensus Estimate for next year increased 2.6% to $3.56 per share over the same time framee.
LeMaitre Vascular, Inc.LMAT : LeMaitre has a Zacks Rank #2 and promises a long-term expected earnings growth rate of 15%. With a Growth Score of A, the company's XenoSure platform is a key catalyst at the moment. The stock has gained 428.7% over the last three years.
Headquartered in Burlington, MA, the company markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company expects its sales to rise almost 3% organically in the next quarter on strong margin expansion.
LeMaitre's estimate revision trend for the next year is quite encouraging. Notably, four analysts moved north compared to no movement in the opposite direction. As a result, the Zacks Consensus Estimate increased almost 8.9% over the same time frame.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really takes off.
See Stocks Now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report
OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report
Lonza Group Ag (LZAGY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among its strategic buyouts, the acquisitions of CFR Pharmaceuticals, Tendyne Holdings, and St. Jude Medical are worth mentioning After spinning off its proprietary pharmaceutical products division in 2013 to form AbbVie Inc. ABBV , Abbott has gained traction in the Established Pharmaceuticals Division. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Lonza Group Ag (LZAGY): Free Stock Analysis Report To read this article on Zacks.com click here. The company develops, manufactures, markets and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe and internationally. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Lonza Group Ag (LZAGY): Free Stock Analysis Report To read this article on Zacks.com click here. Among its strategic buyouts, the acquisitions of CFR Pharmaceuticals, Tendyne Holdings, and St. Jude Medical are worth mentioning After spinning off its proprietary pharmaceutical products division in 2013 to form AbbVie Inc. ABBV , Abbott has gained traction in the Established Pharmaceuticals Division. Apart from flaunting a strong Zacks Rank #1 (Strong Buy) or #2 (Buy), these stocks promise a long-term expected growth rate of 15% or higher, comparing favorably with the broader industry. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Lonza Group Ag (LZAGY): Free Stock Analysis Report To read this article on Zacks.com click here. Among its strategic buyouts, the acquisitions of CFR Pharmaceuticals, Tendyne Holdings, and St. Jude Medical are worth mentioning After spinning off its proprietary pharmaceutical products division in 2013 to form AbbVie Inc. ABBV , Abbott has gained traction in the Established Pharmaceuticals Division. 4 Growth Stocks in Focus The long-term growth parameters are not in favor of Abbott, as it holds a Zacks Rank #3 (Hold) now. | Among its strategic buyouts, the acquisitions of CFR Pharmaceuticals, Tendyne Holdings, and St. Jude Medical are worth mentioning After spinning off its proprietary pharmaceutical products division in 2013 to form AbbVie Inc. ABBV , Abbott has gained traction in the Established Pharmaceuticals Division. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Lonza Group Ag (LZAGY): Free Stock Analysis Report To read this article on Zacks.com click here. The stock has gained 115% over the last three years. |
26013.0 | 2017-09-04 00:00:00 UTC | Revealed: The Secret to Safe 12% Yearly Gains … for Life | ABBV | https://www.nasdaq.com/articles/revealed-secret-safe-12-yearly-gains-life-2017-09-04 | nan | nan | By Brett Owens
Don't let the pundits deceive you. Despite their endless bleating about an overheated market and an imminent crash, now is a great time to buy.
But you need to look beyond the breathless reporting about the S&P 500's daily push higher--or its ratchet-tight P/E ratio.
Because the real winning stocks are cloaked behind something most folks don't pay nearly enough attention to: dividends--particularly dividend growth !
Let me explain.
Dividends Are Great Again
A quietly released report from investment manager Janus Henderson Group ( JHG ) tells the tale--and it's a happy one for American investors.
According to Janus, global dividends jumped 5.4% year-over-year in the second quarter. Buried under that headline was a 9.8% surge from US companies, to $111.6 billion, as fatter corporate bottom lines started flowing to investors in the form of fatter dividend checks.
It gets better: the suits at Janus now expect a record $1.208 trillion in global dividends this year, up 3.9% from 2016 and $50 billion more than the last estimate.
A Shortcut to a Safe Double-Digit Yield
In a moment, I'll reveal 3 all-American stocks that are leading the pack on the dividend-growth front. All 3 are ripe for buying now.
I'll also show you a simple strategy for uncovering the dividend growers that can put you on the path to grinding out a steady 12% yearly total return from your portfoliofor life.
That's enough to double your portfolio's value every 6 years! And it's nearly twice the 7% or so the market's doled out, on average, over the long term.
Plus you'll build an ever-growing income stream, too.
In fact, what I'm about to show you will have you raking in 10% dividends in short order! So even if you have a relatively modest nest egg and a few years to go till retirement, you're looking at a real chance of living on dividends alone when you do clock out.
So let's get going, starting with how a relentlessly rising dividend can ignite your income and your gains in one fell swoop.
The Curious Case of the "Hidden" Yield
For most folks, dividends always take a backseat to capital gains.
It's easy to see why: when you own a stock that could explode for gains of 5%, 10% or more practically overnight, it's tough to get worked up about a sub-2% dividend--particularly when the dividend yield on your average S&P 500 stock is shrinking :
The S&P 500: Thin Gruel for Dividend Fans
But the herd has it backwards. Because when you look past the current yield and focus a completely ignored number--the yield on your initial investment-- the picture changes dramatically.
This is where dividend growth comes in.
Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . (It's up more than 12% since then and still has room to run).
If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield.
Not bad! That's way ahead of both inflation and the S&P 500 average.
But fast-forward to today--not even four years later--and the income stream on your original buy would have surged to 5.1% thanks to a 60% increase in AbbVie's quarterly payout, including a monster 12% hike announced last October!
That's only half the story, though.
Because we haven't talked about capital gains--and big dividend hikes like these have a huge (and underappreciated) impact here. Check out how AbbVie's stock marched higher in lockstep with its dividend increases:
AbbVie Investors Win Twice
The company owns rheumatoid-arthritis treatment Humira, the world's top-selling drug, and spends a massive 18% of revenue on R&D. Management has translated that cash into a pipeline that's the envy of the biotech world, with 17 treatments in Phase 3 trials.
AbbVie also pays out 59% of earnings per share as dividends--easily manageable in light of rising adjusted earnings per share (up 12.7% year-over-year in Q2). That, plus its low valuation of 13.6 times expected earnings, makes this stock ripe for buying now.
Now let's move on to…
Another Overlooked Dividend-Growth Play
Alexandria Real Estate Equities ( ARE ) is a real estate investment trust (REIT) with a current yield you might also be tempted to ignore: 2.8%.
But Alexandria--which owns 202 labs and other tech centers in innovation hotbeds like Boston and San Francisco--has an ace up its sleeve: one of the tightest correlations between share price and dividend growth I've ever seen!
Check out how its surging payout has driven an almost identical rise in the share price over the last five years:
60% Dividend Increase ... 60% Gain
12 times!
A fast look at second-quarter financials shows why: per-share funds from operations (FFO, the REIT equivalent of EPS) jumped 10.3% and occupancy clocked in at a healthy 95.7% (set to rise as high as 97.7% for the full year). The dividend is also well covered at a low (for a REIT) 56% of trailing-twelve-month FFO.
Alexandria's tenant list is a who's-who of the tech and pharma elite. For extra ballast, it includes mainstays like the US government, MIT and New York University:
The time to buy is now--before that growth drives the share price, and the dividend, higher.
The King of the Airwaves
Much as I love Alexandria, American Tower ( AMT ) beats it in two crucial ways: it hikes its dividend even more frequently: every quarter. It also trumps its REIT cousin in dividend growth, with a payout that's surged 178% in five years.
Here's the best part: due to overdone interest-rate fears that have weighed on all REITs, AMT's share price hasn't kept pace with those dividend hikes.
The opportunity here is obvious.
AMT's Wide-Open Buy Window
The company also boasts a growing portfolio and top-flight tenants, including nearly 150,000 communications sites leased to the likes of AT&T (T) and Verizon (VZ) .
More payout growth is dialed in: AMT's adjusted per-share FFO surged 18.8% in the second quarter, and it sends just 35.8% of its adjusted FFO out the door as dividends--ridiculously low for a REIT.
So don't be thrown off by AMT's 1.7% current yield. It's a smokescreen for a company whose dividend--and share price--have lots of jump left.
7 Quick Buys to DOUBLE Your Money in 6 Years or Less
I've just uncovered 7 more stealth dividend growers poised to keep rising while handing you solid income right away.
Together, these 7 low-key income plays can easily grow your money 12% a year FOREVER--doubling your portfolio every 6 years!
You could even throw them together in their own "mini-portfolio" and lean on them for immediate payments, growing retirement income and solid capital gains year in and year out!
If that's not the holy grail of investing, I don't know what is.
I'm ready to share my complete research in a special investor report I've just published here .
Here's a quick look at just 3 of these all-star dividend stocks :
The Dividend Doubler: This company starts out with a gaudy dividend yield--4.7%--but it's already hiked its payout TWICE in the past year! If it keeps up that pace, you'll be in line fora 9.4% yield on your initial buy in short order. But you need to make your move now.
The 800% Income Machine: This company's dividend has exploded eightfold since a dynamic new management team took over four years ago, PLUS they're expertly buying back stocks to goose the share price even more. This one is a complete no-brainer for anyone looking to pocket bigger and bigger dividend checks from here on out!
The 250% Gainer: This one trades for a ridiculous 6 TIMES cash flow --and the last time that number fell below 10, the stock exploded on a monster 252% run! The stars are aligning for a repeat, but the dividend and management's smart buybacks alone could push your investment up 12% or more.
I'm ready to share full details on these stocks and 4 more red-hot dividend-growth plays. All you have to do is CLICK HERE go get my complete research, including each stock's name, ticker and buy-under price .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. But fast-forward to today--not even four years later--and the income stream on your original buy would have surged to 5.1% thanks to a 60% increase in AbbVie's quarterly payout, including a monster 12% hike announced last October! | AbbVie also pays out 59% of earnings per share as dividends--easily manageable in light of rising adjusted earnings per share (up 12.7% year-over-year in Q2). Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. | If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . But fast-forward to today--not even four years later--and the income stream on your original buy would have surged to 5.1% thanks to a 60% increase in AbbVie's quarterly payout, including a monster 12% hike announced last October! | Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. But fast-forward to today--not even four years later--and the income stream on your original buy would have surged to 5.1% thanks to a 60% increase in AbbVie's quarterly payout, including a monster 12% hike announced last October! |
26014.0 | 2017-09-03 00:00:00 UTC | Here's the Best Dividend Stock in Big Pharma | ABBV | https://www.nasdaq.com/articles/heres-best-dividend-stock-big-pharma-2017-09-03 | nan | nan | Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for investors to turn to for high yields and reliable income.
But which big pharma stock is the best dividend stock of all? I looked at all of the largest drugmakers in the world, examining their dividend yields and their ability to keep the dividends flowing at current or higher levels. After reviewing all of them, my conclusion is that the best dividend stock in big pharma is (drum roll, please) AbbVie (NYSE: ABBV) . Here's why AbbVie beat out all the others.
Look at the forest, not the trees
AbbVie doesn't have the highest dividend yield among big pharma stocks. That honor belongs to Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) , which currently has a yield of 6.94%. So why isn't Teva the best dividend stock in big pharma?
Teva reported a huge loss in its latest quarter . It also slashed its full-year 2017 outlook for revenue and earnings. The drugmaker faces significant headwinds with its U.S. generics business and declining sales for its top product, multiple sclerosis drug Copaxone. As a result, Teva stock has plunged more than 50% so far this year. While Teva's cash flow should keep the dividends coming for now, the dividend payments might not be enough to outweigh the stock's performance. Simply put, Teva is too risky right now, in my view.
AbbVie doesn't have the lowest payout ratio, either. Gilead Sciences (NASDAQ: GILD) takes the prize with a low payout ratio of only 21.5%. But Gilead's yield of 2.82% is well below AbbVie's, so the big biotech didn't fare well enough overall to be the best big pharma dividend stock. Gilead also faces some of its own challenges with declining revenue and earnings stemming from falling hepatitis C drug sales.
If we only looked at some of these individual categories, AbbVie wouldn't be the best dividend stock in big pharma. Remember the old saying, though: "Don't miss the forest for the trees." When we look at the big picture, AbbVie stands out as the best dividend stock among drugmakers.
Why AbbVie
With that in mind, let's dig into exactly why AbbVie ranks as the best big pharma dividend stock. Near the top of the list is its strong dividend yield of 3.5%. That's attractive to investors -- and it's the fourth best among all big pharma stocks.
More important, though, is AbbVie's ability to not only keep the dividends flowing but to increase them in the future. The company uses less than 60% of its earnings to fund the dividend program, indicating more flexibility for dividend hikes than any of the three drugmakers with higher yields.
AbbVie also appears to have the best prospects for earnings growth, which should allow the company to pay out higher dividends and drive the stock higher as well. The big biotech claims the top-selling drug in the world with Humira and one of the fastest-growing cancer drugs with Imbruvica. AbbVie's pipeline has also been rated as one of the three best pipelines in the biopharmaceutical industry .
And when it comes to track records for dividend increases, AbbVie stands head and shoulders above nearly every other big pharma with 45 years of consecutive dividend hikes (including the period before the company was spun off by Abbott Labs ). Only Johnson & Johnson claims a longer streak, with 55 years of dividend increases.
Runners-up
The combination of one of the highest yields with what appears to be the greatest likelihood of further dividend increases makes AbbVie the clear winner, in my view, as the best big pharma dividend stock. However, there were a couple of runners-up that performed well in the evaluation.
Pfizer (NYSE: PFE) has a strong dividend yield of 3.82% -- even higher than AbbVie's. The big drugmaker seems to be in good position to increase its dividend in the future, with strong cash flow and an improving payout ratio. Pfizer's earnings outlook should improve as well in the next few years.
Sanofi (NYSE: SNY) also stood out among its peers. The French drugmaker claims a solid dividend yield of 3.35%. Sanofi currently uses less than 80% of its earnings to fund the dividend program. The company should be able to grow earnings over the next several years with strong growth for long-acting insulin product Toujeo and multiple sclerosis drugs Aubagio and Lemtrada.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After reviewing all of them, my conclusion is that the best dividend stock in big pharma is (drum roll, please) AbbVie (NYSE: ABBV) . Here's why AbbVie beat out all the others. Look at the forest, not the trees AbbVie doesn't have the highest dividend yield among big pharma stocks. | Look at the forest, not the trees AbbVie doesn't have the highest dividend yield among big pharma stocks. After reviewing all of them, my conclusion is that the best dividend stock in big pharma is (drum roll, please) AbbVie (NYSE: ABBV) . Here's why AbbVie beat out all the others. | Look at the forest, not the trees AbbVie doesn't have the highest dividend yield among big pharma stocks. But Gilead's yield of 2.82% is well below AbbVie's, so the big biotech didn't fare well enough overall to be the best big pharma dividend stock. Runners-up The combination of one of the highest yields with what appears to be the greatest likelihood of further dividend increases makes AbbVie the clear winner, in my view, as the best big pharma dividend stock. | Runners-up The combination of one of the highest yields with what appears to be the greatest likelihood of further dividend increases makes AbbVie the clear winner, in my view, as the best big pharma dividend stock. After reviewing all of them, my conclusion is that the best dividend stock in big pharma is (drum roll, please) AbbVie (NYSE: ABBV) . Here's why AbbVie beat out all the others. |
26015.0 | 2017-08-30 00:00:00 UTC | The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-kite-pharma-abbvies-and-novartis-ag | nan | nan | For Immediate Release
Chicago, IL - August 30, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday's Analyst Blog:
Gilead to Fly High with Kite Pharma Acquisition
Biotech giant Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ) announced that it will buy Kite Pharma, Inc. (NASDAQ: KITE - Free Report ) to foray into the emerging field of cell therapy.
Terms of the Agreement
As per the agreement, Gilead will pay $180.00 per share in cash at a transaction valued at approximately $11.9 billion. The price represents a 28% premium over the closing share price of Kite as of Aug 25, 2017.
The transaction was approved by shareholders of both companies and is expected to close by the fourth quarter of 2017. The acquisition is expected to be neutral to the bottom line by the third year and accretive thereafter.
Strategic Benefit
We note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. The most advanced therapy candidate in Kite's pipeline is axicabtagene ciloleucel (axi-cel) which is being developed for the treatment of refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). The Biologics License Application (BLA) for the candidate was submitted in Mar 2017.
This CAR T therapy is currently under priority review in the United States and the FDA is expected to give a decision on Nov 29, 2017. The candidate is also under review in the EU with a tentative approval expected in 2018. While Kite is prepared for a commercial launch in the United States as manufacturing preparation are complete, the company is currently building infrastructure in Europe. We remind investors that another pipeline candidate in clinical trials in both hematologic cancers and solid tumors is KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma.
Our Take
The acquisition will diversify Gilead's portfolio and position the company in a dominant position in cellular therapy space.
We note that investors were expecting Gilead to announce an acquisition in the near term given the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure. Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise is under pressure because of competition and pricing issues.
We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's (NYSE: ABBV - Free Report ) Viekira Pak and Viekira XR, among others. Moreover, Gilead was sitting on $21.1 billion of cash and short-term marketable securities. Hence, an acquisition announcement was lurking.
CAR T is manufactured for each individual patient using their own cells thereby making it different from typical small molecule or biologic therapies. During the treatment process, T cells are drawn from a patient's blood. These cells are then reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other Bcells expressing a specific antigen.
While the deal might look expensive given the premium Gilead paid for Kite, the CAR T space is expected to be revolutionary in treatments for cancer. The CAR T space represents immense potential at this juncture and a potential approval of axi-cell will be a significant boost for Gilead's prospects which has dampened of late.
Gilead's stock has declined 4.3% in the year so far, against the industry's 9.3%.
Apart from Kite, Novartis AG (NYSE: NVS - Free Report ) is another company that is focussed on CAR T treatments. In July, the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel) and a decision is expected shortly (September-October).
CTL019 could become the first CAR T cell therapy if approved. CTL019, an investigational CAR-T therapy, is being evaluated for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). A potential approval will also open new frontiers in the treatment of cancer by advancing immunocellular therapy for children and young adults with r/r B-cell ALL.
On the other hand, shares of Kite were up 28% on the news as the company will immensely benefit from Gilead's dominant position in the biotech space upon an anticipated approval for its lead candidate. In fact, this year so far, Kite Pharma's stock is up 297.1%, which compares favorably with a 9.3% increase registered by the industry .
Zacks Rank
Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on KITE - FREE
Get the full Report on GILD - FREE
Get the full Report on ABBV - FREE
Get the full Report on NVS - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's (NYSE: ABBV - Free Report ) Viekira Pak and Viekira XR, among others. Get the full Report on KITE - FREE Get the full Report on GILD - FREE Get the full Report on ABBV - FREE Get the full Report on NVS - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's (NYSE: ABBV - Free Report ) Viekira Pak and Viekira XR, among others. | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). Get the full Report on KITE - FREE Get the full Report on GILD - FREE Get the full Report on ABBV - FREE Get the full Report on NVS - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's (NYSE: ABBV - Free Report ) Viekira Pak and Viekira XR, among others. Get the full Report on KITE - FREE Get the full Report on GILD - FREE Get the full Report on ABBV - FREE Get the full Report on NVS - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. |
26016.0 | 2017-08-30 00:00:00 UTC | Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout? | ABBV | https://www.nasdaq.com/articles/has-gilead-sciences-big-bounce-begun-kite-pharma-buyout-2017-08-30 | nan | nan | Once upon a time, Gilead Sciences (NASDAQ: GILD) was one of the hottest biotech stocks on the market. But for most of the last two years, Gilead was anything but hot, with its market cap losing nearly half of its value at one point. The company in many respects was a victim of its own success, with previous growth from the astronomical rise of its hepatitis C drugs fizzling out as patients were cured.
Gilead announced on Monday that it's acquiring Kite Pharma (NASDAQ: KITE) for $11.9 billion. Some investors are hoping that this new chapter for Gilead will bring a more positive story. Has a big bounce begun for the beleaguered biotech?
Don't count on it
Naysayers can make a pretty compelling argument that the Kite acquisition won't be enough to turn things around for Gilead. The company's own words actually help bolster their case. In its press release announcing the Kite Pharma buyout, Gilead Sciences stated that the acquisition "is expected to be neutral to earnings by year three and accretive thereafter."
Let's put things into perspective. Gilead's earnings fell by more than 24% in the first quarter and another 12% in the second quarter . There's no end yet in sight for the biotech's hepatitis C slump. And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August.
Even if Kite wins approval for its CAR-T therapy axi-cel as expected, Gilead won't see any benefit to its bottom line until over three years from now. The news is actually worse than that, though. Gilead said the deal should be neutral to earnings by year three. That implies the biotech anticipates earnings will be negatively affected for the first couple of years.
There's a legitimate question as to whether a rebound for Gilead stock is warranted at this point. The company's earnings continue to deteriorate, and quite frankly, nothing appears to have changed that dynamic for the better at this point.
Signs point to yes
Now let's look at the optimistic viewpoint. Some investors could maintain that a big bounce started for Gilead even before the Kite deal was announced, and that momentum is only picking up after the news broke. Just look at Gilead's stock performance this year.
GILD data by YCharts
Halfway through 2017, Gilead stock was down more than 10% for the year. Now it's in positive territory. That by itself certainly indicates that a rebound is under way.
One thing that skeptics could be overlooking is the psychological boost that the Kite acquisition could provide for investors interested in Gilead Sciences. Although the transaction won't help the bottom line for a few years to come, there's no question in my mind that Gilead will be in a much stronger position in the oncology market with Kite Pharma's assets in its fold. Investors focus on the future -- and Gilead's future should be brighter over the long run as a result of its latest acquisition.
There's also good reason to believe that the Kite deal is only the beginning of a broader buying spree for Gilead. In his comments during the conference call discussion of the acquisition, Gilead CEO John Milligan said the biotech wouldn't be "going quietly after this deal." I suspect that some investors were beginning to wonder if Gilead would ever make a deal. Now they know the company has the willingness to do so -- and make even more. Again, that should bode well for Gilead's future.
Rest of the story
I realize that there are things to nitpick about Gilead's buyout of Kite Pharma. But there were also plenty of folks who criticized the company's acquisition of Pharmasset in 2012, in which Gilead gained Sovaldi. That deal turned out quite well . I expect the Kite transaction will, too.
Gilead Sciences remains one of the biggest biotechs in the world with an exceptionally strong cash flow. It also still has a huge cash stockpile. The company claims one of the best pipelines in the industry. It pays a really attractive dividend. With the Kite acquisition, Gilead will immediately become a leader in the lucrative oncology arena. And oh, yes, the stock still trades at less than 10 times expected earnings.
My hunch is that Gilead's rebound will continue. And if it doesn't, it should. My prediction is that this fairy tale will end happily ever after -- even if there are a few more twists and turns in the plot.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. In its press release announcing the Kite Pharma buyout, Gilead Sciences stated that the acquisition "is expected to be neutral to earnings by year three and accretive thereafter." | *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. Once upon a time, Gilead Sciences (NASDAQ: GILD) was one of the hottest biotech stocks on the market. | And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Don't count on it Naysayers can make a pretty compelling argument that the Kite acquisition won't be enough to turn things around for Gilead. | And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Gilead said the deal should be neutral to earnings by year three. |
26017.0 | 2017-08-29 00:00:00 UTC | Noteworthy ETF Inflows: IUSG, MA, MO, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-iusg-ma-mo-abbv-2017-08-29 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $34.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 52,400,000 to 53,100,000). Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average:
Looking at the chart above, IUSG's low point in its 52 week range is $40.54 per share, with $49.94 as the 52 week high point - that compares with a last trade of $49.14. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $40.54 per share, with $49.94 as the 52 week high point - that compares with a last trade of $49.14. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $40.54 per share, with $49.94 as the 52 week high point - that compares with a last trade of $49.14. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $34.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 52,400,000 to 53,100,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $40.54 per share, with $49.94 as the 52 week high point - that compares with a last trade of $49.14. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $34.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 52,400,000 to 53,100,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $40.54 per share, with $49.94 as the 52 week high point - that compares with a last trade of $49.14. |
26018.0 | 2017-08-29 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-broadcom-21st-century-fox-intuit-and-china-life | nan | nan | For Immediate Release
Chicago, IL - August 29, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday's Analyst Blog:
Top Analyst Reports for AbbVie, Broadcom & 21st Century Fox
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ) and 21st Century Fox (NASDAQ: FOXA - Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
AbbVie 's shares have gained +15.7% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +10.8% over the same period. AbbVie reported better-than-expected Q2 results, beating estimates for both earnings and sales. Humira and Imbruvica kept up the strong performance, while Viekira continued to be hurt by intensifying competition.
The Zacks analyst likes Humira's performance and thinks sales should continue to be driven by strong demand trends. Imbruvica also has a multibillion dollar potential while AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie has a promising pipeline with several pivotal data readouts and regulatory milestones due in the second half.
However, though Humira is doing well, the company is concerned about the product's long-term growth prospects, given potential biosimilar competition. Viekira also faces intense pricing and competitive pressure in the HCV market.
(You can read the full research report on AbbVie here >>> ).
Shares of Broadcom have handily beaten the technology sector as well as the red-hot semiconductor space in the year-to-date period, gaining +38.9%. The Zacks analyst thinks this outperformance is attributable to consistent results. Broadcom reported impressive third-quarter fiscal 2017 results.
The company now expects fourth-quarter revenue growth to be in the double-digit range on a year-over-year basis, much similar to the second and third quarter. However, gross margin is expected to contract slightly due to unfavorable product mix (higher mix of low margin wireless business). Customer concentration and leveraged balance sheet are other concerns for investors.
(You can read the full research report on Broadcom here >>> ).
21st Century Fox 's shares have increased +10.2% over the last year, widely outperforming the Zacks Film and Television industry, which has gained +4.8% over the same period. This outperformance is primarily attributable to five straight quarters of earnings beats.
The company posted impressive earnings results in the final quarter of 2017. Cable Network Programming, which has been a driving force backed by rising affiliate fees, is expected to do well in fiscal 2018 as well. However, management anticipates costs at this division to go up in fiscal 2018.
Meanwhile, the company's proposed acquisition of the remaining 61% stake in Sky plc has hit a roadblock after the deal was 'minded' by the U.K. government for a second phase of reviews.
(You can read the full research report on 21st Century Fox here >>> ).
Other noteworthy reports we are featuring today include Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ).
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on ABBV - FREE
Get the full Report on AVGO - FREE
Get the full Report on FOXA - FREE
Get the full Report on INTU - FREE
Get the full Report on LFC - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Intuit Inc. (INTU): Free Stock Analysis Report
Broadcom Limited (AVGO): Free Stock Analysis Report
China Life Insurance Company Limited (LFC): Free Stock Analysis Report
Twenty-First Century Fox, Inc. (FOXA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Here are highlights from Monday's Analyst Blog: Top Analyst Reports for AbbVie, Broadcom & 21st Century Fox The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ) and 21st Century Fox (NASDAQ: FOXA - Free Report ). | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ) and 21st Century Fox (NASDAQ: FOXA - Free Report ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Intuit Inc. (INTU): Free Stock Analysis Report Broadcom Limited (AVGO): Free Stock Analysis Report China Life Insurance Company Limited (LFC): Free Stock Analysis Report Twenty-First Century Fox, Inc. (FOXA): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Get the full Report on ABBV - FREE Get the full Report on AVGO - FREE Get the full Report on FOXA - FREE Get the full Report on INTU - FREE Get the full Report on LFC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Intuit Inc. (INTU): Free Stock Analysis Report Broadcom Limited (AVGO): Free Stock Analysis Report China Life Insurance Company Limited (LFC): Free Stock Analysis Report Twenty-First Century Fox, Inc. (FOXA): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Here are highlights from Monday's Analyst Blog: Top Analyst Reports for AbbVie, Broadcom & 21st Century Fox The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ) and 21st Century Fox (NASDAQ: FOXA - Free Report ). |
26019.0 | 2017-08-29 00:00:00 UTC | Gilead to Fly High with Kite Pharma Acquisition for $11.9B | ABBV | https://www.nasdaq.com/articles/gilead-to-fly-high-with-kite-pharma-acquisition-for-%2411.9b-2017-08-29 | nan | nan | Biotech giant Gilead Sciences, Inc.GILD announced that it will buy Kite Pharma, Inc. KITE to foray into the emerging field of cell therapy.
Terms of the Agreement
As per the agreement, Gilead will pay $180.00 per share in cash at a transaction valued at approximately $11.9 billion. The price represents a 28% premium over the closing share price of Kite as of Aug 25, 2017.
The transaction was approved by shareholders of both companies and is expected to close by the fourth quarter of 2017. The acquisition is expected to be neutral to the bottom line by the third year and accretive thereafter.
Strategic Benefit
We note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. The most advanced therapy candidate in Kite's pipeline is axicabtagene ciloleucel (axi-cel) which is being developed for the treatment of refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). The Biologics License Application (BLA) for the candidate was submitted in Mar 2017.
This CAR T therapy is currently under priority review in the United States and the FDA is expected to give a decision on Nov 29, 2017. The candidate is also under review in the EU with a tentative approval expected in 2018. While Kite is prepared for a commercial launch in the United States as manufacturing preparation are complete, the company is currently building infrastructure in Europe. We remind investors that another pipeline candidate in clinical trials in both hematologic cancers and solid tumors is KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma.
Our Take
The acquisition will diversify Gilead's portfolio and position the company in a dominant position in cellular therapy space.
We note that investors were expecting Gilead to announce an acquisition in the near term given the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure. Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise is under pressure because of competition and pricing issues.
We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Viekira XR, among others. Moreover, Gilead was sitting on $21.1 billion of cash and short-term marketable securities. Hence, an acquisition announcement was lurking.
CAR T is manufactured for each individual patient using their own cells thereby making it different from typical small molecule or biologic therapies. During the treatment process, T cells are drawn from a patient's blood. These cells are then reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other Bcells expressing a specific antigen.
While the deal might look expensive given the premium Gilead paid for Kite, the CAR T space is expected to be revolutionary in treatments for cancer. The CAR T space represents immense potential at this juncture and a potential approval of axi-cell will be a significant boost for Gilead's prospects which has dampened of late.
Gilead's stock has declined 4.3% in the year so far, against the industry's 9.3%.
Apart from Kite, Novartis AG NVS is another company that is focussed on CAR T treatments. In July, the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel) and a decision is expected shortly (September-October).
CTL019 could become the first CAR T cell therapy if approved. CTL019, an investigational CAR-T therapy, is being evaluated for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). A potential approval will also open new frontiers in the treatment of cancer by advancing immunocellular therapy for children and young adults with r/r B-cell ALL.
On the other hand, shares of Kite were up 28% on the news as the company will immensely benefit from Gilead's dominant position in the biotech space upon an anticipated approval for its lead candidate. In fact, this year so far, Kite Pharma's stock is up 297.1%, which compares favorably with a 9.3% increase registered by the industry .
Zacks Rank
Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Viekira XR, among others. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. We note that investors were expecting Gilead to announce an acquisition in the near term given the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Viekira XR, among others. Strategic Benefit We note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Viekira XR, among others. Biotech giant Gilead Sciences, Inc.GILD announced that it will buy Kite Pharma, Inc. KITE to foray into the emerging field of cell therapy. | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Viekira XR, among others. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. We note that investors were expecting Gilead to announce an acquisition in the near term given the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure. |
26020.0 | 2017-08-28 00:00:00 UTC | Roche's Gazyva Gets Priority Review for Follicular Lymphoma | ABBV | https://www.nasdaq.com/articles/roches-gazyva-gets-priority-review-for-follicular-lymphoma-2017-08-28 | nan | nan | Roche Holding AGRHHBY announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to Gazyva in combination with chemotherapy followed by Gazyva alone for patients suffering from previously untreated follicular lymphoma.
The FDA is expected announce its final decision by Dec 23. We remind investors that priority review is given to those drugs which the FDA believes have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
We note that Gazyva in combination with chlorambucil is approved for patients suffering from previously untreated chronic lymphocytic leukaemia (CLL).
A potential approval in follicular lymphoma is expected to boost sales further.
The drug is also being evaluated with other approved or investigational medicines, including cancer immunotherapies and small molecule inhibitors.
Roche's stock has gained 11.0% against the industry 's 10.8% gain.
Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie Inc. ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin.
The company also has a hemophilia A candidate, emicizumab, in its pipeline. Last week, the FDA granted emicizumab prophylaxis (preventative) priority review as a once-weekly subcutaneous treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors. The FDA is expected to announce its final decision by Feb 23, 2018. We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with haemophilia A with inhibitors in September 2015.
Approval of new drugs will further boost Roche's hematology portfolio.
Zacks Rank and Stocks to Consider
Roche currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Gilead Sciences, Inc. GILD and Aduro Biotech, Inc. ADRO . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Gilead's earnings per share estimates increased from $8.69 to $8.75 for 2017, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 6.38%.
Aduro Biotech's loss per share estimates have narrowed from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie Inc. ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that priority review is given to those drugs which the FDA believes have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie Inc. ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Last week, the FDA granted emicizumab prophylaxis (preventative) priority review as a once-weekly subcutaneous treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie Inc. ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Roche Holding AGRHHBY announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to Gazyva in combination with chemotherapy followed by Gazyva alone for patients suffering from previously untreated follicular lymphoma. | Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie Inc. ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. A potential approval in follicular lymphoma is expected to boost sales further. |
26021.0 | 2017-08-28 00:00:00 UTC | HRS Investment Holdings, LLC Buys Athene Holding, Goldman Sachs Group Inc, The Kroger Co, Sells ... | ABBV | https://www.nasdaq.com/articles/hrs-investment-holdings-llc-buys-athene-holding-goldman-sachs-group-inc-kroger-co-sells | nan | nan | HRS Investment Holdings, LLC
New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR,
Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV,
Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE,
Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY,
For the details of HRS Investment Holdings, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=HRS+Investment+Holdings%2C+LLC
These are the top 5 holdings of HRS Investment Holdings, LLC
Athene Holding Ltd ( ATH ) - 551,870 shares, 18.18% of the total portfolio. Shares added by 46.49%
Apple Inc ( AAPL ) - 40,000 shares, 3.83% of the total portfolio. Shares added by 6.67%
JPMorgan Chase & Co ( JPM ) - 45,000 shares, 2.73% of the total portfolio. Shares added by 12.50%
AbbVie Inc ( ABBV ) - 50,000 shares, 2.41% of the total portfolio. Shares added by 11.11%
General Motors Co ( GM ) - 90,000 shares, 2.09% of the total portfolio. Shares added by 28.57%
New Purchase: Goldman Sachs Group Inc (GS)
HRS Investment Holdings, LLC initiated holdings in Goldman Sachs Group Inc. The purchase prices were between $211.26 and $229.72, with an estimated average price of $222.34. The stock is now traded at around $219.48. The impact to the portfolio due to this purchase was 1.47%. The holdings were 10,000 shares as of 2017-06-30.
New Purchase: The Kroger Co (KR)
HRS Investment Holdings, LLC initiated holdings in The Kroger Co. The purchase prices were between $22.29 and $30.78, with an estimated average price of $28.42. The stock is now traded at around $21.49. The impact to the portfolio due to this purchase was 1.08%. The holdings were 70,000 shares as of 2017-06-30.
New Purchase: NRG Yield Inc (NYLD)
HRS Investment Holdings, LLC initiated holdings in NRG Yield Inc. The purchase prices were between $16.65 and $18.35, with an estimated average price of $17.51. The stock is now traded at around $18.63. The impact to the portfolio due to this purchase was 0.94%. The holdings were 80,732 shares as of 2017-06-30.
New Purchase: CIT Group Inc (CIT)
HRS Investment Holdings, LLC initiated holdings in CIT Group Inc. The purchase prices were between $42.46 and $48.72, with an estimated average price of $45.87. The stock is now traded at around $44.98. The impact to the portfolio due to this purchase was 0.65%. The holdings were 20,000 shares as of 2017-06-30.
New Purchase: Arconic Inc (ARNC)
HRS Investment Holdings, LLC initiated holdings in Arconic Inc. The purchase prices were between $21.84 and $28.16, with an estimated average price of $26.63. The stock is now traded at around $25.11. The impact to the portfolio due to this purchase was 0.6%. The holdings were 40,000 shares as of 2017-06-30.
New Purchase: Diamondback Energy Inc (FANG)
HRS Investment Holdings, LLC initiated holdings in Diamondback Energy Inc. The purchase prices were between $84.87 and $106.77, with an estimated average price of $97.3. The stock is now traded at around $87.68. The impact to the portfolio due to this purchase was 0.59%. The holdings were 10,000 shares as of 2017-06-30.
Added: Athene Holding Ltd ( ATH )
HRS Investment Holdings, LLC added to the holdings in Athene Holding Ltd by 46.49%. The purchase prices were between $48.79 and $54.3, with an estimated average price of $51.31. The stock is now traded at around $53.02. The impact to the portfolio due to this purchase was 5.77%. The holdings were 551,870 shares as of 2017-06-30.
Added: Molson Coors Brewing Co (TAP)
HRS Investment Holdings, LLC added to the holdings in Molson Coors Brewing Co by 71.43%. The purchase prices were between $85.77 and $96.86, with an estimated average price of $92.8. The stock is now traded at around $89.41. The impact to the portfolio due to this purchase was 0.72%. The holdings were 30,000 shares as of 2017-06-30.
Added: LyondellBasell Industries NV (LYB)
HRS Investment Holdings, LLC added to the holdings in LyondellBasell Industries NV by 100.00%. The purchase prices were between $78.91 and $91.19, with an estimated average price of $83.16. The stock is now traded at around $90.13. The impact to the portfolio due to this purchase was 0.7%. The holdings were 25,000 shares as of 2017-06-30.
Added: General Motors Co ( GM )
HRS Investment Holdings, LLC added to the holdings in General Motors Co by 28.57%. The purchase prices were between $32.42 and $35.36, with an estimated average price of $33.95. The stock is now traded at around $35.34. The impact to the portfolio due to this purchase was 0.46%. The holdings were 90,000 shares as of 2017-06-30.
Added: US Silica Holdings Inc (SLCA)
HRS Investment Holdings, LLC added to the holdings in US Silica Holdings Inc by 77.78%. The purchase prices were between $32.03 and $50.07, with an estimated average price of $39.57. The stock is now traded at around $25.33. The impact to the portfolio due to this purchase was 0.41%. The holdings were 40,000 shares as of 2017-06-30.
Added: EOG Resources Inc (EOG)
HRS Investment Holdings, LLC added to the holdings in EOG Resources Inc by 100.00%. The purchase prices were between $87.04 and $98.57, with an estimated average price of $92.21. The stock is now traded at around $82.58. The impact to the portfolio due to this purchase was 0.3%. The holdings were 10,000 shares as of 2017-06-30.
Sold Out: Allergan PLC (AGN)
HRS Investment Holdings, LLC sold out the holdings in Allergan PLC. The sale prices were between $218.73 and $248.91, with an estimated average price of $234.91.
Sold Out: AmTrust Financial Services Inc (AFSI)
HRS Investment Holdings, LLC sold out the holdings in AmTrust Financial Services Inc. The sale prices were between $11.96 and $21.95, with an estimated average price of $14.82.
Sold Out: Virtu Financial Inc (VIRT)
HRS Investment Holdings, LLC sold out the holdings in Virtu Financial Inc. The sale prices were between $14.95 and $18.25, with an estimated average price of $16.27.
Sold Out: Anadarko Petroleum Corp (APC)
HRS Investment Holdings, LLC sold out the holdings in Anadarko Petroleum Corp. The sale prices were between $43.79 and $62.9, with an estimated average price of $53.29.
Sold Out: Best Buy Co Inc (BBY)
HRS Investment Holdings, LLC sold out the holdings in Best Buy Co Inc. The sale prices were between $47.97 and $61.25, with an estimated average price of $53.36.
Sold Out: Zimmer Biomet Holdings Inc (ZBH)
HRS Investment Holdings, LLC sold out the holdings in Zimmer Biomet Holdings Inc. The sale prices were between $116.54 and $129.39, with an estimated average price of $122.02.
ATH 15-Year Financial Data
The intrinsic value of ATH
Peter Lynch Chart of ATH
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS Investment Holdings, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=HRS+Investment+Holdings%2C+LLC These are the top 5 holdings of HRS Investment Holdings, LLC Athene Holding Ltd ( ATH ) - 551,870 shares, 18.18% of the total portfolio. Shares added by 12.50% AbbVie Inc ( ABBV ) - 50,000 shares, 2.41% of the total portfolio. Shares added by 28.57% New Purchase: Goldman Sachs Group Inc (GS) HRS Investment Holdings, LLC initiated holdings in Goldman Sachs Group Inc. | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS Investment Holdings, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=HRS+Investment+Holdings%2C+LLC These are the top 5 holdings of HRS Investment Holdings, LLC Athene Holding Ltd ( ATH ) - 551,870 shares, 18.18% of the total portfolio. Shares added by 12.50% AbbVie Inc ( ABBV ) - 50,000 shares, 2.41% of the total portfolio. Shares added by 28.57% New Purchase: Goldman Sachs Group Inc (GS) HRS Investment Holdings, LLC initiated holdings in Goldman Sachs Group Inc. | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS Investment Holdings, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=HRS+Investment+Holdings%2C+LLC These are the top 5 holdings of HRS Investment Holdings, LLC Athene Holding Ltd ( ATH ) - 551,870 shares, 18.18% of the total portfolio. Shares added by 12.50% AbbVie Inc ( ABBV ) - 50,000 shares, 2.41% of the total portfolio. Added: Athene Holding Ltd ( ATH ) HRS Investment Holdings, LLC added to the holdings in Athene Holding Ltd by 46.49%. | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS Investment Holdings, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=HRS+Investment+Holdings%2C+LLC These are the top 5 holdings of HRS Investment Holdings, LLC Athene Holding Ltd ( ATH ) - 551,870 shares, 18.18% of the total portfolio. Shares added by 12.50% AbbVie Inc ( ABBV ) - 50,000 shares, 2.41% of the total portfolio. Added: Athene Holding Ltd ( ATH ) HRS Investment Holdings, LLC added to the holdings in Athene Holding Ltd by 46.49%. |
26022.0 | 2017-08-28 00:00:00 UTC | How to Retire on 8% Dividends Paid Monthly | ABBV | https://www.nasdaq.com/articles/how-retire-8-dividends-paid-monthly-2017-08-28 | nan | nan | By Brett Owens
The suits at Merrill Lynch say you need $738,400 to retire well.
Let me explain why they're dead wrong. You'll actually need a lotless than that.
I'm going to show you a simple way to bankroll your golden years on 32% less. That's right: I'm talking about a fully paid for retirement for around $500,000.
Got more? Great. I'll show you how you can retire filthy rich on your current stake.
Plus my "no-withdrawal portfolio" will also let you live on dividends alone --without selling a single stock to generate extra cash.
As I've written before , this approach is a must if you want to safeguard your retirement from the next market calamity.
The Power of Monthly Dividends
While we're at it, let's also set up a smooth income stream that rolls in every month,not every quarter like the dividends you get from most blue-chip stocks.
You probably know that it's a pain to deal with payouts that roll in quarterly when our bills roll in monthly.
But convenience is far from the only benefit you get with monthly dividends. They also give you your cash faster--so you can reinvest it faster if you don't need income from your portfolio right away.
More on that a little further on. First I want to show you...
HowNotto Build a Solid Monthly Income Stream
When it comes to dividend investing, many "first-level" investors take themselves out of the game straight off the hop. That's because they head straight to the list of Dividend Aristocrats--the S&P 500 companies that have hiked their payouts for 25 years or more.
That kind of dividend growth is impressive. And some of these names do have a place in your portfolio--including 3 Aristocrats I pounded the table on in early June .
But here's the problem: these folks are forgetting that companies don't need a high dividend yield to join this club--and without a high, safe payout you can forget about generating a livable income stream on any reasonably sized nest egg.
Worse, you could be forced to sell stocks in retirement--maybe even into a 2008/09-style nosedive--just to make ends meet.
That's a nightmare for any retiree, and leaning too hard on the so-called Aristocrats can easily make it reality: the ProShares S&P 500 Dividend Aristocrats ETF ( NOBL ), which holds all 51 Aristocrats, yields a pathetic 1.9% as I write, exactly the same as the S&P 500 average!
Worse, that yield is in free-fall as stocks grind higher:
The Aristocrats' (Not So) Incredible Shrinking Yield
Solid Monthly Payers Are Rare Birds...
You can certainly build your own monthly dividend portfolio, and the advantage of doing so is obvious: you can target companies that pay much more than your average Aristocrat's paltry sub-2% payout.
Trouble is, only a handful of regular stocks pay in any frequency other than quarterly, so we'll have to patch together different payout schedules to make it happen.
To do that, I've swung back to the Aristocrats, scanning for a combo of above-average yields and payout schedules that line up. Here's an "instant" 6-stock monthly dividend portfolio that fits the bill:
AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November.
Target ( TGT ) and Chevron ( CVX ), with payments in March, June, September and December.
Sysco (SYY) and Wal-Mart Stores (WMT), with payments in January, April, July and October.
Here's what $500,000 evenly split across these six stocks would net you in dividend payouts over the next six months, based on current yields and rates:
You can see the consistency starting to show up here, with payouts coming your way every single month, but they still vary widely--sometimes by nearly $800 a month!
Of course, the bigger problem is that we're pulling in just a 3.7% average yield, which will only get us to $18,600 in income on our $500,000 nest egg. That's less than your local Starbucks barista makes!
We need to do better.
...But It Pays to Own Them
Here's where you need to step away from regular stocks and fish in lesser-known corners of the market--places where high yields and monthly payouts abound.
One of my favorites? Real estate investment trusts (REITs) a special kind of company that owns rental properties--everything from shopping malls to senior-care facilities.
Here's the upshot: the IRS lets REITs skip out on income taxes if they pay out most of their earnings as dividends. That means fatter dividend checks for you and me. Better yet, monthly payouts are more common in the REIT world.
So let's go ahead and build a monthly dividend REIT portfolio with 4 names that should be on any income hound's radar:
Industrial landlord STAG Industrial REIT (STAG), a 5.0% yielder I recommended on August 14 .
Long-term care facility owner LTC Properties (LTC) , with a 4.8% payout.
Apple Hospitality REIT (APLE) a hotel operator that pays 6.7%.
EPR Properties (EPR), owner of theaters and entertainment complexes across the US--and a fat 6.0% payout.
Here's what you could expect every single month for the next six months if you dropped $500k into these four, again based on current yields and rates:
There's one problem, though: that $28,000 is still below the $40,000 or so most folks would need to retire on dividends alone.
Which brings me to...
Your Best Move Now: 8% Dividends AND Monthly Payouts
This is where my "No-Withdrawal Portfolio" comes in. With just $500,000 invested, it'll hand you a rock-solid $40,000-a-year income stream . That's an 8% dividend yield ... and it's easily enough for most folks to retire on.
The best part is you won't have to go back to "lumpy" quarterly payouts to do it! Of the 6 income studs in this unique portfolio, 4 pay dividends monthly, so you can look forward to the steady drip of $3,333 in income, month in and month out --give or take a couple hundred bucks!
I'm ready to give you everything you need to know about this life-changing portfolio now. All you have to do is CLICK HERE and I'll share my proven monthly-dividend strategy, plus the names, tickers and ALL of my research on these 6 income wonders !
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. First I want to show you... HowNotto Build a Solid Monthly Income Stream When it comes to dividend investing, many "first-level" investors take themselves out of the game straight off the hop. ...But It Pays to Own Them Here's where you need to step away from regular stocks and fish in lesser-known corners of the market--places where high yields and monthly payouts abound. | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. But here's the problem: these folks are forgetting that companies don't need a high dividend yield to join this club--and without a high, safe payout you can forget about generating a livable income stream on any reasonably sized nest egg. ...But It Pays to Own Them Here's where you need to step away from regular stocks and fish in lesser-known corners of the market--places where high yields and monthly payouts abound. | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. Worse, that yield is in free-fall as stocks grind higher: The Aristocrats' (Not So) Incredible Shrinking Yield Solid Monthly Payers Are Rare Birds... You can certainly build your own monthly dividend portfolio, and the advantage of doing so is obvious: you can target companies that pay much more than your average Aristocrat's paltry sub-2% payout. Here's what $500,000 evenly split across these six stocks would net you in dividend payouts over the next six months, based on current yields and rates: You can see the consistency starting to show up here, with payouts coming your way every single month, but they still vary widely--sometimes by nearly $800 a month! | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. Worse, that yield is in free-fall as stocks grind higher: The Aristocrats' (Not So) Incredible Shrinking Yield Solid Monthly Payers Are Rare Birds... You can certainly build your own monthly dividend portfolio, and the advantage of doing so is obvious: you can target companies that pay much more than your average Aristocrat's paltry sub-2% payout. Here's what you could expect every single month for the next six months if you dropped $500k into these four, again based on current yields and rates: There's one problem, though: that $28,000 is still below the $40,000 or so most folks would need to retire on dividends alone. |
26023.0 | 2017-08-28 00:00:00 UTC | Gilead Sciences to Buy Kite Pharma for $11.9 Billion: Is It Enough to Move the Needle? | ABBV | https://www.nasdaq.com/articles/gilead-sciences-buy-kite-pharma-119-billion-it-enough-move-needle-2017-08-28 | nan | nan | What happened
Gilead Sciences (NASDAQ: GILD) , prompted by its falling sales of its hepatitis C drugs over the past year, has finally pulled the trigger on a much-anticipated buyout: On Monday, it offered to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion in an all-cash deal. Kite's shares were up by 28.87% in pre-market trading on heavy volume as a result.
Kite is a leader in the field of next-generation cancer treatments known as chimeric antigen receptor T-cell (CAR-T) therapies. The biotech's lead CAR-T candidate, axicabtagene ciloleucel, or Axi-Cel for short, is currently under review by the U.S. Food and Drug Administration as a potential treatment for aggressive non-Hodgkin lymphoma. The FDA is expected to hand down a final decision on Axi-Cel in November .
Shares of fellow CAR-T developers Bellicum Pharmaceuticals (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) , and ZIOPHARM Oncology (NASDAQ: ZIOP) are all trading in positive territory on the back of this news.
So what
Not long ago, the future of the CAR-T therapies was in serious doubt after Juno Therapeutics' then-lead clinical candidate, JCAR015, was shelved due to a handful of patient deaths. The big picture issue is that while CAR-T therapies have produced unprecedented responses against some forms of hard-to-treat blood cancers, they have also caused a number of deadly side effects, such as cytokine release syndrome and neurotoxicity.
Consequently, Bellicum and ZIOPHARM -- the late-comers to the adoptive cell therapy party -- have both had trouble garnering much interest from investors: Both have been trading at market caps that are small fractions of their respective CAR-T pipelines' commercial potential. Gilead's rather rich buyout of Kite Pharma for what amounts to a 29% premium, however, suggests that the top players in the industry have faith in the power of this novel anti-cancer fighting platform.
Now what
By acquiring Kite, Gilead may have gained a significant new source of revenue with the potential to help offset its declining hep C franchise. EvaluatePharma, for instance, forecasts Axi-Cel's sales will top $1.7 billion by 2022, and thinks it will turn out to be one of the top-selling oncology products over the course of the next decade. Even so, this acquisition isn't quite enough to move the needle from a top-line standpoint. Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie.
Based on that, Gilead might be gearing up to acquire additional assets in the CAR-T space to shore up revenues. The biotech, after all, will have another $24 billion or so in cash remaining following this acquisition, and at their current rock-bottom valuations, Bellicum, Juno, and ZIOPHARM may prove too attractive to pass up. Stay tuned.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. The biotech's lead CAR-T candidate, axicabtagene ciloleucel, or Axi-Cel for short, is currently under review by the U.S. Food and Drug Administration as a potential treatment for aggressive non-Hodgkin lymphoma. The big picture issue is that while CAR-T therapies have produced unprecedented responses against some forms of hard-to-treat blood cancers, they have also caused a number of deadly side effects, such as cytokine release syndrome and neurotoxicity. | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. What happened Gilead Sciences (NASDAQ: GILD) , prompted by its falling sales of its hepatitis C drugs over the past year, has finally pulled the trigger on a much-anticipated buyout: On Monday, it offered to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion in an all-cash deal. Shares of fellow CAR-T developers Bellicum Pharmaceuticals (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) , and ZIOPHARM Oncology (NASDAQ: ZIOP) are all trading in positive territory on the back of this news. | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. What happened Gilead Sciences (NASDAQ: GILD) , prompted by its falling sales of its hepatitis C drugs over the past year, has finally pulled the trigger on a much-anticipated buyout: On Monday, it offered to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion in an all-cash deal. Shares of fellow CAR-T developers Bellicum Pharmaceuticals (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) , and ZIOPHARM Oncology (NASDAQ: ZIOP) are all trading in positive territory on the back of this news. | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. Shares of fellow CAR-T developers Bellicum Pharmaceuticals (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) , and ZIOPHARM Oncology (NASDAQ: ZIOP) are all trading in positive territory on the back of this news. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! |
26024.0 | 2017-08-27 00:00:00 UTC | Why I Love AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/why-i-love-abbvie-inc-2017-08-27 | nan | nan | "Where your treasure is, there will your heart be also."
Those profound words were spoken nearly 2,000 years ago. They were true then, and they're still true today. But even when your treasure is divided equally, some of the places where the money is placed will be closer to your heart than others.
That's the case for me with AbbVie (NYSE: ABBV) . My investment portfolio includes quite a few stocks with roughly the same amount invested in each initially. AbbVie, though, is one of my favorites. Here's why I love the biotech stock.
Returning the love
One of the best things about AbbVie is that it returns the love to shareholders. I'm talking about dividends and share buybacks. Both moves reward investors -- and there's plenty to like about AbbVie on both fronts.
If you include the time when AbbVie was part of Abbott Labs , the company claims an impressive streak of 44 consecutive years of dividend increases. But even if you only look at the period after AbbVie's spin-off from Abbott Labs in 2013, the biotech still has a tremendous track record for dividends. AbbVie has raised its dividend every year since becoming a separate entity for a total of 60%. Its yield now stands at 3.58%.
The company has also been generous with share buybacks. AbbVie repurchased $7.8 billion worth of its stock in 2015 and $2.1 billion last year. So far in 2017, the biotech has bought back $500 million of its shares, with another $4.5 billion remaining in a stock repurchase authorization made by its board of directors earlier this year.
Growing affection
There are few things that warm the hearts of investors like the potential for solid earnings growth in the future. AbbVie should be able to deliver average annual earnings growth of around 14% over the next five years.
Humira will continue to be the most important key to AbbVie's financial fortunes. The autoimmune-disease drug generated revenue of $16.1 billion in 2016 and is on track to make even more money this year. AbbVie's fastest-growing blockbuster drug right now, though, is Imbruvica. The cancer drug raked in $1.8 billion in 2016 and could achieve annual sales of $5 billion within a few years.
A couple of other current products in AbbVie's lineup could also be big winners down the road. AbbVie won U.S. regulatory approval for Mavyret for treating all major genotypes of hepatitis C in early August. The drug could give Gilead Sciencesa run for its money in the hepatitis C market. AbbVie's leukemia drug Venclexta also has blockbuster potential.
It's AbbVie's pipeline, though, that really excites investors. Market research firm EvaluatePharma thinks the biotech has the No. 3 pipeline in the biopharmaceutical industry . AbbVie should be able to preserve its leadership position in autoimmune diseases with late-stage candidates such as upadacitinib and risankizumab. Promising experimental cancer drugs in AbbVie's pipeline include Rova-T and veliparib. Elagolix could allow the company to make its mark in treating endometriosis and uterine fibroids.
Don't go breaking my heart
AbbVie has a lot of great things going for it. There's one possibility, however, that could shake investors' confidence in the stock: a freefall in sales of Humira.
Amgen (NASDAQ: AMGN) won U.S. regulatory approval for its biosimilar to Humira last year. So far, though, Amgen hasn't launched the biosimilar, branded as Amjevita, because of a patent lawsuit filed by AbbVie. AbbVie's management team thinks it will be able to fend off biosimilar competition in the U.S. through 2022. That would give the company time to commercialize some of its pipeline candidates that could help offset declining sales for Humira.
I wouldn't expect Humira's sales to implode even if AbbVie loses its lawsuit. If the company isn't successful, though, that will definitely be a heart-breaker for shareholders -- including yours truly.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you include the time when AbbVie was part of Abbott Labs , the company claims an impressive streak of 44 consecutive years of dividend increases. That's the case for me with AbbVie (NYSE: ABBV) . AbbVie, though, is one of my favorites. | Promising experimental cancer drugs in AbbVie's pipeline include Rova-T and veliparib. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. That's the case for me with AbbVie (NYSE: ABBV) . | AbbVie repurchased $7.8 billion worth of its stock in 2015 and $2.1 billion last year. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. | It's AbbVie's pipeline, though, that really excites investors. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's the case for me with AbbVie (NYSE: ABBV) . |
26025.0 | 2017-08-26 00:00:00 UTC | Is the System Rigged Against Biosimilars? | ABBV | https://www.nasdaq.com/articles/system-rigged-against-biosimilars-2017-08-26 | nan | nan | If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story altogether for biologics -- drugs made from living organisms or components of living organisms. Until 2010, biosimilars to biologics weren't even legally allowed in the U.S.
Seven years later, biosimilars still haven't made a huge dent in helping control soaring drug costs in therapeutic categories like autoimmune diseases, where biologics dominate. Could it be that the system is rigged against biosimilars?
Failure to launch
One prime example of the challenges that biosimilars face is Amgen 's (NASDAQ: AMGN) Amjevita. The big biotech won FDA approval last year for Amjevita, the first biosimilar to autoimmune disease drug Humira to obtain U.S. approval. Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016.
AbbVie is on track to make even more money from Humira this year, despite the approval for Amjevita. Why? Amgen still hasn't launched its biosimilar. AbbVie is fighting Amgen in court, alleging patent infringement. The trial doesn't even start until November 2019.
Humira technically lost patent exclusivity at the end of last year. However, that was only for the composition of matter patent for Humira. AbbVie has another 61 patents for the drug and intends to try to use every one of them to keep biosimilar competition off the market in the U.S. through 2022.
AbbVie's strategy makes sense. It's understandable that companies want to go on milking their cash cows for as long as possible. However, the situation with Humira and Amjevita highlights a key reason why biosimilars haven't had a huge impact so far on reigning in overall prescription drug spending. The U.S. legal system is so slow-moving that money-saving biosimilars don't get to market as quickly as they otherwise could.
More roadblocks
It can be tough for biosimilars even after they're launched commercially. Pfizer (NYSE: PFE) introduced its Remicade biosimilar, branded as Inflectra, in October 2016. Like Humira, Remicade treats various autoimmune diseases. In the first half of this year, Pfizer reported sales of Inflectra totaling $172 million, including revenue generated in the U.S. and Europe. Johnson & Johnson (NYSE: JNJ) made $3.2 billion in the same period from Remicade.
Why hasn't Inflectra taken more market share away from Remicade? One reason is that Pfizer priced its biosimilar only 15% below Remicade. Even though that's a significant discount, there's little incentive for physicians to switch patients to the biosimilar.
A more important reason, though, behind Remicade's continued dominance is the strategy used by Johnson & Johnson. The healthcare giant has established exclusive contracts for Remicade with payers representing nearly half of the market. Pfizer can't get Inflectra into those networks at all -- at least not yet.
J&J has also used its other lines of business to its advantage. The company has bundled its drugs and medical devices in deals with hospitals. That makes Remicade just one part of a much larger contract. Ironically, Johnson & Johnson's strategy has even allowed it to increase the price for Remicade, despite having new competition.
Time is on biosimilars' side
Novartis (NYSE: NVS) won FDA approval in 2015 for Zarxio, a biosimilar to Amgen's Neupogen. The Swiss drugmaker priced Zarxio 15% below the price of Neupogen. Over time, sales for Neupogen have declined significantly.
The same scenario is likely to unfold for Remicade. In fact, sales for J&J's top-selling product slipped 10% year over year in the first half of 2017. In the end, payers want to save money. Either J&J will have to match prices for its biosimilar rivals (either through discounts or rebates), or it will lose market share. Either way, prices will come down.
Humira will face a similar future. Even if AbbVie manages to fend off Amgen in court, it's just a matter of time before biosimilars begin chipping away at Humira's market share. When that time comes, AbbVie will have the same options that Johnson & Johnson will have with Remicade.
It's probably an overstatement to say that the system is rigged against biosimilars. However, there are definitely plenty of aspects of the current system that favor incumbents with established products. Still, though, biosimilars will eventually bring down prices of biologics. Time is on their side.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Even if AbbVie manages to fend off Amgen in court, it's just a matter of time before biosimilars begin chipping away at Humira's market share. Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite the approval for Amjevita. | Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite the approval for Amjevita. AbbVie is fighting Amgen in court, alleging patent infringement. | Even if AbbVie manages to fend off Amgen in court, it's just a matter of time before biosimilars begin chipping away at Humira's market share. Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite the approval for Amjevita. | Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite the approval for Amjevita. AbbVie is fighting Amgen in court, alleging patent infringement. |
26026.0 | 2017-08-24 00:00:00 UTC | Roche (RHHBY) Hemophilia A Drug Granted Priority Review | ABBV | https://www.nasdaq.com/articles/roche-rhhby-hemophilia-a-drug-granted-priority-review-2017-08-24 | nan | nan | Roche Holding AGRHHBY announced that the FDA has accepted the company's Biologics License Application (BLA) and granted Priority Review for hemophilia A candidate, emicizumab.
The FDA has granted emicizumab prophylaxis (preventative) priority review as a once-weekly subcutaneous treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors.
Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
The BLA for emicizumab was based on results from the phase III study, HAVEN 1, in adults and adolescents of 12 years or older, as well as interim results from the phase III study, HAVEN 2 study in children younger than 12 years of age.
We note that results from HAVEN 1 were published in The New England Journal of Medicine (NEJM) and results from both studies were presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress in July 2017.
The FDA is expected to give a decision by Feb 23, 2018. We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with haemophilia A with inhibitors in September 2015.
Meanwhile, Roche is evaluating emicizumab in patients with hemophilia A both with and without inhibitors and evaluating less frequent dosing regimens as well.
Roche's stock has lost 10.1% so far in 2017 against the industry 's 10.3% gain.
Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin.
A few other companies are also developing treatments for hemophilia A. Shire plc SHPG also filed an investigational new drug (IND) application with the FDA, seeking approval for recombinant factor VIII (FVIII) gene therapy candidate, SHP654. The drug will be used for the treatment of patients with hemophilia A.
Zacks Rank and Stock to Consider
Roche currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Gilead Sciences, Inc. GILD , which carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Gilead's earnings per share estimates increased from $7.98 to $8.53 for 2017, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 8.18%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Shire PLC (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holding AGRHHBY announced that the FDA has accepted the company's Biologics License Application (BLA) and granted Priority Review for hemophilia A candidate, emicizumab. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Roche Holding AGRHHBY announced that the FDA has accepted the company's Biologics License Application (BLA) and granted Priority Review for hemophilia A candidate, emicizumab. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. The BLA for emicizumab was based on results from the phase III study, HAVEN 1, in adults and adolescents of 12 years or older, as well as interim results from the phase III study, HAVEN 2 study in children younger than 12 years of age. | Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA has granted emicizumab prophylaxis (preventative) priority review as a once-weekly subcutaneous treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors. |
26027.0 | 2017-08-23 00:00:00 UTC | 3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences | ABBV | https://www.nasdaq.com/articles/3-reasons-abbvie-better-dividend-stock-gilead-sciences-2017-08-23 | nan | nan | Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one of the biggest biotechs on the planet, with a market cap of around $95 billion. But AbbVie is even bigger, with a market cap topping $112 billion.
There's one other key area where AbbVie holds an advantage over Gilead -- dividends. Both companies pay out dividends with attractive yields. However, here are three reasons why AbbVie is a better dividend stock than Gilead Sciences.
1. The obvious
First is the obvious reason: AbbVie has a higher dividend yield. Gilead's dividend currently yields 2.88%. That's not bad at all. AbbVie, however, claims a dividend yield of 3.66%. It's not even close between the two companies.
What's more, this isn't a temporary advantage for AbbVie. The drugmaker's dividend yield has been significantly higher than Gilead's yield from the very beginning.
ABBV Dividend Yield (TTM) data by YCharts.
2. The not-so-obvious
There's also a not-so-obvious reason why AbbVie is the better dividend stock. If you compare the two companies' payout ratios, Gilead Sciences appears to be in better position for big dividend increases in the future. While AbbVie is using 59% of earnings to fund its dividend program, Gilead is using less than 22% of its earnings to pay out dividends. Despite the lower payout ratio, though, AbbVie could actually be in better shape for future dividend hikes.
For one thing, the earnings trajectories for these two big biotechs are going in different directions. AbbVie is expected to grow earnings by 14% over the next five years. Gilead's earnings are projected to fall by an average annual rate of more than 8%, due to a continued decline in sales for its hepatitis C franchise.
More important, though, is that Gilead Sciences has a more pressing need to use its cash stockpile and cash flow for making acquisitions. The company's CEO John Milligan has said that Gilead wants to make a "transformative" acquisition. That means a big deal with a big price tag.
I expect that both AbbVie and Gilead Sciences will remain committed to their dividends. Future dividend increases are likely for both companies. However, Gilead has a more important use for its cash than boosting the dividend by a large amount. That's something that most of its shareholders will fully understand and not be upset about.
3. The past
Some might think that, since history doesn't repeat itself, it's not important. However, when it comes to dividends, the past is very important in evaluating motivations and priorities for companies. AbbVie's past track record for dividends gives it another advantage over Gilead Sciences.
Gilead initiated its dividend program in 2015. The company increased its dividend in both of the following years. AbbVie technically initiated its first dividend in 2013 after its spinoff from Abbott Labs . Since then, AbbVie has increased its dividend by 60%.
However, AbbVie's cultural commitment to dividends goes back to its days as part of Abbott Labs. Including the period prior to its spinoff, AbbVie has increased its dividend for a remarkable 44 consecutive years, landing it a place among the elite group of Dividend Aristocrats .
For some stocks, the dividend becomes something of a sacrosanct component of its investing premise. I think that's the case for AbbVie, with its rich tradition of dividend increases. Gilead doesn't have that tradition -- at least not yet.
The potential game changer
There's one thing, though, that could threaten AbbVie's ability to keep its reputation for a strong dividend. Nearly two-thirds of the company's total revenue stems from Humira. A huge decline in sales for the drug would seriously weaken AbbVie and its ability to fund the dividend program at current levels.
A potential threat for Humira looms like a dark cloud over AbbVie already. Amgen (NASDAQ: AMGN) won Food and Drug Administration approval last year for Amjevita, its biosimilar to Humira. AbbVie has taken Amgen to court over potential patent infringement. As a result, Amgen hasn't launched Amjevita in the U.S. yet. The trial is scheduled to begin in November 2019. AbbVie thinks that it will be successful in fending off U.S. rivals to Humira through 2022.
It's unknown just how big an impact biosimilar competition would have on sales for Humira. Even if AbbVie loses in court, the company's dividend probably wouldn't be negatively impacted in the short run. However, the risk to Humira isn't one investors should ignore. In the meantime, though, AbbVie's dividend appears to be safe, growing -- and better than Gilead's.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. But AbbVie is even bigger, with a market cap topping $112 billion. There's one other key area where AbbVie holds an advantage over Gilead -- dividends. | The obvious First is the obvious reason: AbbVie has a higher dividend yield. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. But AbbVie is even bigger, with a market cap topping $112 billion. | However, here are three reasons why AbbVie is a better dividend stock than Gilead Sciences. While AbbVie is using 59% of earnings to fund its dividend program, Gilead is using less than 22% of its earnings to pay out dividends. AbbVie's past track record for dividends gives it another advantage over Gilead Sciences. | However, here are three reasons why AbbVie is a better dividend stock than Gilead Sciences. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. But AbbVie is even bigger, with a market cap topping $112 billion. |
26028.0 | 2017-08-23 00:00:00 UTC | Top 3 Stocks for Retirees to Consider | ABBV | https://www.nasdaq.com/articles/top-3-stocks-retirees-consider-2017-08-23 | nan | nan | Retirement means you no longer need to work to make a living. But that doesn't mean your money needs to stop working for you. For those who know where to look, the stock market can be fantastic tool to make the most of your money after you retire.
So we asked three top Motley Fool investors to each pick a stock that they believe retirees would be wise to consider. Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) .
Investing in a resilient retail niche
Steve Symington (Tanger Factory Outlet Centers): 2017 hasn't been kind to Tanger Factory Outlet Centers stock. Shares of the outlet-mall real estate investment trust (REIT) have fallen more than 30% year to date -- a streak extended earlier this month by the market's negative reaction to Tanger's reasonably solid second-quarter report .
To be fair, Tanger did reduce its forward guidance to call for full-year diluted net income per share of $0.70 to $0.75, down from $1.04 to $1.09 previously, and for funds from operations per share -- which essentailly represents Tanger's cash flow from operations -- in the range of $2.04 to $2.09, down from $2.40 to $2.45. But the company also explained that those changes were primarily the result of a new $300 million public bond offering during the quarter, which Tanger used to restructure some of its debt on more attractive terms. Adjusted for the effects of that offering, Tanger's financial guidance would have remained the same.
In the meantime, Tanger has managed to increase base rents an average of 10.1% year over year on lease renewals through the first half of 2017, simultaneously maintained a healthy portfolio occupancy rate of 96.1%, and increased same-center net operating income 2.2%, excluding centers undergoing major remerchandising projects, marking the latter metric's 55th consecutive quarter of growth. CEO Steven Tanger also pointed out that despite the market's concerns over the current challenging state of the retail industry, the outlet channel is particularly resilient and typically accounts for a "disproportionately small number" of stores targeted for closure by struggling retailers.
So with Tanger stock under pressure right now, and given its healthy dividend yielding 5.7% annually at today's prices, I think it's a great portfolio candidate for retirees today.
In case you already own Ford...
Rich Smith(General Motors): Last week I made a pretty obvious call, arguing that bargain-priced Ford (NYSE: F) is one stock every retiree should consider buying . Today I'm going to make an equally obvious call -- the other side of the coin, pretty much -- and say that Ford rival General Motors (NYSE: GM) is another top stock for retirees to consider.
You may wonder whether buying General Motors stock is a good idea, of course. After all, last month GM's total car and truck sales were down 15.4% -- twice as bad as the sales decline that Ford suffered . Last quarter , GM's sales were down 1%, and its profit plunged 42% in comparison with the year-ago quarter.
None of that sounds like good news.
But here's where silver lining comes in. Bad as GM's news was last quarter, it was still better than analysts expected. In fact, despite the sales and profits declines, GM beat analyst estimates by 12% last quarter, just as it's beaten analyst estimates in each of the past four quarters. These same analysts expect GM stock to grow earnings at a robust 13% pace. What might help GM to rebound? Well, the cyclical nature of the automotive industry, for one thing. If sales are currently cycling down, that just means that at some point, they'll be due to cycle right back up again. In addition, GM has some innovative products in its pocket to help drive earnings growth -- the new GM Bolt electric car, for example, which looks likely to meet or beat Tesla's new Model 3 in range, and at a comparable price.
While GM's earnings will almost certainly be down this year, Wall Street is predicting that products such as the Bolt will help GM's profits to rebound as early as 2018, and if those predictions come to pass, then GM stock at 5.4 times trailing earnings could be a real bargain.
Patient investors -- those willing to ride out the tide of negative sentiment surrounding GM stock and simply cash their 4.4% dividend checks while awaiting the return of earnings growth -- should be amply rewarded.
A big dividend from big drug sales
Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. This big biotech has steadily raised its quarterly payout from $0.40 per share to $0.64 per share since making its stock market debut in 2013.
The healthcare giant that AbbVie spun off from, Abbott , is a dividend-paying legend, with 45 consecutive annual raises under its belt, and the maker of Humira looks well positioned to follow in its parent's footsteps for the foreseeable future. The company used just 44% of profits generated over the past year to make the last four payments, and those profits are on the rise thanks to rising sales of two big drugs.
AbbVie's flagship Humira has been the world's top-selling drug for years, and global sales of the anti-inflammatory are still growing by double digits despite its age. The company thinks its stack of patents can fend off the competition in the U.S. through 2022, giving the rookies in its lineup more time to develop.
Those rookies include Imbruvica, which AbbVie markets in partnership with Johnson & Johnson . AbbVie's share of this blood cancer drug's sales in the first half of the year jumped 43.6% over the same period last year, to about $1.2 billion.
AbbVie also sports one of the best drug pipelines in the industry. Three big standouts -- upadacitinib, elagolix, and Rova-T -- could become multibillion-dollar blockbusters if clinical trial data expected in the quarters ahead continues to impress.
10 stocks we like better than General Motors
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and General Motors wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Cory Renauer has no position in any of the stocks mentioned. Rich Smith has no position in any of the stocks mentioned. Steve Symington has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Ford. The Motley Fool recommends Tanger Factory Outlet Centers. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The healthcare giant that AbbVie spun off from, Abbott , is a dividend-paying legend, with 45 consecutive annual raises under its belt, and the maker of Humira looks well positioned to follow in its parent's footsteps for the foreseeable future. Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) . A big dividend from big drug sales Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. | Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) . A big dividend from big drug sales Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. The healthcare giant that AbbVie spun off from, Abbott , is a dividend-paying legend, with 45 consecutive annual raises under its belt, and the maker of Humira looks well positioned to follow in its parent's footsteps for the foreseeable future. | A big dividend from big drug sales Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) . The healthcare giant that AbbVie spun off from, Abbott , is a dividend-paying legend, with 45 consecutive annual raises under its belt, and the maker of Humira looks well positioned to follow in its parent's footsteps for the foreseeable future. | Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) . A big dividend from big drug sales Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. The healthcare giant that AbbVie spun off from, Abbott , is a dividend-paying legend, with 45 consecutive annual raises under its belt, and the maker of Humira looks well positioned to follow in its parent's footsteps for the foreseeable future. |
26029.0 | 2017-08-21 00:00:00 UTC | iShares Russell 1000 Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-outflow-2017-08-21 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $48.2 million dollar outflow -- that's a 0.1% decrease week over week (from 295,450,000 to 295,050,000). Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average:
Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $123.32 as the 52 week high point - that compares with a last trade of $120.14. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $123.32 as the 52 week high point - that compares with a last trade of $120.14. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $123.32 as the 52 week high point - that compares with a last trade of $120.14. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $48.2 million dollar outflow -- that's a 0.1% decrease week over week (from 295,450,000 to 295,050,000). For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $123.32 as the 52 week high point - that compares with a last trade of $120.14. | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $123.32 as the 52 week high point - that compares with a last trade of $120.14. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26030.0 | 2017-08-21 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Pfizer Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-pfizer-inc-2017-08-21 | nan | nan | There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer.
But, as the statements read on mutual fund, past performance is no guarantee of future results. Which stock is the better pick for long-term investors now? Here's how AbbVie and Pfizer compare.
The case for AbbVie
Investors have three major reasons to like AbbVie. One is the big biotech's dividend. AbbVie's dividend yield currently stands at 3.61%. What's even better, the company has increased its dividend by 60% since being spun off by Abbott Labs in 2013. Future dividend hikes seem likely, considering that AbbVie uses less than 60% of earnings to fund its dividend program.
Another big plus for AbbVie is its growth potential. Wall Street analysts project the company will be able to grow earnings by nearly 14% annually over the next few years. That estimate seems realistic. AbbVie's top-selling drug, Humira, continues to enjoy solid sales momentum. The company has a rising star in cancer drug Imbruvica. AbbVie also recently won Food and Drug Administration approval for Mavyret. The drug, which treats all genotypes of hepatitis C, should be a big winner for the biotech.
AbbVie's pipeline also should help drive growth. Market research firm EvaluatePharma ranked that pipeline third out of all big pharma companies . AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids.
The third big reason to like AbbVie is its valuation. AbbVie stock currently trades at less than 11 times expected earnings. Factoring in the biotech's growth prospects make AbbVie's valuation look even more attractive.
The case for Pfizer
If you like AbbVie's dividend, you'll probably love Pfizer's. The big pharma company's dividend currently yields 3.84%. And although Pfizer's payout ratio is a little high right now, the drugmaker's strong cash flow should mean those nice dividends keep on coming for a long time to come.
Pfizer isn't likely to enjoy the heady growth that AbbVie will in the near term. However, the consensus among Wall Street analysts is that the company will increase its earnings by close to 6% over the next five years. That's nearly twice the rate that Pfizer grew earnings over the past five years, a period in which the stock climbed more than 30%.
There are several reasons to expect good things for Pfizer in the future. The company's product lineup includes strong performers such as cancer drug Ibrance, anticoagulant Eliquis, and autoimmune disease drug Xeljanz. In addition, Pfizer's pipeline has 32 late-stage programs and several more awaiting regulatory approval, including potential big winners like cancer drug Bavencio, chronic pain drug tanezumab, and diabetes drug ertugliflozin.
Pfizer's valuation doesn't look too shabby, either. The stock currently trades at 12 times expected earnings.
Better buy
Now that you've heard the positives about both companies, you should also know about the negatives. For AbbVie, the primary concern relates to competition for Humira. A biosimilar to the drug has already been approved by the FDA. However, AbbVie thinks that its patent portfolio will enable to it to hold off U.S. competition through 2022.
As for Pfizer, loss of exclusivity for multiple products is hurting the drugmaker and will continue to do so for a while. Pfizer is also encountering headwinds for its top-selling product, pneumococcal vaccine Prevnar 13.
With all the pros and cons weighed against each other, which stock is the better pick for long-term investors? I own both of them, but my view is that AbbVie is the winner. It's hard to beat AbbVie's triple whammy of great dividend, solid growth prospects, and attractive valuation. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's hard to beat AbbVie's triple whammy of great dividend, solid growth prospects, and attractive valuation. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Pfizer. | AbbVie's top-selling drug, Humira, continues to enjoy solid sales momentum. AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids. It's hard to beat AbbVie's triple whammy of great dividend, solid growth prospects, and attractive valuation. | Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer. The case for Pfizer If you like AbbVie's dividend, you'll probably love Pfizer's. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy. | Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy. There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. |
26031.0 | 2017-08-21 00:00:00 UTC | Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive | ABBV | https://www.nasdaq.com/articles/vertex-pharmaceuticals-incorporated-vrtx-stock-is-too-expensive-2017-08-21 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in triple-digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved. That's a big deal in the biotech world because treatments for the disease are few and far between, so Vertex is filling a much-needed gap in an underserved market. VRTX stock now boasts a price-to-earnings ratio of 209 and trades at 49 times its forecast earnings, making it a very scary buy for a value investor like myself.
VRTX) Stock Is Too Expensive" src="http://investorplace.com/wp-content/uploads/2017/05/vrtxmsn-300x165.jpg">
Source: Shutterstock
At $149.38 per share, VRTX stock is expensive, but the question is whether or not the stock is too expensive. Have we already missed the boat or does the pharmaceutical company really have the growth potential that investors believe it does.
New Treatments From Vertex
VRTX has had a huge amount of success with its cystic fibrosis drugs, and promising clinical trials suggest the firm will continue to grow its treatment options in the future.
Orkambi, one of the firm's CF drugs, has been credited with putting VRTX on the path to profitability , and rightly so as the drug is one of the only options that many cystic fibrosis patients have. However, new clinical trials show that a new drug, tezacaftor, together with Vertex's Kalydeco could be a successful combination therapy and the duo could hit the market as early as next year.
Analysts also say that the combined therapy treatment would significantly expand Vertex's patient population. But the real momentum behind VRTX stock has been news that a triple combo therapy of tezacaftor, Kalydeco and another corrector , which has been successful thus far in clinical trials, will allow the drugmaker to treat 90% of CF patients.
The 7 Best Stocks to Survive a Chaotic Next Few Months
Compare that to the 50% that the firm currently addresses and you have a huge amount of growth potential in front of you.
Profitability for VRTX Stock
One of the worries for VRTX stock is that the company has yet to turn a profit. Yes, the firm has been able to grow its sales by 65% from 2015 to 2016, but the fact remains that VRTX hasn't made any money yet.
Now, the increasing number of patients that Vertex will be able to treat with its double and triple combo therapies will add a significant amount to the firm's bottom line. Plus, the new therapies are expected to generate reoccurring revenue, as patients will likely continue them for longer than Orkambi, which many patients stopped using when they developed respiratory issues .
As fellow InvestorPlace contributor Dana Blankenhorn pointed out , adding just 600 new patients translates into roughly $136 million in additional revenue. What VRTX is talking about doing could add more than 30,000 new patients to its roster.
At the moment, Vertex's addressable market is 29,000 and has the potential to increase to 44,000 with the new combo treatment and label expansions. If one of VRTX's triple combo treatments makes it to market, that figure could jump up to 68,000- roughly 90% of all cystic fibrosis patients.
The Problem with VRTX
So, when you look at those numbers, a forward P/E of 49 doesn't look quite as intimidating. However, there are some other factors to consider which make me a little bit dubious.
For one, there's the fact that Vertex is currently treating about half of cystic fibrosis patients without turning a profit. That's a problem because while VRTX is coming up with ground-breaking treatments, those discoveries haven't been translating into gains for shareholders.
A lot of the drugmaker's success will depend on whether or not the firm can raise prices, increase margins and expand its labels for Orkambi and the Kalydeco/tezacaftor combo therapy. That's a big question mark because it means the firm will need to gain approval in Europe, where new treatments are often resisted due to their prices. Then there's the possibility that the FDA will turn either drug down for certain patient populations.
There's also the ongoing political battle over the price of new drugs.
The bottom line is that VRTX's valuation is based on a lot of what-if's, and in the biotech space, those what-if's are pretty unpredictable. New drugs fail all the time for a multitude of reasons, and VRTX stock would feel the burn for even the smallest missteps now that these sky-high aspirations are priced in.
Competition
Then there's the potential competition in the CF space. Even I have to admit that VRTX is head and shoulders above its competitors when it comes to getting a triple combo therapy approved, but that doesn't mean they're not out there. AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX.
Why Apple Inc.'s (AAPL) iTunes Plan Is Scaring Movie Theater Chains
Granted, those drugs are still very early on in the approval process, with trials on a combo treatment expected to begin at the end of the year , but that doesn't mean that they won't catch up, especially if Vertex runs into some roadblocks in the approval process.
The Bottom Line
VRTX stock has a lot of potential, there's no doubt about that. But at the moment, it's too expensive. Investors are excited about big things to come for the biotech firm, but the uncertain nature of the biotech space makes me cautious about banking on so many what-if's. I'd wait for the inevitable bad news pull-back before taking a position.
As of this writing, Laura Hoy did not hold a position in any of the aforementioned securities.
More From InvestorPlace
10 Cash-Rich Stocks to Buy (And What They Should Buy)
10 Investments You Should Hold in an IRA
Go Long Chipotle Mexican Grill, Inc. (CMG) Stock, But Leave Room for Error
The post Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. However, new clinical trials show that a new drug, tezacaftor, together with Vertex's Kalydeco could be a successful combination therapy and the duo could hit the market as early as next year. But the real momentum behind VRTX stock has been news that a triple combo therapy of tezacaftor, Kalydeco and another corrector , which has been successful thus far in clinical trials, will allow the drugmaker to treat 90% of CF patients. | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in triple-digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved. New Treatments From Vertex VRTX has had a huge amount of success with its cystic fibrosis drugs, and promising clinical trials suggest the firm will continue to grow its treatment options in the future. | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in triple-digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved. VRTX) Stock Is Too Expensive" src="http://investorplace.com/wp-content/uploads/2017/05/vrtxmsn-300x165.jpg"> Source: Shutterstock At $149.38 per share, VRTX stock is expensive, but the question is whether or not the stock is too expensive. | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in triple-digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved. Now, the increasing number of patients that Vertex will be able to treat with its double and triple combo therapies will add a significant amount to the firm's bottom line. |
26032.0 | 2017-08-20 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2017-08-20 | nan | nan | There's nothing more exciting on planet Earth than dividend stocks .
OK, I know that's laying it on thick. There are plenty of more exciting things. Still, though, dividend stocks are pretty exciting when you consider the long-term wealth they can generate. And there are more solid dividend stocks than you can shake a stick at (if you enjoy shaking sticks).
AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. Here's why these are three dividend stocks that I'd buy right now.
AT&T
AT&T is a telecommunications giant with a gigantic dividend. Its yield currently stands north of 5%. And AT&T's dividend continues to grow. The company has hiked its dividend for the past 33 consecutive years.
I'm not worried in the least that AT&T's dividend streak will end anytime soon. The company's cash flow looks to be rock-solid. It's easy to see why. AT&T generates most of its revenue by providing wireless and internet services. Those are two things that have become necessities for most Americans.
Granted, AT&T faces some challenges. There's more competition in the telecom industry now than in the past. A few of these companies have cut or even eliminated their dividend programs. However, I don't think AT&T is in any danger of going down those paths. Its dividend appears to be pretty safe .
The company also should be able to grow in the future. AT&T awaits regulatory approval to acquire Time Warner . The deal would give AT&T a huge video content library to use in offering new products to customers. In addition, AT&T is building high-speed 5G networks that will be used in many applications, including navigation for self-driving cars.
Intel
Intel is another giant in its field that offers an attractive dividend. It's the biggest chipmaker in the world -- and has held that spot for a long time. Intel's dividend currently yields just over 3%. Although the company can't claim the impressive run of dividend increases that AT&T can, Intel is in great position for future dividend hikes with a low payout ratio of 40%.
There are a couple of key challenges for Intel, however. The PC market has been somewhat sluggish, which dampened demand for the company's chips. Intel also faces intense competition. Will these factors impact the company's ability to keep the dividends flowing? I don't think so.
Despite challenges, Intel also has some tremendous opportunities. The biggest of these lie in non-volatile memory and autonomous vehicles. Intel thinks these two areas present the potential for $200 billion in revenue .
While A&T is working hard to roll out 5G networks, Intel has already built the first 5G-ready platform for the auto industry. This platform powers all of the sophisticated artificial intelligence needed for self-driving cars to operate.
AbbVie
I like AbbVie so much that I already own the stock. This big biotech claims the top-selling drug in the world with Humira. It also boasts one of the best dividends in the healthcare industry, with a current yield of 3.64%.
If you like AT&T's track record for dividend increases, you'll probably love AbbVie. The company has increased its dividend for 45 years in a row, counting the period that it was part of Abbott Labs . Since being spun off from Abbott in 2013, AbbVie has increased its dividend by 60%.
The biggest question mark for AbbVie right now is over competition for Humira. Amgen won Food and Drug Administration approval for a biosimilar to the autoimmune disease drug last year. So far, however, that biosimilar hasn't reached the market. AbbVie is trying to use its patent portfolio for Humira to keep Amgen from selling its product. The court trial between the two biotechs begins in November 2019. AbbVie thinks it will be able to prevent U.S. biosimilar competition for Humira through 2022.
In the meantime, AbbVie has a big winner with its cancer drug Imbruvica. The biotech also has a stellar drug pipeline with multiple candidates that have the potential to generate sales in the billions of dollars.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie. The Motley Fool recommends Intel and Time Warner. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie. AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. AbbVie I like AbbVie so much that I already own the stock. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. AbbVie I like AbbVie so much that I already own the stock. | AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. AbbVie I like AbbVie so much that I already own the stock. If you like AT&T's track record for dividend increases, you'll probably love AbbVie. | AbbVie I like AbbVie so much that I already own the stock. AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. If you like AT&T's track record for dividend increases, you'll probably love AbbVie. |
26033.0 | 2017-08-18 00:00:00 UTC | Rikoon Group, LLC Buys SPDR S&P Dividend, CVS Health Corp, Accenture PLC, Sells Smith & ... | ABBV | https://www.nasdaq.com/articles/rikoon-group-llc-buys-spdr-sp-dividend-cvs-health-corp-accenture-plc-sells-smith-2017-08 | nan | nan | Rikoon Group, LLC
New Purchases: SDY , ACN , ORAN ,
Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL,
Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY,
Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP,
For the details of Rikoon Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rikoon+Group%2C+LLC
These are the top 5 holdings of Rikoon Group, LLC
Johnson & Johnson ( JNJ ) - 95,832 shares, 5.67% of the total portfolio. Shares reduced by 0.29%
Procter & Gamble Co ( PG ) - 127,453 shares, 4.97% of the total portfolio. Shares added by 0.06%
3M Co ( MMM ) - 36,661 shares, 3.42% of the total portfolio.
Walgreens Boots Alliance Inc ( WBA ) - 94,717 shares, 3.32% of the total portfolio.
AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Shares reduced by 0.11%
New Purchase: SPDR S&P Dividend (SDY)
Rikoon Group, LLC initiated holdings in SPDR S&P Dividend. The purchase prices were between $86.77 and $90.78, with an estimated average price of $88.59. The stock is now traded at around $88.29. The impact to the portfolio due to this purchase was 0.37%. The holdings were 9,364 shares as of 2017-06-30.
New Purchase: Accenture PLC (ACN)
Rikoon Group, LLC initiated holdings in Accenture PLC. The purchase prices were between $114.86 and $127.77, with an estimated average price of $121.71. The stock is now traded at around $127.78. The impact to the portfolio due to this purchase was 0.23%. The holdings were 4,217 shares as of 2017-06-30.
New Purchase: Orange SA (ORAN)
Rikoon Group, LLC initiated holdings in Orange SA. The purchase prices were between $15.01 and $17.59, with an estimated average price of $16.24. The stock is now traded at around $16.79. The impact to the portfolio due to this purchase was 0.16%. The holdings were 22,425 shares as of 2017-06-30.
Added: CVS Health Corp (CVS)
Rikoon Group, LLC added to the holdings in CVS Health Corp by 53.15%. The purchase prices were between $75.95 and $82.79, with an estimated average price of $78.9. The stock is now traded at around $77.66. The impact to the portfolio due to this purchase was 0.25%. The holdings were 19,590 shares as of 2017-06-30.
Added: Dollar General Corp (DG)
Rikoon Group, LLC added to the holdings in Dollar General Corp by 131.07%. The purchase prices were between $68.35 and $78.91, with an estimated average price of $71.99. The stock is now traded at around $74.07. The impact to the portfolio due to this purchase was 0.19%. The holdings were 10,338 shares as of 2017-06-30.
Sold Out: Smith & Nephew PLC (SNN)
Rikoon Group, LLC sold out the holdings in Smith & Nephew PLC. The sale prices were between $30.93 and $35.71, with an estimated average price of $33.78.
Sold Out: iShares Russell 1000 Growth (IWF)
Rikoon Group, LLC sold out the holdings in iShares Russell 1000 Growth. The sale prices were between $112.48 and $121.1, with an estimated average price of $117.37.
Sold Out: iShares Russell 1000 Value (IWD)
Rikoon Group, LLC sold out the holdings in iShares Russell 1000 Value. The sale prices were between $112.89 and $117.41, with an estimated average price of $115.06.
Sold Out: Target Corp (TGT)
Rikoon Group, LLC sold out the holdings in Target Corp. The sale prices were between $50.52 and $58.41, with an estimated average price of $54.62.
Sold Out: Barrick Gold Corp (ABX)
Rikoon Group, LLC sold out the holdings in Barrick Gold Corp. The sale prices were between $15.58 and $20.22, with an estimated average price of $17.17.
Sold Out: Canadian Natural Resources Ltd (CNQ)
Rikoon Group, LLC sold out the holdings in Canadian Natural Resources Ltd. The sale prices were between $27.75 and $33.98, with an estimated average price of $30.8.
Reduced: Verizon Communications Inc (VZ)
Rikoon Group, LLC reduced to the holdings in Verizon Communications Inc by 26.82%. The sale prices were between $44.41 and $49.31, with an estimated average price of $46.63. The stock is now traded at around $47.84. The impact to the portfolio due to this sale was -0.12%. Rikoon Group, LLC still held 15,425 shares as of 2017-06-30.
Reduced: SAP SE (SAP)
Rikoon Group, LLC reduced to the holdings in SAP SE by 22.83%. The sale prices were between $96.18 and $108.6, with an estimated average price of $103.03. The stock is now traded at around $104.99. The impact to the portfolio due to this sale was -0.08%. Rikoon Group, LLC still held 5,935 shares as of 2017-06-30.
Reduced: Shire PLC (SHPG)
Rikoon Group, LLC reduced to the holdings in Shire PLC by 24.4%. The sale prices were between $162.35 and $190, with an estimated average price of $174.91. The stock is now traded at around $145.19. The impact to the portfolio due to this sale was -0.06%. Rikoon Group, LLC still held 2,398 shares as of 2017-06-30.
Reduced: Gilead Sciences Inc (GILD)
Rikoon Group, LLC reduced to the holdings in Gilead Sciences Inc by 28.18%. The sale prices were between $64.12 and $71.92, with an estimated average price of $66.5. The stock is now traded at around $72.33. The impact to the portfolio due to this sale was -0.04%. Rikoon Group, LLC still held 3,250 shares as of 2017-06-30.
Reduced: Medtronic PLC (MDT)
Rikoon Group, LLC reduced to the holdings in Medtronic PLC by 25.4%. The sale prices were between $80.01 and $89.3, with an estimated average price of $84.21. The stock is now traded at around $83.70. The impact to the portfolio due to this sale was -0.03%. Rikoon Group, LLC still held 2,423 shares as of 2017-06-30.
Reduced: iShares Russell 2000 Growth (IWO)
Rikoon Group, LLC reduced to the holdings in iShares Russell 2000 Growth by 21.95%. The sale prices were between $157.41 and $170.58, with an estimated average price of $164.5. The stock is now traded at around $163.43. The impact to the portfolio due to this sale was -0.03%. Rikoon Group, LLC still held 1,351 shares as of 2017-06-30.
Warning! GuruFocus has detected 1 Warning Sign with CVS. Click here to check it out.
High Yield Dividend Stocks in Gurus' Portfolio
Top dividend stocks of Warren Buffett
Top dividend stocks of George Soros
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Rikoon Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rikoon+Group%2C+LLC These are the top 5 holdings of Rikoon Group, LLC Johnson & Johnson ( JNJ ) - 95,832 shares, 5.67% of the total portfolio. Walgreens Boots Alliance Inc ( WBA ) - 94,717 shares, 3.32% of the total portfolio. | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Rikoon Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rikoon+Group%2C+LLC These are the top 5 holdings of Rikoon Group, LLC Johnson & Johnson ( JNJ ) - 95,832 shares, 5.67% of the total portfolio. Added: CVS Health Corp (CVS) Rikoon Group, LLC added to the holdings in CVS Health Corp by 53.15%. | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Rikoon Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rikoon+Group%2C+LLC These are the top 5 holdings of Rikoon Group, LLC Johnson & Johnson ( JNJ ) - 95,832 shares, 5.67% of the total portfolio. Shares reduced by 0.11% New Purchase: SPDR S&P Dividend (SDY) Rikoon Group, LLC initiated holdings in SPDR S&P Dividend. | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Rikoon Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rikoon+Group%2C+LLC These are the top 5 holdings of Rikoon Group, LLC Johnson & Johnson ( JNJ ) - 95,832 shares, 5.67% of the total portfolio. Shares added by 0.06% 3M Co ( MMM ) - 36,661 shares, 3.42% of the total portfolio. |
26034.0 | 2017-08-18 00:00:00 UTC | Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada | ABBV | https://www.nasdaq.com/articles/gilead-gild-hcv-drug-vosevi-receives-approval-in-canada-2017-08-18 | nan | nan | Gilead Sciences, Inc . GILD announced that Health Canada has granted a Notice of Compliance for its single-tablet regimen, Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), for the treatment of chronic hepatitis C virus (HCV) infection.
Vosevi has been approved for the treatment of HCV infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1, 2, 3 or 4 previously treated with sofosbuvir-containing regimen without an NS5A inhibitor. The drug is already approved in the U.S.
Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. The HCV portfolio received a huge a boost when Epclusa gained approval in both the U.S. (Jun 2016) and EU (Jul 2016) to become the first and only all-oral, pan-genotypic, STR consisting of Sovaldi and velpatasvir (an NS5A inhibitor), for the treatment of adults with genotype 1-6 chronic HCV infection. The approval of Voseviwill further boost Gilead's strong HCV portfolio.
However, the HCV franchise is under pressure as a result of competition and pricing issues. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Competition as well as pricing pressure intensified further with the launch of Merck's MRK Zepatier.
Gilead's stock has moved up 1.0% in the year so far compared with the industry's gain of 7.3%.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU, which now represent 51% of total prescription volume. Genvoya is now the company's bestselling HIV product with a treatment-naïve patient share of 41%. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting is expected to further boost sales. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which will impact sales.
Zacks Rank
Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really takes off.
S ee Stocks Now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. GILD announced that Health Canada has granted a Notice of Compliance for its single-tablet regimen, Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), for the treatment of chronic hepatitis C virus (HCV) infection. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Vosevi has been approved for the treatment of HCV infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1, 2, 3 or 4 previously treated with sofosbuvir-containing regimen without an NS5A inhibitor. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Vosevi has been approved for the treatment of HCV infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1, 2, 3 or 4 previously treated with sofosbuvir-containing regimen without an NS5A inhibitor. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The approval of Voseviwill further boost Gilead's strong HCV portfolio. |
26035.0 | 2017-08-17 00:00:00 UTC | Tandem Investment Advisors, Inc. Buys FactSet Research Systems Inc, National Retail Properties ... | ABBV | https://www.nasdaq.com/articles/tandem-investment-advisors-inc-buys-factset-research-systems-inc-national-retail | nan | nan | Tandem Investment Advisors, Inc.
New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL,
Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD,
Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL,
Sold Out:QCOM,
For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc.
These are the top 5 holdings of Tandem Investment Advisors, Inc.
Walgreens Boots Alliance Inc ( WBA ) - 149,226 shares, 4.64% of the total portfolio. Shares added by 8.91%
Republic Services Inc ( RSG ) - 179,631 shares, 4.54% of the total portfolio. Shares added by 18.21%
Abbott Laboratories ( ABT ) - 229,576 shares, 4.43% of the total portfolio. Shares added by 1.78%
AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Shares added by 3.35%
Scripps Networks Interactive Inc ( SNI ) - 153,670 shares, 4.17% of the total portfolio. Shares added by 7.97%
New Purchase: FactSet Research Systems Inc (FDS)
Tandem Investment Advisors, Inc. initiated holdings in FactSet Research Systems Inc. The purchase prices were between $157.92 and $171.63, with an estimated average price of $163.5. The stock is now traded at around $163.66. The impact to the portfolio due to this purchase was 3.58%. The holdings were 54,332 shares as of 2017-06-30.
New Purchase: Dollar General Corp (DG)
Tandem Investment Advisors, Inc. initiated holdings in Dollar General Corp. The purchase prices were between $68.35 and $78.91, with an estimated average price of $71.99. The stock is now traded at around $74.50. The impact to the portfolio due to this purchase was 0.72%. The holdings were 25,195 shares as of 2017-06-30.
New Purchase: Verisk Analytics Inc (VRSK)
Tandem Investment Advisors, Inc. initiated holdings in Verisk Analytics Inc. The purchase prices were between $76.75 and $84.06, with an estimated average price of $80.9. The stock is now traded at around $81.65. The impact to the portfolio due to this purchase was 0.2%. The holdings were 5,981 shares as of 2017-06-30.
New Purchase: Johnson & Johnson (JNJ)
Tandem Investment Advisors, Inc. initiated holdings in Johnson & Johnson. The purchase prices were between $121.37 and $136.43, with an estimated average price of $127.47. The stock is now traded at around $134.17. The impact to the portfolio due to this purchase was 0.13%. The holdings were 2,445 shares as of 2017-06-30.
New Purchase: The Kraft Heinz Co (KHC)
Tandem Investment Advisors, Inc. initiated holdings in The Kraft Heinz Co. The purchase prices were between $85.76 and $93.77, with an estimated average price of $90.76. The stock is now traded at around $86.50. The impact to the portfolio due to this purchase was 0.09%. The holdings were 2,521 shares as of 2017-06-30.
New Purchase: Apple Inc (AAPL)
Tandem Investment Advisors, Inc. initiated holdings in Apple Inc. The purchase prices were between $140.68 and $156.1, with an estimated average price of $147.76. The stock is now traded at around $160.95. The impact to the portfolio due to this purchase was 0.08%. The holdings were 1,484 shares as of 2017-06-30.
Added: National Retail Properties Inc (NNN)
Tandem Investment Advisors, Inc. added to the holdings in National Retail Properties Inc by 108.87%. The purchase prices were between $36.72 and $45.53, with an estimated average price of $40.5. The stock is now traded at around $41.11. The impact to the portfolio due to this purchase was 1.19%. The holdings were 147,015 shares as of 2017-06-30.
Added: Signature Bank (SBNY)
Tandem Investment Advisors, Inc. added to the holdings in Signature Bank by 32.52%. The purchase prices were between $136.06 and $152.96, with an estimated average price of $141.86. The stock is now traded at around $130.43. The impact to the portfolio due to this purchase was 0.14%. The holdings were 10,326 shares as of 2017-06-30.
Added: Dollar Tree Inc (DLTR)
Tandem Investment Advisors, Inc. added to the holdings in Dollar Tree Inc by 73.77%. The purchase prices were between $66.6 and $83.13, with an estimated average price of $77.33. The stock is now traded at around $74.44. The impact to the portfolio due to this purchase was 0.06%. The holdings were 4,916 shares as of 2017-06-30.
Added: Fiserv Inc (FISV)
Tandem Investment Advisors, Inc. added to the holdings in Fiserv Inc by 23.19%. The purchase prices were between $115.19 and $125.71, with an estimated average price of $120.86. The stock is now traded at around $124.83. The impact to the portfolio due to this purchase was 0.02%. The holdings were 2,247 shares as of 2017-06-30.
Sold Out: Qualcomm Inc (QCOM)
Tandem Investment Advisors, Inc. sold out the holdings in Qualcomm Inc. The sale prices were between $52.5 and $59.28, with an estimated average price of $55.9.
Warning! GuruFocus has detected 3 Warning Signs with NNN. Click here to check it out.
NNN 15-Year Financial Data
The intrinsic value of NNN
Peter Lynch Chart of NNN
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. These are the top 5 holdings of Tandem Investment Advisors, Inc. Walgreens Boots Alliance Inc ( WBA ) - 149,226 shares, 4.64% of the total portfolio. | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. Shares added by 7.97% New Purchase: FactSet Research Systems Inc (FDS) Tandem Investment Advisors, Inc. initiated holdings in FactSet Research Systems Inc. | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. Shares added by 7.97% New Purchase: FactSet Research Systems Inc (FDS) Tandem Investment Advisors, Inc. initiated holdings in FactSet Research Systems Inc. | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. New Purchase: Apple Inc (AAPL) Tandem Investment Advisors, Inc. initiated holdings in Apple Inc. |
26036.0 | 2017-08-16 00:00:00 UTC | 3 Dividend Healthcare Stocks | ABBV | https://www.nasdaq.com/articles/3-dividend-healthcare-stocks-2017-08-16 | nan | nan | The rapid aging of the world's population should ensure that demand for healthcare products and services remains on the rise for decades to come. But how can income investors take advantage of the trend? We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , and ResMed (NYSE: RMD) . Here's why.
A proven winner
George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 due to the patent headwinds surrounding the megablockbuster anti-inflammatory medicine Humira, AbbVie has proven to be an outstanding dividend and growth stock. Since 2013, for example, AbbVie has produced industry-leading levels of revenue growth and has bumped up its dividend by a handsome 60% over the past four years. The net result is that AbbVie's shares have generated total shareholder returns in excess of 111% since inception.
This top healthcare dividend stock, though, does have its fair share of risk. As Humira still makes up over 60% of the company's annual revenue, and the company has leveraged its balance sheet to unsightly levels in order to acquire additional clinical assets to specifically address this issue, the drugmaker is undoubtedly in a delicate position at the moment.
Long story short, AbbVie needs most of its newly acquired cancer medicines like Imbruvica, Venclexta, and Rova-T, and its emerging anti-inflammatory product candidates such as upadacitinib, to live up to their megablockbuster potential. Otherwise, Humira's eventual decline will be extremely tough to overcome from a value creation standpoint.
The good news is that AbbVie's management does have an outstanding track record in bringing novel medicines to market in a timely fashion. That's not to say that clinical setbacks won't occur along the way, but the company has so far been one of the best at vetting its early-stage pipeline to avoid costly late-stage pitfalls.
In all, AbbVie's juicy dividend of 3.63% is arguably worth considering because of management's aggressive pursuit of new sources of revenue and the company's reasonable trailing-12-month payout ratio of only 59.5%.
This healthcare stock is in the driver's seat of a numbers game it can win
Sean Williams (Medtronic): When I think of a dividend healthcare stock that investors could buy and hold over the long term with minimal worries, medical device giant Medtronic pops into my head.
In recent years, Medtronic's growth rate has slowed amid stiff competition and uncertainty regarding the future of healthcare in the U.S. and spending in Europe. Debt issues in the EU have been a drag on the healthcare industry, while the Affordable Care Act's murky future with Republicans in charge of Congress in the U.S. may delay optional surgical procedures and impede device makers' pricing power.
However, Medtronic is in the driver's seat of a numbers game that it should win. Within the U.S., and in practically every other country around the globe, life expectancies are on the rise. Simply put, it means we're living longer, and the number of elderly folks on this planet is rising. This is a trend that's expected to continue as access to medical care and prescription medicines improve. Medtronic, which specializes in improving the quality of life of its patients with its devices, would be expected to play a key role in assisting these elderly folks. With the U.S. Census Bureau calling for an explosion in the elderly population from 48 million in 2015 to 88 million by 2050, Medtronic is primed to win the numbers game.
Innovation is another separator for Medtronic. For example, last year the Food and Drug Administration approved the very first artificial pancreas device developed by MiniMed, a subsidiary of Medtronic. The MiniMed 670G could revolutionize treatment for the roughly 1.25 million people in the U.S. with type 1 diabetes. The device measures a patient's blood glucose levels every five minutes and administers insulin on an as-needed basis. Medtronic is often on the leading edge of medical device innovations.
As the icing on the cake, and a testament to its profitability, the company has increased its annual dividend in each of the past 40 years. What's more, CEO Omar Ishrak recently reaffirmed the company's stance of returning at least 50% of free cash flow to shareholders via dividends and share buybacks. Its 2.2% yield is modestly above that of the S&P 500 , and all the more reason for you to consider adding this dividend healthcare stock to your portfolio.
A sleep-well-at-night stock
Brian Feroldi (ResMed): There's roughly 1-in-5 chance that you suffer from some type of sleep-disordered breathing, even if you don't know it. That's a big problem as sleep-related breathing disorders can greatly increase a person's risk of developing heart disease, diabetes, and many other adverse conditions.
Medical device maker ResMed is on a mission to help fix this problem. The company is a leading provider continuous positive airway pressure (CPAP) machines that work all night to keep a patient's airway open.
Millions of patients around the world now depend on ResMed each day to help them get the sleep that they need each day. That's great news for investors because ResMed sells tubes and mask that are changed out frequently, which provides the company with a dependable stream of income. In turn, ResMed has been able to invest that recurring revenue into research and development so that it can continuously churn out new and better products that help to attract new customers. Recent innovations include a memory-foam mask called the AirTouch UltraSoft and the AirMini, which is the world's smallest CPAP machine.
Looking ahead, ResMed looks poised to continue delivering revenue, profit, and dividend growth for years to come as more patients worldwide are properly diagnosed with diseases like COPD and sleep apnea. With a current yield of 1.9% that only consumes 55% of net income and double-digit profit growth potential, ResMed is a rock-solid company that should appeal to income- and growth-focused investors alike.
10 stocks we like better than Medtronic
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Medtronic wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Brian Feroldi has no position in any stocks mentioned. George Budwell has no position in any stocks mentioned. Sean Williams has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool recommends ResMed. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Long story short, AbbVie needs most of its newly acquired cancer medicines like Imbruvica, Venclexta, and Rova-T, and its emerging anti-inflammatory product candidates such as upadacitinib, to live up to their megablockbuster potential. We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , and ResMed (NYSE: RMD) . A proven winner George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 due to the patent headwinds surrounding the megablockbuster anti-inflammatory medicine Humira, AbbVie has proven to be an outstanding dividend and growth stock. | A proven winner George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 due to the patent headwinds surrounding the megablockbuster anti-inflammatory medicine Humira, AbbVie has proven to be an outstanding dividend and growth stock. We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , and ResMed (NYSE: RMD) . Since 2013, for example, AbbVie has produced industry-leading levels of revenue growth and has bumped up its dividend by a handsome 60% over the past four years. | We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , and ResMed (NYSE: RMD) . A proven winner George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 due to the patent headwinds surrounding the megablockbuster anti-inflammatory medicine Humira, AbbVie has proven to be an outstanding dividend and growth stock. Since 2013, for example, AbbVie has produced industry-leading levels of revenue growth and has bumped up its dividend by a handsome 60% over the past four years. | We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , and ResMed (NYSE: RMD) . A proven winner George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 due to the patent headwinds surrounding the megablockbuster anti-inflammatory medicine Humira, AbbVie has proven to be an outstanding dividend and growth stock. Since 2013, for example, AbbVie has produced industry-leading levels of revenue growth and has bumped up its dividend by a handsome 60% over the past four years. |
26037.0 | 2017-08-15 00:00:00 UTC | Stonebridge Capital Advisors LLC Buys Gilead Sciences Inc, Microsoft Corp, SPDR S&P 500, ... | ABBV | https://www.nasdaq.com/articles/stonebridge-capital-advisors-llc-buys-gilead-sciences-inc-microsoft-corp-spdr-sp-500-2017 | nan | nan | Stonebridge Capital Advisors LLC
New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH,
Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX,
Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WWD, MCHP,
Sold Out:UN, GLW, BHGE, BAX, BMS, OXY,
For the details of Stonebridge Capital Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonebridge+Capital+Advisors+LLC
These are the top 5 holdings of Stonebridge Capital Advisors LLC
Apple Inc ( AAPL ) - 125,536 shares, 4.75% of the total portfolio. Shares reduced by 6.28%
JPMorgan Chase & Co ( JPM ) - 114,754 shares, 2.75% of the total portfolio. Shares added by 2.27%
Procter & Gamble Co ( PG ) - 117,056 shares, 2.68% of the total portfolio. Shares added by 1.50%
The Home Depot Inc ( HD ) - 55,072 shares, 2.22% of the total portfolio. Shares added by 0.35%
AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Shares added by 1.24%
New Purchase: SPDR S&P 500 (SPY)
Stonebridge Capital Advisors LLC initiated holdings in SPDR S&P 500. The purchase prices were between $232.51 and $244.66, with an estimated average price of $239.5. The stock is now traded at around $246.50. The impact to the portfolio due to this purchase was 0.1%. The holdings were 1,604 shares as of 2017-06-30.
New Purchase: SPDR S&P Dividend (SDY)
Stonebridge Capital Advisors LLC initiated holdings in SPDR S&P Dividend. The purchase prices were between $86.77 and $90.78, with an estimated average price of $88.59. The stock is now traded at around $89.06. The impact to the portfolio due to this purchase was 0.07%. The holdings were 2,880 shares as of 2017-06-30.
New Purchase: Hormel Foods Corp (HRL)
Stonebridge Capital Advisors LLC initiated holdings in Hormel Foods Corp. The purchase prices were between $33.12 and $35.43, with an estimated average price of $34.46. The stock is now traded at around $34.15. The impact to the portfolio due to this purchase was 0.06%. The holdings were 6,550 shares as of 2017-06-30.
New Purchase: ProShares S&P 500 Dividend Aristocrats (NOBL)
Stonebridge Capital Advisors LLC initiated holdings in ProShares S&P 500 Dividend Aristocrats. The purchase prices were between $55.72 and $58.9, with an estimated average price of $57.16. The stock is now traded at around $53.91. The impact to the portfolio due to this purchase was 0.06%. The holdings were 3,653 shares as of 2017-06-30.
New Purchase: Baker Hughes Inc (BHI)
Stonebridge Capital Advisors LLC initiated holdings in Baker Hughes Inc. The purchase prices were between $53.37 and $61.71, with an estimated average price of $57.6. The stock is now traded at around $57.68. The impact to the portfolio due to this purchase was 0.06%. The holdings were 4,113 shares as of 2017-06-30.
New Purchase: Oracle Corp (ORCL)
Stonebridge Capital Advisors LLC initiated holdings in Oracle Corp. The purchase prices were between $44 and $50.95, with an estimated average price of $45.49. The stock is now traded at around $48.96. The impact to the portfolio due to this purchase was 0.05%. The holdings were 3,995 shares as of 2017-06-30.
Added: Gilead Sciences Inc (GILD)
Stonebridge Capital Advisors LLC added to the holdings in Gilead Sciences Inc by 260.64%. The purchase prices were between $64.12 and $71.92, with an estimated average price of $66.5. The stock is now traded at around $73.03. The impact to the portfolio due to this purchase was 0.99%. The holdings were 73,943 shares as of 2017-06-30.
Added: Microsoft Corp (MSFT)
Stonebridge Capital Advisors LLC added to the holdings in Microsoft Corp by 121.53%. The purchase prices were between $64.95 and $72.52, with an estimated average price of $68.6. The stock is now traded at around $73.25. The impact to the portfolio due to this purchase was 0.6%. The holdings were 60,378 shares as of 2017-06-30.
Added: United Technologies Corp (UTX)
Stonebridge Capital Advisors LLC added to the holdings in United Technologies Corp by 32.20%. The purchase prices were between $111.93 and $122.5, with an estimated average price of $118.85. The stock is now traded at around $116.48. The impact to the portfolio due to this purchase was 0.02%. The holdings were 2,603 shares as of 2017-06-30.
Added: Adamis Pharmaceuticals Corp (ADMP)
Stonebridge Capital Advisors LLC added to the holdings in Adamis Pharmaceuticals Corp by 22.22%. The purchase prices were between $3.5 and $5.75, with an estimated average price of $4.26. The stock is now traded at around $4.73. The impact to the portfolio due to this purchase was 0.01%. The holdings were 27,500 shares as of 2017-06-30.
Added: Colgate-Palmolive Co (CL)
Stonebridge Capital Advisors LLC added to the holdings in Colgate-Palmolive Co by 20.56%. The purchase prices were between $70.76 and $77.23, with an estimated average price of $74.24. The stock is now traded at around $71.73. The impact to the portfolio due to this purchase was 0.01%. The holdings were 4,280 shares as of 2017-06-30.
Sold Out: Unilever NV (UN)
Stonebridge Capital Advisors LLC sold out the holdings in Unilever NV. The sale prices were between $49.57 and $57.7, with an estimated average price of $53.92.
Sold Out: Corning Inc (GLW)
Stonebridge Capital Advisors LLC sold out the holdings in Corning Inc. The sale prices were between $26.32 and $30.5, with an estimated average price of $28.68.
Sold Out: Baker Hughes, a GE Co (BHGE)
Stonebridge Capital Advisors LLC sold out the holdings in Baker Hughes, a GE Co. The sale prices were between $53.37 and $61.71, with an estimated average price of $57.6.
Sold Out: Bemis Co Inc (BMS)
Stonebridge Capital Advisors LLC sold out the holdings in Bemis Co Inc. The sale prices were between $43.75 and $50.19, with an estimated average price of $46.09.
Sold Out: Occidental Petroleum Corp (OXY)
Stonebridge Capital Advisors LLC sold out the holdings in Occidental Petroleum Corp. The sale prices were between $58.02 and $65.06, with an estimated average price of $61.28.
Sold Out: Baxter International Inc (BAX)
Stonebridge Capital Advisors LLC sold out the holdings in Baxter International Inc. The sale prices were between $51.86 and $61.38, with an estimated average price of $56.7.
GILD 15-Year Financial Data
The intrinsic value of GILD
Peter Lynch Chart of GILD
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WWD, MCHP, Sold Out:UN, GLW, BHGE, BAX, BMS, OXY, For the details of Stonebridge Capital Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonebridge+Capital+Advisors+LLC These are the top 5 holdings of Stonebridge Capital Advisors LLC Apple Inc ( AAPL ) - 125,536 shares, 4.75% of the total portfolio. Added: United Technologies Corp (UTX) Stonebridge Capital Advisors LLC added to the holdings in United Technologies Corp by 32.20%. | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WWD, MCHP, Sold Out:UN, GLW, BHGE, BAX, BMS, OXY, For the details of Stonebridge Capital Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonebridge+Capital+Advisors+LLC These are the top 5 holdings of Stonebridge Capital Advisors LLC Apple Inc ( AAPL ) - 125,536 shares, 4.75% of the total portfolio. New Purchase: Hormel Foods Corp (HRL) Stonebridge Capital Advisors LLC initiated holdings in Hormel Foods Corp. | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WWD, MCHP, Sold Out:UN, GLW, BHGE, BAX, BMS, OXY, For the details of Stonebridge Capital Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonebridge+Capital+Advisors+LLC These are the top 5 holdings of Stonebridge Capital Advisors LLC Apple Inc ( AAPL ) - 125,536 shares, 4.75% of the total portfolio. Shares added by 1.24% New Purchase: SPDR S&P 500 (SPY) Stonebridge Capital Advisors LLC initiated holdings in SPDR S&P 500. | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WWD, MCHP, Sold Out:UN, GLW, BHGE, BAX, BMS, OXY, For the details of Stonebridge Capital Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonebridge+Capital+Advisors+LLC These are the top 5 holdings of Stonebridge Capital Advisors LLC Apple Inc ( AAPL ) - 125,536 shares, 4.75% of the total portfolio. Shares added by 1.24% New Purchase: SPDR S&P 500 (SPY) Stonebridge Capital Advisors LLC initiated holdings in SPDR S&P 500. |
26038.0 | 2017-08-14 00:00:00 UTC | Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review | ABBV | https://www.nasdaq.com/articles/gilead-gild-nda-for-hiv-combo-regimen-gets-priority-review-2017-08-14 | nan | nan | Gilead Sciences, Inc . GILD announced that the FDA has granted priority review for the company's New Drug Application (NDA) for an investigational, fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection.
The NDA was filed on Jun 12, 2017. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of Feb 12, 2018.
A marketing application for BIC/FTC/TAF is also under review in the European Union, and was validated by the European Medicines Agency (EMA) in July.
A potential approval is expected toboost Gilead's HIV portfoliofurther.
Gilead is a dominant player in the HIV market with an impressive portfolio for the same.
The newly launched TAF-based products Genvoya, Odefsey and Descovy are performing well with strong adoption in both the U.S. and EU. Genvoya has already become the most-prescribed regimen for both treatment-naïve and switch patients since its launch in Nov 2015. The TAF-based regimens now represent 51% of total Gilead HIV prescription volume following the launch of Genvoya and Odefsey and Descovy in 2016. Genvoya is now the company's bestselling HIV product, surpassing both Truvada and Atripla since fourth-quarter 2016. Genvoya is now the company's bestselling HIV product with a treatment-naïve patient share of 41%.
Gilead expects use of Truvada for pre-exposure prophylaxis (PrEP) to continue boosting sales of HIV franchise going forward, particularly in the U.S. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 136,000 patients using Truvada by the end of the second quarter.
Meanwhile, Gilead's stock has gained only 1.1% in the year so far, against the industry's gain of 6.1%.
The uptake in HIV franchise should help the company combat the persistent decline in HCV franchise due to competitive pressure. The HCV business saw some improvement in the second quarter. The HCV franchise was boosted by the FDA approval of Vosevi. HCV patient starts in the first half were better than expectations but should see a gradual decline in the second half due to increased competition.
Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza. Competition as well as pricing pressure intensified further with the launch of Merck's MRK Zepatier.
Zacks Rank
Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of Feb 12, 2018. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza. Gilead expects use of Truvada for pre-exposure prophylaxis (PrEP) to continue boosting sales of HIV franchise going forward, particularly in the U.S. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 136,000 patients using Truvada by the end of the second quarter. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza. Gilead expects use of Truvada for pre-exposure prophylaxis (PrEP) to continue boosting sales of HIV franchise going forward, particularly in the U.S. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 136,000 patients using Truvada by the end of the second quarter. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The uptake in HIV franchise should help the company combat the persistent decline in HCV franchise due to competitive pressure. |
26039.0 | 2017-08-12 00:00:00 UTC | 3 High-Yield Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-id-buy-right-now-2017-08-12 | nan | nan | You can find a boatload of dividend stocks with super-high yields. I wouldn't touch many of those stocks with a 10-foot pole, though. Those high yields reflect beaten-down stocks that aren't likely to come back anytime soon in a lot of cases.
However, there are several high-yield dividend stocks that I'd buy right now with no major qualms. Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list.
AT&T
AT&T currently claims a tremendous dividend yield of 5.11% -- the highest of the three stocks. The telecommunications giant uses nearly 92% of earnings to fund the dividend program. That's a pretty high level, but I'm not too concerned about the dividend being in any jeopardy for several reasons.
First, AT&T's cash flow is solid. Over the last 12 months, the company generated free cash flow of $15.8 billion. Second, the company's commitment to paying out dividends is exemplary. AT&T has increased its dividend for 32 consecutive years, landing it a spot among the elite group of stocks known as Dividend Aristocrats .
Perhaps the most important reason I like AT&T, though, is that the company could soon acquire Time Warner (NYSE: TWX) if regulators approve the deal. While there are some risks with the massive acquisition, scooping up Time Warner would instantly make AT&T a major owner of content with the HBO, TNT, TBS, and CNN cable networks and Warner Bros. studio. If the deal isn't blocked, it could position AT&T very well for future growth.
Cisco Systems
Cisco Systems' dividend yields 3.66%. While that's lower than AT&T, it's still quite attractive. The technology company also appears to be in great shape to boost its dividend in the future: Cisco's payout ratio is only 54%. The company has also hiked its dividend every year since 2011 when it first initiated its dividend program.
It's true that the Cisco of today doesn't generate the dazzling growth the company did in the past. Its core networking-hardware business has a lot more competition than it used to. In particular, Cisco faces a threat from software-defined networking , which relies on generic "white box" routers and switches using open-source software.
However, Cisco is developing its own software-defined networking solutions. The company is also rapidly diversifying into software services, especially in cybersecurity. With billions of devices likely to be connected as the Internet of Things becomes more of a reality, Cisco should be able to both survive and thrive in the years to come.
AbbVie
AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. The big biotech shouldn't have any problems keeping the dividends flowing well into the future. AbbVie uses less than 60% of earnings to cover its dividends. Like AT&T, the company is also a Dividend Aristocrat, with a 44-year streak of consecutive dividend increases (including the period in which AbbVie was part of parent Abbott Labs ).
Earnings growth shouldn't be a problem for AbbVie, either. Revenue from its top-selling product, autoimmune disease drug Humira, continues to climb steadily. Sales for cancer drug Imbruvica are soaring. AbbVie also boasts one of the top drug pipelines in the biopharmaceutical industry .
The biggest knock against AbbVie is that competition will hurt sales of Humira sooner or later. However, AbbVie thinks it can fend off rivals in the U.S. through 2022 by aggressively defending its patents for the drug. By then, several of the company's promising pipeline candidates should be generating plenty of money to help offset potential falling sales for Humira.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of AbbVie. The Motley Fool recommends Cisco Systems and Time Warner. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list. AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. AbbVie uses less than 60% of earnings to cover its dividends. | Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list. AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. AbbVie uses less than 60% of earnings to cover its dividends. | AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. Like AT&T, the company is also a Dividend Aristocrat, with a 44-year streak of consecutive dividend increases (including the period in which AbbVie was part of parent Abbott Labs ). Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list. | Earnings growth shouldn't be a problem for AbbVie, either. Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list. AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. |
26040.0 | 2017-08-10 00:00:00 UTC | AbbVie a Top 25 Dividend Giant With 3.56% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-top-25-dividend-giant-356-yield-abbv-2017-08-10 | nan | nan | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points.
The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/12/2017. Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
25 Dividend Giants Widely Held By ETFs »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points. Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points. The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/12/2017. | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/12/2017. The report noted a strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points. | The report noted a strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points. The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/12/2017. AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. |
26041.0 | 2017-08-10 00:00:00 UTC | 3 Value Stocks for Wise Investors | ABBV | https://www.nasdaq.com/articles/3-value-stocks-wise-investors-2017-08-10 | nan | nan | The S&P 500 's bull run continues to rage on, making it harder and harder for value investors to find good stocks to buy. Thankfully, there are always bargains to be found if you are willing to turn over enough rocks.
So which discounted stocks do we think are worthy of consideration today? We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) .
A healthy snack maker ready to pop
Rich Duprey(Amplify Snack Brands): It's been two years since Amplify Snack Brands went public, and after hitting an all-time high a year ago, its stock has lost more than 40% of its value. But the maker of SkinnyPop popcorn and Oatmega grass-fed whey bars could be ready to pop again.
The market researchers at Technavio say the global savory snacks market is expected to hit almost $176 billion by 2021, a 5% compounded annual growth rate, with 83% of consumers in 2016 (compared to 76% two years prior) saying they snack daily, feeding into the concept of snacking as a trend. And analysts at IRI note that 60% of consumers want additional health benefits beyond the food's inherent nutrition, an 8% increase over last year.
Amplify's own market research further highlights how consumers are moving in its direction, with 55% of millennials reportedly eating healthier snacks at least three times a week and 89% eating them at least once a week. They're described as "the drivers behind the better-for-you snacking trend, defining both how we snack as a population as well as our expectations of the category."
Retailing isn't dead
Demitri Kalogeropoulos (Target): Few major retailers have been punished as severely as Target in 2017. The stock is down over 20% so far this year as investors fear its entire business -- from home goods to apparel to groceries -- is exposed to disruption from e-commerce specialists.
Sure, its operating trends haven't impressed lately. Target's customer traffic tumbled in two of the last three fiscal years, after all. And despite major investments in the digital sales channel, its overall expansion pace slipped into negative territory in 2016.
Target's turnaround plan involves pairing increased price investments with a renewed focus on the exclusive brands that have helped distinguish the retailer from its competition in the decades since its founding in the late 1960s. The profit slump that this strategy promises has spooked investors, but the early growth results are encouraging so far. Target recently announced improving traffic trends ahead of its second-quarter earnings release slated for mid-August.
Even if that report includes a surprising sales boost, though, investors should brace for volatility in the business over the coming quarters, especially around the ultra-competitive holiday shopping season. Yet Target's valuation of just 12 times the past year of earnings (compared to 24 for the broader market) means much of the pessimism is already reflected in the stock. The Dividend Aristocrat's 4.3% yield, meanwhile, provides a market-thumping income that investors can collect while they wait to see if the rebound strategy takes hold.
Growth at a reasonable price
Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's not the case for pharma giant AbbVie. This profit machine can be purchased today for only 11 times next year's earnings estimates. What gives?
The discounted valuation can be traced to the company's huge reliance on a single drug for the bulk of its revenue and profits. Humira is the world's best-selling drug, and it is used to treat a number of autoimmune diseases like arthritis, plaque psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Total Humira sales were more than $16 billion last year. Despite that huge number, Humira's sales are still growing at double-digit rates today.
However, investors are worried that the gravy train could be coming to an end. Last year, Amgen won Food and Drug Administration approval for a biosimilar version of Humira called Amjevita. What's more, Coherus Biosciences has a biosimilar Humira drug candidate that should be in regulators' hands by early 2018. The markets are worried that these drugs will launch and put the hurt on Humira's sales.
In spite of this potential competition, AbbVie's management team doesn't appear to be worried. In fact, it is on record saying that sales and profits will grow by double digits each year until 2020. One reason for this confidence is that the company has dozens of patents in place that should protect Humira from the biosimilar competition for several more years. What's more, biosimilar drugs are expensive to manufacture so they are generally not priced at enormous discounts when they come to market. These factors give AbbVie confidence that Humira will still crank out profits for years to come. Furthermore, it believes that it will launch more than 20 new products of indications over the next few years. That should help to cushion the blow if Humira biosimilar candidates come to market sooner than expected.
Overall, AbbVie looks like a growth company that is trading at a value price. Throw in a 3.6% dividend yield that only consumes 60% of the company's profits and there are plenty of reasons to warm up to this pharma giant.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Brian Feroldi has no position in any stocks mentioned. Demitrios Kalogeropoulos has no position in any stocks mentioned. Rich Duprey has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's not the case for pharma giant AbbVie. In spite of this potential competition, AbbVie's management team doesn't appear to be worried. | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's not the case for pharma giant AbbVie. In spite of this potential competition, AbbVie's management team doesn't appear to be worried. | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's not the case for pharma giant AbbVie. In spite of this potential competition, AbbVie's management team doesn't appear to be worried. | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's not the case for pharma giant AbbVie. In spite of this potential competition, AbbVie's management team doesn't appear to be worried. |
26042.0 | 2017-08-09 00:00:00 UTC | Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-q2-earnings-regeneron-kite-more-fibrogen-ipf-data-2017-08-09 | nan | nan | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates.
Recap of the Week's Most Important Stories
A Look at Earnings Results: Regeneron reported a strong quarter with the company surpassing both earnings and revenue estimates on the back of Eylea sales. The company raised its 2017 outlook for Eylea as well (Read more: Regeneron Beats on Q2 Earnings & Sales, Raises View ). Immuno-oncology focused companies like Juno (Read more: Juno Therapeutics Q2 Loss Widens, Revenues Surpass ) and Kite KITE also reported second quarter results. Kite has a key regulatory event coming up later this year with the FDA expected to respond on the approval status of the company's CAR-T treatment, axicabtagene ciloleucel, by Nov 29, 2017. The investigational treatment has been submitted for review in the EU as well for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) in patients who are ineligible for autologous stem cell transplant.
Regeneron is a Zacks Rank #1 (Strong Buy) stock -- you can see the complete list of today's Zacks #1 Rank stocks here .
Dynavax Hepatitis B Vaccine PDUFA Date Pushed Back by 3 Months: Dynavax, which got a favorable vote from an FDA advisory panel for its investigational hepatitis B vaccine Heplisav-B, is facing a delay in getting the vaccine approved with the FDA asking for detailed information on the company's proposed post-marketing study for the treatment. The advisory panel, which had voted 12 to 1 in favor of the safety data for Heplisav-B, had commented on the design of Dynavax's proposed post-marketing study. Based on this, the company and the FDA agreed that more time is needed to finalize key details of the post-marketing study. As a result, the FDA action date was pushed back by three months to Nov 10, 2017. The company still expects to launch Heplisav-B in the U.S. in early 2018. Dynavax's shares are up a whopping 372.2% year to date, significantly outperforming the industry's 9.7% rally.
AbbVie's New HCV Treatment Gets FDA Nod: AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily hepatitis C virus (HCV) treatment, Mavyret, gained FDA approval for use in HCV patients without cirrhosis and who are new to treatment. With this approval, competition in the HCV market is going to heat up further. According to AbbVie, Mavyret may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. The company said that about 3.4 million Americans are chronically infected with HCV. Mavyret gained EU approval recently.
FibroGen Hits 52-Week High on IPF Drug Data: FibroGen's FGEN shares shot up 48.2% on positive data on the company's investigational idiopathic pulmonary fibrosis (IPF) drug, pamrevlumab, from a mid-stage study as well as two combination safety sub-studies. The proprietary, first-in-class, anti-connective tissue growth factor (CTGF) antibody is being evaluated in fibrotic disease and cancer. The IPF indication represents huge commercial potential - IPF or abnormal scarring of the lungs is a rare and serious lung disease with survival rates comparable to those of some of the deadliest cancers. If approved, pamrevlumab could bring in significant sales for FibroGen. Currently approved IPF drugs include Esbriet and Ofev (Read more: Why Did FibroGen Stock Hit All-Time High Today? ).
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index declined 0.5% over the last five trading sessions. Among major biotech stocks, Celgene CELG and Vertex VRTX recorded minimal gains while Gilead lost 3.2% reflecting the impact of the approval of AbbVie's new HCV drug. Over the last six months, Vertex was up 74.7% (See the last biotech stock roundup here: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote ).
What's Next in the Biotech World?
Watch out for earnings reports from small and mid-cap biotechs as well as the usual regulatory and pipeline updates.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
FibroGen, Inc (FGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates. Among major biotech stocks, Celgene CELG and Vertex VRTX recorded minimal gains while Gilead lost 3.2% reflecting the impact of the approval of AbbVie's new HCV drug. AbbVie's New HCV Treatment Gets FDA Nod: AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily hepatitis C virus (HCV) treatment, Mavyret, gained FDA approval for use in HCV patients without cirrhosis and who are new to treatment. | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report FibroGen, Inc (FGEN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's New HCV Treatment Gets FDA Nod: AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily hepatitis C virus (HCV) treatment, Mavyret, gained FDA approval for use in HCV patients without cirrhosis and who are new to treatment. | AbbVie's New HCV Treatment Gets FDA Nod: AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily hepatitis C virus (HCV) treatment, Mavyret, gained FDA approval for use in HCV patients without cirrhosis and who are new to treatment. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report FibroGen, Inc (FGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates. | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates. AbbVie's New HCV Treatment Gets FDA Nod: AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily hepatitis C virus (HCV) treatment, Mavyret, gained FDA approval for use in HCV patients without cirrhosis and who are new to treatment. According to AbbVie, Mavyret may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. |
26043.0 | 2017-08-08 00:00:00 UTC | Bellwether Investment Group, LLC Buys Salesforce. ... | ABBV | https://www.nasdaq.com/articles/bellwether-investment-group-llc-buys-salesforce-2017-08-08 | nan | nan | Bellwether Investment Group, LLC
New Purchases: HIG ,
Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL,
Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ,
Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, FB, FTAI, GLD,
For the details of Bellwether Investment Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Bellwether+Investment+Group%2C+LLC
These are the top 5 holdings of Bellwether Investment Group, LLC
The Home Depot Inc ( HD ) - 5,921 shares, 4.43% of the total portfolio. Shares added by 9.69%
Microsoft Corp ( MSFT ) - 12,389 shares, 4.17% of the total portfolio. Shares added by 0.22%
AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Shares reduced by 0.31%
Gabelli Dividend & Income Trust of Beneficial Inte ( GDV ) - 34,067 shares, 3.62% of the total portfolio. Shares reduced by 0.29%
UnitedHealth Group Inc ( UNH ) - 3,551 shares, 3.21% of the total portfolio. Shares added by 1.28%
New Purchase: The Hartford Financial Services Group Inc (HIG)
Bellwether Investment Group, LLC initiated holdings in The Hartford Financial Services Group Inc. The purchase prices were between $47.26 and $52.75, with an estimated average price of $49.49. The stock is now traded at around $56.23. The impact to the portfolio due to this purchase was 1.62%. The holdings were 6,308 shares as of 2017-06-30.
Added: Salesforce.com Inc (CRM)
Bellwether Investment Group, LLC added to the holdings in Salesforce.com Inc by 3196.69%. The purchase prices were between $82.31 and $91.39, with an estimated average price of $87.01. The stock is now traded at around $90.69. The impact to the portfolio due to this purchase was 2.04%. The holdings were 4,978 shares as of 2017-06-30.
Added: Boeing Co (BA)
Bellwether Investment Group, LLC added to the holdings in Boeing Co by 1930.19%. The purchase prices were between $175.62 and $202.23, with an estimated average price of $185.84. The stock is now traded at around $239.55. The impact to the portfolio due to this purchase was 0.99%. The holdings were 1,076 shares as of 2017-06-30.
Added: First Trust Enhanced Equity Income Fund (FFA)
Bellwether Investment Group, LLC added to the holdings in First Trust Enhanced Equity Income Fund by 198.04%. The purchase prices were between $14.32 and $15.1, with an estimated average price of $14.7. The stock is now traded at around $15.07. The impact to the portfolio due to this purchase was 0.84%. The holdings were 17,829 shares as of 2017-06-30.
Sold Out: Avnet Inc (AVT)
Bellwether Investment Group, LLC sold out the holdings in Avnet Inc. The sale prices were between $35.96 and $45.76, with an estimated average price of $39.73.
Sold Out: Intel Corp (INTC)
Bellwether Investment Group, LLC sold out the holdings in Intel Corp. The sale prices were between $33.54 and $37.43, with an estimated average price of $35.82.
Sold Out: Kinder Morgan Inc (KMI)
Bellwether Investment Group, LLC sold out the holdings in Kinder Morgan Inc. The sale prices were between $18.42 and $21.75, with an estimated average price of $19.92.
Sold Out: Verizon Communications Inc (VZ)
Bellwether Investment Group, LLC sold out the holdings in Verizon Communications Inc. The sale prices were between $44.41 and $49.31, with an estimated average price of $46.65.
Sold Out: E.I. du Pont de Nemours & Co (DD)
Bellwether Investment Group, LLC sold out the holdings in E.I. du Pont de Nemours & Co. The sale prices were between $76.56 and $83.88, with an estimated average price of $79.87.
Sold Out: Comcast Corp (CMCSA)
Bellwether Investment Group, LLC sold out the holdings in Comcast Corp. The sale prices were between $37.14 and $41.99, with an estimated average price of $39.39.
Warning! GuruFocus has detected 4 Warning Signs with CRM. Click here to check it out.
CRM 15-Year Financial Data
The intrinsic value of CRM
Peter Lynch Chart of CRM
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Bellwether Investment Group, LLC New Purchases: HIG , Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL, Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ, Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, FB, FTAI, GLD, For the details of Bellwether Investment Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Bellwether+Investment+Group%2C+LLC These are the top 5 holdings of Bellwether Investment Group, LLC The Home Depot Inc ( HD ) - 5,921 shares, 4.43% of the total portfolio. Added: First Trust Enhanced Equity Income Fund (FFA) Bellwether Investment Group, LLC added to the holdings in First Trust Enhanced Equity Income Fund by 198.04%. | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Bellwether Investment Group, LLC New Purchases: HIG , Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL, Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ, Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, FB, FTAI, GLD, For the details of Bellwether Investment Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Bellwether+Investment+Group%2C+LLC These are the top 5 holdings of Bellwether Investment Group, LLC The Home Depot Inc ( HD ) - 5,921 shares, 4.43% of the total portfolio. Shares added by 1.28% New Purchase: The Hartford Financial Services Group Inc (HIG) Bellwether Investment Group, LLC initiated holdings in The Hartford Financial Services Group Inc. | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Bellwether Investment Group, LLC New Purchases: HIG , Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL, Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ, Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, FB, FTAI, GLD, For the details of Bellwether Investment Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Bellwether+Investment+Group%2C+LLC These are the top 5 holdings of Bellwether Investment Group, LLC The Home Depot Inc ( HD ) - 5,921 shares, 4.43% of the total portfolio. Shares added by 1.28% New Purchase: The Hartford Financial Services Group Inc (HIG) Bellwether Investment Group, LLC initiated holdings in The Hartford Financial Services Group Inc. | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Added: Salesforce.com Inc (CRM) Bellwether Investment Group, LLC added to the holdings in Salesforce.com Inc by 3196.69%. du Pont de Nemours & Co (DD) Bellwether Investment Group, LLC sold out the holdings in E.I. |
26044.0 | 2017-08-08 00:00:00 UTC | Here's Why Coherus Biosciences Rose as Much as 22.2% Today | ABBV | https://www.nasdaq.com/articles/heres-why-coherus-biosciences-rose-much-222-today-2017-08-08 | nan | nan | What happened
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to invalidate certain Amgen (NASDAQ: AMGN) patents pertaining to the manufacture of Enbrel. If the United States Patent and Trademark Office rules in favor of the biosimilar company, it could open up a sizable revenue stream.
Coherus Biosciences isn't stopping at Enbrel, though. The company had a busy second quarter and, judging by its guidance, expects to keep busy through the first half of 2018 by taking aim at other high-profile blockbuster biologics on the market. As of 11:05 a.m. EDT, the stock had settled to a 16.3% gain.
So what
Investors will notice that total revenue for the second quarter of 2017 was just $1.4 million, which is a steep drop-off from the year-ago period, which brought in $14.1 million. The difference can be attributed to an agreement with Shire to market a biosimilar to Enbrel that was terminated in the third quarter of 2016. All marketing rights were retained by Coherus Biosciences, and the company realized, all at once, $162 million in deferred revenue that had built up over time.
Things have been slow since. However, the previous agreement with Shire focused on Europe, Brazil, Canada, and other territories, so the new petition announced today is a step toward allowing Coherus Biosciences to market its biosimilar to patients in the United States -- a larger market.
The biosimilars developer also reminded investors of progress in the following programs:
Neulasta biosimilar candidate: Received complete response letter from the FDA regarding its Biologics License Application, announced completion of talks with Amgen over pricing. Coherus Biosciences expects to resubmit the BLA in the U.S. by the end of 2017 and expects a separate positive opinion in Europe during the first half of 2018.
Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. Coherus Biosciences expects to submit a BLA in the first half of 2018.
Now what
Coherus Biosciences expects to be working through regulatory issues for its Enbrel biosimilar for much of 2018 and, in a best-case scenario, its Humira biosimilar would hit the market in 2019. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible. That means investors shouldn't expect progress to happen too quickly.
10 stocks we like better than Coherus BioSciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Coherus BioSciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Maxx Chatsko has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible. If the United States Patent and Trademark Office rules in favor of the biosimilar company, it could open up a sizable revenue stream. | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible. What happened Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to invalidate certain Amgen (NASDAQ: AMGN) patents pertaining to the manufacture of Enbrel. | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible. What happened Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to invalidate certain Amgen (NASDAQ: AMGN) patents pertaining to the manufacture of Enbrel. | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible. Coherus Biosciences isn't stopping at Enbrel, though. |
26045.0 | 2017-08-07 00:00:00 UTC | 3 Value Stocks for Retirement | ABBV | https://www.nasdaq.com/articles/3-value-stocks-retirement-2017-08-07 | nan | nan | When choosing the best stocks for your retirement, it's no time to start playing games. You want to go with the best companies in the business for their respective industries that provide a combination of opportunity and security.
We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IRM) .
It pays to own this telecom giant
Keith Noonan (AT&T): Trading at roughly 13 times forward earnings estimates and backed by a tremendous returned-income profile, AT&T is a standout value investment for retirees.
Stocks that pay substantial dividends create a source of passive income that can provide a valuable safety net in your non-working years, but it's important to look for companies that offer dividend growth and strong business foundations rather than just chasing yield. AT&T checks all of those boxes. The stock yields a whopping 5.1% and the company has delivered annual dividend growth for 32 years running -- a record that exemplifies dedication to rewarding shareholders.
AT&T is also a cash machine, generating $15.8 billion in free cash flow over the trailing-12-month period. Its payout ratios of 76% of free cash flow and 66% of earnings aren't exactly low, but they still leave considerable room for payout growth -- particularly as the company implements cost-saving measures and continues to repurchase its own shares.
On the operational side of things, AT&T is currently the largest wireless carrier in America and, through its DirecTV subsidiary, the largest pay-TV provider. If its planned acquisition of Time Warner goes through, AT&T will also immediately become a leader in content. Between its strength in wireless, its DirecTV satellite television wing, and the pending addition of a leading media company, that makes for a very compelling package -- and one that would put AT&T in good position for a future that's likely to see big growth in mobile content distribution . The company's position in wireless networks also makes it a good pick-and-shovel stock for investing in connectivity-based tech trends like the Internet of Things.
With its low earnings multiple, great dividend, and sturdy business, AT&T is a top stock for retirement portfolios.
Checking off all the boxes
Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value stock. AbbVie checks off all the boxes -- value, growth, and income. Shares of the big biotech trade at less than 11 times expected earnings. By comparison, the S&P 500 (of which AbbVie is a member) trades at 18 times expected earnings. I'd say AbbVie definitely qualifies as a value stock.
What about growth? Wall Street analysts project that AbbVie will grow earnings by an annual average rate of more than 14% over the next few years. The company claims the top-selling drug in the world with Humira -- and sales for Humira continue to climb. AbbVie's current No. 2 drug, Imbruvica, is on track to become one of the top five best-selling cancer drugs. And the biotech boasts one of the best drug pipelines in the biopharmaceutical industry.
Then there's income. AbbVie's dividend currently yields around 3.6%. What's more, the company is in great position to raise its dividend in the future, since AbbVie uses less than 61% of earnings to fund its dividend program. Dividend hikes are a way of life for AbbVie, which has a track record of over four decades of dividend increases including the time before it was spun off from parent Abbott Labs .
A lockbox of value
Rich Duprey(Iron Mountain): There's a lot to recommend Iron Mountain as a great value stock for retirement, even though it sports a price-to-earnings ratio north of 50. It promises consistent growth at a reasonable price considering how overheated the stock market as a whole is.
Iron Mountain is structured as a real estate investment trust, meaning it is required to pay out the vast majority of its profits as dividends to investors. The reason it offers consistency and reliability is because its services are so vital to companies. What started as a simple paper document storage company has evolved into a massive, global data storage center housing 89 million pieces of media, 1 billion medical images, and over 682 million cubic feet of space dedicated to storing hard copies of critical corporate documentation in over 1,400 facilities in 52 countries.
Just as Iron Mountain has evolved as the marketplace for the types of data that needs protection and storage, so, too, it is offering malleability in geographic representation. Two years ago, the data storage REIT saw less than 15% of its revenues derived from emerging markets, but earlier this year it was almost 18%, and it believes that 20% of its revenue by 2020 will have been diversified into these regions.
All of this is achieved by providing investors with a generous dividend yield of almost 6% on its $2.20 payout. Its growth plans include sustainable, compounded annual revenue growth of 5.3%, and adjusted funds from operations growth of 8.2%, leading to annual 4% growth in its dividend.
Certainly, no stock grows in a straight line forever, but Iron Mountain has given investors a reasonable facsimile of one and should provide any retirement portfolio a great long-term value.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Noonan has no position in any stocks mentioned. Keith Speights owns shares of AbbVie. Rich Duprey has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IRM) . Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value stock. AbbVie checks off all the boxes -- value, growth, and income. | We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IRM) . Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value stock. AbbVie checks off all the boxes -- value, growth, and income. | Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value stock. We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IRM) . AbbVie checks off all the boxes -- value, growth, and income. | Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value stock. We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IRM) . AbbVie checks off all the boxes -- value, growth, and income. |
26046.0 | 2017-08-07 00:00:00 UTC | What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? | ABBV | https://www.nasdaq.com/articles/whats-behind-tg-therapeutics-incs-144-rally-july-2017-08-07 | nan | nan | What happened
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence , despite a lack of positive announcements. It doesn't take much to move a clinical-stage biotech stocks by double-digit percentages, and I'd wager investors digesting developments that took place during the previous month played a role in this price bump.
So what
In June, TG Therapeutics announced positive results from a pivotal trial with its lead drug candidate plus Imbruvica for the treatment of high-risk chronic lymphocytic leukemia. Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. None of the patients given Imbruvica plus a placebo experienced a complete remission and just 45% achieved an objective response.
TG Therapeutics also announced impressive results from an early-stage trial testing a three-drug cocktail containing two of its new drug candidates and a well-known chemotherapy among patients with a variety of hard to treat blood cancers. All four patients with relapsed diffuse large B-Cell lymphoma patients showed an objective response to treatment with ublituximab, TGR-1202, and bendamustine, and the triple-threat combo sent two of the patients' disease into complete remission.
Now what
Among a recent deluge of new blood cancer drugs, TG Therapeutics' candidates have largely been overlooked. Similarly high complete response rates across a variety of patients with difficult to treat malignancies in the three-way combination study suggests TG Therapeutics is on to something big.
Based on the phase 3 success reported in June, odds are strong that an FDA application for ublituximab in combination with Imbruvica will earn a green light. Management thinks such an approval could lead to between $200 and $500 million in peak annual sales, which would push the shares well above recent prices.
Racking up approvals for ublituximab in combination with TGR-1202 further ahead could eventually lead to a few billion in annual sales for TG Therapeutics. It's still a long way out, and cancer drug development is anything but certain, but this stock has multibagger written all over it.
10 stocks we like better than TG Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TG Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Cory Renauer owns shares of Johnson & Johnson. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. It doesn't take much to move a clinical-stage biotech stocks by double-digit percentages, and I'd wager investors digesting developments that took place during the previous month played a role in this price bump. So what In June, TG Therapeutics announced positive results from a pivotal trial with its lead drug candidate plus Imbruvica for the treatment of high-risk chronic lymphocytic leukemia. | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. So what In June, TG Therapeutics announced positive results from a pivotal trial with its lead drug candidate plus Imbruvica for the treatment of high-risk chronic lymphocytic leukemia. Now what Among a recent deluge of new blood cancer drugs, TG Therapeutics' candidates have largely been overlooked. | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. TG Therapeutics also announced impressive results from an early-stage trial testing a three-drug cocktail containing two of its new drug candidates and a well-known chemotherapy among patients with a variety of hard to treat blood cancers. All four patients with relapsed diffuse large B-Cell lymphoma patients showed an objective response to treatment with ublituximab, TGR-1202, and bendamustine, and the triple-threat combo sent two of the patients' disease into complete remission. | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. So what In June, TG Therapeutics announced positive results from a pivotal trial with its lead drug candidate plus Imbruvica for the treatment of high-risk chronic lymphocytic leukemia. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TG Therapeutics wasn't one of them! |
26047.0 | 2017-08-06 00:00:00 UTC | Weekly Top Insider Buys Highlight for the Week of August 4 | ABBV | https://www.nasdaq.com/articles/weekly-top-insider-buys-highlight-week-august-4-2017-08-06 | nan | nan | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ).
AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares
Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price of $70.45. The price of the stock has increased by 0.77% since.
AbbVie Inc. is an American international pharmaceutical company that focuses on discovering, developing, and marketing both biopharmaceuticals and small molecule drugs. The company was created in 2013 as a spin-off of Abbott Laboratories. The company has 30,000 employees as of 2016. The company has a market cap of $112.98 billion, and as of Aug. 4 it traded at $70.99.
On Aug. 3 AbbVie Inc. announced that it has received U.S. FDA approval of MAVYRET for the treatment of chronic hepatitis C in all major genotypes in as short as eight weeks. The drug is a new eight-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment. The FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment.
Bristol-Myers Squibb Co. ( BMY ): Director Theodore R. Samuels II bought 6,000 shares
Director Theodore R. Samuels II bought 6,000 shares of Bristol-Myers Squibb stock on August 2 at the average price of $55.94. The price of the stock has increased by 0.02% since.
Bristol-Myers Squibb Co. is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis and HIV. The current CEO of the company is Dr. Giovanni Caforio and the company had 25,000 employees as of December 2015. The company has a market cap of $91.75 billion, and as of Aug. 4 it traded at $55.95.
On Aug. 3 Bristol-Myers Squibb Company announced that it has signed a definitive agreement with IFM Therapeutics under which Bristol-Myers Squibb will acquire all the outstanding capital stock of the other company. IFM Therapeutics is venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer and autoimmunity disorders.
General Motors Co. ( GM ): Director Thomas M. Schoewe bought 14,360 shares
Director Thomas M. Schoewe bought 14,360 shares of General Motors stock on Aug. 1 at the average price of $34.76. The price of the stock has increased by 1.47% since.
General Motors Co. is an American international manufacturer and distributor of vehicles and vehicle parts. The company manufactures cars and trucks in 35 countries, with brands including Buick, Cadillac, Chevrolet, GMC, Holden and Wuling. The company held the title of largest automobile manufacturer from 1931 through 2007. The company has a market cap of $51.4 billion, and as of Aug. 4 it traded at $35.27.
On Aug. 2 General Motors Co. announced the pricing of four series of senior unsecured notes for a total of $3.0 billion. These notes include $0.5 billion of floating rate notes due in 2020, $0.75 billion of 4.2% notes due 2027, $1 billion of 5.15% notes due in 2038, and $0.75 billion of 5.4% notes due in 2048. The offering is expected to settle on Aug. 7, 2017.
Kinder Morgan Inc. ( KMI ): Director William A. Smith bought 4,903 shares
Director William A. Smith bought 4,903 shares of Kinder Morgan stock on July 31 at the average price of $20.24. The price of the stock has decreased by 0.2% since.
Kinder Morgan Inc. is an American energy infrastructure company that specializes in owning and controlling oil and natural gas pipelines and terminals. Currently, the company is the largest energy infrastructure company in North America and operates approximately 84,000 miles of pipelines and owns about 180 terminals. The company has a market cap of $45.11 billion, and as of Aug. 4 it traded at $20.20.
On May 30 Kinder Morgan Canada Limited Inc., a subsidiary of Kinder Morgan Inc., announced the completion of the initial public offering of 102,942,000 restricted voting shares of the company at a price to the public of C$17.00 per share for total gross proceeds of approximately C$1.75 billion. The proceeds of the offering will be used by the company to indirectly acquire from Kinder Morgan an approximate 30% interest in a limited partnership that holds the Canadian business of Kinder Morgan.
For the complete list of stocks that were bought by their company executives, go to: Insider Trades.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Warning! GuruFocus has detected 4 Warning Sign with ABBV. Click here to check it out.
ABBV 15-Year Financial Data
The intrinsic value of ABBV
Peter Lynch Chart of ABBV
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price of $70.45. AbbVie Inc. is an American international pharmaceutical company that focuses on discovering, developing, and marketing both biopharmaceuticals and small molecule drugs. | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price of $70.45. AbbVie Inc. is an American international pharmaceutical company that focuses on discovering, developing, and marketing both biopharmaceuticals and small molecule drugs. | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price of $70.45. AbbVie Inc. is an American international pharmaceutical company that focuses on discovering, developing, and marketing both biopharmaceuticals and small molecule drugs. | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc. is an American international pharmaceutical company that focuses on discovering, developing, and marketing both biopharmaceuticals and small molecule drugs. AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price of $70.45. |
26048.0 | 2017-08-06 00:00:00 UTC | The Top Stock You Should Consider for Your IRA | ABBV | https://www.nasdaq.com/articles/top-stock-you-should-consider-your-ira-2017-08-06 | nan | nan | If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA , you won't have to pay taxes on any of your gains along the way.
But how should you invest the money you put into an IRA? For retirement accounts, it's important to choose a variety of stocks that are well positioned for success over the long haul. Here are three key reasons why I think AbbVie (NYSE: ABBV) is the top stock you should consider adding to your IRA.
1. Dividends
Dividend stocks are often smart choices for investors. And the smartest investors put dividend stocks in their IRAs first before owning them in fully taxable accounts. Why? Unlike capital gains, which are only taxable when you sell a stock, Uncle Sam will want his share of your dividend payments every year. But if the dividends are paid into a traditional IRA, you can defer that tax bill. And if you have a Roth IRA, you won't pay any taxes on those dividend payments in retirement.
All this is very pertinent for AbbVie, because the big biotech pays out a very nice dividend. AbbVie's dividend currently yields 3.6%, among the highest in the healthcare industry. That dividend seems likely to grow in the future for a couple of reasons.
First, AbbVie's commitment to paying out dividends is exemplary. The company belongs to an elite group of stocks known as Dividend Aristocrats . The minimum requirement for inclusion in this group is 25 consecutive years of dividend increases. AbbVie has increased its dividend for 45 years in a row, counting the period that it was part of Abbott Laboratories .
Second, AbbVie has plenty of flexibility to increase its dividend payout. The biotech currently uses less than 61% of earnings to fund the dividend program. Even if its earnings remain stagnant, AbbVie shouldn't have any problem with dividend hikes down the road.
2. Growth
Even better news for investors is that AbbVie's earnings are likely to grow -- a lot. Wall Street analysts project the company will grow earnings by an average annual rate of nearly 14.5% over the next five years.
AbbVie's autoimmune disease drug Humira continues to perform admirably. It's not just the company's top-selling drug -- Humira has been the No. 1 drug in the world for the last few years.
There are several other up-and-coming stars for AbbVie as well. Imbruvica is already a huge success and is projected to rank among the top five cancer drugs in the world by 2022. AbbVie also recently won European and U.S. approval for its pan-genotypic hepatitis C drug Maviret, which could position it to finally start stealing hep C market share.
The company also claims a strong pipeline that market research firm EvaluatePharma ranks as the third-best in the biopharmaceutical industry . AbbVie's pipeline candidates include potential blockbusters Elagolix, which targets treatment of endometriosis and uterine fibroids, as well as lung cancer drug Rova-T.
3. Value
With its great dividend and tremendous growth prospects, you might think that AbbVie stock would be priced to perfection. But it's not. AbbVie shares currently trade at around 12 times expected earnings.
Of course, any time you see something seemingly priced below what it's worth, it's smart to ask why that's the case. For AbbVie, concerns about the potential for competition for Humira have held the stock's valuation down. Amgen won U.S. approval last year for Amjevita, a biosimilar to Humira.
AbbVie's management team, however, thinks that it will be able to fend off biosimilar rivals in the U.S. through 2022. The company is defending its 61 patents for Humira in a legal dispute with Amgen. That trial doesn't begin until November 2019.
Of course, sooner or later Humira will face stiff competition. Even then, though, sales won't dry up overnight. That should give AbbVie plenty of time to roll out its experimental drugs currently in the pipeline, which include promising autoimmune disease candidates risankizumab and upadacitinib.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie also recently won European and U.S. approval for its pan-genotypic hepatitis C drug Maviret, which could position it to finally start stealing hep C market share. AbbVie's pipeline candidates include potential blockbusters Elagolix, which targets treatment of endometriosis and uterine fibroids, as well as lung cancer drug Rova-T. 3. That should give AbbVie plenty of time to roll out its experimental drugs currently in the pipeline, which include promising autoimmune disease candidates risankizumab and upadacitinib. | AbbVie's autoimmune disease drug Humira continues to perform admirably. AbbVie's pipeline candidates include potential blockbusters Elagolix, which targets treatment of endometriosis and uterine fibroids, as well as lung cancer drug Rova-T. 3. Here are three key reasons why I think AbbVie (NYSE: ABBV) is the top stock you should consider adding to your IRA. | Value With its great dividend and tremendous growth prospects, you might think that AbbVie stock would be priced to perfection. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Here are three key reasons why I think AbbVie (NYSE: ABBV) is the top stock you should consider adding to your IRA. | Growth Even better news for investors is that AbbVie's earnings are likely to grow -- a lot. Here are three key reasons why I think AbbVie (NYSE: ABBV) is the top stock you should consider adding to your IRA. All this is very pertinent for AbbVie, because the big biotech pays out a very nice dividend. |
26049.0 | 2017-08-05 00:00:00 UTC | Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance? | ABBV | https://www.nasdaq.com/articles/abbvie-about-deliver-blow-gilead-sciences-guidance-2017-08-05 | nan | nan | After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences ' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Could Mavyret deliver a big blow to Gilead Sciences' hopes for higher hepatitis C sales?
A changing marketplace
Hepatitis C treatment has taken big steps forward over the past decade. Previous treatments including the side effect-causing drugs peg interferon and ribavirin have been replaced by next-generation drugs that deliver functional cure rates that are above 90% in as few as 12 weeks, and in some patients, as little as eight weeks.
Gilead Sciences is largely responsible for these advances in patient treatment. Its Sovaldi rolled out in early 2014 to fanfare because of its 90%-plus cure rates and 12-week treatment duration. Later that year, it also launched Harvoni, which delivered even higher cure rates and a eight-week treatment duration for about 40% of genotype 1 patients. At their peak, these two drugs were hauling in about $20 billion in annualized sales.
Gilead Sciences paved the road toward better treatments in this indication, but it wasn't the only company developing hepatitis C drugs. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too.
AbbVie's Viekira was the most competitive of these drugs because it competed fiercely on price. Gilead Sciences was forced to respond with its own discounts, and the resulting price war took a big toll on its sales, profit, and share price. Gilead Sciences' annualized hepatitis C sales have been more than cut in half from their peak, and that's caused shares to tumble from over $120 in 2015 to the mid-$60s earlier this year.
GILD data by YCharts .
Recently, however, Gilead Sciences' share price has turned higher after management boosted its full-year hepatitis C sales guidance last month. Gilead Sciences' hepatitis C drugs enjoyed sequential sales growth in Q2, with U.S. sales increasing 13% and worldwide hepatitis C sales increasing 11%. As a result, management was able to increase its 2017 hepatitis C sales outlook to at least $8.5 billion, up $1 billion from its prior forecast.
A new challenger on deck
This week's FDA approval of Mavyret could crimp Gilead Sciences' momentum.
Mavyret can be prescribed to patients regardless of their genotype and in trials. It delivered an average functional cure rate of 97.5%. That cure rate appears to match up well against Gilead Sciences' hepatitis C drugs, but what could really threaten Gilead Sciences' market share is Mavyret's price and its shorter treatment duration.
Mavyret's list price is only $13,200 for four weeks of treatment, and for comparison, Evercore ISI calculates that Gilead Sciences' two newest hepatitis C drugs -- Epclusa and Vosevi -- cost about $25,000 each for four weeks of treatment. Mavyret's cost advantage is even bigger when you consider that Mavyret patients will start on an eight-week treatment course that's four weeks shorter than how long most patients take Gilead Sciences' drugs.
On Gilead Sciences' second-quarter earnings conference call, management was asked about Mavyret's threat.
COO Kevin Young said, "We'll just have to cross some bridges when we see their label, we see their pricing, we see how they begin to promote the product, perhaps eventually see how they come on the market with their contracting strategies. So I think there are unknowns, and we'll just have to wait and see."
Norbert Bischofberger, its chief scientific officer, dug in a bit deeper, saying, "They had excellent clinical results in genotype 1 in treatment-naive very early disease mostly F0 and F1. Actually, 80% of the population was F0 and F1 and in treatment-naïve patients. But the data in the other genotypes and also in treatment-experienced and cirrhotic patients were less good, particularly if you look at genotype 3 where they compared in eight weeks to 12 weeks to 12 weeks of sofosbuvir/daclatasvir, the regimen that had the most virological failures was the eight weeks of the AbbVie dual followed by the 12 weeks of the AbbVie dual, and the best-performing regimen was actually sofosbuvir/daclatasvir."
What's next?
Clearly, Gilead Sciences wants to make the argument that its drugs offer efficacy advantages to Mavyret, particularly in specific patient populations. However, Mavyret's eight-week dosing and its price point are clearly shots across Gilead Sciences' bow.
Gilead Sciences will have to convince payers that its efficacy advantages trump Mavyret's potential cost savings. They might be able to make a compelling argument given that re-treating patients who fail on Mavyret with other therapies could get expensive quickly. If Gilead Sciences isn't successful in arguing it has an efficacy advantage, then it will once again have to compete on price, and it's hard to imagine how that wouldn't hurt its top and bottom lines.
Because of the importance of hepatitis C revenue to Gilead Sciences' financials and uncertainty surrounding how payers will view Mavyret, Gilead Sciences' and AbbVie's third-quarter earnings reports will be mandatory reading for investors looking for clues as to how this battle will shake out.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. The Motley Fool has the following options: short August 2017 $75 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbVie's Viekira was the most competitive of these drugs because it competed fiercely on price. | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbVie's Viekira was the most competitive of these drugs because it competed fiercely on price. | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbVie's Viekira was the most competitive of these drugs because it competed fiercely on price. | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbVie's Viekira was the most competitive of these drugs because it competed fiercely on price. |
26050.0 | 2017-08-04 00:00:00 UTC | Infinity (INFI) Q2 Loss Wider than Expected, View Intact | ABBV | https://www.nasdaq.com/articles/infinity-infi-q2-loss-wider-than-expected-view-intact-2017-08-04 | nan | nan | Infinity Pharmaceuticals, Inc . INFI reported a loss of 34 cents per share in second-quarter 2017, wider than the Zacks Consensus Estimate loss of 22 cents. The company had reported a loss of 12 cents in the year-ago quarter.
Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Infinity Pharmaceuticals, Inc. Quote
Since Infinity does not have any approved product in its portfolio, the company earns revenues in the form of royalties, license and milestone payments as well as research and development (R&D) support fees paid by its partners.
Infinity did not record any revenues during second-quarter 2017. However, it recorded collaboration revenues of $9.5 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV .
Infinity's share price has increased 0.7% year to date compared with the industry 's gain of 1.0%.
Quarter in Detail
In the reported quarter, R&D expenses plummeted to $3.9 million from $52.9 million. The decline was mainly related to a decrease in clinical development expenses for duvelisib in addition to the company's 2016 restructuring activities.
General and administrative (G&A) expenses were $6.2 million for the reported quarter, down from $15.7 million in the year-ago quarter. The decrease was mainly due to the company's 2016 restructuring activities.
2017 Outlook Reiterated
Infinity expects net loss to be in the range of $40-$50 million in 2017. The company anticipates ending 2017 with year-end cash and cash equivalents and available-for-sale securities balance in the $40-$50 million band. Moreover, Infinity expects that its existing cash and cash equivalents as of Jun 30, 2017, should be adequate to fund the company's capital needs into the first-quarter 2019.
Pipeline Update
Currently, Infinity is evaluating IPI-549 as a monotherapy and in combination with Bristol-Myers Squibb Company's BMY Opdivo (nivolumab) in a phase I study in patients with advanced solid tumors.
The company completed an evaluation of escalating monotherapy doses of IPI-549 ranging from 10 - 60 mg QD once daily and has determined the 60 mg dose for evaluation in the expansion component of the study. The selection of the mentioned dose was based on pharmacokinetic and pharmacokinetic analyses, which showed that IPI-549 maintained full suppression of PI3K-gamma at this dose level.
Further, data from the study also showed that the IPI-549 dosed at 60 mg QD was well tolerated, and no dose-limiting toxicities were observed. Subsequently, the monotherapy expansion component of the study is now available for enrolment. The study will evaluate the safety and activity of IPI-549 dosed at 60 QD in approximately 25 patients.
Meanwhile, dose escalation evaluating IPI-549 in combination with Opdivo is currently ongoing. The company plans to initiate the combination expansion component of the study in the second half of 2017.
On the other hand, the company amended its license agreement with Takeda Oncology in Jul 2017 for IPI-549. Per the amended agreement, the company will no longer have an obligation to pay Takeda future royalties on worldwide net sales of selective inhibitors of PI3K-gamma, including IPI-549. In lieu, Infinity issued unsecured convertible notes of $6.0 million to Takeda that mature in 2018 and accrues interest at an annual rate of 8%.
Our Take
The wider-than-expected loss in the second quarter was disappointing. Infinity received a huge setback when AbbVie terminated their collaboration agreement for the development and commercialization of duvelisib. Hence, we expect investor focus on pipeline progress in the upcoming quarters.
Zacks Rank & Key Pick
Infinity currently holds a Zacks Rank #3 (Hold).
A better-ranked stock in the healthcare sector is Gilead Sciences. Inc. GILD which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Gilead's earnings per share estimates increased from $7.92 to $8.53 for 2017, over last 30days following strong results in the second quarter. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 8.18%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, it recorded collaboration revenues of $9.5 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Infinity received a huge setback when AbbVie terminated their collaboration agreement for the development and commercialization of duvelisib. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. | However, it recorded collaboration revenues of $9.5 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. Infinity received a huge setback when AbbVie terminated their collaboration agreement for the development and commercialization of duvelisib. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. However, it recorded collaboration revenues of $9.5 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Infinity received a huge setback when AbbVie terminated their collaboration agreement for the development and commercialization of duvelisib. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. However, it recorded collaboration revenues of $9.5 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Infinity received a huge setback when AbbVie terminated their collaboration agreement for the development and commercialization of duvelisib. |
26051.0 | 2017-08-03 00:00:00 UTC | 3 Sector Gainers And Losers; 2 Equity Plays Near Buy Zone | ABBV | https://www.nasdaq.com/articles/3-sector-gainers-and-losers-2-equity-plays-near-buy-zone-2017-08-03 | nan | nan | The Dow Jones industrial average continues to hit highs while the S&P 500 and Nasdaq take a breather.
[ibd-display-video id=2067944 width=50 float=left autostart=true]That could help new buy opportunities to take shape. Two ETFs with big weightings in PayPal ( PYPL ) and Apple ( AAPL ) are poised near buy points.
First Trust US Equity Opportunities ( FPX ) is pulling back near its 50-day moving average , after marking a record high last week. It gained about 3% from an early July bounce off the support line to the peak.
The fund tracks the IPOX-100 U.S. Index, which is a market-cap-weighted index of the 100 biggest and most liquid U.S. initial public offerings. The index sets a 10% cap on weightings in all constituents and is reconstituted quarterly.
[ibdchart symbol="FPX" type="daily" size="threequarter" position="leftchart" /]
FPX, which turned 11 in April, has gathered $858.2 million in assets. Its biggest sector weightings as of Aug. 1 were technology, at about 21%, health care at 19% and consumer defensive at 15%. Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ).
PayPal has rallied about 50% this year. AbbVie has advanced 13%. Kraft Heinz is slightly negative. The top five holdings accounted for nearly 33% of assets.
The fund outperformed the S&P 500 with a 12.8% vs. 11.9% gain through Aug. 1, according to Morningstar Inc. It lagged the benchmark index over the past three years but has outpaced the S&P 500 on a five- and 10-year basis. FPX has a 0.60% expense ratio.
IShares Edge MSCI U.S. Quality Factor (QUAL), which gained 2% from a June 1 breakout past a 74.39 buy point to a June 19 peak, is testing support at its 50-day line for the second time since the breakout.
A solid rebound off the line could set up a buy opportunity. The $3.5 billion fund, which marked its fourth anniversary last month, trails the S&P 500 this year with a 10.2% gain. Its three-year average annual return of 11.4% is just ahead of the benchmark index's 11.1% advance.
[ibdchart symbol="QUAL" type="daily" size="threequarter" position="leftchart" /]
QUAL, featured in this column June 1, counted among its top holdings as of Monday: Altria Group (MO), Johnson & Johnson (JNJ), Microsoft (MSFT) and Apple ( AAPL ). Apple leapt 5% Tuesday on the heels of its quarterly earnings report. QUAL carries a 0.15% expense ratio.
Wednesday's picks remain slightly below their respective buy points: iShares Edge Min Vol USA (USMV) is just shy of a 50.13 flat-base entry; FlexShares Quality Dividend Index Fund (QDF) is less than 1% away from a 41.85 flat-base buy point.
Indexes Narrowly Mixed; Oil Funds Reverse Lower
Key U.S. index funds were mixed in the stock market today . SPDR Dow Jones Industrial Average (DIA) up 0.1%, while SPDR S&P 500 (SPY) and PowerShares QQQ Trust (QQQ) gave up 0.1% and 0.2%, respectively.
Health care, utilities and retail ETFs held modest gains. SPDR Health Care (XLV) advanced 0.4%. It's near the top of a buy range from a 76.84 flat-base entry. The fund is drawing close to its 50-day line, where it could set up a buy opportunity on a solid bounce.
Oil plays were lower as West Texas intermediate prices dipped 0.7% to $49.26 a barrel. United States Oil Fund (USO) and PowerShares DB Oil Fund (DBO) gained nearly 1% each.VanEck Vectors Oil Services (OIH) was down 1%, while SPDR S&P Oil & Gas Exploration & Production (XOP) sank nearly 4%, on track for a fifth straight slide.
Energy, banks and gold miners also lagged. But SPDR Gold Trust (GLD) and iShares Gold Trust (IAU) were slightly higher.
Among foreign ETFs iShares MSCI South Korea Capped (EWY) gapped down and fell 2%. The Kospi Composite Index tumbled 1.7%. The move sent EWY shares to a test of the 50-day line. If they find support and rebound off the line, that could set up a potential buy opportunity.
RELATED:
Dow Holds Up, Oil Reverses Higher; 2 Big-Dividend Plays Near Breakout
Dow Keeps Win Streak Alive; Which Foreign Plays Breaking Out?
Like Apple? Watch These 2 Big ETFs For Potential Breakout
Snapped Up! First Trust ETF Is First To Pick Up Red-Hot Snap IPO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. First Trust US Equity Opportunities ( FPX ) is pulling back near its 50-day moving average , after marking a record high last week. | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. [ibdchart symbol="FPX" type="daily" size="threequarter" position="leftchart" /] FPX, which turned 11 in April, has gathered $858.2 million in assets. | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. IShares Edge MSCI U.S. Quality Factor (QUAL), which gained 2% from a June 1 breakout past a 74.39 buy point to a June 19 peak, is testing support at its 50-day line for the second time since the breakout. | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. Two ETFs with big weightings in PayPal ( PYPL ) and Apple ( AAPL ) are poised near buy points. |
26052.0 | 2017-08-03 00:00:00 UTC | Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat | ABBV | https://www.nasdaq.com/articles/momenta-mnta-q2-loss-in-line-with-estimates-sales-beat-2017-08-03 | nan | nan | Momenta Pharmaceuticals Inc.MNTA reported a loss of 50 cents per share in the second quarter of 2017, in line with the Zacks Consensus Estimate. The reported loss was, however, wider than the year-ago loss of 31 cents.
Momenta Pharmaceuticals, Inc. Price and EPS Surprise
Momenta Pharmaceuticals, Inc. Price and EPS Surprise | Momenta Pharmaceuticals, Inc. Quote
Revenues in the quarter improved 10.8% to $23.6 million and topped the Zacks Consensus Estimate of $22.9 million.
Momenta's stock has rallied 6.3% year to date compared with the industry's rally of 9.9%.
Quarter in Detail
Momenta's top line comprises product revenues of $19.1 million earned from Sandoz's sales of Glatopa, a generic version of Copaxone (20 mg), compared with $20.7 million in the year-ago quarter. The decrease was primarily due to lower sales deductions in the second quarter of 2016, as well as legal reimbursement in the second quarter of 2017.
Collaborative research and development revenues came in at $4.4 million, down from $5.8 million in the year-ago quarter. The decline in revenues was mainly due to the termination of the Baxalta Collaboration Agreement, effective Dec 31, 2016.
While, research and development expenses were up to $39.1 million from $33.2 million, general and administrative expenses increased 52% to $22.6 million.
Outlook Updated
Momenta now expects operating expenses (excluding stock-based compensation and net of collaborative revenues) in the range of $210-$230 million, compared with the previous guidance of $200-$240 million in 2017. The guidance also includes approximately $55 million of capital expenditure on M923. Operating expenses in the third quarter of 2017 are projected around $50-$60 million.
Momenta expect to generate revenues of $45 million from Mylan N.V. MYL as upfront payment on a quarterly basis. In Jul 2017, Momenta earned a $10 million milestone payment from Sandoz as Glatopa 20 mg continues to be the sole FDA-approved generic of Copaxone 20 mg.
Pipeline Update
Sandoz's abbreviated New Drug Application (ANDA) for the 40-mg thrice-weekly formulation of Copaxone (Glatopa 40mg) was under the FDA review. However, Momenta suffered a setback with the FDA issuing a warning letter to Pfizer Inc. PFE in Feb 2017, which is Sandoz's contracted fill/finish manufacturing partner for Glatopa.
Pfizer has submitted a comprehensive response to the observations cited in the warning letter. The ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued to Pfizer.
Meanwhile, Momenta continues to progress with its other pipeline candidates. Currently, Momenta's M923, a biosimilar version of AbbVie, Inc. ABBV Humira, is being evaluated in a phase III study in patients suffering from moderate-to-severe chronic plaque psoriasis. Moving ahead, the company plans to submit the candidate for approval to regulatory bodies in the fourth quarter of 2017. Also, it expects first commercial launch of M923 to be as early as the 2020 timeframe.
The company completed enrolment in the phase I study on M834, a biosimilar version of Orencia (abatacept) in Apr 2017 under its collaboration with Mylan. Top-line data from the study are expected in the second half of 2017.
Furthermore, Momenta's novel autoimmune portfolio includes: M230, a Selective Immunomodulator of Fc receptors (SIF3) and M281, an anti-FcRn monoclonal antibody. In Jan 2017, the company entered into a research collaboration and license agreement with CSL for M230 and potential future Fc multimer programs. The candidate is expected to enter clinic in 2017.
Momenta successfully completed a phase I single ascending dose study in healthy volunteers for M281. The multiple ascending dose portion of the study was initiated in Jan 2017 (expected to be completed in Aug 2017) and data from the single and multiple ascending dose portions of the study are projected in the second half of 2017.
Our Take
Momenta's loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates. The ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. We expect the warning letter will remain a drag on the company's shares till the issue is solved.
Nevertheless, sales of Glatopa 20mg continue to do well. Glatopa 20mg has captured approximately 40% of the market in the U.S. In addition, a potential approval of M923 will boost investor confidence.
Zacks Rank
Momenta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Currently, Momenta's M923, a biosimilar version of AbbVie, Inc. ABBV Humira, is being evaluated in a phase III study in patients suffering from moderate-to-severe chronic plaque psoriasis. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. However, Momenta suffered a setback with the FDA issuing a warning letter to Pfizer Inc. PFE in Feb 2017, which is Sandoz's contracted fill/finish manufacturing partner for Glatopa. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Momenta's M923, a biosimilar version of AbbVie, Inc. ABBV Humira, is being evaluated in a phase III study in patients suffering from moderate-to-severe chronic plaque psoriasis. Momenta Pharmaceuticals, Inc. Price and EPS Surprise Momenta Pharmaceuticals, Inc. Price and EPS Surprise | Momenta Pharmaceuticals, Inc. Quote Revenues in the quarter improved 10.8% to $23.6 million and topped the Zacks Consensus Estimate of $22.9 million. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Momenta's M923, a biosimilar version of AbbVie, Inc. ABBV Humira, is being evaluated in a phase III study in patients suffering from moderate-to-severe chronic plaque psoriasis. Momenta Pharmaceuticals, Inc. Price and EPS Surprise Momenta Pharmaceuticals, Inc. Price and EPS Surprise | Momenta Pharmaceuticals, Inc. Quote Revenues in the quarter improved 10.8% to $23.6 million and topped the Zacks Consensus Estimate of $22.9 million. | Currently, Momenta's M923, a biosimilar version of AbbVie, Inc. ABBV Humira, is being evaluated in a phase III study in patients suffering from moderate-to-severe chronic plaque psoriasis. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Momenta's top line comprises product revenues of $19.1 million earned from Sandoz's sales of Glatopa, a generic version of Copaxone (20 mg), compared with $20.7 million in the year-ago quarter. |
26053.0 | 2017-08-03 00:00:00 UTC | Top Buys by Directors: Rapp's $281.8K Bet on ABBV | ABBV | https://www.nasdaq.com/articles/top-buys-directors-rapps-2818k-bet-abbv-2017-08-03 | nan | nan | The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money - maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So in this series we look at the largest insider buys by company directors over the trailing six month period, one of which was a total of $281.8K by Edward J. Rapp, Director at AbbVie Inc (Symbol: ABBV).
Rapp's average cost works out to $70.45/share. In trading on Thursday, bargain hunters could buy shares of AbbVie Inc (Symbol: ABBV) and achieve a cost basis lower than Rapp, with shares changing hands as low as $70.36 per share. Shares of AbbVie Inc were changing hands at $70.50 at last check, trading down about 0.3% on Thursday. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average:
Looking at the chart above, ABBV's low point in its 52 week range is $55.06 per share, with $75.04 as the 52 week high point - that compares with a last trade of $70.50.
The current annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/12/2017. Below is a long-term dividend history chart for ABBV, which can be of good help in judging whether the most recent dividend with approx. 3.6% annualized yield is likely to continue.
According to the ETF Finder at ETF Channel, ABBV makes up 9.96% of the First Trust US Equity Opportunities ETF (Symbol: FPX) which is trading lower by about 0.5% on the day Thursday.
Click here to find out which other top insider buys by company directors you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of AbbVie Inc were changing hands at $70.50 at last check, trading down about 0.3% on Thursday. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $55.06 per share, with $75.04 as the 52 week high point - that compares with a last trade of $70.50. So in this series we look at the largest insider buys by company directors over the trailing six month period, one of which was a total of $281.8K by Edward J. Rapp, Director at AbbVie Inc (Symbol: ABBV). | In trading on Thursday, bargain hunters could buy shares of AbbVie Inc (Symbol: ABBV) and achieve a cost basis lower than Rapp, with shares changing hands as low as $70.36 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $55.06 per share, with $75.04 as the 52 week high point - that compares with a last trade of $70.50. So in this series we look at the largest insider buys by company directors over the trailing six month period, one of which was a total of $281.8K by Edward J. Rapp, Director at AbbVie Inc (Symbol: ABBV). | In trading on Thursday, bargain hunters could buy shares of AbbVie Inc (Symbol: ABBV) and achieve a cost basis lower than Rapp, with shares changing hands as low as $70.36 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $55.06 per share, with $75.04 as the 52 week high point - that compares with a last trade of $70.50. So in this series we look at the largest insider buys by company directors over the trailing six month period, one of which was a total of $281.8K by Edward J. Rapp, Director at AbbVie Inc (Symbol: ABBV). | In trading on Thursday, bargain hunters could buy shares of AbbVie Inc (Symbol: ABBV) and achieve a cost basis lower than Rapp, with shares changing hands as low as $70.36 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $55.06 per share, with $75.04 as the 52 week high point - that compares with a last trade of $70.50. So in this series we look at the largest insider buys by company directors over the trailing six month period, one of which was a total of $281.8K by Edward J. Rapp, Director at AbbVie Inc (Symbol: ABBV). |
26054.0 | 2017-08-02 00:00:00 UTC | Westchester Capital Management, Inc. Buys Microchip Technology Inc, SPDR S&P Dividend, Ford ... | ABBV | https://www.nasdaq.com/articles/westchester-capital-management-inc-buys-microchip-technology-inc-spdr-sp-dividend-ford | nan | nan | Westchester Capital Management, Inc.
New Purchases: MCHP , SDY , VZ ,
Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B,
Reduced Positions:MCD, CAT, GLD,
Sold Out:SPY,
For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Capital+Management%2C+Inc.
These are the top 5 holdings of Westchester Capital Management, Inc.
Apple Inc ( AAPL ) - 79,397 shares, 5.21% of the total portfolio. Shares added by 1.07%
Berkshire Hathaway Inc (BRK.B) - 66,429 shares, 5.13% of the total portfolio. Shares added by 2.38%
AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. Shares added by 1.73%
Bank of New York Mellon Corp ( BK ) - 189,076 shares, 4.4% of the total portfolio. Shares added by 1.96%
Microsoft Corp ( MSFT ) - 132,418 shares, 4.16% of the total portfolio. Shares added by 3.66%
New Purchase: Microchip Technology Inc ( MCHP )
Westchester Capital Management, Inc. initiated holdings in Microchip Technology Inc. The purchase prices were between $72.15 and $86.86, with an estimated average price of $78.59. The stock is now traded at around $79.79. The impact to the portfolio due to this purchase was 3.58%. The holdings were 101,600 shares as of 2017-06-30.
New Purchase: SPDR S&P Dividend (SDY)
Westchester Capital Management, Inc. initiated holdings in SPDR S&P Dividend. The purchase prices were between $86.77 and $90.78, with an estimated average price of $88.59. The stock is now traded at around $89.77. The impact to the portfolio due to this purchase was 2.08%. The holdings were 51,362 shares as of 2017-06-30.
New Purchase: Verizon Communications Inc (VZ)
Westchester Capital Management, Inc. initiated holdings in Verizon Communications Inc. The purchase prices were between $44.41 and $49.31, with an estimated average price of $46.65. The stock is now traded at around $48.32. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 100 shares as of 2017-06-30.
Added: Ford Motor Co (F)
Westchester Capital Management, Inc. added to the holdings in Ford Motor Co by 76.80%. The purchase prices were between $10.76 and $11.64, with an estimated average price of $11.17. The stock is now traded at around $10.97. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 1,151 shares as of 2017-06-30.
Sold Out: SPDR S&P 500 (SPY)
Westchester Capital Management, Inc. sold out the holdings in SPDR S&P 500. The sale prices were between $232.51 and $244.66, with an estimated average price of $239.5.
Warning! GuruFocus has detected 5 Warning Signs with F. Click here to check it out.
High Yield Dividend Stocks in Gurus' Portfolio
Top dividend stocks of Warren Buffett
Top dividend stocks of George Soros
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. Westchester Capital Management, Inc. New Purchases: MCHP , SDY , VZ , Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B, Reduced Positions:MCD, CAT, GLD, Sold Out:SPY, For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Capital+Management%2C+Inc. These are the top 5 holdings of Westchester Capital Management, Inc. Apple Inc ( AAPL ) - 79,397 shares, 5.21% of the total portfolio. | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. Westchester Capital Management, Inc. New Purchases: MCHP , SDY , VZ , Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B, Reduced Positions:MCD, CAT, GLD, Sold Out:SPY, For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Capital+Management%2C+Inc. Shares added by 3.66% New Purchase: Microchip Technology Inc ( MCHP ) Westchester Capital Management, Inc. initiated holdings in Microchip Technology Inc. | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. Westchester Capital Management, Inc. New Purchases: MCHP , SDY , VZ , Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B, Reduced Positions:MCD, CAT, GLD, Sold Out:SPY, For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Capital+Management%2C+Inc. Shares added by 3.66% New Purchase: Microchip Technology Inc ( MCHP ) Westchester Capital Management, Inc. initiated holdings in Microchip Technology Inc. | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. These are the top 5 holdings of Westchester Capital Management, Inc. Apple Inc ( AAPL ) - 79,397 shares, 5.21% of the total portfolio. Shares added by 3.66% New Purchase: Microchip Technology Inc ( MCHP ) Westchester Capital Management, Inc. initiated holdings in Microchip Technology Inc. |
26055.0 | 2017-08-02 00:00:00 UTC | Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-q2-earnings-gilead-celg-more-dynavax-panel-vote-2017-08-02 | nan | nan | Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Companies like Gilead and Amgen AMGN also provided regulatory updates.
Recap of the Week's Most Important Stories
A Look at Q2 Earnings Results: Gilead's results were strong with the company's HIV franchise putting in a strong performance and the hepatitis C virus (HCV) franchise performing better than expected. The company raised its revenue outlook including for the HCV franchise (Read more: Gilead Tops Q2 Earnings & Revenue Estimates, Stock Up ). Celgene also topped estimates and raised its earnings guidance for the year (Read more: Celgene Beats Q2 Earnings & Sales Estimates, Ups View ) as did Alexion (Read more: Alexion Tops Q2 Earnings & Revenues, Ups 2017 View ). Vertex (Read more: Vertex Q2 Earnings Top on Solid Cystic Fibrosis Sales ) and AbbVie too topped expectations (Read more: AbbVie Tops Q2 Earnings & Revenues, Outlook Intact ).
Earlier-Than-Expected FDA Approval for Celgene/Agios Cancer Drug: Celgene and partner, Agios AGIO gained FDA approval for Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with IDH2 mutation as detected by an FDA approved test. The approval came ahead of the FDA action date of Aug 30, 2017.
This makes Idhifa the first and only FDA-approved therapy for this patient population, which represents 8 - 19% of AML patients, as per information provided by the companies. More than 21,000 new cases of AML are detected every year in the U.S. with the majority of patients seeing their disease relapse eventually. The prognosis for R/R AML is poor with overall survival for this patient population estimated to be less than six months. Although Idhifa comes with a boxed warning regarding differentiation syndrome, uptake should be strong given the significant unmet medical need.
Will it be Third Time Lucky for Dynavax's Heplisav-B? Dynavax's DVAX shares shot up on a favorable recommendation (12-1) from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) for Heplisav-B, a vaccine for immunization against hepatitis B infection in adults. With the positive vote, expectations are high that the company will finally gain approval for the vaccine which had previously received two complete response letters (one in Nov 2016 and the other in Feb 2013). A decision from the agency is expected on Aug 10. If approved, Dynavax plans to launch the vaccine early next year. Dynavax's shares are up a whopping 284.8% year to date, significantly outperforming the industry's 9.8% rally (Read more: Dynavax Shares Jump 75% after FDA Committee Approval ).
Vertex Ups CF Outlook on Kalydeco Label Expansion: Vertex's cystic fibrosis (CF) drug Kalydeco's label has been expanded in the U.S. and can now be used in the more than 600 CF patients (2 years and older) who have one of five residual function mutations that result in a splicing defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With this label expansion, Vertex upped its 2017 sales guidance for the drug to $770 million - $800 million (old guidance: $740 - $770 million). Vertex now expects total CF product revenues of $1.87 billion - $2.1 billion (old guidance: $1.84 - $2.07 billion), including Orkambi sales of $1.1 billion - $1.3 billion (unchanged).
Regulatory Updates from Amgen and Gilead: Amgen provided quite a few regulatory updates over the last few days. The company said that it has submitted a regulatory application in the U.S. seeking label expansion for Prolia for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). Prolia brought in sales of $930 million in the first half of 2017.
Amgen along with partner Allergan also said that they have filed for FDA approval of ABP 980, a biosimilar candidate to Roche's Herceptin (trastuzumab). Herceptin is approved for the treatment of HER2+ adjuvant breast cancer, metastatic breast cancer and metastatic gastric cancer in the U.S.
Meanwhile, Amgen's PCSK9 inhibitor, Repatha, got priority review in the U.S. for the inclusion of FOURIER cardiovascular outcomes study data on the reduction in the risk of cardiovascular events. A decision from the agency is expected on Dec 2, 2017. Amgen said that a second application for the expansion of the lipid-lowering indication to include additional patient populations studied was also accepted by the agency.
Gilead also had some updates on the regulatory front. The company said that its HCV drug, Epclusa's label was updated in the U.S. to include use in patients co-infected with HIV. Epclusa, which initially gained approval in Jun 2016, is an all-oral, pan-genotypic, once-daily single tablet regimen. The label expansion provides co-infected patients with a convenient one-pill-a-day regimen that works across all HCV genotypes and is compatible with widely-used antiretroviral regimens. Epclusa sales crossed $2 billion in the first half of 2017.
Moreover, Gilead's latest HCV offering Vosevi gained approval in the EU for the treatment of all genotypes. The marketing authorization for Harvoni in the EU was also extended allowing use in the adolescent population. Vosevi was approved in the U.S. a few weeks back in July.
Gilead is a Zacks Rank #2 (Buy) stock -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index declined 2.5% over the last five trading sessions. Among major biotech stocks, Alexion gained 6.5% while Regeneron lost 8.1%. Over the last six months, Vertex was up 77.6% (See the last biotech stock roundup here: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug ).
What's Next in the Biotech World?
Watch out for earnings reports from companies like BioMarin and Regeneron among others.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.
See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Vertex (Read more: Vertex Q2 Earnings Top on Solid Cystic Fibrosis Sales ) and AbbVie too topped expectations (Read more: AbbVie Tops Q2 Earnings & Revenues, Outlook Intact ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Vertex (Read more: Vertex Q2 Earnings Top on Solid Cystic Fibrosis Sales ) and AbbVie too topped expectations (Read more: AbbVie Tops Q2 Earnings & Revenues, Outlook Intact ). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Vertex (Read more: Vertex Q2 Earnings Top on Solid Cystic Fibrosis Sales ) and AbbVie too topped expectations (Read more: AbbVie Tops Q2 Earnings & Revenues, Outlook Intact ). | Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Vertex (Read more: Vertex Q2 Earnings Top on Solid Cystic Fibrosis Sales ) and AbbVie too topped expectations (Read more: AbbVie Tops Q2 Earnings & Revenues, Outlook Intact ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. |
26056.0 | 2017-08-01 00:00:00 UTC | 3 Growth Stocks for the Long Term | ABBV | https://www.nasdaq.com/articles/3-growth-stocks-long-term-2017-08-01 | nan | nan | Growth stocks are key components of any well-rounded portfolio. However, it's not always easy to identify stocks that can produce respectable returns on capital over long periods of time.
With this theme in mind, we asked three of our Foolish investors which growth stocks they think might be worth buying and holding right now. They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . Read on to find out why these three stocks may be exceptional long-term growth vehicles.
A super-charged growth stock
George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading levels of growth, and this trend should be sustainable for the foreseeable future.
While Humira's sales do make up a disproportionate amount of the biotech's revenue at this stage (over 60%) and the threat of biosimilars is indeed real, AbbVie also sports one of the best late-stage clinical pipelines in the business. The drugmaker's slew of high-value clinical assets should not only be enough to offset Humira's eventual decline, but to keep the company's top line headed northwards.
At present, AbbVie is close to bringing an eight-week pan-genotypic hepatitis C treatment dubbed Maviret (glecaprevir/pibrentasvir) to market in the EU, the U.S., and Japan. Although it's hard to forecast how this drug will fare against Gilead Sciences ' hepatitis C franchise, Maviret is in a good position from a competitive standpoint to turn into a fairly significant revenue source for the drugmaker moving forward.
Additionally, AbbVie's oral JAK1-selective inhibitor, upadacitinib (ABT-494), recently reported strong late-stage results in patients with moderate to severe rheumatoid arthritis. This experimental anti-inflammatory medicine, if approved, is forecast to generate sales exceeding $1.2 billion by 2022.
Last but not least, AbbVie's heavy investment in next-generation cancer medicines should also ensure that it keeps growing once Humira's sales start to slip. The game-changing blood cancer medicines Imbruvica and Venclexta, for instance, are expected to rake in over $9 billion in combined sales by 2023.
All told, AbbVie seems well-positioned to continue producing top-notch revenue growth thanks to its stellar late-stage pipeline and foray into the high-growth oncology space.
Worth playing the long game
Keith Noonan (Take-Two Interactive): Video game stocks have been hot performers recently, but buying a company just because it operates in a hot industry can be a good way to trim the value of your investment dollars. I don't think that's the case for Take-Two Interactive stock, or the big-budget video game industry at large. While the barrier to entry for making mobile games has greatly eroded, producing and marketing the next blockbuster video game remains resource-intensive and requires a heavy degree of specialization.
Consider the fact that Disney , with its massive capital and treasure trove of great franchises, couldn't make its video game division sufficiently profitable and ultimately left the business. That speaks to the difficulty of operating in the space. So, given that a rush of new competitors capable of challenging Take-Two when it comes to bringing games to market doesn't seem likely, I think the company stands out as a compelling stock for the long term.
The global video game industry is still growing at a solid clip, and Take-Two's collection of properties and development teams puts it in good position to continue benefiting from high-margin digitally delivered content , expanding in international markets like China (where the company's NBA 2K Online is currently the top-performing online sports game on PC), and taking advantage of emerging opportunities like virtual reality and esports.
Compared to film and television, video games are still relatively young as a medium, and I think Take-Two has what it takes to capitalize as the industry continues to evolve.
Put your portfolio into orbit with this stock
Dan Caplinger (Iridium Communications): Most people take wireless communications for granted, with land-based networks covering most of the world's major population centers and a large swath of the remaining area of the globe. Yet there are still parts of the world where you won't find conventional cellular service, and for those areas, the satellite communications network that Iridium Communications provides is vital for getting voice and data services to the clients who need them.
Iridium has been in the process of upgrading its satellite network, and so far, implementation of the Iridium NEXT program has gone smoothly. The company just made its second launch of satellites in late June, and it expects the next group to go up near the end of September with expectations for full completion by next year. Although Iridium is largely treading water at this point, calls for dramatic rises in revenue and improvements on the bottom line by 2019 reflect the potential that Iridium NEXT has to drive further business. Add to that the potential for applications related to the Internet of Things in remote areas of the world, and Iridium has plenty of opportunities for future growth that could allow it to tap into the ever-increasing demand for ubiquitous connectivity.
10 stocks we like better than Take-Two Interactive
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Take-Two Interactive wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Dan Caplinger owns shares of DIS. George Budwell has no position in any stocks mentioned. Keith Noonan owns shares of Take-Two Interactive. The Motley Fool owns shares of and recommends GILD, Take-Two Interactive, and DIS. The Motley Fool has the following options: short August 2017 $75 calls on GILD. The Motley Fool recommends Iridium Communications. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading levels of growth, and this trend should be sustainable for the foreseeable future. While Humira's sales do make up a disproportionate amount of the biotech's revenue at this stage (over 60%) and the threat of biosimilars is indeed real, AbbVie also sports one of the best late-stage clinical pipelines in the business. | They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading levels of growth, and this trend should be sustainable for the foreseeable future. While Humira's sales do make up a disproportionate amount of the biotech's revenue at this stage (over 60%) and the threat of biosimilars is indeed real, AbbVie also sports one of the best late-stage clinical pipelines in the business. | A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading levels of growth, and this trend should be sustainable for the foreseeable future. They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . While Humira's sales do make up a disproportionate amount of the biotech's revenue at this stage (over 60%) and the threat of biosimilars is indeed real, AbbVie also sports one of the best late-stage clinical pipelines in the business. | They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading levels of growth, and this trend should be sustainable for the foreseeable future. While Humira's sales do make up a disproportionate amount of the biotech's revenue at this stage (over 60%) and the threat of biosimilars is indeed real, AbbVie also sports one of the best late-stage clinical pipelines in the business. |
26057.0 | 2017-08-01 00:00:00 UTC | Validea Joel Greenblatt Strategy Daily Upgrade Report - 8/1/2017 | ABBV | https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-812017-2017-08-01 | nan | nan | The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt changed from 60% to 80% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Joel Greenblatt has returned 110.98% vs. 93.93% for the S&P 500. For more details on this strategy, click here
About Joel Greenblatt : In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.
About Validea : Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). | Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. |
26058.0 | 2017-08-01 00:00:00 UTC | Key FDA Events to Watch Out for in Aug 2017 | ABBV | https://www.nasdaq.com/articles/key-fda-events-watch-out-aug-2017-2017-08-01 | nan | nan | The FDA, which approved 22 treatments last year, has given its approval to 26 drugs so far in 2017 including 3 in July. Key approvals this year include Gilead's Vosevi (hepatitis C virus), Puma's Nerlynx (to reduce the risk of breast cancer returning), J&J's Tremfya (moderate-to-severe plaque psoriasis), Regeneron/Sanofi's Kevzara (rheumatoid arthritis), Roche's multiple sclerosis treatment, Ocrevus, Regeneron and Sanofi's eczema treatment, Dupixent, Tesaro's PARP inhibitor, Zejula, and BioMarin's Brineura (treatment of a specific form of Batten disease) among others. Some of these drugs have blockbuster potential.
With the drug development process being lengthy and time-consuming and requiring the utilization of a lot of funds and resources, key pipeline events including data readouts and regulatory updates are of paramount importance and could act as major catalysts. Here is a look at a few important regulatory events scheduled for the month of August.
Another New Indication for Bristol-Myers' Opdivo?
Bristol-Myers Squibb BMY is looking to get the label of its PD-1 inhibitor expanded for use in patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC) after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. The regulatory application is currently under priority review with a response expected on Aug 2, 2017. Opidivo is currently approved for a wide range of indications and brought in sales of $2.3 billion in the first half of 2017. Bristol-Myers has lost 2.6% of its value year to date (YTD) versus the 10.5% growth of its industry .
Will J&J RA Drug Win Support of FDA Panel?
The FDA's Arthritis Advisory Committee will be meeting tomorrow to discuss the BLA for Johnson & Johnson's JNJ investigational rheumatoid arthritis (RA) treatment, Plivensia (sirukumab), an IL-6 inhibitor. The company is looking to get Plivensia approved for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). RA is a common, chronic, life-long, autoimmune disease that affects about 1.3 million people in the U.S. While new treatment options have entered the market over the last couple of decades, RA patients are still not adequately managed with many left with fewer therapeutic options due to loss of response to available agents, and poor compliance due to inconvenient dosing.
Earlier this week, the FDA had released briefing documents for the meeting which indicate a lot of emphasis will be placed on the safety profile of the drug especially the imbalance in all cause death between Plivensia and placebo. If approved, Plivensia would enter a pretty crowded market given the presence of drugs like Humira, Actemra and Kevzara among others, though its once-monthly dosing schedule could give it an advantage. Shares of J&J have gained 15.2% YTD, outperforming the industry's rally.
Will FDA Follow in EU's Path and Give the Green Signal to AbbVie's Maviret?
AbbVie ABBV also has an important regulatory event coming up with the FDA expected to respond on the approval status of the company's latest hepatitis C virus (HCV) offering this month. Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), is a once-daily ribavirin-free treatment that has the potential to provide a faster path to virologic cure for all major HCV genotypes (GT1-6). Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched. We note that Maviret gained EU approval just last week. Shares of AbbVie have gained 11.6% YTD, outperforming the industry's rally.
Third Time Lucky for Dynavax's Heplisav-B?
It's been a great week for clinical-stage immunology company Dynavax Technologies Corp. DVAX which got a favorable recommendation (12-1) from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) for Heplisav-B, a vaccine for immunization against hepatitis B infection in adults. With the positive vote, will it be third time lucky for the company which has previously received two complete response letters for Heplisav-B (one in Nov 2016 and the other in Feb 2013) from the FDA? A decision from the agency is expected on Aug 10. If approved, Dynavax plans to launch the vaccine early next year. Dynavax's shares shot up 71.4% on the positive panel vote and are up a whopping 301.3% YTD, significantly outperforming the industry 's10.5% rally.
Pfizer's Xeljanz to Be Reviewed by FDA Advisory Panel
Pfizer PFE has two regulatory events this month -- the first is an FDA advisory panel meeting and the other a PDUFA date. The FDA's Arthritis Advisory Committee will be meeting on Aug 3 to discuss supplemental new drug applications (sNDAs) submitted by the company for its JAK inhibitor, Xeljanz and Xeljanz XR, for the treatment of adult patients with active psoriatic arthritis. Efficacy and safety data and benefit-risk considerations will be discussed by the panel. Xeljanz, currently approved for RA, brought in sales of $927 million in 2016.
Meanwhile, the FDA is expected to give a response regarding the approval status of Pfizer's Besponsa which recently gained approval in the EU. If approved in the U.S., Besponsa will provide a new treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), an aggressive type of blood cancer with poor prognosis in adults. According to information provided by Pfizer, the 5-year overall survival rate for patients with relapsed or refractory adult ALL is less than 10%. Pfizer stock has gained 2.1% YTD, lagging the industry it belongs to. Pfizer is a Zacks Rank #3 (Hold) stock -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Some other FDA decisions scheduled for this month include a response regarding Agios Pharmaceuticals, Inc. AGIO and partner Celgene's CELG Idhifa (under priority review for relapsed and/or refractory (R/R) acute myeloid leukemia (AML) with an IDH2 mutation) on Aug 30. Meanwhile, the FDA is expected to decide on the approval status of Valeant's eye drug, Vesneo (latanoprostene bunod) and Adamas' ADS-5102 (treatment of levodopa-induced dyskinesia in people with Parkinson's disease) on Aug 24.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report
Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Will FDA Follow in EU's Path and Give the Green Signal to AbbVie's Maviret? AbbVie ABBV also has an important regulatory event coming up with the FDA expected to respond on the approval status of the company's latest hepatitis C virus (HCV) offering this month. Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Will FDA Follow in EU's Path and Give the Green Signal to AbbVie's Maviret? AbbVie ABBV also has an important regulatory event coming up with the FDA expected to respond on the approval status of the company's latest hepatitis C virus (HCV) offering this month. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Will FDA Follow in EU's Path and Give the Green Signal to AbbVie's Maviret? AbbVie ABBV also has an important regulatory event coming up with the FDA expected to respond on the approval status of the company's latest hepatitis C virus (HCV) offering this month. | Will FDA Follow in EU's Path and Give the Green Signal to AbbVie's Maviret? AbbVie ABBV also has an important regulatory event coming up with the FDA expected to respond on the approval status of the company's latest hepatitis C virus (HCV) offering this month. Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched. |
26059.0 | 2017-07-31 00:00:00 UTC | 7 Explosive Healthcare Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/7-explosive-healthcare-stocks-to-buy-now-2017-07-31 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The healthcare sector, along with its many sub-industries, has taken a leadership role in the market again in 2017. The strength in the sector can be attributed to a few things.
First, the sector is benefiting from the lack of volatility that had been tied to a potential overhaul of the regulatory environment. Investors are feeling much surer of their outlooks as the political rhetoric continues to subside.
7 Blue-Chip Stocks You Shouldn't Hold Anymore
The resulting cash that is flowing back into the sector brings with it many opportunities to buy some names that have strong double-digit growth potential for the second half of 2017.
Explosive Healthcare Stocks to Buy: Quest Diagnostics (DGX)
Click to Enlarge Quest Diagnostics Inc (NYSE: DGX ) has been one of the low volatility price leaders of 2017 along with paying a dividend of 1.7%. The stock remains a "strong buy" according to the current model readings.
Last week, DGX announced earnings that beat expectations with a positive outlook. The stock has been trading in a technically strong pattern since February 2016.
Investors sentiment has been discounting the stock as the short-interest patterns and the analyst rankings both underestimate the strength of the stock's rally. DGX stock dropped about 3% after the positive report as the "sell the profit" crowd added to pressure. On an intraday basis though, the 100-day moving average almost came into play, but some clear program-trading came in twice through the day to buoy the stock back to its 50-day.
A break above the 50-day will put DGX back into rally mode and bring more upgrades (currently only 22% of the analysts covering the stock have it ranked a "buy").
DGX stock looks attractive with a $120 price target.
Explosive Healthcare Stocks to Buy: Baxter International Inc (BAX)
Click to Enlarge Baxter International Inc (NYSE: BAX ) shares continue to move higher through the year, returning 37% year-to-date. Baxter's performance comes on the backdrop of a positive fundamental picture and some clarity on the regulatory front after the Donald Trump administration took office.
More powerful is the bearish sentiment toward this market leader. Currently, only 23% of the analysts covering the stock have it ranked a "buy," while eight actually have it ranked a "sell." This on a stock that is outperforming the market strongly.
Short sellers have been closing their positions on the stock, which has helped to drive the stock even higher, but we're expecting the analyst recommendations to really drive things here in the second half of 2017.
7 'Millennial' Stocks to Buy No Matter What Age You Are
With technical support currently sitting at $60, Baxter International shares should see some buyers begin to come in to support Baxter shares over the short term. BAX stock has been trading at its highs, so there is little overhead pressure to keep them from moving to our target of $70.
Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV)
Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. Something that most of the biotech companies haven't been able to pull off.
AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the rally that kicked-off in May. Recently, the stock has pulled back to a critical technical test that will give us an idea of the market's willingness to buy this stock on a dip.
Last week, after earnings, AbbVie shares pulled back to their 50-day moving average, where they are holding a bull/bear battle. A successful hold of this powerful trendline will signal that the "trend is the friend" of AbbVie, attracting more bulls into the stock.
Analysts still dislike the stock, with only 36% of those covering it rating the stock a "buy." The continued technical success and outpacing of the market's gains will change that as we should expect to see analyst upgrades help to drive prices higher.
Our models hold an intermediate-term bullish outlook on AbbVie with a target of $80.
Explosive Healthcare Stocks to Buy: Biogen Inc (BIIB)
Click to Enlarge Shares of Biogen Inc (NASDAQ: BIIB ) just transitioned into an intermediate-term bullish pattern as the stock is now attracting more investor cash.
Shares have been trading in a long-term range that looks ready to break and allow the stock to move higher. Chart watchers will be monitoring the $295-$300 range, as this is where the stock has failed to break higher on a regular basis. This time around, the stock has more momentum, which should increase the odds of a breakout.
We've been watching the dollar balanced volume on Biogen and noted that more cash is flowing into the company. This suggests that the momentum should be more reliable with fewer traders looking to sell into the strength of that top.
Sentiment supports further growth as the analyst recommendations remain somewhat low. Currently, 60% of the analysts covering the stock have it ranked a "buy," which allows for some upgrade potential.
7 Small-Cap Stocks With Big-League Potential
The break through $300 will strengthen the bull market trend for Biogen shares and target another 15%-20% move in the second half of the year.
Explosive Healthcare Stocks to Buy: Express Scripts Holding Company (ESRX)
Click to Enlarge A little further down the list, in terms of year-to-date performance, is Express Scripts Holding Company (NASDAQ: ESRX ). The company has lost 8% year-to-date, but out models are picking-up on a potential turnaround that should have the bulls interested.
Express Scripts stock recently moved above their 50-day moving average, which is now transitioning into a bullish pattern. This suggests that the stock is amid a technical turnaround that will attract investors, both long and short term.
Sentiment is decidedly bearish as the analyst community has shunned the stock with its 35% "buy" recommendations. Additionally, the current short interest ratio on Express Scripts stands at 11.5. This means that the stock is set for a short covering rally.
A positive earnings report has Express Scripts shares trending higher with the likelihood of analyst upgrades and short covering acting as an additional catalyst. Our models target a price of $72.
Explosive Healthcare Stocks to Buy: AmerisourceBergen Corp. (ABC)
Click to Enlarge The healthcare sector, including pharmaceuticals, has been resuscitated as investors and traders are beginning to see some resolution and more clarity of what, if any, regulatory changes could occur. This has affected the sector, including AmerisourceBergen Corp. (NYSE: ABC ) positively, as cash is beginning to flow back into these companies after years of them being avoided by investors.
AmerisourceBergen is a pharmaceutical sourcing and distribution services company that services healthcare providers and pharmaceutical development companies. Like many stocks in the sector, it has been range bound over the last year or two, but the technical picture has been on the mend. This is what attracts investors to the group.
Pessimism runs abound on AmerisourceBergen shares, as only 33% of the analysts covering the stock rank it a "buy" and the current short interest ratio for the stock stands at 14. This means that we are likely to money flow into the company as the technical patterns continue to improve and the bears turn into bulls. For its third-quarter report Aug. 3, analysts expect flat year-over-year growth to $1.37 in per-share earnings and a 6.2% sales bump to $39.16 billion. Just remember, ABC has surprised in the past six quarters.
The Top 10 ETFs Money Can Buy
Watch for a break above $98 to give the stock a real boost and head toward our target of $105.
Explosive Healthcare Stocks to Buy: Varian Medical Systems (VAR)
Click to Enlarge Healthcare and healthcare equipment companies had a tougher go in 2016 as the market concerned itself with the political climate. Potential changes to the regulatory environment for all healthcare related companies had investors on edge. The exact kind of activity that generates high-pressure earnings buys, such as Varian Medical Systems, Inc. (NYSE: VAR ).
The stock recently emerged from a consolidation period to engage in an intermediate-term bullish trend. This immediately resulted in an upgrade to VAR shares ahead of the earnings announcement. Specifically, the stock saw technically engaged buyers enter the market as earnings approached with the 50-day moving average transitioning into a bullish trend.
Our model has detected added potential pressure from the short-selling crowd as the already high short interest saw a last minute push higher as the short interest ratio for VAR shares surged to a reading of 16. This is the highest reading of the short interest ratio in more than two years and adds pressure to variant shares for a short-covering rally.
Considering the technical strength and pessimistic backdrop, our models are targeting a move to $115.
As of this writing, Johnson Research Group did not hold a position in any of the aforementioned securities.
The post 7 Explosive Healthcare Stocks to Buy Now appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the rally that kicked-off in May. Last week, after earnings, AbbVie shares pulled back to their 50-day moving average, where they are holding a bull/bear battle. | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the rally that kicked-off in May. Last week, after earnings, AbbVie shares pulled back to their 50-day moving average, where they are holding a bull/bear battle. | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the rally that kicked-off in May. Last week, after earnings, AbbVie shares pulled back to their 50-day moving average, where they are holding a bull/bear battle. | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the rally that kicked-off in May. Last week, after earnings, AbbVie shares pulled back to their 50-day moving average, where they are holding a bull/bear battle. |
26060.0 | 2017-07-31 00:00:00 UTC | 5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You | ABBV | https://www.nasdaq.com/articles/5-things-gilead-sciences-q2-earnings-numbers-didnt-tell-you-2017-07-31 | nan | nan | The numbers didn't lie: Gilead Sciences (NASDAQ: GILD) posted pretty good second-quarter results . While revenue and earnings fell compared to the prior-year period, the big biotech still managed to beat expectations thanks to strong HIV drug sales and a better-than-expected performance from its hepatitis C virus (HCV) franchise. Gilead even upped its full-year 2017 guidance.
But any company's quarterly results are just a snapshot looking in the rearview mirror. They don't reveal everything investors need to know about where a company is headed.
However, management sometimes provides a few clues in theearnings conference callthat can hepatitis investors get a better feel for what could be in store. With that in mind, here are five things Gilead Sciences' second-quarter earnings numbers didn't tell you -- but for which the biotech's management shared some insight. (Quotes courtesy of S&P Global Market Intelligence .)
1. What effect new competition will have on HCV sales
While Gilead's second-quarter HCV sales came in higher than analysts (and Gilead itself) expected, the company will have a new rival to contend with in the third quarter. AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S.
AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. Maviret, though, could be in position to challenge Gilead's pan-genotypic HCV drug, Epclusa. AbbVie's level of success with Maviret is important for Gilead, since Epclusa has been the main bright spot amid the dark overall picture for Gilead's HCV franchise.
Gilead's COO, Kevin Young, used guarded language when asked about the potential threat from AbbVie, saying that Gilead would need to see its rival's pricing and promotional strategy to determine what steps to take. Norbert Bischofberger, Gilead's head of research and development, was a little less cautious, though. He thought that AbbVie's clinical results weren't so impressive outside of HCV genotype 1. Expect Gilead's sales reps to hammer this point hard when positioning Epclusa against Maviret.
2. When HCV sales will stabilize
Despite a better-than-expected quarter for its HCV franchise, don't read too much into the results just yet. Kevin Young stated that Gilead continues to project "a gradual trend down" for HCV sales. He added, "where that sort of turns the corner or bottoms out right now still remains to be seen."
While Gilead will face increased competition from AbbVie, there was a nugget of good news in the second quarter. Gilead launched a major educational campaign in October 2016 to encourage baby boomers to get tested for HCV. Young said that Gilead's research "shows that there has been an 80% increase in HCV antibody screening by baby boomers since the start of this initiative."
3. Just how dominant Gilead is in HIV
The second-quarter numbers for Gilead's HIV franchise looked great. That was especially the case for Genvoya, with sales of $857 million in the quarter -- up 184% year over year. But these numbers still don't reveal just how dominant Gilead continues to be in HIV.
Genvoya has a 41% market share in the treatment-naive HIV market, more than twice that of the No. 2 therapy. In France, the largest HIV market in Europe, Genvoya became the most-prescribed treatment for treatment-naive and switch patients just four months after its launch. Gilead's single-tablet regimens take four of the top five spots among the most-prescribed HIV treatments.
4. How big of an impact the pipeline will have
Although the numbers in Gilead's latest financial update don't tell us anything about its pipeline prospects, there was plenty of good news in the second quarter and shortly afterward. The biotech won FDA approval for HCV drug Vosevi in July. It submitted the bictegravir/F/TAF combo for U.S. approval in treating HIV.
The bictegravir combo will be enormously important for Gilead's future. The expected strength of this HIV drug landed Gilead a spot in the top five drug pipelines as ranked by market research firm EvaluatePharma.
But how well will the bictegravir combo compete against GlaxoSmithKline 's (NYSE: GSK) Tivicay in combination with F/TAF? Norbert Bischofberger acknowledged that the two combos are "virologically identical." However, he pointed out that Gilead will have one single pill with only one co-pay required -- a potentially key differentiation from Glaxo's drug.
5. Which company Gilead will acquire and when it will happen
The main unanswered questions for Gilead are related to its acquisition strategy. Investors have been waiting a while for the big biotech to make a deal.
Gilead CEO John Milligan said that the company's focus and priorities on the business development front haven't changed. He referenced Gilead's staff additions, stating that this allows the company to "evaluate more different kinds of opportunities." Milligan added that Gilead is "very, very active" with respect to looking at acquisition opportunities.
When will something happen? Milligan simply stated, "When the things are right for us, we'll announce them. That's all I can say."
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short August 2017 $75 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S. AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. AbbVie's level of success with Maviret is important for Gilead, since Epclusa has been the main bright spot amid the dark overall picture for Gilead's HCV franchise. | AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S. AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. AbbVie's level of success with Maviret is important for Gilead, since Epclusa has been the main bright spot amid the dark overall picture for Gilead's HCV franchise. | AbbVie's level of success with Maviret is important for Gilead, since Epclusa has been the main bright spot amid the dark overall picture for Gilead's HCV franchise. AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S. AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. | AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S. AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. AbbVie's level of success with Maviret is important for Gilead, since Epclusa has been the main bright spot amid the dark overall picture for Gilead's HCV franchise. |
26061.0 | 2017-07-28 00:00:00 UTC | Dow Hits Another Record, NASDAQ Hits a Wall | ABBV | https://www.nasdaq.com/articles/dow-hits-another-record-nasdaq-hits-wall-2017-07-28 | nan | nan | It appeared that the NASDAQ was well on its way to an amazing 14th gain in 15 days on Thursday...and then the bottom dropped out. All of a sudden, the index plunged by approximately 1.5% at its lowest point. It was able to make up a good amount of that loss by the closing bell, but was still off by 0.63% today to 6382.2.
The editors aren't alarmed. Steve suggested that it could be "nothing more than a temporary case of altitude sickness" in RTA . And as you'll see in the highlights section below, Dave said in Momentum Trader that this drop provides one of the better buying opportunities in a while.
The other two major indices dipped along with the NASDAQ, but the concern was with technology stocks. Therefore, though slipping momentarily into negative territory, the Dow recovered nicely to advance 0.39% for another new high of 21796.6. The S&P also had a nice rebound but still declined 0.10% to 2475.4. Tomorrow could be a big day for the market as Q2 GDP is released in the morning. Also, it looks like Amazon's numbers after the bell today were disappointing, so that could have an impact as well.
It was a busy day in the portfolios with several editors taking some big profits off the table. Look at all the moves in the highlights section below:
Today's Portfolio Highlights:
Zacks Counterstrike: In early May, Craft Brew Alliance (BREW) announced a positive surprise of 50%, and now its getting prepared to report again next week. It's been a winner for the portfolio, though it has recently slipped to a Zacks Rank #3 (Hold). Jeremy decided that this was a good time to sell half of the position and take a 13.5% profit. He'll watch to see what the other half does from here.
In other moves, shares of Wynn Resorts (WYNN) have slipped to the $130 level despite beating on both the top and bottom lines in its latest report. This has "Zacks Counterstrike" written all over it, especially since it has now dropped into Jeremy's beloved Fibonacci long scenario. The editor thinks this best-in-breed casino is worth more than $145, so he bought it today with a 7% allocation. WYNN has already been a winner for the portfolio when it was sold for 12.7% back in June. Furthermore, Jeremy also doubled down on his Thor Industries (THO) position with an extra 5% allocation. Read the complete write up for more.
Reitmeister Trading Alert: Sometimes you just get lucky. There's no way to sugar coat the recent earnings report from Penn Gaming (PENN); it was a bad showing with a big miss and a lowered guidance. Steve expected the stock to plunge by 10% or maybe even 20%. But the stock only dropped by about 2%. The editor's first instinct was to only sell half, but the surprising response convinced him to sell the whole thing and take a more than 11% profit. Phew! Steve also decided to sell some of Aaron's (AAN) ahead of its earnings report for a 9.6% return. He's holding onto a 6.1% allocation in case the company continues to impress with its turnaround efforts.
Options Trader: The portfolio had a trio of moves on Thursday. Here they are:
• Landstar (LSTR) is getting pounded today despite a positive beat last night. Kevin believes the move is way overdone, but he sees an opportunity now that the plunge has decimated the short side of yesterday's bull call spread. He decided to leg out of the spread by buying to close the Oct. 95.00 Call and taking an 82% profit. The editor still likes LSTR and has no problem keeping the long call for the eventual move back up.
• CDW (CDW): Kevin still likes this stock, but it has a negative Earnings ESP heading into next week's report on Thursday (8/3). So he decided to remove the bull call spreads by selling to close the two Sept 60.00 Calls AND buying to close the two Sept 65.00 Calls. The spreads brought a gain of 38%.
• AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. If they miss, then the Nov 70.00 Call would get crushed. However, a smaller risk profile would limit the loss, but still make money if it beats. Therefore, the editor sold to close the Nov call for a 21% gain and then bought to open an Aug. 72.50 Call.
Learn a lot more about these moves in the complete commentary.
Large-Cap Trader:"Yes, that was profit-taking today. I think this rally is not over, as the second quarter keeps showing us more beats than any quarter we have seen in some time.
"However, as our portfolio shows this week, underlying the broad move upwards in major indexes is lots and lots of sloppy share price action.
"I can't help but see the algos shorting and thrashing their way across the earnings landscape, manipulating what news they can to their advantage.
"Once the battlefield clears, and the troops look for their flag, the news that we are headed to record earnings, on top of record stock prices, will be seen more broadly.
"In other words, don't pay too much attention to any given stock right now. Pay attention to overall earnings and overall price action." -- John Blank
Momentum Trader:"Seemingly out of nowhere the market got an upset stomach this afternoon and turned things upside down. The NASDAQ led the way down and several names lost their footing. No real cause for alarm as there wasn't really much fundamental justification for the selling. I think this afternoon gave the market a great buying opportunity.
"It's extraordinary to me that the NASDAQ finished the day off just 63 bps, cutting the losses in half. I see Amazon's profits were off a bit and that's certainly not going to help us overnight. However, I will be out there looking for stocks to add tomorrow morning. I'm hoping we gap lower so I find some deals.
"A little black eye for tech today shouldn't scare off investors. Rather, we should be looking at this as an opportunity to add more exposure. The large caps didn't seem to be bothered by the action so neither should you. Get your shopping list together and get to work." -- Dave Bartosiak
All the Best,
Jim Giaquinto
Recommendations from Zacks' Private Portfolios:
Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >>
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. Kevin believes the move is way overdone, but he sees an opportunity now that the plunge has decimated the short side of yesterday's bull call spread. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. Look at all the moves in the highlights section below: Today's Portfolio Highlights: Zacks Counterstrike: In early May, Craft Brew Alliance (BREW) announced a positive surprise of 50%, and now its getting prepared to report again next week. So he decided to remove the bull call spreads by selling to close the two Sept 60.00 Calls AND buying to close the two Sept 65.00 Calls. | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. Look at all the moves in the highlights section below: Today's Portfolio Highlights: Zacks Counterstrike: In early May, Craft Brew Alliance (BREW) announced a positive surprise of 50%, and now its getting prepared to report again next week. So he decided to remove the bull call spreads by selling to close the two Sept 60.00 Calls AND buying to close the two Sept 65.00 Calls. | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. The editors aren't alarmed. And as you'll see in the highlights section below, Dave said in Momentum Trader that this drop provides one of the better buying opportunities in a while. |
26062.0 | 2017-07-28 00:00:00 UTC | Health Care Sector Update for 07/28/2017: ENTA, ABBV, CYTR, ATNM | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-07282017-enta-abbv-cytr-atnm-2017-07-28 | nan | nan | Top Health Care Stocks
JNJ +0.84%
PFE +0.47%
ABT -0.91%
MRK +0.72%
AMGN +1.52%
Health care stocks continued to add to their prior gains on Friday, with the NYSE Health Care Index rising more than 0.3% while shares of health care companies in the S&P 500 were up almost 0.6% as a group.
In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 52-week high of $38.40 a share after the company said corporate partner AbbVie ( ABBV ) today received marketing authorization for its Maviret drug treatment for hepatitis C virus from European regulators, triggering a $25 million milestone payment for Enanta from AbbVie.
AbbVie shares also were lower this afternoon, falling more than 2% to around $70 apiece shortly before the closing bell.
In other sector news,
(+) CYTR, NantCell licenses the company's aldoxorubicin chemotherapy drug and acquires 11.8 mln CytRx shares for $13 mln, or $1.10 per share - a 92% premium over Thursday's closing price. License pact also includes up to $343 mln in milestone payments plus double-digit royalties.
(-) ATNM, Prices $16.1 mln public offering of 21.5 mln shares at 75 cents each, a 22.5% discount to Thursday's closing price. Also issues five-year warrants to buy up to 18.3 mln more shares at $1.05 apiece.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 52-week high of $38.40 a share after the company said corporate partner AbbVie ( ABBV ) today received marketing authorization for its Maviret drug treatment for hepatitis C virus from European regulators, triggering a $25 million milestone payment for Enanta from AbbVie. AbbVie shares also were lower this afternoon, falling more than 2% to around $70 apiece shortly before the closing bell. License pact also includes up to $343 mln in milestone payments plus double-digit royalties. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 52-week high of $38.40 a share after the company said corporate partner AbbVie ( ABBV ) today received marketing authorization for its Maviret drug treatment for hepatitis C virus from European regulators, triggering a $25 million milestone payment for Enanta from AbbVie. AbbVie shares also were lower this afternoon, falling more than 2% to around $70 apiece shortly before the closing bell. | In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 52-week high of $38.40 a share after the company said corporate partner AbbVie ( ABBV ) today received marketing authorization for its Maviret drug treatment for hepatitis C virus from European regulators, triggering a $25 million milestone payment for Enanta from AbbVie. AbbVie shares also were lower this afternoon, falling more than 2% to around $70 apiece shortly before the closing bell. Health care stocks continued to add to their prior gains on Friday, with the NYSE Health Care Index rising more than 0.3% while shares of health care companies in the S&P 500 were up almost 0.6% as a group. | AbbVie shares also were lower this afternoon, falling more than 2% to around $70 apiece shortly before the closing bell. In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 52-week high of $38.40 a share after the company said corporate partner AbbVie ( ABBV ) today received marketing authorization for its Maviret drug treatment for hepatitis C virus from European regulators, triggering a $25 million milestone payment for Enanta from AbbVie. Top Health Care Stocks |
26063.0 | 2017-07-28 00:00:00 UTC | AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q2-earnings-revenues-outlook-intact-2017-07-28 | nan | nan | AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. The company surpassed both earnings and sales expectations.
In the year so far, AbbVie's shares have rallied 11.8%, thus favorably comparing with the industry 's increase of 9.9%.
The company posted revenues of $6.94 billion in the reported quarter, which again narrowly surpassed the Zacks Consensus Estimate of $6.93 billion. Revenues also increased 8% year over year. On operational basis, revenue increased 8.9%.
Quarter in Detail
Key drug Humira recorded sales growth of 14.9%, on an operational basis, with revenues coming in at $4.72 billion. Sales in the U.S. increased 18% to $3.2 billion. Humira sales in the ex-U.S. market were up 9.1% on operational basis and 5.5% on reported basis to $1.52 billion. Growth across all three major market categories drove the upside despite increasing competition from new classes of drugs as well as indirect biosimilar competition in international markets.
Second-quarter net revenue from Imbruvica stood at $626 million, up 42.6% year over year. U.S. sales of Imbruvica were $528 million, up 37.6% compared to the year-ago figure. AbbVie recorded $98 million of international profit-sharing with Johnson & Johnson JNJ .
Other products that delivered an impressive performance include Duodopa, showing revenues of $81 million, up 16% on operational and 12.7% on reported basis. Another product called Creon reported revenues of $196 million, up 9.5% on both operational and reported basis.
HCV product Viekira recorded sales of $225 million, down 14.4% sequentially. Sales were also down on operational and reported basis by 45.9% and 46.4%, respectively, due to intense pricing and competitive pressure in the HCV market.
Adjusted SG&A expenses dipped 2.2% to $1.41 billion while R&D expenses escalated 21.6% to $1.21 billion in the quarter. Adjusted operating margin was 44.6% of sales in the reported quarter.
2017 Outlook
AbbVie reiterated its previously issued outlook for 2017. The company maintains its adjusted EPS in the range of $5.44-$5.54, thus reflecting year-over-year growth of 13.9% at the mid-point.
AbbVie Inc. Price, Consensus and EPS Surprise
AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote
Zacks Rank & Key Picks
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Sanofi SNY , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Eli Lilly's earnings per share estimates inched up from $4.11 to $4.14 for 2017 and from $4.35 to $4.49 for 2018, over the last 30 days. The company's shares have shot up 12.9% so far this year.
Sanofi's earnings per share estimates increased from $3.18 to $3.24 for 2017 and from $3.30 to $3.38 for 2018, over the last 30 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 5.10%. Shares of the company have risen 18.9% so far this year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. In the year so far, AbbVie's shares have rallied 11.8%, thus favorably comparing with the industry 's increase of 9.9%. AbbVie recorded $98 million of international profit-sharing with Johnson & Johnson JNJ . | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. In the year so far, AbbVie's shares have rallied 11.8%, thus favorably comparing with the industry 's increase of 9.9%. |
26064.0 | 2017-07-28 00:00:00 UTC | AbbVie (ABBV) Tops Q2 Earnings and Revenue | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q2-earnings-and-revenue-2017-07-28 | nan | nan | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment).
Humira, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on Viekira's performance as well as pipeline updates.
Meanwhile, the Pharmacyclics acquisition has diversified AbbVie's product portfolio with the addition of Imbruvica.
AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. The average earnings beat over the last four quarters is 1.65%.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AbbVie's second-quarter earnings came in at $1.42 per share, beating the Zacks Consensus Estimate of $1.40.
Revenues: AbbVie posted revenues of $6.94 billion, marginally beating the Zacks Consensus Estimate of $6.93 billion.
Key Stats: Humira sales came in at $4.7 billion, up 14.9% year over year excluding currency impact. Second-quarter Imbruvica net revenues were $626 million, up 42.6% year over year.
2017 Outlook: AbbVie reiterated its previously issues outlook for 2017. The company maintains its adjusted EPS in the range of $5.44-$5.54. The Zacks Consensus Estimate is currently pegged at $5.52 per share.
Share Price Impact: Shares were up almost 2% in pre-market trading .
Check back later for our full write up on this AbbVie earnings report.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaries," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. Revenues: AbbVie posted revenues of $6.94 billion, marginally beating the Zacks Consensus Estimate of $6.93 billion. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's second-quarter earnings came in at $1.42 per share, beating the Zacks Consensus Estimate of $1.40. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's second-quarter earnings came in at $1.42 per share, beating the Zacks Consensus Estimate of $1.40. Revenues: AbbVie posted revenues of $6.94 billion, marginally beating the Zacks Consensus Estimate of $6.93 billion. |
26065.0 | 2017-07-28 00:00:00 UTC | Opus Investment Management Inc Buys Vanguard High Dividend Yield ETF - DNQ, Schwab US Dividend ... | ABBV | https://www.nasdaq.com/articles/opus-investment-management-inc-buys-vanguard-high-dividend-yield-etf-dnq-schwab-us | nan | nan | Opus Investment Management Inc
New Purchases: OKE , COST , XOM , FITB, USB, OGE,
Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS,
Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR,
Sold Out:DVY,
For the details of OPUS INVESTMENT MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=OPUS+INVESTMENT+MANAGEMENT+INC
These are the top 5 holdings of OPUS INVESTMENT MANAGEMENT INC
Vanguard Total Stock Market ( VTI ) - 1,078,755 shares, 23.43% of the total portfolio. Shares added by 0.43%
Vanguard FTSE Developed Markets ( VEA ) - 1,694,300 shares, 12.22% of the total portfolio. Shares added by 1.52%
Schwab US Dividend Equity ( SCHD ) - 579,500 shares, 4.56% of the total portfolio. Shares added by 47.64%
Vanguard High Dividend Yield ETF - DNQ ( VYM ) - 263,200 shares, 3.59% of the total portfolio. Shares added by 70.14%
AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Shares reduced by 4.92%
New Purchase: ONEOK Inc (OKE)
Opus Investment Management Inc initiated holdings in ONEOK Inc. The purchase prices were between $47.41 and $56.33, with an estimated average price of $51.84. The stock is now traded at around $56.79. The impact to the portfolio due to this purchase was 0.27%. The holdings were 30,000 shares as of 2017-06-30.
New Purchase: Costco Wholesale Corp (COST)
Opus Investment Management Inc initiated holdings in Costco Wholesale Corp. The purchase prices were between $157.13 and $182.45, with an estimated average price of $172.43. The stock is now traded at around $152.61. The impact to the portfolio due to this purchase was 0.2%. The holdings were 7,200 shares as of 2017-06-30.
New Purchase: Exxon Mobil Corp (XOM)
Opus Investment Management Inc initiated holdings in Exxon Mobil Corp. The purchase prices were between $79.5 and $83.49, with an estimated average price of $81.84. The stock is now traded at around $79.00. The impact to the portfolio due to this purchase was 0.11%. The holdings were 8,000 shares as of 2017-06-30.
New Purchase: Fifth Third Bancorp (FITB)
Opus Investment Management Inc initiated holdings in Fifth Third Bancorp. The purchase prices were between $23.62 and $26.07, with an estimated average price of $24.71. The stock is now traded at around $26.28. The impact to the portfolio due to this purchase was 0.06%. The holdings were 13,000 shares as of 2017-06-30.
New Purchase: US Bancorp (USB)
Opus Investment Management Inc initiated holdings in US Bancorp. The purchase prices were between $49.69 and $52.94, with an estimated average price of $51.48. The stock is now traded at around $52.35. The impact to the portfolio due to this purchase was 0.06%. The holdings were 6,300 shares as of 2017-06-30.
New Purchase: OGE Energy Corp (OGE)
Opus Investment Management Inc initiated holdings in OGE Energy Corp. The purchase prices were between $33.61 and $36.47, with an estimated average price of $34.98. The stock is now traded at around $35.73. The impact to the portfolio due to this purchase was 0.05%. The holdings were 8,700 shares as of 2017-06-30.
Added: Vanguard High Dividend Yield ETF - DNQ ( VYM )
Opus Investment Management Inc added to the holdings in Vanguard High Dividend Yield ETF - DNQ by 70.14%. The purchase prices were between $76.38 and $79.87, with an estimated average price of $77.86. The stock is now traded at around $79.11. The impact to the portfolio due to this purchase was 1.48%. The holdings were 263,200 shares as of 2017-06-30.
Added: Schwab US Dividend Equity ( SCHD )
Opus Investment Management Inc added to the holdings in Schwab US Dividend Equity by 47.64%. The purchase prices were between $44.09 and $46.05, with an estimated average price of $44.99. The stock is now traded at around $45.64. The impact to the portfolio due to this purchase was 1.47%. The holdings were 579,500 shares as of 2017-06-30.
Added: BB&T Corp (BBT)
Opus Investment Management Inc added to the holdings in BB&T Corp by 20.57%. The purchase prices were between $41.65 and $45.61, with an estimated average price of $43.41. The stock is now traded at around $46.94. The impact to the portfolio due to this purchase was 0.17%. The holdings were 123,100 shares as of 2017-06-30.
Added: Wells Fargo & Co (WFC)
Opus Investment Management Inc added to the holdings in Wells Fargo & Co by 20.59%. The purchase prices were between $51.14 and $55.78, with an estimated average price of $53.58. The stock is now traded at around $53.30. The impact to the portfolio due to this purchase was 0.17%. The holdings were 102,500 shares as of 2017-06-30.
Added: International Paper Co (IP)
Opus Investment Management Inc added to the holdings in International Paper Co by 46.15%. The purchase prices were between $49.64 and $56.94, with an estimated average price of $53.28. The stock is now traded at around $56.46. The impact to the portfolio due to this purchase was 0.12%. The holdings were 38,000 shares as of 2017-06-30.
Added: Dr Pepper Snapple Group Inc (DPS)
Opus Investment Management Inc added to the holdings in Dr Pepper Snapple Group Inc by 27.50%. The purchase prices were between $90.23 and $98.88, with an estimated average price of $93.67. The stock is now traded at around $91.40. The impact to the portfolio due to this purchase was 0.05%. The holdings were 15,300 shares as of 2017-06-30.
Sold Out: iShares Select Dividend (DVY)
Opus Investment Management Inc sold out the holdings in iShares Select Dividend. The sale prices were between $90.06 and $94.5, with an estimated average price of $91.92.
List of 52-Week Lows
List of 3-Year Lows
List of 5-Year Lows
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, For the details of OPUS INVESTMENT MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=OPUS+INVESTMENT+MANAGEMENT+INC These are the top 5 holdings of OPUS INVESTMENT MANAGEMENT INC Vanguard Total Stock Market ( VTI ) - 1,078,755 shares, 23.43% of the total portfolio. Added: Vanguard High Dividend Yield ETF - DNQ ( VYM ) Opus Investment Management Inc added to the holdings in Vanguard High Dividend Yield ETF - DNQ by 70.14%. | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, For the details of OPUS INVESTMENT MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=OPUS+INVESTMENT+MANAGEMENT+INC These are the top 5 holdings of OPUS INVESTMENT MANAGEMENT INC Vanguard Total Stock Market ( VTI ) - 1,078,755 shares, 23.43% of the total portfolio. New Purchase: Costco Wholesale Corp (COST) Opus Investment Management Inc initiated holdings in Costco Wholesale Corp. | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, For the details of OPUS INVESTMENT MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=OPUS+INVESTMENT+MANAGEMENT+INC These are the top 5 holdings of OPUS INVESTMENT MANAGEMENT INC Vanguard Total Stock Market ( VTI ) - 1,078,755 shares, 23.43% of the total portfolio. Shares reduced by 4.92% New Purchase: ONEOK Inc (OKE) Opus Investment Management Inc initiated holdings in ONEOK Inc. | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, For the details of OPUS INVESTMENT MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=OPUS+INVESTMENT+MANAGEMENT+INC These are the top 5 holdings of OPUS INVESTMENT MANAGEMENT INC Vanguard Total Stock Market ( VTI ) - 1,078,755 shares, 23.43% of the total portfolio. Shares added by 1.52% Schwab US Dividend Equity ( SCHD ) - 579,500 shares, 4.56% of the total portfolio. |
26066.0 | 2017-07-28 00:00:00 UTC | AbbVie Inc (ABBV) Q2 Beat Fueled by Best World’s Best-Selling Drug | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-q2-beat-fueled-by-best-worlds-best-selling-drug-2017-07-28 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. ABBV stock was little changed at 9:22 am ahead of the market open.
Source: Black Stripe via Wikimedia (Modified)
The Chicago-based biopharmaceutical company beat analysts estimates of $1.40 per share
AbbVie's net revenue rose 7.6% to $6.94 billion; Analysts average forecast was $6.93 billion
ABBV said sales of Humira increased 13.7% to $4.72 billion in the quarter ended June 30; the rheumatoid arthritis treatment is the world's top selling drug, according to Reuters
AbbVie management confirmed its 2017 GAAP diluted EPS guidance in the range of $4.55 to $4.65; 2017 adjusted diluted EPS guidance range of $5.44 to $5.54
Guidance reflects growth of 13.9% at the midpoint
ABBV stock is up almost 20% in past six months
InvestorPlace contributor Nicolas Chahine wrote on July 14 that ABBV stock "isn't done charting new highs yet."
More From InvestorPlace
The Top 10 ETFs Money Can Buy
7 'Millennial' Stocks to Buy No Matter What Age You Are
3 Hot Semiconductor Stocks, 3 Time Bombs
The post AbbVie Inc (ABBV) Q2 Beat Fueled by Best World's Best-Selling Drug appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. Source: Black Stripe via Wikimedia (Modified) The Chicago-based biopharmaceutical company beat analysts estimates of $1.40 per share AbbVie's net revenue rose 7.6% to $6.94 billion; Analysts average forecast was $6.93 billion ABBV said sales of Humira increased 13.7% to $4.72 billion in the quarter ended June 30; the rheumatoid arthritis treatment is the world's top selling drug, according to Reuters AbbVie management confirmed its 2017 GAAP diluted EPS guidance in the range of $4.55 to $4.65; 2017 adjusted diluted EPS guidance range of $5.44 to $5.54 Guidance reflects growth of 13.9% at the midpoint ABBV stock is up almost 20% in past six months InvestorPlace contributor Nicolas Chahine wrote on July 14 that ABBV stock "isn't done charting new highs yet." More From InvestorPlace The Top 10 ETFs Money Can Buy 7 'Millennial' Stocks to Buy No Matter What Age You Are 3 Hot Semiconductor Stocks, 3 Time Bombs The post AbbVie Inc (ABBV) Q2 Beat Fueled by Best World's Best-Selling Drug appeared first on InvestorPlace . | Source: Black Stripe via Wikimedia (Modified) The Chicago-based biopharmaceutical company beat analysts estimates of $1.40 per share AbbVie's net revenue rose 7.6% to $6.94 billion; Analysts average forecast was $6.93 billion ABBV said sales of Humira increased 13.7% to $4.72 billion in the quarter ended June 30; the rheumatoid arthritis treatment is the world's top selling drug, according to Reuters AbbVie management confirmed its 2017 GAAP diluted EPS guidance in the range of $4.55 to $4.65; 2017 adjusted diluted EPS guidance range of $5.44 to $5.54 Guidance reflects growth of 13.9% at the midpoint ABBV stock is up almost 20% in past six months InvestorPlace contributor Nicolas Chahine wrote on July 14 that ABBV stock "isn't done charting new highs yet." The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. Source: Black Stripe via Wikimedia (Modified) The Chicago-based biopharmaceutical company beat analysts estimates of $1.40 per share AbbVie's net revenue rose 7.6% to $6.94 billion; Analysts average forecast was $6.93 billion ABBV said sales of Humira increased 13.7% to $4.72 billion in the quarter ended June 30; the rheumatoid arthritis treatment is the world's top selling drug, according to Reuters AbbVie management confirmed its 2017 GAAP diluted EPS guidance in the range of $4.55 to $4.65; 2017 adjusted diluted EPS guidance range of $5.44 to $5.54 Guidance reflects growth of 13.9% at the midpoint ABBV stock is up almost 20% in past six months InvestorPlace contributor Nicolas Chahine wrote on July 14 that ABBV stock "isn't done charting new highs yet." ABBV stock was little changed at 9:22 am ahead of the market open. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. ABBV stock was little changed at 9:22 am ahead of the market open. Source: Black Stripe via Wikimedia (Modified) The Chicago-based biopharmaceutical company beat analysts estimates of $1.40 per share AbbVie's net revenue rose 7.6% to $6.94 billion; Analysts average forecast was $6.93 billion ABBV said sales of Humira increased 13.7% to $4.72 billion in the quarter ended June 30; the rheumatoid arthritis treatment is the world's top selling drug, according to Reuters AbbVie management confirmed its 2017 GAAP diluted EPS guidance in the range of $4.55 to $4.65; 2017 adjusted diluted EPS guidance range of $5.44 to $5.54 Guidance reflects growth of 13.9% at the midpoint ABBV stock is up almost 20% in past six months InvestorPlace contributor Nicolas Chahine wrote on July 14 that ABBV stock "isn't done charting new highs yet." |
26067.0 | 2017-07-28 00:00:00 UTC | 4 Drug Stocks in Focus this World Hepatitis Day | ABBV | https://www.nasdaq.com/articles/4-drug-stocks-focus-world-hepatitis-day-2017-07-28 | nan | nan | Every year on Jul 28, World Hepatitis Day (WHD) is observed to raise awareness about viral hepatitis, one of the leading causes of death across the world.
According to the World Health Organization (WHO), viral hepatitis caused 1.34 million deaths across the world in 2015 and many people remain unaware of being infected by the same. While there are five types of hepatitis (A, B, C, D and E), hepatitis B and C are the two main killers with 257 million people living with hepatitis B and 71 million people living with hepatitis C.
About 90% of people living with hepatitis B and 80% living with hepatitis C are unaware of their status. Hepatitis B and C together account for 80% of liver cancer cases across the world.
Considering these numbers, it is not a surprise that quite a few pharma and biotech companies are working on bringing innovative treatments in this area to the market. However, challenges in the hepatitis C virus (HCV) market exist in the form of intense competition and pricing pressure.
Stocks in Focus
Here is a look at some of the key players in the hepatitis B and/or C markets.
Biotech major, Gilead Sciences, Inc. GILD is perhaps the most well-known name in the HCV market. HCV drugs include Harvoni, Sovaldi, Epclusa and the recently approved Vosevi while HBV offerings include Viread and Vemlidy.
However, the Foster City, CA-based company has seen a lot of ups and downs in this market. Gilead's HCV franchise was a major revenue contributor bringing in multi-billion dollar sales but increasing competition and pricing pressure resulted in a significant decline in HCV product sales in 2016. Even though Gilead recently raised its 2017 guidance for its HCV franchise, sales are nevertheless expected to witness a significant decline.
Gilead launched an educational campaign in 2016 to encourage baby boomers to get tested. According to the company, there has been an 80% increase in HCV antibody screening by baby boomers since the campaign started resulting in an increase in diagnosis as well. The company estimates that about 190,000 people were newly diagnosed with HCV in 2016, up 32% from 2015.
Gilead is conducting additional studies on Harvoni as well as Vemlidy and has an early-stage HBV candidate in its pipeline (GS-9688, a TLR-8 agonist). Gilead is a Zacks Rank #2 (Buy) stock. Year-to-date (YTD), the company's stock is up 4.7%, lagging the 10% rally of the industry it belongs to. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Large-cap pharma company, Merck & Co., Inc. MRK , is another big name in the HCV market. According to information provided by Merck, about 3.5 million people in the U.S. have chronic HCV infection. Merck's HCV portfolio comprises Zepatier, which was launched last year, PegIntron and Victrelis. However, the company's HCV franchise is not a major revenue generator. Earlier this year, Merck took a major impairment charge related to an HCV candidate that became a part of its pipeline following the 2014 acquisition of Idenix. The decision was taken based on changes to the product profile, as well as changes to the company's expectations for pricing and the market opportunity. Merck is a Zacks Rank #2 stock. YTD, the company's stock is up 8.2%, lagging the 10.7% rally of the industry it belongs to.
AbbVie Inc. ABBV also has a major presence in the HCV market. The company's HCV products include Viekira Pak and Technivie. AbbVie is currently seeking approval for Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). The once-daily ribavirin-free treatment has the potential to provide a faster path to virologic cure for all major HCV genotypes (GT1-6). Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched.
AbbVie is a Zacks Rank #3 (Hold) stock. AbbVie stock has gained 14.6% YTD, performing better than the industry it belongs to.
Watertown, MA-based Enanta Pharmaceuticals, Inc. ENTA has a collaboration with AbbVie for its protease inhibitors - paritaprevir and glecaprevir. While paritaprevir is a key compound in AbbVie's direct-acting-antiviral (DAA) regimen Viekira Pak and its other 3-DAA and 2-DAA treatment regimens currently on the market for HCV, glecaprevir in combination with pibrentasvir (G/P, Maviret) is currently under regulatory review. Enanta earns royalties from AbbVie on product sales. Meanwhile, Enanta is also working on developing its HBV pipeline -- the focus is currently on core inhibitors with clinical candidate identification planned for 2017.
Enanta is a Zacks Rank #3 stock. YTD, Enanta stock has gained 13.6%, outperforming the 5.5% rally of the industry it belongs to.
Bottom Line
The HCV market will continue to face challenges as more treatments enter the market resulting in increased competition and additional pricing pressure. In fact, HCV drugs have faced immense scrutiny due to their high prices. That said, the market nevertheless represents significant commercial opportunity. As per information provided by Enanta, the market for HCV therapies was worth about $16 billion in 2016. HCV patient starts usually witness a surge following the introduction of new drugs in the market. With a major part of HCV-infected people remaining undiagnosed, there remains significant opportunity in this market as awareness increases and newly diagnosed patients seek treatment.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ABBV also has a major presence in the HCV market. AbbVie is currently seeking approval for Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched. | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV also has a major presence in the HCV market. AbbVie is currently seeking approval for Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV also has a major presence in the HCV market. AbbVie is currently seeking approval for Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). | Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched. AbbVie Inc. ABBV also has a major presence in the HCV market. AbbVie is currently seeking approval for Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). |
26068.0 | 2017-07-28 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 45.5% Follow-Through Indicator, 3.1% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-455-follow-through-indicator-31-sensitive-2017-07-28 | nan | nan | Expected Earnings Release: 07/28/2017, Premarket
Avg. Extended-Hours Dollar Volume: $8,562,832
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 60%
Average next regular session additional gain: 2.2%
Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.2%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 33.3%
Average next regular session additional loss: 1%
Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 2.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 33.3% Average next regular session additional loss: 1% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close. Extended-Hours Dollar Volume: $8,562,832 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 2.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 33.3% Average next regular session additional loss: 1% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 2.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 33.3% Average next regular session additional loss: 1% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close. Extended-Hours Dollar Volume: $8,562,832 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $8,562,832 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 2.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.2%. |
26069.0 | 2017-07-27 00:00:00 UTC | Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV | ABBV | https://www.nasdaq.com/articles/fridays-earnings-reports-watch-xom-cvx-mrk-abbv-2017-07-27 | nan | nan | Earnings season is upon us, which means that countless publicly traded companies continue to release quarterly earnings reports, updating investors on the company's financial results and providing insight on how the economy has performed throughout the past quarter.
However, the insane amount of press releases during earnings season make it easy to for investors to become lost in the ocean of reports. Fortunately, the Zacks Earnings Calendar lists each company that is expected to report earnings on any given calendar date, making it a useful organizational tool for any investor.
With that said, let's break down a few of the most important upcoming reports. Check out these four major companies that will release earnings reports on Friday, July 28:
Exxon Mobil Corporation (XOM) - Friday, July 28 - Before Market Open
Crude oil giant Exxon Mobil will release its quarterly earnings report tomorrow morning before the market opens. Our Zacks Consensus Estimate calls for revenues of $61.16 billion, which would represent year-over-year growth of 6%. Additionally, the company is projected to report earnings of $0.83 per share, which would constitute year-over-year growth of a whopping 101.90%.
Exxon has collaborated with Russia for exploring potential commercial reserves in the country, yet tensions between the United States and Russia might lead to sanctions on the country. This would thwart any attempt Exxon could make to capitalize on oil reserves within Russia. Also, Exxon features a dividend yield of 3.8%, which is one of the lowest among major energy firms and sits below the industry average of 4.76%. These facts, along with a Zacks Rank #4 (Sell), should turn heads for the wrong reasons as the company prepares to release its earnings report.
Chevron Corporation (CVX) - Friday, July 28 - Before Market Open
Energy behemoth Chevron is expected to post its quarterly earnings report before the market opens on July 28. Our Zacks Consensus Estimate calls for Chevron to real in $31.18 billion in revenues and report earnings of $0.89 per share, which would constitute strong year-over-year growth of 6.49% and 85.68%, respectively.
However, in the first-quarter, Chevron generated just $3.9 billion in operating cash flow while dealing out around $5.3 billion in dividends and capital expenditures. This trend could be detrimental for the company if it continues over the next few quarters, as the company would be relying on asset sales and debt to fill the deficit. Also, Chevron's mass production in the violence-prone regions of Nigeria poses additional risk for investors. Chevron currently holds a Zacks Rank #4 (Sell), which could provide a gloomy financial outlook moving forward.
Merck & Company, Inc. (MRK) - Friday, July 28 - Before Market Open
Merck & Company is a large global research-driven pharmaceutical company that discovers, develops and manufactures vaccines and medicines to address unmet medical needs. More importantly, the company is expected to release its quarterly earnings report tomorrow morning. According to the latest Zacks Consensus Estimates, Merck & Company is projected to report sales of $9.79 billion and earnings of $0.87 per share.
Merck features an impressive product portfolio and pipeline, including many candidates in the advanced stages of development targeting multiple diseases such as atherosclerosis, cancer, diabetes, and cardiovascular disease. The company has continued to prioritize its pipeline so that the candidates with the highest potential get the required support. Investors should feel a sense of optimism since Merck currently sports a Zacks Rank #2 (Buy) and has beaten its earnings estimates in each of its past thirteen operational quarters dating back to 2014.
AbbVie Inc. (ABBV) - Friday, July 28 - Before Market Open
AbbVie is a global, research-based biopharmaceutical company which focuses developing and marketing advanced therapies that address some of the world's most complex diseases. According to the Zacks Consensus Estimates, AbbVie is projected to report revenues of $6.93 billion and earnings of $1.40 per share, which would constitute year-over-year growth of 7.43% and 11.27%, respectively.
AbbVie's flagship product, Humira, continues to drive revenues. The anti-inflammatory product has witnessed sales increases of 11.7% in 2015 and 16.1% in 2016. The company expects Humira to real in total sales of more than $18 billion in 2020. The fact that AbbVie has defeated its earnings projections in each of its past thirteen operational quarters dating back to 2014, coupled with its adequate Zacks Rank #3 (Hold), should instill some confidence in investors as we approach the report.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Chevron Corporation (CVX): Free Stock Analysis Report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The fact that AbbVie has defeated its earnings projections in each of its past thirteen operational quarters dating back to 2014, coupled with its adequate Zacks Rank #3 (Hold), should instill some confidence in investors as we approach the report. AbbVie Inc. (ABBV) - Friday, July 28 - Before Market Open AbbVie is a global, research-based biopharmaceutical company which focuses developing and marketing advanced therapies that address some of the world's most complex diseases. According to the Zacks Consensus Estimates, AbbVie is projected to report revenues of $6.93 billion and earnings of $1.40 per share, which would constitute year-over-year growth of 7.43% and 11.27%, respectively. | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. (ABBV) - Friday, July 28 - Before Market Open AbbVie is a global, research-based biopharmaceutical company which focuses developing and marketing advanced therapies that address some of the world's most complex diseases. According to the Zacks Consensus Estimates, AbbVie is projected to report revenues of $6.93 billion and earnings of $1.40 per share, which would constitute year-over-year growth of 7.43% and 11.27%, respectively. | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. (ABBV) - Friday, July 28 - Before Market Open AbbVie is a global, research-based biopharmaceutical company which focuses developing and marketing advanced therapies that address some of the world's most complex diseases. According to the Zacks Consensus Estimates, AbbVie is projected to report revenues of $6.93 billion and earnings of $1.40 per share, which would constitute year-over-year growth of 7.43% and 11.27%, respectively. | AbbVie Inc. (ABBV) - Friday, July 28 - Before Market Open AbbVie is a global, research-based biopharmaceutical company which focuses developing and marketing advanced therapies that address some of the world's most complex diseases. According to the Zacks Consensus Estimates, AbbVie is projected to report revenues of $6.93 billion and earnings of $1.40 per share, which would constitute year-over-year growth of 7.43% and 11.27%, respectively. AbbVie's flagship product, Humira, continues to drive revenues. |
26070.0 | 2017-07-27 00:00:00 UTC | Pre-Market Earnings Report for July 28, 2017 : XOM, CVX, MRK, ABBV, TRP, LYB, HCN, BEN, WY, IMO, AAL, VTR | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-july-28-2017-xom-cvx-mrk-abbv-trp-lyb-hcn-ben-wy-imo-aal-vtr | nan | nan | The following companies are expected to report earnings prior to market open on 07/28/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation ( XOM ) is reporting for the quarter ending June 30, 2017. The oil company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.83. This value represents a 102.44% increase compared to the same quarter last year. XOM missed the consensus earnings per share in the 2nd calendar quarter of 2016 by -35.94%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for XOM is 22.90 vs. an industry ratio of 21.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Chevron Corporation ( CVX ) is reporting for the quarter ending June 30, 2017. The oil company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.89. This value represents a 85.42% increase compared to the same quarter last year. CVX missed the consensus earnings per share in the 4th calendar quarter of 2016 by -65.63%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for CVX is 26.02 vs. an industry ratio of 21.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Merck & Company, Inc. ( MRK ) is reporting for the quarter ending June 30, 2017. The large cap pharmaceutical company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.87. This value represents a 6.45% decrease compared to the same quarter last year. In the past year MRK has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 6.02%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for MRK is 16.05 vs. an industry ratio of 17.30.
AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. The large cap pharmaceutical company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.40. This value represents a 11.11% increase compared to the same quarter last year. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30.
TransCanada Corporation ( TRP ) is reporting for the quarter ending June 30, 2017. The oil (production/pipeline) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.50. This value represents a 25.00% increase compared to the same quarter last year. The last two quarters TRP had negative earnings surprises; the latest report they missed by -7.58%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for TRP is 24.10 vs. an industry ratio of 27.00.
LyondellBasell Industries NV ( LYB ) is reporting for the quarter ending June 30, 2017. The chemical company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.73. This value represents a 11.43% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for LYB is 8.80 vs. an industry ratio of 17.00.
Welltower Inc. ( HCN ) is reporting for the quarter ending June 30, 2017. The reit company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.05. This value represents a 8.70% decrease compared to the same quarter last year. In the past year HCN has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for HCN is 17.49 vs. an industry ratio of 29.30.
Franklin Resources, Inc. ( BEN ) is reporting for the quarter ending June 30, 2017. The finance/investment management company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.73. This value represents a 5.19% decrease compared to the same quarter last year. In the past year BEN has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 10.45%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BEN is 15.95 vs. an industry ratio of 9.50, implying that they will have a higher earnings growth than their competitors in the same industry.
Weyerhaeuser Company ( WY ) is reporting for the quarter ending June 30, 2017. The building company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.27. This value represents a 58.82% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for WY is 33.25 vs. an industry ratio of 26.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Imperial Oil Limited ( IMO ) is reporting for the quarter ending June 30, 2017. The consensus earnings per share forecast from the 4 analysts that follow the stock is $0.23. IMO reported earnings of $-0.16 per share for the same quarter a year ago; representing a a decrease of -243.75%.
American Airlines Group, Inc. ( AAL ) is reporting for the quarter ending June 30, 2017. The airline company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.87. This value represents a 5.65% increase compared to the same quarter last year. In the past year AAL has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for AAL is 9.85 vs. an industry ratio of 9.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Ventas, Inc. ( VTR ) is reporting for the quarter ending June 30, 2017. The reit company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.05. This value represents a 0.96% increase compared to the same quarter last year. In the past year VTR has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for VTR is 16.33 vs. an industry ratio of 29.30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. |
26071.0 | 2017-07-27 00:00:00 UTC | Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales | ABBV | https://www.nasdaq.com/articles/vertex-vrtx-q2-earnings-top-on-solid-cystic-fibrosis-sales-2017-07-27 | nan | nan | Vertex Pharmaceuticals IncorporatedVRTX reported second-quarter 2017 earnings per share of 10 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 6 cents. Notably, the company had posted a loss of 1 cent in the year-ago quarter. Strong product revenues led to higher profits in the quarter.
Excluding stock-based compensation expense, second-quarter adjusted earnings were 39 cents per share compared with the year-ago figure of 24 cents.
Vertex reported revenues of $544.1 million in the second quarter, up 26.1% year over year driven by strong product revenues. Revenues also beat the Zacks Consensus Estimate of $487.9 million by 11.5%.
CF Franchise Sales Strong
Vertex's second-quarter revenues consisted of sales from cystic fibrosis (CF) products - Kalydeco and Orkambi, collaborative ($27.3 million) and royalty revenues ($2.9 million). CF product revenues were $514 million in the second quarter, up 21% year over year.
Kalydeco sales rose 5% to $190 million gaining from inventory stocking of $5 million ahead of the Jul 4 holiday.
In May this year, Kalydeco was approved for use in CF patients 2 years and older who have one of 23 residual function mutations in the CFTR gene. More than 900 people in the U.S. have one of these mutations. The expanded indication should boost sales of the drug in future quarters.
Orkambi (lumacaftor/ivacaftor) delivered sales of $324.0 million, up 32% year over year. On a sequential basis, Orkambi sales rose almost 10% in the second quarter, supported by continued uptake globally and further uptake in the pediatric indication for which approval was received in Sep 2016. Meanwhile, an inventory stocking of $10 million ahead of the Jul4 holiday also benefited sales in the second quarter.
Costs Rise
Adjusted (including stock-based compensation expenses) research and development expenses increased 10% to $284.3 million in the second quarter due to higher costs related to development of triple combination CF regimens. Adjusted (including stock-based compensation expenses) selling, general and administrative (SG&A) expenses increased 10.7% to $121.7 million due to increased investment to support the global launch of Orkambi.
Maintains 2017 Guidance
Vertex maintained its 2017 guidance for Orkambi and Kalydeco sales but raised its guidance for combined operating costs.
Orkambi revenues are expected in the range of $1.1-$1.3 billion while Kalydeco revenues are estimated in the range of $740 million - $770 million. We remind investors that following the approval for the additional indication in May, Kalydeco 2017 revenue guidance was upped to $740 million - $770 million from $710 to $730 million. Total CF product revenues are expected in the range of $1.84 billion to $2.07 billion in 2017.
Combined adjusted research and development (R&D) and selling, general and administrative (SG&A) expenses in 2017 are anticipated in the range of $1.33 to $1.36 billion, higher than $1.25-$1.30 billion expected previously.
Costs are expected to be higher due to accelerated development of the triple combination CF pipeline and investment to develop CTP-656.
Focus on Triple Combination CF Regimens
Vertex is evaluating some next-generation CFTR correctors (VX-152, VX-440, VX-659 and VX-445) as part of a triple combination withVX-661 (tezacaftor) and ivacaftor.
Data from VX-152 and VX-440 phase II and VX-659 phase I triple combination studies, conducted on CF patients who have one F508del mutation and one minimal function mutation (F508del/Min), were presented last week. The data demonstrated that all three combinations led to pronounced improvement in lung function. In fact, these are the first data to show the potential to treat the underlying cause of CF in patients who have a severe and difficult-to-treat type of the disease.
Following discussions with regulatory agencies, Vertex will initiate pivotal phase III studies on one or two of the four triple combination regimens in the first half of 2018.
OtherCF Pipeline Update
In March, positive data from two phase III studies - EVOLVE and EXPAND - evaluating Kalydeco in combination with VX-661 (tezacaftor) in CF patients with two copies of the F508del mutation were also announced. Both studies met their primary endpoints and demonstrated statistically significant improvements in lung function. Based on positive outcome from the studies, the company recently submitted regulatory applications in both the U.S. and EU. Encouragingly, the combination was also granted Orphan Drug designation by the FDA in June.
Earlier this week, Vertex announced that it has closed the previously announced agreement to buy Concert Pharmaceuticals, Inc.'s CNCE CF pipeline candidate, CTP-656. Vertex plans to develop CTP-656 for potential use in future once-daily regimens in combination with its other pipeline drugs to treat the underlying cause of CF.
Our Take
Vertex's second-quarter results were encouraging, topping estimates on both counts as sales of both its CF drugs rose.
Shares declined slightly in after-hours trading probably in response to the hike in operating costs expectations for the year. However, so far this year, Vertex's share priceis up a massive 121.8%, comparing favorably with an increase of 12% for the industry .
Meanwhile, Vertex's CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Its triple combination CF regimens are considered crucial for long-term growth. If the triple-combo regimes are successful, Vertex can address a significantly larger CF patient population- almost 90% of patients with CF - in the future.
However, one cannot forget potential competition for Vertex's triple combos. Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF.
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surpris e
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise | Vertex Pharmaceuticals Incorporated Quote
Vertex sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click here. OtherCF Pipeline Update In March, positive data from two phase III studies - EVOLVE and EXPAND - evaluating Kalydeco in combination with VX-661 (tezacaftor) in CF patients with two copies of the F508del mutation were also announced. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF. Costs Rise Adjusted (including stock-based compensation expenses) research and development expenses increased 10% to $284.3 million in the second quarter due to higher costs related to development of triple combination CF regimens. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF. CF Franchise Sales Strong Vertex's second-quarter revenues consisted of sales from cystic fibrosis (CF) products - Kalydeco and Orkambi, collaborative ($27.3 million) and royalty revenues ($2.9 million). | Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex reported revenues of $544.1 million in the second quarter, up 26.1% year over year driven by strong product revenues. |
26072.0 | 2017-07-27 00:00:00 UTC | Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up | ABBV | https://www.nasdaq.com/articles/gilead-gild-tops-q2-earnings-revenue-estimates-stock-up-2017-07-27 | nan | nan | Gilead Sciences, Inc.'sGILD reported results for the second quarter wherein both earnings and revenues surpassed expectations.
Second-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.51 per share beat the Zacks Consensus Estimate of $2.11. However, earnings were below the year-ago quarter figure of $3.03.
Moreover, total revenue in the reported quarter was $7.1 billion and topped the Zacks Consensus Estimate of $6.4 billion. However, revenues declined 8.2% year over year.
Shares were up 1.8% in after-market hours trading following the release of second-quarter results. However, shares of Gilead have underperformed the Zacks classified industry in the year so far with the stock gaining 3.6% during this period, compared with the industry's gain of 11.5%.
HIV Impresses Yet Again
Product sales came in at $7.0 billion, down 9% year over year. The decline was due to lower hepatitis C virus (HCV) sales, partially offset by higher sales across HIV and other therapeutic areas.
Antiviral product sales, which include Gilead's HIV and liver disease portfolios, came in at $6.4 billion in the reported quarter, down 9.8%.
HCV product sales, which include Harvoni, Sovaldi and the recently launched Epclusa, were $2.9 billion, down from $4.0 billion reported in the year-ago quarter. The downside was mainly attributed to lower sales of Harvoni and Sovaldi across all major markets, partially offset by sales of Epclusa (launched in 2016) across various locations.
Sales of Harvoni declined 46.1% year over year to $1.4 billion in the reported quarter. The decline was mainly due to lower sales in the U.S and Europe. Further, Sovaldi sales recorded a steep year-over-year decline of 76.8% to $315 million.
Epclusa garnered sales of $1.2 billion in the reported quarter, lower than the prior-quarter figure of $892 million. We note that Epclusa was launched in the U.S. and Europe in June and Jul 2016, respectively.
Meanwhile, HIV and HBV product sales came in at $3.6 billion, up 16.1% year over year. The increase was primarily driven by continuous strong uptake of tenofoviral afenamide (TAF)-based products such as Genvoya, which generated sales of $857 million, up from $302 million in the year-ago quarter, Descovy, which recorded sales of $286 million, up from $61 million, and Odefsey, which registered sales of $258 million, up from $58 million. HIV treatments like Stribild and Complera/Eviplera sales declined. Viread sales were up at $300 million, up 4.5%. Atripla sales tanked 29.4% to $475 million, while Truvada sales fell 13.8% to $812 million.
Other products like Letairis, Ranexa, AmBisome and Zydelig recorded sales of $230 million (up 13.3%), $200 million (up 30.7%), $92 million (up 8.2%) and $35 million (down 14.6%), respectively.
Research & development (R&D) expenses declined 41.8% to $864 million due to purchase of Nimbus Apollo, Inc. and a U.S. Food and Drug Administration (FDA) priority review voucher. On the other hand, selling, general and administrative (SG&A) expenses were roughly flat at $897 million. Adjusted product gross margin was 87.3%, up from 91.5% in the year-ago period.
2017 Guidance Updated
Based on a better-than-expected performance in the first half of 2017 specifically in the U.S, Gilead raised its guidance for 2017. Gilead now expects net product sales in the range of $24.0-$25.5 billion, up from $22.5-$24.5 billion provided earlier. Non-HCV product sales are projected between $15.5 and $16.0 billion (earlier projection: $15 and $15.5 billion). HCV product sales are projected between $8.5 and $9.5 billion (earlier projection: $7.5 and $9.0 billion). Adjusted R&D expenses and adjusted SG&A expenses are now projected in the range of $3.2-$3.4 billion and $3.2-$3.4 billion, respectively. Adjusted product gross margin is expected in the range of 86-88%. Earnings per share are now projected around 86 - 93 cents (earlier projection: 84 - 91 cents).
Dividend and Share Repurchase
Concurrently, Gilead declared a cash dividend of 52 cents per share of common stock for third-quarter 2017. The dividend is payable on Sep 28 to stockholders of record at the close of business on Sep 15. During the second quarter, the company paid cash dividends of $680 million and repurchased 2 million shares for $130 million.
Gilead Sciences, Inc. Price and EPS Surprise
Gilead Sciences, Inc. Price and EPS Surprise | Gilead Sciences, Inc. Quote
Our Take
The better-than-expected performance in the second quarter was driven by positive trends in the non-HCV business and better-than-expected results from HCV business (market share of 80%), particularly in the U.S due to rapid uptake of Epclusa. The HCV franchise was boosted by the FDA approval of Vosevi. HCV patient starts in the first six months were better than the company's expectation. The company, however, expects a gradual decline in the second half of the year (market starts of 185,000 to 200,000 in the U.S) for 2017 due to increased competition. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's, Inc. ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company BMY Daklinza among others.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU. The TAF-based regimens now represent 51% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. Genvoya is now the company's bestselling HIV product with a treatment-naïve patient share of 41%.
Strong uptake for Truvada for use in the pre-exposure prophylaxis setting is alsoexpected toboost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 136,000 patients using Truvada by the end of the second quarter. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which may impact sales.
Zacks Rank & Key Pick
Gilead currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Exelixis, Inc. EXEL which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Exelixis has delivered positive earnings surprises in the trailing four quarters with an average beat of 512.11%. Exelixis's shares have soared 87.9% so far this year.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Exelixis, Inc. (EXEL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's, Inc. ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Antiviral product sales, which include Gilead's HIV and liver disease portfolios, came in at $6.4 billion in the reported quarter, down 9.8%. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's, Inc. ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company BMY Daklinza among others. HCV product sales, which include Harvoni, Sovaldi and the recently launched Epclusa, were $2.9 billion, down from $4.0 billion reported in the year-ago quarter. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's, Inc. ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company BMY Daklinza among others. HCV product sales, which include Harvoni, Sovaldi and the recently launched Epclusa, were $2.9 billion, down from $4.0 billion reported in the year-ago quarter. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's, Inc. ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.'sGILD reported results for the second quarter wherein both earnings and revenues surpassed expectations. |
26073.0 | 2017-07-27 00:00:00 UTC | Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK | ABBV | https://www.nasdaq.com/articles/pharma-stocks-to-watch-for-earnings-on-jul-28%3A-abbv-mrk-2017-07-27 | nan | nan | The second-quarter reporting cycle is in full swing. The quarter, undoubtedly, is off to a strong start.
As of Jul 26, 2017, 171 S&P 500 members, accounting for 44.1% of the index's total market capitalization, reported results, according to Earnings Preview .
Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. The beat ratio was 78.9% for earnings and 70.8% for revenues.
The earnings momentum is expected to continue through the season. Per the report, total earnings for S&P 500 companies in the second quarter are expected to grow 8.7% year over year on 4.7% higher revenues. This follows 13.3% earnings growth in the first quarter on 7% increase in revenues, the highest in almost two years.
Among the pharma bigwigs, Eli Lilly and Company LLY and Biogen Inc. BIIB released their second-quarter results this week. Both the companies beat earnings and revenue estimates and raised their sales and earnings expectations for the full year. Moreover, Vertex Pharmaceuticals Incorporated VRTX and Amgen Inc. AMGN reported encouraging second-quarter results on Jul 26, beating estimates on both counts. However, GlaxoSmithKline plc GSK reported mixed second-quarter results the same day, beating on earnings but missing on sales.
Let's take a look at two large-cap pharma companies that are set to report second-quarter results on Jul 28.
AbbVie Inc.ABBV
AbbVie, which is scheduled to release earnings before market opens, had delivered a positive earnings surprise of 1.59% last quarter. AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in an average positive surprise of 1.65%.
For this quarter, AbbVie has an Earnings ESP of -0.71% and a Zacks Rank #3 (Hold). This does not conclusively show that AbbVieis likely to beat estimates this quarter. The Zacks Consensus Estimate is pegged at $1.40 per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
AbbVie's key drug Humira is performing well and is expected to continue to do well in the second quarter. Imbruvica has been recording strong sales since the past few quarters. We expect the trend to continue. However, the HCV franchise continues to be under pricing pressure. (Read More: AbbVie Q2 Earnings: Disappointment in Store? )
Merck & Co., Inc.MRK
Merck is also scheduled to announce results before the opening bell. Merck has beaten estimates in each of the last four quarters, resulting in an average positive surprise of 4.36%. In the last reported quarter, Merck delivered a positive surprise of 6.02%.
Merck & Company, Inc. Price and EPS Surprise
Merck & Company, Inc. Price and EPS Surprise | Merck & Company, Inc. Quote
The company has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy) and thus does not look poised to deliver a beat this time around.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Merck's new products like Keytruda (cancer), Zepatier (HCV) and Bridion (sugammadex) injection may drive the top line this quarter. However, the company is expected to face headwinds in the form of genericization, increasing competition and the negative impact of currency exchange. (Read More: Can Merck Pull Off a Surprise this Earnings Season? )
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artifical intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before market opens, had delivered a positive earnings surprise of 1.59% last quarter. AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in an average positive surprise of 1.65%. For this quarter, AbbVie has an Earnings ESP of -0.71% and a Zacks Rank #3 (Hold). | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before market opens, had delivered a positive earnings surprise of 1.59% last quarter. AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in an average positive surprise of 1.65%. | AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in an average positive surprise of 1.65%. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before market opens, had delivered a positive earnings surprise of 1.59% last quarter. | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before market opens, had delivered a positive earnings surprise of 1.59% last quarter. AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in an average positive surprise of 1.65%. For this quarter, AbbVie has an Earnings ESP of -0.71% and a Zacks Rank #3 (Hold). |
26074.0 | 2017-07-26 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2017-07-26 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on ABBV - FREE
Get the latest Zacks research report on APD - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. |
26075.0 | 2017-07-26 00:00:00 UTC | Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense | ABBV | https://www.nasdaq.com/articles/gilead-sciences-has-3-available-options-only-1-makes-sense-2017-07-26 | nan | nan | Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward.
That's seriously bad news from a value-creation standpoint. Gilead's hep C sales, after all, are already on track to fall by more than 65% over the next three years due to the dual headwinds of price erosion and lower demand.
Although the biotech's hep C woes have been weighing on its valuation for some time now, this latest competitive threat may finally force Gilead's hand on the business development front. All things considered, the biotech has three available choices:
Stay the course and hope its clinical pipeline can deliver a handful of new blockbusters sooner than expected.
Engage in a high-dollar megadeal to buy revenue.
Split the company in order to protect its growing HIV franchise from its declining hep C business.
In an odd twist, Gilead's best option -- and arguably least anticipated -- is to split the company into two. Here's why.
Gilead's alternative options don't maximize value
Standing pat and waiting for its clinical pipeline to mature seems to be management's preferred course of action. But it is clearly not the best option for shareholders. As proof, the market has been penalizing Gilead's stock due to management's inaction on the business development issue -- evinced by its rock-bottom forward price to earnings ratio of 9.78.
Even if the biotech can accelerate the development of its more attractive clinical assets such as its anti-inflammatory drug filgotinib, it simply won't be enough to head off the entry of AbbVie's latest hep C therapy -- or counteract the other negative headwinds that are literally crushing its hep C franchise right now.
Regarding a possible megadeal to bring in new sources of revenue, this idea seems dead on arrival for two reasons. First off, Gilead has largely shunned high-dollar business development deals in the past -- that is, outside of its roughly $11 billion deal to acquire Pharmasset. Megadeals, in other words, are simply not in the biotech's DNA -- especially ones that would be large enough (> $30 billion) to move the needle from a growth perspective at present.
Secondly, Gilead's hesitation to go the megadeal route is rooted in some solid reasoning. Point of fact: Massive mergers and acquisitions in the pharma space have historically produced extremely poor returns on capital.
Pfizer , for instance, has repeatedly spent large sums to augment its clinical pipeline and product portfolio with rather questionable results. The drugmaker's latest multibillion-dollar acquisition of Medivation for its advanced prostate cancer drug Xtandi is already proving to be a dubious move from a return on investment standpoint. And that's just one example of many where high-dollar acquisitions in pharma haven't gone nearly as smoothly as planned.
Killing two birds with one stone
The idea of Gilead splitting into two business -- one growth-oriented HIV business and another built around the biotech's hep C franchise and other liver disease assets -- isn't exactly new. Management, in fact, addressed this possibility head on with analysts late last year.
While Gilead's brass previously eschewed a break up, a split is unquestionably the single best option the biotech has on the table at the moment. There's tremendous value trapped in Gilead's HIV franchise thanks to its association with the company's plummeting hep C segment, after all. As a stand-alone, the biotech's HIV business should easily produce high double-digit sales growth over the next five or so years and, hence, merit a much richer multiple than the company is currently being assigned by the market.
As an added bonus, Gilead could continue to pursue its small to mid-size acquisition strategy that's worked wonders so far by splitting the company into two. It would arguably only take a handful of medium-sized deals, after all, to shore up the biotech's hep C business as a stand-alone.
The key takeaway is that Gilead could kill two birds with one stone by separating its HIV and hep C segments. A break up would allow its strong HIV sales to shine through, and the biotech wouldn't have to grossly overpay for a large, revenue-generating peer in a deal that almost certainly wouldn't maximize shareholder value.
Unfortunately, Gilead's management hasn't expressed much interest in either a megadeal or a split to address its faltering growth engine. So, while a split is one possible solution to unlock the biotech's trapped value and avoid a capital-intensive acquisition, investors can most likely expect more of the same out of the company moving forward.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
George Budwell owns shares of Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short August 2017 $75 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward. Even if the biotech can accelerate the development of its more attractive clinical assets such as its anti-inflammatory drug filgotinib, it simply won't be enough to head off the entry of AbbVie's latest hep C therapy -- or counteract the other negative headwinds that are literally crushing its hep C franchise right now. As proof, the market has been penalizing Gilead's stock due to management's inaction on the business development issue -- evinced by its rock-bottom forward price to earnings ratio of 9.78. | In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward. Even if the biotech can accelerate the development of its more attractive clinical assets such as its anti-inflammatory drug filgotinib, it simply won't be enough to head off the entry of AbbVie's latest hep C therapy -- or counteract the other negative headwinds that are literally crushing its hep C franchise right now. First off, Gilead has largely shunned high-dollar business development deals in the past -- that is, outside of its roughly $11 billion deal to acquire Pharmasset. | Even if the biotech can accelerate the development of its more attractive clinical assets such as its anti-inflammatory drug filgotinib, it simply won't be enough to head off the entry of AbbVie's latest hep C therapy -- or counteract the other negative headwinds that are literally crushing its hep C franchise right now. In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward. Although the biotech's hep C woes have been weighing on its valuation for some time now, this latest competitive threat may finally force Gilead's hand on the business development front. | In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward. Even if the biotech can accelerate the development of its more attractive clinical assets such as its anti-inflammatory drug filgotinib, it simply won't be enough to head off the entry of AbbVie's latest hep C therapy -- or counteract the other negative headwinds that are literally crushing its hep C franchise right now. In an odd twist, Gilead's best option -- and arguably least anticipated -- is to split the company into two. |
26076.0 | 2017-07-25 00:00:00 UTC | Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up | ABBV | https://www.nasdaq.com/articles/biogen-biib-tops-q2-earnings-sales-spinraza-sales-up-2017-07-25 | nan | nan | Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, surpassed expectations both for earnings and sales in the second quarter of 2017. The drugmaker also raised its revenue guidance for 2017 as sales of its newest drug Spinraza (spinal muscular atrophy) witnessed faster-than-expected adoption in the U.S.
Shares of Biogen rose almost 5% in pre-market trading in response to the strong results. However, we note that Biogen's shares have inched up 0.8% so far this year, comparing unfavorably with the industry 's increase of 12.7%.
Sales came in at $3.08 billion, up 6% from the year-ago period. Sales also surpassed the Zacks Consensus Estimate of $2.81 billion by 9.6%. The top line, excluding hemophilia revenues, grew 15% year over year. The company spun off its hemophilia business in February.
Quarter in Detail
Biogen's MS revenues grew 5% year over year in the second quarter of 2017 with stable global share.
Tecfidera sales rallied 13% from the year-ago period to $1.11 billion. The drug recorded a 16% sequential surge in revenues. This included the U.S. sales of $875 million and ex-U.S. sales of $235.6 million. In the U.S., Tecfidera revenues benefited from seasonal recovery in both unit volumes and discounts as well as allowances.
Second-quarter Tysabri revenues were flat year over year and the same decreased 9% sequentially to $496 million (U.S. $289.4 million, ex-U.S. $206.6 million).
Note that Tysabri revenues in the first quarter of 2017 benefited by approximately $45 million in the ex-U.S. markets due to an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (AIFA) related to Tysabri sales. This benefit was missing in the second quarter, leading to the sequential decline.
Combined interferon revenues (Avonex and Plegridy) in the second quarter were $691 million (U.S. $501.7 million, ex-U.S. $188.9 million), down 5% from the year-ago period. Avonex revenues declined 8% from the year-ago period to $557 million. Plegridy contributed $133 million to second-quarter 2017 revenues, up 8% year over year and 19% sequentially.
U.S. Interferon revenues are experiencing declining trends due to patients transitioning to other oral MS therapies as well as higher discounts and allowance.
Zinbryta, launched in collaboration with AbbVie Inc. ABBV in August last year, contributed $16 million to revenues in the second quarter compared with $11 million in first-quarter 2017.
Newly launched Spinraza brought revenues of $203 million (U.S. revenues $195 million) in the second quarter, registering massive growth of 328% sequentially as the drug witnesses a strong demand in the U.S. U.S. Spinraza revenues included approximately $30 million related to an inventory build in the U.S. The company is working on expanding access to all patients.
Notably in Jun 2017, Spinraza was granted a marketing authorization in the EU for treatment of 5q spinal muscular atrophy (SMA). It was also approved of in Japan and Canada recently.
This quarter, Biogen recorded biosimilar revenues of $91 million compared with $66 million in first-quarter 2017. The company markets Benepali, a biosimilar referencing Amgen Inc.'s AMGN Enbrel in Europe. Benepali recorded revenues of $88.7 million, thus registering a growth rate of 35.8% sequentially. Biogen also markets Flixabi, a biosimilar referencing Johnson & Johnson's JNJ blockbuster drug Remicade, which recorded revenues of $1.9 million in the reported quarter compared with $0.6 million in the first quarter.
Revenues from Anti-CD20 therapeutic programs, which include Biogen's shares of Rituxan and Gazyva operating profits, climbed 14% from the year-ago period to $397 million in the second quarter.
R&D spend soared 68% in the reported quarter to $796 million, while SG&A spend decreased 12% year over year to $430 million.
This quarter, the company repurchased 2.9 million shares worth $782 million under its $5.0 billion share repurchase program.
2017 Outlook
Biogen raised its earnings and revenue outlook for 2017.
Biogen now expects earnings in the range of $20.80-$21.40 per share (old guidance: $20.45-$21.25 per share) for 2017.
Revenues are now expected in a range of $11.5-$11.8 billion comapred with the earlier guidance of $11.1-$11.4 billion in 2017. This increase from prior guidance is primarily attributed to faster-than-anticipated adoption of Spinraza in the U.S.
In terms of percentage of the total revenue, the company's R&D and SG&A expenses are expected to be 19% and 16% respectively.
Biogen Inc. Price, Consensus and EPS Surprise
Biogen Inc. Price, Consensus and EPS Surprise | Biogen Inc. Quote
Zacks Rank
Biogen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artifical intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in August last year, contributed $16 million to revenues in the second quarter compared with $11 million in first-quarter 2017. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The drugmaker also raised its revenue guidance for 2017 as sales of its newest drug Spinraza (spinal muscular atrophy) witnessed faster-than-expected adoption in the U.S. Shares of Biogen rose almost 5% in pre-market trading in response to the strong results. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc. ABBV in August last year, contributed $16 million to revenues in the second quarter compared with $11 million in first-quarter 2017. Newly launched Spinraza brought revenues of $203 million (U.S. revenues $195 million) in the second quarter, registering massive growth of 328% sequentially as the drug witnesses a strong demand in the U.S. U.S. Spinraza revenues included approximately $30 million related to an inventory build in the U.S. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc. ABBV in August last year, contributed $16 million to revenues in the second quarter compared with $11 million in first-quarter 2017. Newly launched Spinraza brought revenues of $203 million (U.S. revenues $195 million) in the second quarter, registering massive growth of 328% sequentially as the drug witnesses a strong demand in the U.S. U.S. Spinraza revenues included approximately $30 million related to an inventory build in the U.S. | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in August last year, contributed $16 million to revenues in the second quarter compared with $11 million in first-quarter 2017. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This included the U.S. sales of $875 million and ex-U.S. sales of $235.6 million. |
26077.0 | 2017-07-25 00:00:00 UTC | 7 All-Weather Stocks to Buy for the Next 30 Years | ABBV | https://www.nasdaq.com/articles/7-all-weather-stocks-to-buy-for-the-next-30-years-2017-07-25 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Unless you are truly investing for the long-term - and by that, I mean 10 years at a minimum - you expose yourself to a much higher degree of risk. That's why the best stocks to buy if you're a conservative investor are those that are durable, so you can hold them for years and expect them to easily bounce back anytime the market throws a tantrum.
Source: Shutterstock
Swing trading and using options are perfectly acceptable ways for more aggressive investors to achieve returns, but you have to know that when you do that, you're introducing a number of risks that, if not handled properly, could end up setting you back.
But the longer the time frame you have for investing, the better off you are positioning a large part of your portfolio with a buy-and-hold mantra in mind. After all, there has been no 30-year rolling period in which the market did not provide a positive return.
The Top 10 Vanguard Funds on the Market
So if you are investing for the long-term and seeking market-beating returns without taking on too much risk, let me show you the way. Please read on as I explore seven all-weather stocks to buy that should serve conservative investors well for the next 30 years.
All-Weather Stocks to Buy: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Sector: Healthcare
Dividend: 3.5%
AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Tricor.
I'm not keen on pharma and biotech these days, since most stocks in the healthcare sector are highly overvalued. However, you must have exposure to this sector. It has too appealing a combination of growth and income to ignore.
ABBV (including its business' performance within Abbott) is one of the most consistent stocks you can buy for the long-term. It's developing new products in the arenas of virology, neuroscience, immunology and oncology.
Financially, it's hard to argue with 13% anticipated growth in earnings per share this year. We also enjoyed a 12% dividend increase in 2016, maintaining AbbVie's status as a Dividend Aristocrat , and another one should hit later this year.
All-Weather Stocks to Buy: Berkshire Hathaway (BRK.B)
Source: Elyka Haryani via YouTube
Sector: Financials (Insurance/Conglomerate)
Dividend: N/A
Berkshire Hathaway Inc. (NYSE: BRK.B ) is, in a way, more than one stock.
For one, Berkshire Hathaway is an insurance company that operates among several brands, including Geico, United States Liability and the namesake Berkshire Hathaway. Insurance is a fantastic, and very reliable, business if underwriting is done with care. Collect premiums, make sure you don't pay out more than you take in, invest the rest, watch it all grow.
Then there's Berkshire's other subsidiary companies, which include the likes of See's Candies, Fruit of the Loom Companies and Lubrizol.
10 'Cheap' Stocks That Are Actually Cheap
The cherry on top is Warren Buffett himself, who is one of the greatest investors of all time, and whose stakes in companies like Bank of America Corp (NYSE: BAC ) more often than not work out wonderfully for both the Oracle of Omaha and shareholders alike.
All-Weather Stocks to Buy: Cintas (CTAS)
Source: Dwight Burdette via Wikimedia (Modified)
Sector: Industrials
Dividend: 1%
Cintas Corporation (NASDAQ: CTAS ) is another Dividend Aristocrat that belongs on this list.
It's funny that I would choose Cintas considering I hate clothing retailers, but then, CTAS isn't exactly your typical retailer. Instead, CTAS designs and makes uniforms for all sorts of industries, including specialized equipment for dangerous work such as firefighting.
CTAS is a cash flow business, throwing off modest but consistent earnings growth of about 7% annually, and analysts think that could grow to as much as 12% expansion going forward.
There's not much in the way of yield here, as Cintas pays out roughly 1% based on its annually paid dividend, but investors sitting on 265% gains in five years don't seem to mind. Besides, the income has more than doubled over the same time period.
CTAS has a defensible position. And nobody else is really assaulting Cintas' market.
All-Weather Stocks to Buy: Disney (DIS)
Source: Shutterstock
Sector: Consumer Discretionary
Dividend: 1.5%
Ever wanted to buy into an empire? Then buy Walt Disney Co (NYSE: DIS ).
Sure, I think ESPN has huge problems, but I think it'll either be spun off or sold outright. Yet, DIS owns the world right now, with all of its Marvel films, its occasional Pixar film and the constantly expanding universe of Star Wars. Better still, Disney's resorts division is wholly immersing itself in … well, the immersive experience trend, where it's able to use its story-telling prowess to make guests feel like they're playing a part in fictional universes.
Disney is synonymous with family entertainment, with a global brand name, enough content to power it for the next 30 years and one of the best stock out there.
7 Safe High-Yield Dividend Stocks
Among these seven stocks, I think Disney and one still to come are tied for the best chance of providing the highest returns over time.
All-Weather Stocks to Buy: Exxon Mobil (XOM)
Source: Shutterstock
Sector: Energy
Dividend: 3.9%
The energy sector has been bludgeoned over the past few years, but you still can't go without any exposure to this space. It will recover. At some point, producers will buckle - whether it's OPEC or some of the smaller U.S. firms that for now insist on drilling, drilling, drilling.
That's why I think you can't go wrong with any of the big names, though among those, my favorite stock to buy is Exxon Mobil Corporation (NYSE: XOM ).
Exxon has assets all across the world, and has its hands in every part of the E&P cycle, or that it has great financials … all of which are strong enough to cement the bull case. But XOM also has a wild card in the form of Secretary of State Rex Tillerson, Exxon's former CEO who obviously was chosen to enhance U.S. oil production around the globe via Exxon's deal with Russian state-owned Rosneft (OTCMKTS: OJSCY ).
Even if rumors about Tillerson quitting the administration end up coming to fruition (though I don't think they will), Exxon Mobil is the biggest, most powerful oil and gas play on the planet. If it goes, everything else probably went first.
All-Weather Stocks to Buy: National Grid (NGG)
Source: Shutterstock
Sector: Utilities
Dividend: 4.8%
National Grid plc (ADR) (NYSE: NGG ) represents utilities in this portfolio of all-weather stocks to buy.
National Grid is a primary provider of electricity and gas infrastructure in the U.S. and the U.K. As a utility, it is able to count on a certain amount of revenue because it is a monopoly, and has regulated rates. It has fantastic net margins and ROE, and offers a dividend of nearly 5%.
7 Top Stocks That Would Survive an Apocalypse
Shares have cooled off thanks in large part to movements in the British pound this year, though the chart looks a bit worse than reality thanks to a big special dividend a couple months back. This is a great opportunity to get into the stock for the long-term. NGG boasts solid financials, a never-ending need for its product and additional upside when the British pound recovers.
All-Weather Stocks to Buy: AutoZone (AZO)
Source: time anchor via Flickr (Modified)
Sector: Consumer Discretionary
Dividend: N/A
While the auto parts sector has been hit by a big selloff lately, that's good news for those looking at stocks to buy for the next 30 years.
AutoZone, Inc. (NYSE: AZO ) is a phenomenal choice right now, and might be one of the most misunderstood bargains on the market.
AZO has plunged nearly 35% this year, in part on the heels of a disappointing fiscal third-quarter earnings report that saw comps decline. That has analysts panicking and lumping it in with the rest of the retail space, but AutoZone is suffering from other macro issues, as well as a hit thanks to the timing of tax refunds this year.
However, new and used cars will need parts for a long, long time. Even though car sales have been on the decline of late, they'll rise again in the next cycle. Every car ages, and every car needs parts. With more than 5,000 locations, AZO has plenty of footprint - not to mention diagnostic and repair programs you can't get via Amazon.com, Inc. (NASDAQ: AMZN ). How convenient.
Despite the worries, AZO still is expected to grow earnings 8% this year and next on low-single-digit revenue expansion. That's not great, but that also doesn't look like a dying retailer to me. Expect AutoZone to bounce back once the market gets over its hysteria.
Lawrence Meyers is the CEO of PDL Capital, a specialty lender focusing on consumer finance and is the Manager of The Liberty Portfolio at www.thelibertyportfolio.com. He has 22 years' experience in the stock market, and has written more than 1,600 articles on investing. Lawrence Meyers can be reached atTheLibertyPortfolio@gmail.com . As of this writing, he was long DIS.
The post 7 All-Weather Stocks to Buy for the Next 30 Years appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Tricor. ABBV (including its business' performance within Abbott) is one of the most consistent stocks you can buy for the long-term. We also enjoyed a 12% dividend increase in 2016, maintaining AbbVie's status as a Dividend Aristocrat , and another one should hit later this year. | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Tricor. ABBV (including its business' performance within Abbott) is one of the most consistent stocks you can buy for the long-term. We also enjoyed a 12% dividend increase in 2016, maintaining AbbVie's status as a Dividend Aristocrat , and another one should hit later this year. | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Tricor. ABBV (including its business' performance within Abbott) is one of the most consistent stocks you can buy for the long-term. We also enjoyed a 12% dividend increase in 2016, maintaining AbbVie's status as a Dividend Aristocrat , and another one should hit later this year. | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Tricor. ABBV (including its business' performance within Abbott) is one of the most consistent stocks you can buy for the long-term. We also enjoyed a 12% dividend increase in 2016, maintaining AbbVie's status as a Dividend Aristocrat , and another one should hit later this year. |
26078.0 | 2017-07-24 00:00:00 UTC | Noteworthy ETF Inflows: VYM, PFE, MMM, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-vym-pfe-mmm-abbv-2017-07-24 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.6 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 234,750,118 to 235,553,033). Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average:
Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.86. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.86. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.86. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.6 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 234,750,118 to 235,553,033). For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.86. | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.6 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 234,750,118 to 235,553,033). For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.86. |
26079.0 | 2017-07-24 00:00:00 UTC | Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs | ABBV | https://www.nasdaq.com/articles/surprise-store-healthcare-q2-buy-top-ranked-etfs-2017-07-24 | nan | nan | Despite the hurdles in Trump's plans to repeal and replace Obamacare, healthcare is the second best performing sector this year lagging technology. The optimism comes especially from encouraging industry trends and hopes of a favorable policy environment.
The Trump administration plans to focus on easing regulatory hurdles rather than lowering drug prices, and expedite new drug approvals. Additionally, the shift in investors' sentiment to defensive sectors like healthcare, which generally outperform during periods of low-to-moderate growth and rising geopolitical uncertainty, has led to a rally in healthcare stocks (read: Top Ranked Healthcare ETFs for Long Term Investors ).
As such, popular funds - Health Care Select Sector SPDR Fund XLV , Vanguard Health Care ETF VHT , iShares U.S. Healthcare ETF IYH and Fidelity MSCI Health Care Index ETF FHLC - have gained at least 18% so far this year. The trend is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. All these stocks collectively account for 26.3% share in XLV, 25.2% in IYH, 22.8% in VHT and 22.5% in FHLC.
Let's dig deeper into the earnings picture of these companies that would drive the performance of the above-mentioned funds in the coming days:
According to the our methodology, a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) when combined with a positive Earnings ESP increases our chances of predicting an earnings beat, while a Zacks Rank #4 or 5 (Sell rated) are best avoided. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Inside Our Surprise Prediction of These Stocks
Pfizer has a Zacks Rank #3 and an Earnings ESP of +1.54%, indicating a reasonable chance of beating estimates this quarter. The stock saw no earnings estimate revision for the yet-to-be-reported quarter and delivered negative earnings surprise of 0.35% over the past four quarters. Additionally, it has an impressive Growth and Momentum Style Score of C and F, respectively, though a Value Style Score of B is favorable. Pfizer is scheduled to report earnings on August 1 before the opening bell (read: How to Build a Winning ETF Portfolio for Second-Half 2017 ).
Pfizer, Inc. Price, Consensus and EPS Surprise
Pfizer, Inc. Price, Consensus and EPS Surprise | Pfizer, Inc. Quote
Merck is expected to report results on July 28 before the market opens. It has a Zacks Rank #2 and an Earnings ESP of 0.00%, which makes surprise prediction difficult. The stock witnessed a positive earnings estimate revision of a penny over the past 90 days for the to-be-reported quarter and delivered positive earnings surprises in the last four quarters, with an average beat of 4.36%. Merck has a strong Value and Momentum Style Score of B each and an unfavorable Growth Style Score of D.
Merck & Company, Inc. Price, Consensus and EPS Surprise
Merck & Company, Inc. Price, Consensus and EPS Surprise | Merck & Company, Inc. Quote
Amgen has a Zacks Rank #3 and an Earnings ESP of -0.32%, indicating less chances of beating estimates this quarter. Though the earnings surprise track over the past four quarters is robust with an average positive surprise of 5.31%, Amgen witnessed negative earnings estimate revision of a couple of cents over the past 90 days for the yet-to-be-reported quarter. The stock has a solid Value and Momentum Style Score of B and A, respectively, but the Growth Style Score of C looks dull. Amgen will report earnings on July 25 after market close.
Amgen Inc. Price, Consensus and EPS Surprise
Amgen Inc. Price, Consensus and EPS Surprise | Amgen Inc. Quote
AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.71%, indicating less chance of beating estimates this quarter. The company delivered positive earnings surprises in the last four quarters, with an average beat of 1.65% and saw positive earnings estimate revision by a couple of cents over the past three months for the to-be-reported quarter. The stock has a solid Value Style Score of B while the Growth and Momentum Style Score of C and F, respectively, is unimpressive. The company is scheduled to report on July 28 before the opening bell (read: J&J Brightens Outlook: Healthcare ETFs in Focus ).
AbbVie Inc. Price, Consensus and EPS Surprise
AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote
Gilead is expected to release earnings on July 26 after market close. It has a Zacks Rank #3 and an Earnings ESP of +3.32%, indicating reasonable chance of beating estimates. Gilead delivered positive earnings surprises in three of the last four quarters, with an average beat of 3.52% but saw no earnings estimate revision over the past three months for the to-be-reported quarter. Though it has a solid Value and Momentum Style Score of A and B, respectively, the Growth Style Score of F looks ugly.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. Price, Consensus and EPS Surprise | Gilead Sciences, Inc. Quote
Bristol-Myers will likely report earnings on July 27 before the opening bell. It has a Zacks Rank #3 and an Earnings ESP of 0.00%, which makes surprise prediction difficult. The stock delivered positive earnings surprises in three of the past four quarters with an average beat of 8.39% and witnessed positive earnings estimate revision of three cents for the to-be-reported quarter. It has an unfavorable Value, Growth and Momentum Style Score of C, C, and F respectively (see: all the Healthcare ETFs here ).
Bristol-Myers Squibb Company Price, Consensus and EPS Surprise
Bristol-Myers Squibb Company Price, Consensus and EPS Surprise | Bristol-Myers Squibb Company Quote
Summing Up
Though the healthcare sector is expected to post an earnings decline of 0.1% in the second quarter and has a dismal Zacks Rank in the bottom 31% , some surprises may well be in the cards, suggesting upside for healthcare ETFs. In particular, XLV, VHT and IYH have a Zacks ETF Rank #1 while FHLC has a Zacks ETF Rank #3.
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
SPDR-HLTH CR (XLV): ETF Research Reports
VIPERS-HLTH CR (VHT): ETF Research Reports
ISHARS-US HLTHC (IYH): ETF Research Reports
FID-H CARE (FHLC): ETF Research Reports
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The trend is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. Amgen Inc. Price, Consensus and EPS Surprise Amgen Inc. Price, Consensus and EPS Surprise | Amgen Inc. Quote AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.71%, indicating less chance of beating estimates this quarter. AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Gilead is expected to release earnings on July 26 after market close. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The trend is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. Amgen Inc. Price, Consensus and EPS Surprise Amgen Inc. Price, Consensus and EPS Surprise | Amgen Inc. Quote AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.71%, indicating less chance of beating estimates this quarter. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The trend is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. Amgen Inc. Price, Consensus and EPS Surprise Amgen Inc. Price, Consensus and EPS Surprise | Amgen Inc. Quote AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.71%, indicating less chance of beating estimates this quarter. | Amgen Inc. Price, Consensus and EPS Surprise Amgen Inc. Price, Consensus and EPS Surprise | Amgen Inc. Quote AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.71%, indicating less chance of beating estimates this quarter. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The trend is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. |
26080.0 | 2017-07-24 00:00:00 UTC | Why Reata Pharmaceuticals Is Rallying 17.5% Today | ABBV | https://www.nasdaq.com/articles/why-reata-pharmaceuticals-rallying-175-today-2017-07-24 | nan | nan | What happened
Reata Pharmaceuticals (NASDAQ: RETA) shares were surging 17.5% higher at 3 p.m. EST today, after the company reported that its experimental drug bardoxolone improved kidney function in patients with Alport syndrome.
So what
Alport syndrome is a rare genetic disease that increases the reabsorption of protein in the kidney, causing inflammation and fibrosis. There are about 12,000 people with Alport syndrome in the U.S., and almost all of these patients will develop end-stage renal disease. By age 25, roughly 50% of male patients with the most common form of Alport syndrome require dialysis or kidney transplant.
In the phase 2 portion of Reata Pharmaceuticals' phase 2/3 trial of bardoxolone, patients saw a significant improvement in kidney function, with over 80% of patients demonstrating a clinically meaningful improvement in estimated glomerular filtration rate (eGFR).
The company is now proceeding to the phase 3 portion of its study, which will enroll 150 patients and measure changes in eGFR after 48 weeks of treatment. It will also measure rates again at the 52-week mark, after patients have been off bardoxolone for four weeks.
Now what
Bardoxolone's phase 2 trial only enrolled 30 patients, making this a pretty small trial. In 2012, bardoxolone stumbled in a 2,000-patient study of chronic kidney disease when subjects taking it experienced a high rate of cardiac adverse events. At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals.
Currently, AbbVie isn't participating in developing bardoxolone for Alport syndrome patients (it's got plenty else going on ), but it does have opt-in rights to this indication. While it sold 450,000 shares of Reata Pharmaceuticals in the first quarter, it still owned 1.2 million shares as of March 31.
Given the prior trial failure, perhaps the most important news today was that there were no serious adverse events in the phase 2 portion of this trial. Whether that continues in a larger phase 3 study is anyone's guess, but today's news is still encouraging for people with Alport syndrome, because currently, there are no treatments for it approved by the U.S. Food and Drug Administration.
10 stocks we like better than Reata Pharmaceuticals, Inc. Class A Common Stock
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Reata Pharmaceuticals, Inc. Class A Common Stock wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in developing bardoxolone for Alport syndrome patients (it's got plenty else going on ), but it does have opt-in rights to this indication. | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in developing bardoxolone for Alport syndrome patients (it's got plenty else going on ), but it does have opt-in rights to this indication. | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in developing bardoxolone for Alport syndrome patients (it's got plenty else going on ), but it does have opt-in rights to this indication. | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in developing bardoxolone for Alport syndrome patients (it's got plenty else going on ), but it does have opt-in rights to this indication. |
26081.0 | 2017-07-24 00:00:00 UTC | Better Buy: Johnson & Johnson vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy-johnson-johnson-vs-abbvie-2017-07-24 | nan | nan | It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie.
Which of these two stocks is the better buy right now? The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Here's how Johnson & Johnson and AbbVie compare.
Current products
Johnson & Johnson is basically three huge healthcare businesses rolled into one. None of them, though, is growing at impressive rates. J&J's consumer segment's revenue increased only 1.7% year over year in the second quarter. Medical devices performed better, with sales 4.9% higher than the prior-year period. However, the company's pharmaceuticals segment is struggling, with revenue slipping slightly in the second quarter compared with the same period in 2016.
What's going on with J&J's pharmaceuticals group? The biggest problem is that sales for its top-selling drug, Remicade, are falling as a result of competition from a new biosimilar . Although several other top drugs are performing exceptionally well, especially cancer drugs Darzalex and Imbruvica, the drag from Remicade is too much to offset.
AbbVie, on the other hand, continues to enjoy solid growth from its top product, Humira. The big biotech also makes more money off Imbruvica than J&J does. There have been mixed results for AbbVie's other products, but because their sales are low relative to Humira, the company is in great shape overall.
Winner: AbbVie.
Growth prospects
Johnson & Johnson has been busy buying other businesses to fuel its growth. Just this year, the company acquired Abbott Labs ' (NYSE: ABT) medical optics unit and Swiss drugmaker Actelion. J&J also should continue to benefit from growth from several of the drugs in its current lineup. It also recently won approval for promising psoriasis drug Tremfya.
In addition, the healthcare giant's pipeline includes nearly 30 late-stage programs. Several of those are pursuing additional indications for already-approved drugs such as Darzalex and Xarelto. However, J&J also has new candidates in the development, including experimental prostate cancer drug apalutamide. Wall Street analysts project that the company will grow earnings by 6% annually over the next few years.
AbbVie hasn't made any big deals so far this year, but its past acquisitions activity has added several strong products to its pipeline. Perhaps the most important of these is experimental cancer drug Rova-T, which AbbVie picked up with its acquisition last year of Stemcentrx.
The company's pipeline also includes several other candidates with blockbuster sales potential. Elagolix is in late-stage studies for treating endometriosis and uterine fibroids. AbbVie has two promising late-stage autoimmune-disease candidates with risankizumab and upadacitinib. Thanks to expectations of sustained momentum for Humira and Imbruvica and these new products potentially on the way, Wall Street estimated AbbVie will grow earnings by more than 14% annually over the next five years.
Winner:AbbVie.
Dividend
Johnson & Johnson has been a longtime favorite for dividend investors. Its dividend currently yields 2.5%. J&J uses around 54% of earnings to fund the dividend program. The company has increased its dividend for 54 consecutive years.
AbbVie is also attractive when it comes to dividends, with a 3.54% yield. The biotech uses roughly 61% of earnings to fund its dividend. And if you count the period where AbbVie was part of its parent Abbott Labs, the company claims a track record of 45 years in a row of dividend increases.
Winner: AbbVie.
Valuation
Johnson & Johnson stock trades at just under 18 times expected earnings. AbbVie's shares trade at a little over 11 times expected earnings.
Winner: AbbVie.
Better buy
Based on the criteria we've examined, it's pretty clear that AbbVie emerges as the better pick right now. However, Johnson & Johnson has been a great stock to own in past years and is likely to continue its winning ways into the future.
The primary challenge for AbbVie is one that J&J is already facing: the threat of biosimilar competition for its top-selling drug. AbbVie is fighting in court to prevent biosimilars from entering the market. The company thinks it can hold off competition in the U.S. through 2022. If it's able to do so, that should give AbbVie ample time for its pipeline candidates to step up.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Winner: AbbVie. Thanks to expectations of sustained momentum for Humira and Imbruvica and these new products potentially on the way, Wall Street estimated AbbVie will grow earnings by more than 14% annually over the next five years. And if you count the period where AbbVie was part of its parent Abbott Labs, the company claims a track record of 45 years in a row of dividend increases. | Winner: AbbVie. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie. | Winner: AbbVie. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. Here's how Johnson & Johnson and AbbVie compare. | Winner: AbbVie. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie. |
26082.0 | 2017-07-23 00:00:00 UTC | These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet | ABBV | https://www.nasdaq.com/articles/these-5-drugs-could-be-worth-45-billion-and-theyre-not-even-market-yet-2017-07-23 | nan | nan | $45 billion for five experimental drugs.
That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present value (the current value of potential future sales) of all the experimental drugs in biopharmaceutical companies' pipelines for which sales forecasts are available, then ranked them.
Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Here's which drugs made the list and why they're worth so much -- even before they've made it to market.
1. Aducanumab
EvaluatePharma estimates that the net present value of Biogen's aducanumab is $10.2 billion. Biogen is currently evaluating the experimental Alzheimer's disease drug in a late-stage study. Aducanumab is a monoclonal antibody that binds to amyloid plaques in the brain and could reduce these plaques, potentially slowing the progress of Alzheimer's disease.
While there have been numerous failures with other experimental Alzheimer's disease drugs, aducanumab could be the most promising treatment so far. In December 2016, Biogen reported positive results from a phase 1b study that showed slowing of the progression of Alzheimer's disease in patients who took aducanumab.
2. Apalutamide
A net present value of $9.8 billion was calculated for Johnson & Johnson's apalutamide. The drug is in multiple late-stage studies targeting treatment of prostate cancer, including one study in combination with J&J's Zytiga.
Johnson & Johnson picked up apalutamide (also known as ARN-509) with its 2013 acquisition of Aragon Pharmaceuticals. J&J expects to submit its first filing for approval of the drug within the next year and could have three other submissions by the end of 2021.
3. Abemaciclib
Eli Lilly's abemaciclib received a net present value of more than $8.8 billion from EvaluatePharma. The experimental drug is being evaluated in late-stage studies for treatment of non-small cell lung cancer and breast cancer. Lilly is also exploring the potential for abemaciclib in treating pancreatic cancer and squamous non-small cell lung cancer in phase 2 studies.
The FDA recently granted priority review for Lilly's new drug application for abemaciclib in treating breast cancer. An approval decision is expected in the first quarter of 2018. Lilly also plans to file for regulatory approval of the drug in Europe and Japan in the second half of 2017.
4. Rova-T
Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. It could be the most valuable of the bunch, according to EvaluatePharma, which pegs the net present value for Rova-T at nearly $8.5 billion.
AbbVie scooped up Rova-T last year with its buyout of Stemcentrx. The drug is currently in a phase 3 study as a first-line treatment for non-small cell lung cancer and is in a phase 2 study as a third-line treatment for the indication. AbbVie's management highlights Rova-T as one of the top assets in the biotech's pipeline and is looking to expand the drug's opportunities through combination studies with immuno-oncology therapies.
5. Ozanimod
Celgene's ozanimod ranks as EvaluatePharma's fifth-most valuable pipeline candidate, with a net present value of nearly $8.2 billion. Ozanimod is being evaluated in two late-stage studies, one targeting relapsing multiple sclerosis and the other targeting ulcerative colitis. The drug is also in a phase 2 study for treatment of Crohn's disease.
Like AbbVie and Johnson & Johnson, Celgene added ozanimod to its pipeline as a result of an acquisition -- in this case, the 2015 buyout of Receptos. Celgene has a tremendously promising pipeline , but ozanimod looks to be one of its brightest stars. If it's approved for all three indications, the biotech thinks the drug could generate peak annual sales between $4 billion and $6 billion.
Plus or minus...a lot
Every one of these pipeline candidates holds the potential to be a huge success story. In several cases, the drugs could be worth a lot more over time than the net present values calculated by EvaluatePharma.
On the other hand, any of these drugs could also stumble in clinical studies or in the regulatory approval process. A major setback could dramatically reduce the value of any of these candidates. Out of all of these drugs, I'd say that Biogen's aducanumab has the potential to be much more valuable than EvaluatePharma calculates -- or to be a total bust.
10 stocks we like better than Biogen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Keith Speights owns shares of AbbVie and Celgene. The Motley Fool owns shares of and recommends Biogen, Celgene, and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's management highlights Rova-T as one of the top assets in the biotech's pipeline and is looking to expand the drug's opportunities through combination studies with immuno-oncology therapies. Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Rova-T Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. | Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Rova-T Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. AbbVie scooped up Rova-T last year with its buyout of Stemcentrx. | Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Rova-T Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. AbbVie scooped up Rova-T last year with its buyout of Stemcentrx. | Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Rova-T Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. AbbVie scooped up Rova-T last year with its buyout of Stemcentrx. |
26083.0 | 2017-07-22 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2017-07-22 | nan | nan | U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls for hard caps on prescription drug prices, and his administration continues to push for corporate tax reform that could bring back hundreds of billions in foreign profits currently stored overseas.
The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. With this in mind, let's consider which of these top dividend pharma stocks is the better buy right now.
AbbVie: Is the best yet to come?
AbbVie, a dividend aristocrat by virtue of its separation from Abbott Laboratories in 2013, has more than proven its value to shareholders by producing industry-leading levels of both top-line and dividend growth over the past four years. But the drugmaker has reached a crossroads of sorts following the patent expiration of its main growth driver Humira. Long story short, AbbVie is banking on its deliberate pivot to oncology to keep the growth party rolling.
Through a number of acquisitions in recent years, AbbVie has built one of the most valuable oncology pipelines in the industry. Exciting experimental products like Rova-T for small-cell lung cancer, for instance, are expected to complement the drugmaker's high-value blood cancer drug Imbruvica in the near future. The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022.
AbbVie, though, does have some other extremely promising growth drivers outside of oncology. The drugmaker's next-generation hepatitis C therapy, composed of glecaprevir and pibrentasvir, appears primed to take a big chunk out of Gilead Sciences ' market share. This novel combo, after all, is likely to gain approval as an eight-week regimen across a variety of genotypes -- giving it a distinct competitive advantage over most of Gilead's therapies that typically require at least 12 weeks of treatment.
Now that AbbVie no longer has to seriously worry about a hard cap on Humira's ever-growing price tag, and the possibility of deleveraging its balance sheet following corporate tax reform in the U.S. remains in play, this drugmaker's best days may indeed be yet to come.
Johnson & Johnson: The power of diversification
It's no secret that biosimilars are having a negative impact on J&J's all-important pharmaceutical segment. Sales of the company's blockbuster anti-inflammatory medicine Remicade, for instance, have been slipping in recent quarters, presumably because of competition from Pfizer 's copycat medicine Inflectra.
Most importantly, though, the considerable drag emanating from Remicade's downward trend has also been offsetting the spectacular growth from newer products, such as the multiple myeloma drug Darzalex. As proof, J&J reported that total pharma sales only grew by 1% in the second quarter of 2017, despite Darzalex's sales rising by a whopping 177% to $299 million for the three-month period.
The good news is that J&J has addressed this issue head on by first spending $30 billion to acquire Actelion's portfolio of pulmonary arterial hypertension medicines, as well as maintaining a top-flight clinical pipeline that sports numerous blockbuster candidates. In fact, J&J's late-stage pipeline is currently ranked second in terms of net present value, falling behind only AbbVie's on this particular metric.
The point is that J&J's highly diversified pipeline and pharma product portfolio have clearly been an important counterbalance to the ongoing patent cliff, as well as the emergence of unexpectedly strong disruptive competitive threats in the past few years. And corporate tax reform, if instituted, should allow J&J to further diversify its pharma segment through additional M&A activity.
Which stock is the better buy?
This is a really tough matchup. Both companies offer stellar growth prospects, top notch dividends, and best-in-class clinical pipelines. So in a sense, you really can't go wrong with either stock. Having said that, J&J is probably the better buy simply because of its far more diversified product portfolio. AbbVie, after all, still relies on Humira for about 60% of its total sales . So while this unbalanced revenue mix should flatten out as the company's oncology pipeline matures, J&J is already proving beyond the shadow of a doubt that there's safety in numbers.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
George Budwell owns shares of Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. The Motley Fool has the following options: short August 2017 $75 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Now that AbbVie no longer has to seriously worry about a hard cap on Humira's ever-growing price tag, and the possibility of deleveraging its balance sheet following corporate tax reform in the U.S. remains in play, this drugmaker's best days may indeed be yet to come. The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. AbbVie: Is the best yet to come? | The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022. AbbVie: Is the best yet to come? | The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022. AbbVie: Is the best yet to come? | AbbVie: Is the best yet to come? The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022. The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. |
26084.0 | 2017-07-21 00:00:00 UTC | AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store? | ABBV | https://www.nasdaq.com/articles/abbvie-incs.-abbv-q2-earnings%3A-disappointment-in-store-2017-07-21 | nan | nan | AbbVie Inc.ABBV is scheduled to release second-quarter 2017 earnings, before the opening bell on Jul 28.
AbbVie's shares have rallied 18.2% so far this year, while the industry has recorded an increase of 13.2%.
Last quarter, the company delivered a positive surprise of 1.59%. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. The average earnings beat for the last four quarters is 1.65%.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Let's see how things are shaping up for the company this quarter.
Factors to Consider
At the first-quarter 2017 conference call, management revealed that it expects second-quarter 2017 earnings in the range of $1.39-$1.41 per share. Revenues are expected to grow between 7% and 8% on a reported basis. Currency headwinds are expected to hurt revenues by 1%.
The company's key drug, Humira, is likely to remain the main growth driver in the second quarter. Increasing awareness, favorable clinical data, additional indications and expansion into new markets are expected to help the product continue making significant contributions to the top line. This quarter, AbbVie also expects Humira sales growth in the U.S. in the mid-to-high teens range while internationally, Humira sales are expected to rise in a mid-single-digit range on an operational basis.
Though Humira is doing well, the company is concerned about the product's long-term prospects owing to the potential biosimilar competition.
Another area of focus is the performance of Imbruvica, added to AbbVie's portfolio following its May 2015 acquisition of Pharmacyclics. The drug recorded strong sales since past few quarters, a trend that we expect to continue. Imbruvica has multi-billion dollar potential and the company is looking to expand the drug's label for solid tumors and autoimmune diseases.
The company expects the Imbruvica sales growth in the U.S. to approach 35% in the second quarter.
Although Imbruvica has huge commercial potential, investors should know that revenues from it will be shared with Johnson & Johnson JNJ , which has a collaboration agreement with Pharmacyclics.
Other drugs like Duopa and Creon are also expected to continue to perform well in the soon-to-be-reported quarter.
However, Abbvie's Hepatitis C virus (HCV) treatment, Viekira, will continue to be adversely impacted by an intense pricing and competitive pressure in the HCV market.
Notably, last month, the company announced that the Committee for Medicinal Products for Human Use (CHMP) recommended a marketing approval of its investigational, hepatitis C virus (HCV) combo regimen of glecaprevir/pibrentasvir (G/P). The candidate will be marketed by the trade name of Maviret.
A decision from the European Commission is expected in the third quarter of 2017. An approval will definitely provide the company with a stronger presence against the competitive dynamics in the HCV market.
Earnings Whispers
Our proven model does not conclusively show that AbbVie is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP for AbbVie is -0.71% as the Most Accurate estimate is pegged at $1.39 per share and the Zacks Consensus Estimate stands higher at $1.40. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of the ESP, its -0.71% Earnings ESP makes the surprise prediction difficult.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some better-ranked health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Novo Nordisk A/S NVO is scheduled to release its results on Aug 9. The company has an Earnings ESP of +3.57% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Pfizer Inc. PFE , scheduled to release its results on Aug 1, has an Earnings ESP of +1.54% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV is scheduled to release second-quarter 2017 earnings, before the opening bell on Jul 28. AbbVie's shares have rallied 18.2% so far this year, while the industry has recorded an increase of 13.2%. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of the ESP, its -0.71% Earnings ESP makes the surprise prediction difficult. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of the ESP, its -0.71% Earnings ESP makes the surprise prediction difficult. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc.ABBV is scheduled to release second-quarter 2017 earnings, before the opening bell on Jul 28. AbbVie's shares have rallied 18.2% so far this year, while the industry has recorded an increase of 13.2%. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. |
26085.0 | 2017-07-21 00:00:00 UTC | Rothschild Investment Corp Buys United Parcel Service Inc, United Parcel Service Inc, Costco ... | ABBV | https://www.nasdaq.com/articles/rothschild-investment-corp-buys-united-parcel-service-inc-united-parcel-service-inc-costco | nan | nan | Rothschild Investment Corp
New Purchases: PEG , APO , CRM , CRM, HPQ, EZU, ACM, SIG, CME, FAST,
Added Positions:AXP, AXP, COST, NUE, GS, KRE, KITE, FEZ, TGT, AGN,
Reduced Positions:KR, BMY, BMY, F, F, CSCO, SO, RCL, HD, JPM,
Sold Out:UPS, TSLA, FMBI, USB, AON, MMC, WSTC, CBI, AZSEY, GPS,
For the details of ROTHSCHILD INVESTMENT CORP 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ROTHSCHILD+INVESTMENT+CORP+
These are the top 5 holdings of ROTHSCHILD INVESTMENT CORP
Apple Inc ( AAPL ) - 210,066 shares, 3.85% of the total portfolio. Shares reduced by 1.29%
JPMorgan Chase & Co ( JPM ) - 234,869 shares, 2.73% of the total portfolio. Shares reduced by 4.5%
Boeing Co ( BA ) - 78,013 shares, 1.96% of the total portfolio. Shares reduced by 0.32%
AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Shares added by 0.92%
MetLife Inc ( MET ) - 238,944 shares, 1.67% of the total portfolio. Shares added by 1.03%
New Purchase: Public Service Enterprise Group Inc (PEG)
Rothschild Investment Corp initiated holdings in Public Service Enterprise Group Inc. The purchase prices were between $42.7 and $45.68, with an estimated average price of $44.22. The stock is now traded at around $44.52. The impact to the portfolio due to this purchase was 0.3%. The holdings were 55,650 shares as of 2017-06-30.
New Purchase: Apollo Global Management LLC (APO)
Rothschild Investment Corp initiated holdings in Apollo Global Management LLC. The purchase prices were between $24.32 and $28.42, with an estimated average price of $26.6. The stock is now traded at around $28.08. The impact to the portfolio due to this purchase was 0.27%. The holdings were 81,560 shares as of 2017-06-30.
New Purchase: Salesforce.com Inc (CRM)
Rothschild Investment Corp initiated holdings in Salesforce.com Inc. The purchase prices were between $49.69 and $52.94, with an estimated average price of $51.48. The stock is now traded at around $89.75. The impact to the portfolio due to this purchase was 0.24%. The holdings were 35,603 shares as of 2017-06-30.
New Purchase: Salesforce.com Inc (CRM)
Rothschild Investment Corp initiated holdings in Salesforce.com Inc. The purchase prices were between $49.69 and $52.94, with an estimated average price of $51.48. The stock is now traded at around $89.75. The impact to the portfolio due to this purchase was 0.24%. The holdings were 35,603 shares as of 2017-06-30.
New Purchase: HP Inc (HPQ)
Rothschild Investment Corp initiated holdings in HP Inc. The purchase prices were between $17.27 and $19.47, with an estimated average price of $18.37. The stock is now traded at around $19.18. The impact to the portfolio due to this purchase was 0.16%. The holdings were 72,662 shares as of 2017-06-30.
New Purchase: iShares MSCI Eurozone (EZU)
Rothschild Investment Corp initiated holdings in iShares MSCI Eurozone. The purchase prices were between $36.97 and $41.95, with an estimated average price of $39.91. The stock is now traded at around $30.66. The impact to the portfolio due to this purchase was 0.16%. The holdings were 30,774 shares as of 2017-06-30.
Added: United Parcel Service Inc (AXP)
Rothschild Investment Corp added to the holdings in United Parcel Service Inc by 1225.52%. The purchase prices were between $102.87 and $111.01, with an estimated average price of $106.83. The stock is now traded at around $85.73. The impact to the portfolio due to this purchase was 0.92%. The holdings were 70,213 shares as of 2017-06-30.
Added: United Parcel Service Inc (AXP)
Rothschild Investment Corp added to the holdings in United Parcel Service Inc by 1225.52%. The purchase prices were between $102.87 and $111.01, with an estimated average price of $106.83. The stock is now traded at around $85.73. The impact to the portfolio due to this purchase was 0.92%. The holdings were 70,213 shares as of 2017-06-30.
Added: Costco Wholesale Corp (COST)
Rothschild Investment Corp added to the holdings in Costco Wholesale Corp by 363.42%. The purchase prices were between $157.13 and $182.45, with an estimated average price of $172.43. The stock is now traded at around $150.40. The impact to the portfolio due to this purchase was 0.91%. The holdings were 56,926 shares as of 2017-06-30.
Added: Nucor Corp (NUE)
Rothschild Investment Corp added to the holdings in Nucor Corp by 548.87%. The purchase prices were between $54.6 and $62, with an estimated average price of $58.67. The stock is now traded at around $60.39. The impact to the portfolio due to this purchase was 0.85%. The holdings were 135,095 shares as of 2017-06-30.
Added: Goldman Sachs Group Inc (GS)
Rothschild Investment Corp added to the holdings in Goldman Sachs Group Inc by 34.31%. The purchase prices were between $211.26 and $229.72, with an estimated average price of $222.32. The stock is now traded at around $219.87. The impact to the portfolio due to this purchase was 0.35%. The holdings were 48,906 shares as of 2017-06-30.
Added: SPDR S&P Regional Banking (KRE)
Rothschild Investment Corp added to the holdings in SPDR S&P Regional Banking by 114.72%. The purchase prices were between $51.71 and $55.75, with an estimated average price of $53.76. The stock is now traded at around $54.50. The impact to the portfolio due to this purchase was 0.21%. The holdings were 56,900 shares as of 2017-06-30.
Sold Out: Valero Energy Corp (UPS)
Rothschild Investment Corp sold out the holdings in Valero Energy Corp. The sale prices were between $102.87 and $111.01, with an estimated average price of $106.83.
Sold Out: Tesla Inc (TSLA)
Rothschild Investment Corp sold out the holdings in Tesla Inc. The sale prices were between $278.3 and $383.45, with an estimated average price of $328.86.
Sold Out: First Midwest Bancorp Inc (FMBI)
Rothschild Investment Corp sold out the holdings in First Midwest Bancorp Inc. The sale prices were between $21.78 and $24.26, with an estimated average price of $22.97.
Sold Out: Aon PLC (AON)
Rothschild Investment Corp sold out the holdings in Aon PLC. The sale prices were between $118.1 and $136.8, with an estimated average price of $126.21.
Sold Out: TJX Companies Inc (USB)
Rothschild Investment Corp sold out the holdings in TJX Companies Inc. The sale prices were between $49.69 and $52.94, with an estimated average price of $51.48.
Sold Out: Marsh & McLennan Companies Inc (MMC)
Rothschild Investment Corp sold out the holdings in Marsh & McLennan Companies Inc. The sale prices were between $71.88 and $80.27, with an estimated average price of $75.45.
AXP 15-Year Financial Data
The intrinsic value of AXP
Peter Lynch Chart of AXP
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Rothschild Investment Corp New Purchases: PEG , APO , CRM , CRM, HPQ, EZU, ACM, SIG, CME, FAST, Added Positions:AXP, AXP, COST, NUE, GS, KRE, KITE, FEZ, TGT, AGN, Reduced Positions:KR, BMY, BMY, F, F, CSCO, SO, RCL, HD, JPM, Sold Out:UPS, TSLA, FMBI, USB, AON, MMC, WSTC, CBI, AZSEY, GPS, For the details of ROTHSCHILD INVESTMENT CORP 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ROTHSCHILD+INVESTMENT+CORP+ These are the top 5 holdings of ROTHSCHILD INVESTMENT CORP Apple Inc ( AAPL ) - 210,066 shares, 3.85% of the total portfolio. Shares added by 1.03% New Purchase: Public Service Enterprise Group Inc (PEG) Rothschild Investment Corp initiated holdings in Public Service Enterprise Group Inc. | Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Shares added by 1.03% New Purchase: Public Service Enterprise Group Inc (PEG) Rothschild Investment Corp initiated holdings in Public Service Enterprise Group Inc. New Purchase: Apollo Global Management LLC (APO) Rothschild Investment Corp initiated holdings in Apollo Global Management LLC. | Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Rothschild Investment Corp New Purchases: PEG , APO , CRM , CRM, HPQ, EZU, ACM, SIG, CME, FAST, Added Positions:AXP, AXP, COST, NUE, GS, KRE, KITE, FEZ, TGT, AGN, Reduced Positions:KR, BMY, BMY, F, F, CSCO, SO, RCL, HD, JPM, Sold Out:UPS, TSLA, FMBI, USB, AON, MMC, WSTC, CBI, AZSEY, GPS, For the details of ROTHSCHILD INVESTMENT CORP 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ROTHSCHILD+INVESTMENT+CORP+ These are the top 5 holdings of ROTHSCHILD INVESTMENT CORP Apple Inc ( AAPL ) - 210,066 shares, 3.85% of the total portfolio. Shares added by 1.03% New Purchase: Public Service Enterprise Group Inc (PEG) Rothschild Investment Corp initiated holdings in Public Service Enterprise Group Inc. | New Purchase: Salesforce.com Inc (CRM) Rothschild Investment Corp initiated holdings in Salesforce.com Inc. Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Shares added by 0.92% MetLife Inc ( MET ) - 238,944 shares, 1.67% of the total portfolio. |
26086.0 | 2017-07-20 00:00:00 UTC | Is Gilead (GILD) Poised for a Beat This Earnings Season? | ABBV | https://www.nasdaq.com/articles/is-gilead-gild-poised-for-a-beat-this-earnings-season-2017-07-20 | nan | nan | Gilead Sciences Inc.GILD is scheduled to report second-quarter 2017 results on Jul 26, after the market closes . Last quarter, the company beat expectations by 0.92%.
Gilead Sciences, Inc. Price and EPS Surprise
Gilead Sciences, Inc. Price and EPS Surprise | Gilead Sciences, Inc. Quote
Gilead's track record is pretty mixed, with the company beating estimates in three of the last four and missing in the other one. Overall, the company recorded an average positive earnings surprise of 3.52%.
Shares of Gilead have moved up 1.5% in the year so far, underperforming the Zacks classified Medical-Biomedical and Genetics industry's gain of 10.5%.
Earnings Whispers
Our proven model shows that Gilead is likely to beat on earnings estimates this quarter. This is because it has the right combination of two key ingredients, a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold).
Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +3.32%. This is because the Most Accurate estimate is $2.18 while the Zacks Consensus Estimate is pegged lower at $2.11. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Gilead currently carries a Zacks Rank #3. The combination of Zacks Rank #3 and a positive ESP makes us confident of an earnings beat.
Conversely, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Factors at Play
Concurrent with the first-quarter earnings call, Gilead reiterated its guidance for annual guidance for 2017. Gilead expects net product sales in the range of $22.5-$24.5 billion. Non-HCV product sales are projected between $15 billion and $15.5 billion. HCV product sales are projected between $7.5 billion and $9.0 billion.
Strong performance by HIV and other antiviral product sales driven by continued uptake of its tenofovir alafenamide (TAF) based products - Genvoya, Descovy and Odefsey continue to boost sales. We expect the trend to continue in the second quarter as well. Genvoya has already become the most prescribed regimen for both treatment-naïve and switch patients since its launch.
By the end of first-quarter 2017, the TAF-based regimens made up 42% of Gilead's HIV prescription volume in the treatment market. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting is also expected to boost sales. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which might impact sales.
However, the HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales in 2016. Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Higher discounts and payer mix continue to impact sales adversely. Total HCV treatment starts in the U.S. were an estimated 231,000 in 2016, approximately 25,000 less than 2015. The company expects a further decline in patients starts in 2017.
On a positive note, the HCV portfolio received a major boost when Epclusa gained approval in 2016 to become the first and only all-oral, pan-genotypic, STR consisting of Sovaldi and velpatasvir (an NS5A inhibitor), for the treatment of adults with genotype 1-6 chronic HCV infection. Initial uptake of Epclusa has been encouraging while formulary reviews are on track. The recently approved HBV drug Vemlidy is also expected to start contributing to the top line. The FDA recently approved Vosevi (Sovaldi, velpatasvir 100 mg/voxilaprevir 100 mg) tablets as a single-tablet regimen (STR) for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6, previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a Sovaldi-containing regimen without an NS5A inhibitor.
During the second-quarter call, investors are likely to keep an eye on Gilead's performance while pipeline updates will also be keenly awaited. Focus would also be on the performance of Epclusa and TAF-based regimens.
Other Stocks Poised to Beat Estimates
Here are some other health care stocks that you may want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
Vertex Pharmaceuticals Incorporated VRTX has an Earnings ESP of +66.7% and a Zacks Rank #1. The company is scheduled to release results on Jul 26. You can see the complete list of today's Zacks #1 Rank stocks here .
Alexion Pharmaceuticals, Inc. ALXN has an Earnings ESP of +6.48% and a Zacks Rank #3. The company is scheduled to release results on Jul 27.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. However, the HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales in 2016. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Gilead Sciences, Inc. Price and EPS Surprise Gilead Sciences, Inc. Price and EPS Surprise | Gilead Sciences, Inc. Quote Gilead's track record is pretty mixed, with the company beating estimates in three of the last four and missing in the other one. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Gilead Sciences, Inc. Price and EPS Surprise Gilead Sciences, Inc. Price and EPS Surprise | Gilead Sciences, Inc. Quote Gilead's track record is pretty mixed, with the company beating estimates in three of the last four and missing in the other one. | Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company beat expectations by 0.92%. |
26087.0 | 2017-07-19 00:00:00 UTC | Gilead's HCV Portfolio Receives a Boost With Vosevi Approval | ABBV | https://www.nasdaq.com/articles/gileads-hcv-portfolio-receives-a-boost-with-vosevi-approval-2017-07-19 | nan | nan | Gilead Sciences, Inc . GILD announced that the FDA has approved Vosevi (Sovaldi, velpatasvir 100 mg/voxilaprevir 100 mg) tablets. The drug is a single-tablet regimen (STR) for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6, previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a Sovaldi-containing regimen without an NS5A inhibitor.
The approval came on the back of positive data from the phase III studies - POLARIS-1 and POLARIS-4 studies. The studies evaluated 12 weeks of Vosevi in direct-acting antiviral-experienced chronic HCV-infected patients without cirrhosis or with compensated cirrhosis.
However, Vosevi has been warned for its product label regarding the risk of hepatitis B virus (HBV) reactivation in HCV/HBV co infected patients.
Nevertheless, the approval makes Vosevi the first once-daily STR available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors. The approval is expected to boost Gilead's strong HCV portfolio.
Gilead has a strong presence in the HCV market due to its blockbuster HCV drugs, Sovaldi and Harvoni. While Sovaldi continues to be a very important product for the company, Harvoni's label has been expanded twice in the U.S. since approval and is now approved for use in a broader range of patient population. The HCV portfolio got a huge a boost when Epclusa gained approval in both the U.S. (Jun 2016) and the EU (Jul 2016) to become the first and only all-oral, pan-genotypic, STR consisting of Sovaldi and velpatasvir (an NS5A inhibitor), for the treatment of adults with genotype 1-6 chronic HCV infection. Initial uptake of Epclusa has been encouraging while formulary reviews are on track. Gilead expects to launch Epclusa in other large EU markets once pricing and reimbursement is in place by the second half of 2017, which should boost sales further.
Last month, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Vosevi following an accelerated assessment procedure.
Gilead's HCV franchise is under pressure due to intense competition and pricing issues. HCV product sales were weaker than expected mainly due to fewer new patient starts for Harvoni and lower revenues per patient. Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio.
The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year-over-year decrease in revenues in 2017 along with increased competition which will impact patient share and pricing.
Shares of Gilead have underperformed the Zacks classified Medical-Biomedical and Genetics industry in the year so far, with the stock losing 0.1% during this period, against the industry's gain of 8.8%. Nevertheless, the HIV franchise of Gilead is performing well and is expected to help the company combat the persistent decline in HCV franchise.
Zacks Rank
Gilead currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upsi
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Nevertheless, the approval makes Vosevi the first once-daily STR available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The drug is a single-tablet regimen (STR) for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6, previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a Sovaldi-containing regimen without an NS5A inhibitor. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Nevertheless, the approval makes Vosevi the first once-daily STR available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The approval is expected to boost Gilead's strong HCV portfolio. |
26088.0 | 2017-07-19 00:00:00 UTC | Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? | ABBV | https://www.nasdaq.com/articles/can-biogen-biib-keep-the-earnings-streak-alive-in-q2-2017-07-19 | nan | nan | Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will report second-quarter 2017 results on Jul 25, before the market opens. Last quarter, the company delivered a positive earnings surprise of 4.63%.
Biogen's shares have declined 0.4% this year so far while the Zacks classified Biomed-Genetics industry recorded an increase of 8.8%.
Let's see how things are shaping up for this announcement.
Factors to Consider
At the first quarter call, the company had said that it expects relatively stable demand for both Tecfidera and Tysabri (its multiple sclerosis drugs) in 2017 as patient growth in ex-U.S. markets offsets the modest decline in the U.S. due to rising competition from drugs like Roche's Ocrevus. It remains to be seen whether its second-quarter performance reflects the trend.
Meanwhile, the combined number of patients using Avonex and Plegridy is on the decline as patients transition to other oral multiple sclerosis therapies or other high-efficacy products.
Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to continue to contribute to revenues in the U.S. and the EU. The drug benefits from increased use of high-efficacy products.
Spinraza approved for spinal muscular atrophy in Dec 2016 was off to a promising start backed by robust underlying demand Notably, Spinraza, which added $47.4 million to the top line in the first quarter of 2017, should contribute further to sales. At the Q1 conference call, the company had said that it is working on expanding access to Spinraza to all patients.
However, at the call, the company had warned of possible logistics and coverage restriction on the drug in the U.S. as well as other markets. We expect management to provide an update on the issue at its second quarter conference call.
Biogen's biosimilar products - Flixabi (a biosimilar referencing Remicade) and Benepali (a biosimilar referencing Enbrel) are also generating higher revenues. The trend should continue this quarter as well.
Headcount reduction and restructuring initiatives are expected to continue to lower operating expenses. Meanwhile, R&D expenses are expected to increase due to increased business development payments.
At the second quarter call, investor focus will remain on Tecfidera's scrip trends, sales ramp-up of Spinraza, pipeline progress and acquisition plans.
Earnings Whispers
Our proven model does not conclusively show that Biogen is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: Its Earnings ESP is -5.61% as the Most Accurate estimate stands at $4.21 while the Zacks Consensus Estimate is pegged higher at $4.46. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Biogen's Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Biogen Inc. Price and EPS Surprise
Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote
Stocks to Consider
Stocks in the pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank include
Eli Lilly & Company LLY , scheduled to release results on Jul 25, with an Earnings ESP of +0.97% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Pfizer, Inc. PFE with an Earnings ESP of +1.54% and a Zacks Rank #3. The company is scheduled to release results on Aug 1.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to continue to contribute to revenues in the U.S. and the EU. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. At the second quarter call, investor focus will remain on Tecfidera's scrip trends, sales ramp-up of Spinraza, pipeline progress and acquisition plans. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to continue to contribute to revenues in the U.S. and the EU. Zacks Rank: Biogen's Zacks Rank #3 increases the predictive power of ESP. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to continue to contribute to revenues in the U.S. and the EU. Factors to Consider At the first quarter call, the company had said that it expects relatively stable demand for both Tecfidera and Tysabri (its multiple sclerosis drugs) in 2017 as patient growth in ex-U.S. markets offsets the modest decline in the U.S. due to rising competition from drugs like Roche's Ocrevus. | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to continue to contribute to revenues in the U.S. and the EU. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. At the Q1 conference call, the company had said that it is working on expanding access to Spinraza to all patients. |
26089.0 | 2017-07-18 00:00:00 UTC | Perrigo Company Gets FDA Approval for Generic Topical Gel | ABBV | https://www.nasdaq.com/articles/perrigo-company-gets-fda-approval-for-generic-topical-gel-2017-07-18 | nan | nan | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for Androgel Topical Gel, 1.62% packets for the 12 months ending May 2017 were about $88 million.
Shares of Perrigo have significantly underperformed the Zacks classified Medical Products industry so far this year. The stock has declined 12.8% against the broader industry's gain of 21.3%.
However, on the same date, Perrigo settled the litigation related to Meda Pharmaceuticals Inc. and Cipla Ltd's generic version of Dymista (azelastine hydrochloride and fluticasone propionate) nasal spray. Dymista is indicated for the relief of symptoms of seasonal allergic rhinitis in patients between six years of age and older, who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief.
The approval for the generic version of a drug bodes well for the company as it will help in boosting revenues. The ANDA once approved will also lead to increased revenues.
Meanwhile, the company has been constantly making acquisitions to expand its business and drive growth. In fact, we are impressed by Perrigo's growth-by-acquisition strategy. Perrigo has also undertaken certain restructuring initiatives that are expected to support the bottom line, going forward.
Perrigo Company Price and Consensus
Perrigo Company Price and Consensus | Perrigo Company Quote
Zacks Rank & Stocks to Consider
Perrigo currently carries a Zacks Rank #3 (Hold). Better-ranked health care stocks in the same space include Enzo Biochem, Inc. ENZ and Sanofi SNY . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Enzo Biochem's loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in each of the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 68.1% year to date.
Sanofi's earnings per share estimates increased from $3.08 to $3.18 for 2017 and from $3.26 to $3.30 for 2018, over last 60 days. The company came up with positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18.9% year to date.
5 Trades Could Profit "Big-League" from Trump Policies If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Perrigo Company (PRGO): Free Stock Analysis Report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. However, on the same date, Perrigo settled the litigation related to Meda Pharmaceuticals Inc. and Cipla Ltd's generic version of Dymista (azelastine hydrochloride and fluticasone propionate) nasal spray. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. Perrigo Company Price and Consensus Perrigo Company Price and Consensus | Perrigo Company Quote Zacks Rank & Stocks to Consider Perrigo currently carries a Zacks Rank #3 (Hold). | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company Price and Consensus Perrigo Company Price and Consensus | Perrigo Company Quote Zacks Rank & Stocks to Consider Perrigo currently carries a Zacks Rank #3 (Hold). | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. The approval for the generic version of a drug bodes well for the company as it will help in boosting revenues. |
26090.0 | 2017-07-18 00:00:00 UTC | 5 Big Pharma Stocks With the Best Drug Pipelines | ABBV | https://www.nasdaq.com/articles/5-big-pharma-stocks-best-drug-pipelines-2017-07-18 | nan | nan | Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.
Market research firm EvaluatePharma recently released its report looking at the state of the biopharmaceutical industry five years from now. One key area the firm researched was the potential value creation from pipeline products between now and 2022. Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top.
1. Roche
Roche's pipeline is projected to generate sales totaling $24.5 billion over the next five years. Two potential candidates should be the Swiss drugmaker's biggest winners -- emicizumab and lampalizumab.
Emicizumab is currently being evaluated in several late-stage studies for treating hemophilia A. EvaluatePharma thinks the drug could generate $1.6 billion in sales in 2022 if approved. Lampalizumab is also part of multiple phase 3 studies. The drug targets treatment of geographic atrophy associated with age-related macular degeneration. Lampalizumab could make over $900 million in 2022, according to EvaluatePharma.
Overall, Roche's pipeline includes over 35 programs in late-stage development for which the company expects to file for regulatory approval in the next few years. Several of these are for additional indications of already-approved drugs such as Kadcyla, Perjeta, and Tecentriq.
2. AstraZeneca
AstraZeneca looks to have the second-most valuable near-term pipeline. EvaluatePharma estimates that the British drugmaker could make cumulative sales of $21 billion between now and 2022.
Imfinzi recently won accelerated approval from the FDA as a second-line treatment for advanced bladder cancer. AstraZeneca is also evaluating the drug for other cancer indications and as part of combination therapies. EvaluatePharma projects the drug could generate total sales of more than $41 billion over the next five years.
Several late-stage studies are in progress with Imfinzi and another potentially big winner for AstraZeneca -- tremelimumab. EvaluatePharma thinks tremelimumab could be knocking on the door of blockbuster sales by 2022.
3. AbbVie
AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. Three candidates stand out in particular for AbbVie: elagolix, Rova-T, and ABT-494.
Elagolix is being evaluated in late-stage studies for treating endometriosis and uterine fibroids. EvaluatePharma estimates the drug will rake in close to $1.5 billion in 2022. Rova-T is in late-stage studies as a first-line treatment for small cell lung cancer. The drug could also make close to $1.5 billion in 2022. ABT-494 (also known as upadacitinib) is being evaluated for treating multiple autoimmune diseases. It could generate sales of $1.2 billion in 2022.
AbbVie also has several other promising pipeline candidates. Autoimmune-=disease drug risankizumab and cancer drug veliparib look especially promising.
4. Gilead Sciences
Gilead Sciences ranks No. 4 for its pipeline's value-creation potential. EvaluatePharma thinks the biotech's pipeline could produce cumulative sales of $19.1 billion over the next five years.
The biggest star for Gilead is its bictegravir/F/TAF combination treatment for HIV. Gilead submitted the combo for U.S. approval in June and plans to submit for approval in Europe in the next few months. EvaluatePharma estimates that this HIV therapy could make $4.3 billion in 2022 if approved.
A couple of other candidates in Gilead's pipeline could also make plenty of money in the relatively near term. EvaluatePharma projects that the sofosbuvir/velpatasvir/voxilaprevir combination for hepatitis C should make more than $1.4 billion in 2022, while Gilead's autoimmune-disease drug filgotinib could $227 million in 2022.
5. Johnson & Johnson
Johnson & Johnson rounds out the top five big pharma pipelines. J&J's pipeline is expected to generate total sales of $14.9 billion between now and 2022.
Two of the healthcare giant's pipeline candidates particularly stand out. J&J awaits approval for guselkumab in treating psoriasis. If approved, the drug could make nearly $1.6 billion in 2022. Apalutamide is being evaluated in several late-stage studies for treating prostate cancer. EvaluatePharma thinks the drug could pull in over $1.6 billion in 2022.
Several of J&J's pipeline candidates are evaluating already-approved drugs for additional indications. Darzalex, which first won approval as a third-line treatment for multiple myeloma in 2016, could be one of the biggest winners. Assuming the drug gains approval for additional indications, Darzalex could be one of the top-selling drugs in the world in 2022, with estimated sales that year of $5.8 billion.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. The Motley Fool has the following options: short August 2017 $75 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | *Stock Advisor returns as of July 6, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. | Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. Three candidates stand out in particular for AbbVie: elagolix, Rova-T, and ABT-494. | Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. Three candidates stand out in particular for AbbVie: elagolix, Rova-T, and ABT-494. | Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. Three candidates stand out in particular for AbbVie: elagolix, Rova-T, and ABT-494. |
26091.0 | 2017-07-18 00:00:00 UTC | Tealwood Asset Management Inc Buys Carnival Corp, Cypress Semiconductor Corp, Crown Castle ... | ABBV | https://www.nasdaq.com/articles/tealwood-asset-management-inc-buys-carnival-corp-cypress-semiconductor-corp-crown-castle | nan | nan | Tealwood Asset Management Inc
New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO,
Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC,
Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX,
Sold Out:LAMR, GM, TU, SNCR, XOM, CVS,
For the details of TEALWOOD ASSET MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=TEALWOOD+ASSET+MANAGEMENT+INC
These are the top 5 holdings of TEALWOOD ASSET MANAGEMENT INC
AbbVie Inc ( ABBV ) - 106,876 shares, 3.09% of the total portfolio. Shares added by 1.49%
Principal Financial Group Inc ( PFG ) - 109,685 shares, 2.81% of the total portfolio. Shares reduced by 27.16%
Brookfield Infrastructure Partners LP ( BIP ) - 147,324 shares, 2.41% of the total portfolio. Shares reduced by 4.36%
Merck & Co Inc ( MRK ) - 87,387 shares, 2.24% of the total portfolio. Shares added by 13.13%
Meredith Corp ( MDP ) - 88,486 shares, 2.1% of the total portfolio. Shares added by 1.13%
New Purchase: Carnival Corp (CCL)
Tealwood Asset Management Inc initiated holdings in Carnival Corp. The purchase prices were between $57.47 and $66.45, with an estimated average price of $62.21. The stock is now traded at around $66.65. The impact to the portfolio due to this purchase was 1.63%. The holdings were 62,267 shares as of 2017-06-30.
New Purchase: Cypress Semiconductor Corp (CY)
Tealwood Asset Management Inc initiated holdings in Cypress Semiconductor Corp. The purchase prices were between $12.79 and $14.4, with an estimated average price of $13.61. The stock is now traded at around $14.45. The impact to the portfolio due to this purchase was 1.61%. The holdings were 296,293 shares as of 2017-06-30.
New Purchase: Crown Castle International Corp (CCI)
Tealwood Asset Management Inc initiated holdings in Crown Castle International Corp. The purchase prices were between $93.69 and $104.59, with an estimated average price of $98.16. The stock is now traded at around $96.58. The impact to the portfolio due to this purchase was 1.54%. The holdings were 38,490 shares as of 2017-06-30.
New Purchase: Nielsen Holdings PLC (NLSN)
Tealwood Asset Management Inc initiated holdings in Nielsen Holdings PLC. The purchase prices were between $37.14 and $42, with an estimated average price of $39.75. The stock is now traded at around $39.03. The impact to the portfolio due to this purchase was 1.49%. The holdings were 96,750 shares as of 2017-06-30.
New Purchase: Bioverativ Inc (BIVV)
Tealwood Asset Management Inc initiated holdings in Bioverativ Inc. The purchase prices were between $51.9 and $62.57, with an estimated average price of $56.85. The stock is now traded at around $60.56. The impact to the portfolio due to this purchase was 1.11%. The holdings were 46,238 shares as of 2017-06-30.
New Purchase: ProPetro Holding Corp (PUMP)
Tealwood Asset Management Inc initiated holdings in ProPetro Holding Corp. The purchase prices were between $11.93 and $14.7, with an estimated average price of $13.42. The stock is now traded at around $13.46. The impact to the portfolio due to this purchase was 1%. The holdings were 180,250 shares as of 2017-06-30.
Added: Hanesbrands Inc (HBI)
Tealwood Asset Management Inc added to the holdings in Hanesbrands Inc by 231.73%. The purchase prices were between $20.24 and $22.99, with an estimated average price of $21.54. The stock is now traded at around $22.56. The impact to the portfolio due to this purchase was 0.42%. The holdings were 65,195 shares as of 2017-06-30.
Added: Delphi Automotive PLC (DLPH)
Tealwood Asset Management Inc added to the holdings in Delphi Automotive PLC by 182.06%. The purchase prices were between $73.75 and $89.18, with an estimated average price of $83.35. The stock is now traded at around $91.47. The impact to the portfolio due to this purchase was 0.39%. The holdings were 17,073 shares as of 2017-06-30.
Added: Rice Midstream Partners LP (RMP)
Tealwood Asset Management Inc added to the holdings in Rice Midstream Partners LP by 35.90%. The purchase prices were between $17.75 and $26, with an estimated average price of $24.06. The stock is now traded at around $20.52. The impact to the portfolio due to this purchase was 0.28%. The holdings were 132,779 shares as of 2017-06-30.
Added: General Electric Co (GE)
Tealwood Asset Management Inc added to the holdings in General Electric Co by 60.09%. The purchase prices were between $27.02 and $30.27, with an estimated average price of $28.65. The stock is now traded at around $26.81. The impact to the portfolio due to this purchase was 0.05%. The holdings were 11,893 shares as of 2017-06-30.
Sold Out: Lamar Advertising Co (LAMR)
Tealwood Asset Management Inc sold out the holdings in Lamar Advertising Co. The sale prices were between $68.91 and $74.87, with an estimated average price of $71.81.
Sold Out: General Motors Co (GM)
Tealwood Asset Management Inc sold out the holdings in General Motors Co. The sale prices were between $32.42 and $35.36, with an estimated average price of $33.96.
Sold Out: TELUS Corp (TU)
Tealwood Asset Management Inc sold out the holdings in TELUS Corp. The sale prices were between $32.39 and $34.8, with an estimated average price of $33.52.
Sold Out: Synchronoss Technologies Inc (SNCR)
Tealwood Asset Management Inc sold out the holdings in Synchronoss Technologies Inc. The sale prices were between $10.18 and $24.64, with an estimated average price of $16.7.
Sold Out: Exxon Mobil Corp (XOM)
Tealwood Asset Management Inc sold out the holdings in Exxon Mobil Corp. The sale prices were between $79.5 and $83.49, with an estimated average price of $81.84.
Sold Out: CVS Health Corp (CVS)
Tealwood Asset Management Inc sold out the holdings in CVS Health Corp. The sale prices were between $75.95 and $82.79, with an estimated average price of $78.93.
Warning! GuruFocus has detected 2 Warning Signs with HBI. Click here to check it out.
HBI 15-Year Financial Data
The intrinsic value of HBI
Peter Lynch Chart of HBI
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=TEALWOOD+ASSET+MANAGEMENT+INC These are the top 5 holdings of TEALWOOD ASSET MANAGEMENT INC AbbVie Inc ( ABBV ) - 106,876 shares, 3.09% of the total portfolio. New Purchase: Crown Castle International Corp (CCI) Tealwood Asset Management Inc initiated holdings in Crown Castle International Corp. Added: Rice Midstream Partners LP (RMP) Tealwood Asset Management Inc added to the holdings in Rice Midstream Partners LP by 35.90%. | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=TEALWOOD+ASSET+MANAGEMENT+INC These are the top 5 holdings of TEALWOOD ASSET MANAGEMENT INC AbbVie Inc ( ABBV ) - 106,876 shares, 3.09% of the total portfolio. New Purchase: Cypress Semiconductor Corp (CY) Tealwood Asset Management Inc initiated holdings in Cypress Semiconductor Corp. New Purchase: Crown Castle International Corp (CCI) Tealwood Asset Management Inc initiated holdings in Crown Castle International Corp. | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=TEALWOOD+ASSET+MANAGEMENT+INC These are the top 5 holdings of TEALWOOD ASSET MANAGEMENT INC AbbVie Inc ( ABBV ) - 106,876 shares, 3.09% of the total portfolio. New Purchase: Nielsen Holdings PLC (NLSN) Tealwood Asset Management Inc initiated holdings in Nielsen Holdings PLC. New Purchase: ProPetro Holding Corp (PUMP) Tealwood Asset Management Inc initiated holdings in ProPetro Holding Corp. | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=TEALWOOD+ASSET+MANAGEMENT+INC These are the top 5 holdings of TEALWOOD ASSET MANAGEMENT INC AbbVie Inc ( ABBV ) - 106,876 shares, 3.09% of the total portfolio. Shares reduced by 4.36% Merck & Co Inc ( MRK ) - 87,387 shares, 2.24% of the total portfolio. Shares added by 1.13% New Purchase: Carnival Corp (CCL) Tealwood Asset Management Inc initiated holdings in Carnival Corp. |
26092.0 | 2017-07-18 00:00:00 UTC | Hendershot Investments Inc. Buys Walgreens Boots Alliance Inc, DXC Technology Co, Ross Stores ... | ABBV | https://www.nasdaq.com/articles/hendershot-investments-inc-buys-walgreens-boots-alliance-inc-dxc-technology-co-ross-stores | nan | nan | Hendershot Investments Inc.
New Purchases: DXC , ROST , PPL ,
Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN,
Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC,
Sold Out:ABT, ACWI, BMY,
For the details of Hendershot Investments Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Hendershot+Investments+Inc.
These are the top 5 holdings of Hendershot Investments Inc.
Berkshire Hathaway Inc (BRK.B) - 91,014 shares, 7.31% of the total portfolio. Shares reduced by 0.81%
Apple Inc ( AAPL ) - 90,377 shares, 6.18% of the total portfolio. Shares added by 0.56%
AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Shares added by 1.11%
Canadian National Railway Co ( CNI ) - 119,215 shares, 4.58% of the total portfolio. Shares reduced by 0.03%
United Parcel Service Inc ( UPS ) - 80,408 shares, 4.22% of the total portfolio. Shares added by 0.12%
New Purchase: DXC Technology Co ( DXC )
Hendershot Investments Inc. initiated holdings in DXC Technology Co. The purchase prices were between $67.95 and $80.59, with an estimated average price of $76.6. The stock is now traded at around $78.04. The impact to the portfolio due to this purchase was 0.78%. The holdings were 21,350 shares as of 2017-06-30.
New Purchase: Ross Stores Inc (ROST)
Hendershot Investments Inc. initiated holdings in Ross Stores Inc. The purchase prices were between $55.97 and $66.05, with an estimated average price of $62.54. The stock is now traded at around $54.68. The impact to the portfolio due to this purchase was 0.43%. The holdings were 15,587 shares as of 2017-06-30.
New Purchase: PPL Corp (PPL)
Hendershot Investments Inc. initiated holdings in PPL Corp. The purchase prices were between $37.11 and $40.06, with an estimated average price of $38.65. The stock is now traded at around $37.75. The impact to the portfolio due to this purchase was 0.1%. The holdings were 5,528 shares as of 2017-06-30.
Added: Walgreens Boots Alliance Inc (WBA)
Hendershot Investments Inc. added to the holdings in Walgreens Boots Alliance Inc by 98.55%. The purchase prices were between $76.34 and $86.54, with an estimated average price of $82.36. The stock is now traded at around $78.80. The impact to the portfolio due to this purchase was 1.17%. The holdings were 63,302 shares as of 2017-06-30.
Added: Genuine Parts Co (GPC)
Hendershot Investments Inc. added to the holdings in Genuine Parts Co by 51.20%. The purchase prices were between $88.94 and $95.61, with an estimated average price of $91.89. The stock is now traded at around $83.29. The impact to the portfolio due to this purchase was 0.24%. The holdings were 16,256 shares as of 2017-06-30.
Added: F5 Networks Inc (FFIV)
Hendershot Investments Inc. added to the holdings in F5 Networks Inc by 49.90%. The purchase prices were between $125.9 and $142.57, with an estimated average price of $131.24. The stock is now traded at around $126.20. The impact to the portfolio due to this purchase was 0.2%. The holdings were 10,199 shares as of 2017-06-30.
Sold Out: Abbott Laboratories (ABT)
Hendershot Investments Inc. sold out the holdings in Abbott Laboratories. The sale prices were between $42.67 and $49.27, with an estimated average price of $45.2.
Sold Out: iShares MSCI ACWI Index Fund (ACWI)
Hendershot Investments Inc. sold out the holdings in iShares MSCI ACWI Index Fund. The sale prices were between $62.59 and $66.66, with an estimated average price of $64.86.
Sold Out: Bristol-Myers Squibb Company (BMY)
Hendershot Investments Inc. sold out the holdings in Bristol-Myers Squibb Company. The sale prices were between $51.66 and $57.33, with an estimated average price of $54.39.
Warning! GuruFocus has detected 5 Warning Signs with WBA. Click here to check it out.
WBA 15-Year Financial Data
The intrinsic value of WBA
Peter Lynch Chart of WBA
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For the details of Hendershot Investments Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Hendershot+Investments+Inc. These are the top 5 holdings of Hendershot Investments Inc. Berkshire Hathaway Inc (BRK.B) - 91,014 shares, 7.31% of the total portfolio. | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For the details of Hendershot Investments Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Hendershot+Investments+Inc. New Purchase: PPL Corp (PPL) Hendershot Investments Inc. initiated holdings in PPL Corp. | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For the details of Hendershot Investments Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Hendershot+Investments+Inc. Shares added by 0.12% New Purchase: DXC Technology Co ( DXC ) Hendershot Investments Inc. initiated holdings in DXC Technology Co. | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For the details of Hendershot Investments Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Hendershot+Investments+Inc. Shares added by 0.12% New Purchase: DXC Technology Co ( DXC ) Hendershot Investments Inc. initiated holdings in DXC Technology Co. |
26093.0 | 2017-07-18 00:00:00 UTC | Repros' Proellex Stays on Partial Clinical Hold, Shares Fall | ABBV | https://www.nasdaq.com/articles/repros-proellex-stays-on-partial-clinical-hold-shares-fall-2017-07-18 | nan | nan | Repros Therapeutics Inc.RPRX announced that it received preliminary feedback from the FDA on its clinical development program for Proellex to treat uterine fibroids by oral mechanism. Per the FDA's review, Proellex will remain on partial clinical hold and the company will be required to accumulate a large pre-approval safety data base in order for the candidate to be evaluated further. To meet the FDA's requirement, the company will be required to conduct a much larger clinical study which will be time consuming and also expensive.
The shares of the company plunged about 34% on Monday after the news was announced. We note that Repros' shares have underperformed the Zacks classified Medical - Biomedical and Genetics industry in the last year. The stock has declined 70.8% as against the industry's gain of 8.7% in the same period.
We note that the company is also evaluating Proellex, a selective progesterone modulator (SPRM), in a phase IIb study for uterine fibroids by vaginal delivery. However, this study has no clinical hold issues. The company said that it will now increase its focus on this study. The company presented positive top line data from this study in November last year.
Meanwhile, Repros also mentioned that it received a notice that on Aug 2, 2017 it will be granted a European patent relating to the use of SPRMs, in particular Proellex, with an Off Drug Interval (ODI) for the treatment of estrogen-dependent hyperproliferative uterine conditions, such as uterine fibroids and endometriosis.
Notably, Repros' other key pipeline candidate, enclomiphene, is being evaluated for the treatment of low testosterone level in overweight men. The company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for enclomiphene ifor secondary hypogonadism in Europe in Sep 2016.
There are other companies that have been evaluating candidates for uterine fibroids. In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciencesis also evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids which is in mid-stage studies. Another company, Bayer Aktiengesellschaft BAYRY is evaluating vilaprisan in women suffering from uterine fibroids, which is in late stage studies.
Repros Therapeutics Inc. Price and Consensus
Repros Therapeutics Inc. Price and Consensus | Repros Therapeutics Inc. Quote
Zacks Rank & Other Stocks to Consider
Repros currently holds a Zacks Rank #3 (Hold). Some other top-ranked health care stocks in the same space include Enzo Biochem, Inc. ENZ sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Enzo Biochem's loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 69% year to date.
5 Trades Could Profit "Big-League" from Trump Policies If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Bayer AG (BAYRY): Free Stock Analysis Report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciencesis also evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids which is in mid-stage studies. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Per the FDA's review, Proellex will remain on partial clinical hold and the company will be required to accumulate a large pre-approval safety data base in order for the candidate to be evaluated further. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciencesis also evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids which is in mid-stage studies. Repros Therapeutics Inc. Price and Consensus Repros Therapeutics Inc. Price and Consensus | Repros Therapeutics Inc. Quote Zacks Rank & Other Stocks to Consider Repros currently holds a Zacks Rank #3 (Hold). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciencesis also evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids which is in mid-stage studies. We note that the company is also evaluating Proellex, a selective progesterone modulator (SPRM), in a phase IIb study for uterine fibroids by vaginal delivery. | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciencesis also evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids which is in mid-stage studies. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. There are other companies that have been evaluating candidates for uterine fibroids. |
26094.0 | 2017-07-14 00:00:00 UTC | Notable ETF Inflow Detected - VHT, PFE, MDT, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-vht-pfe-mdt-abbv-2017-07-14 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $66.8 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 45,451,522 to 45,902,345). Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average:
Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $151.23 as the 52 week high point - that compares with a last trade of $148.55. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $151.23 as the 52 week high point - that compares with a last trade of $148.55. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $151.23 as the 52 week high point - that compares with a last trade of $148.55. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $66.8 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 45,451,522 to 45,902,345). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $151.23 as the 52 week high point - that compares with a last trade of $148.55. | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $66.8 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 45,451,522 to 45,902,345). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $151.23 as the 52 week high point - that compares with a last trade of $148.55. |
26095.0 | 2017-07-14 00:00:00 UTC | J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab | ABBV | https://www.nasdaq.com/articles/jj-jnj-gets-fda-nod-for-psoriasis-drug-guselkumab-2017-07-14 | nan | nan | Johnson &JohnsonJNJ , a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.
The drug was approved under an accelerated process, following the filing of a priority voucher by J&J.
J&J's shares have gained 14.4% so far this year, significantly ahead of the 11.3% increase witnessed by the Zacks classified Large-Cap Pharma industry.
Data from the VOYAGE 2 trial (n=992), announced earlier, had showed that significantly higher proportions of patients with moderate-to-severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo. Around 70% of the patients receiving guselkumab achieved at least 90% clearer skin versus 2.4% on placebo.
The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. The study demonstrated the statistically significant efficacy of guselkumab compared to Humira at week 16, which was maintained through 24 weeks of treatment. Almost 46.8% of the patients treated with Humira achieved at least 90% clearer skin versus 70% for guselkumab.
The NAVIGATE (n=871) study evaluated the efficacy and safety of switching to guselkumab in moderate-to-severe plaque psoriasis patients who were not achieving clear or almost clear skin with J&J's other plaque psoriasis medicine Stelara. Data from the study showed that patients who switched to guselkumab showed significantly greater improvements in skin clearance compared with patients who continued to receive Stelara.
Per the company's press release, around 7.5 million Americans suffer from this disease in which an overproduction of skin cells can cause itching, pain, burning sensation and skin tightness. Hence, an approval of guselkumab has given the company access to a wide patient population in the U.S.
Guselkumab is under review in the EU and Japan for the plaque psoriasis indication. A phase III head-to-head study of Tremfya against Novartis AG's NVS Cosentyx for moderate-to-severe plaque psoriasis is ongoing. Meanwhile, a phase II trial evaluating guselkumab in moderate-to-severely active psoriatic arthritis is also ongoing.
J&J had previously mentioned that Tremfya has blockbuster potential and could rake in sales of more than $1 billion. Other than Tremfya, J&J expects another key pipeline candidate, sirukumab for rheumatoid arthritis to also gain FDA approval this year. Sirukumab is also under review in the U.S. and EU.
J&J carries a Zacks Rank #3 (Hold). A better-ranked stock in the same space is AstraZeneca plc AZN , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Shares of AstraZeneca have rallied 18.5% so far this year. Also, its earnings estimates for 2017 moved up 0.5%, while the same for 2018 climbed 3.3% in the last 60 days. Its earnings performance has been pretty impressive as well, with consistent positive surprises. The company delivered an average earnings beat of 142.6% in the last four quarters.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson &JohnsonJNJ , a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. | The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the VOYAGE 2 trial (n=992), announced earlier, had showed that significantly higher proportions of patients with moderate-to-severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. Data from the VOYAGE 2 trial (n=992), announced earlier, had showed that significantly higher proportions of patients with moderate-to-severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo. | The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The drug will be marketed by the trade name of Tremfya. |
26096.0 | 2017-07-14 00:00:00 UTC | Can Novartis (NVS) Spring a Surprise This Earnings Season? | ABBV | https://www.nasdaq.com/articles/can-novartis-nvs-spring-a-surprise-this-earnings-season-2017-07-14 | nan | nan | Swiss pharmaceutical company Novartis AGNVS is scheduled to report second-quarter 2017 results on Jul 18.
A look at Novartis' share price movement year to date shows that the stock has outperformed the Zacks classified Large Cap Pharma industry. Its shares have rallied 13.3% compared with the industry's gain of 11.3%.
In the last reported quarter, Novartis delivered a positive earnings surprise of 2.7%. The company has posted an average positive earnings surprise of 3.28% in the trailing four quarters. Let's see how things are shaping up for this announcement.
Factors to Impact the Quarter
Novartis operates under three segments: Innovative Medicines (Pharmaceuticals), Alcon and Sandoz (Generics).
New products like Cosentyx and Entresto should boost the top line. Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Cosentyx achieved the blockbuster status in 2016 and recorded over $1 billion of sales.
Novartis has broadened its oncology portfolio through acquisitions. FDA's recent approval of Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will further boost the company's oncology portfolio. Meanwhile, the FDA has also recently approved a label expansion of Zykadia as the first-line treatment of patients with metastatic non-small cell lung cancer.
Additionally, Novartis' generic arm, Sandoz, is making efforts to strengthen its biosimilars portfolio. The company plans to launch four biosimilars of major oncology and immunology biologics across key geographies by 2020. The company is, however, facing significant pricing pressures in the U.S. due to a delay in the launch of Glatopa 40mg. This is expected to impact the second-quarter results.
Also, exclusivity of some of the key drugs in Novartis' portfolio is hurting the company's top line. The company's blockbuster drug, Diovan, is facing stiff generic competition in the U.S., the EU and Japan. Gleevec lost exclusivity in the U.S. in Feb 2016 and in the EU in Dec 2016, thereby leading to generic competition. Exforge is also facing generic competition in the U.S. and the EU. Furthermore, the oncology drugs are facing new competition in the form of immuno-oncology therapies.
The negative impact of generic competition is expected to impact sales by $2.5 billion in 2017.
The company's ophthalmologic division, Alcon, continues to face challenges due to lower surgical equipments sales. Stiff competition faced by intraocular lens and a slowdown in demand for equipment purchases continue to act as dampeners. We do not expect any improving trends in the division's sales in the to-be-reported quarter.
Earnings Whispers
Our proven model does not conclusively show that Novartis will beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. Unfortunately, that is not the case here, as you will see below.
Zacks ESP : The Earnings ESP for Novartis is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.16. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Novartis currently carries a Zacks Rank #3. Although the rank is favorable, the company's 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Novartis AG Price and EPS Surprise
Novartis AG Price and EPS Surprise | Novartis AG Quote
Stock to Consider
Here is one stock in the healthcare sector that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Vertex Pharmaceuticals Incorporated VRTX has an Earnings ESP of +16.7% and a Zacks Rank #1. The company is scheduled to release results on Jul 26. You can see the complete list of today's Zacks #1 Rank stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. A look at Novartis' share price movement year to date shows that the stock has outperformed the Zacks classified Large Cap Pharma industry. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie's ABBV Humira and Amgen's AMGN Enbrel. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions. | Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The negative impact of generic competition is expected to impact sales by $2.5 billion in 2017. |
26097.0 | 2017-07-14 00:00:00 UTC | AbbVie Inc (ABBV) Stock Isn’t Done Charting New Highs Yet | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-stock-isnt-done-charting-new-highs-yet-2017-07-14 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. Add to it an election cycle where they've been the hottest political football and you get a sector wilder than the real running of the bulls in Pamplona.
Case in point, ABBV stock is now 30% higher than last November and 60% since a year prior to that. So why am I sharing a bullish trade today this late in the rally? Potential.
Between March and May the stock established a strong base from which it leapt higher. I consider it a tabletop that is likely to hold or at least provide strong support should there be a correction in the near future. This is support that I can leverage to capture the positive potential that could be coming.
However, since indeed this seems late in the upside cycle on this rally I won't buy the stock at $73 and without any room for error hope it lives up to it. Instead, I will use options to get paid from the action even if it turns out to be less than perfect. There I can spend less and build a buffer to set my thesis in motion.
Click to Enlarge It is important to note that I don't employ these strategies with just any stock. ABBV is a fundamentally sound company and from a PE perspective it's half as cheap as Merck & Co., Inc. (NYSE: MRK ).
It's even cheaper than Pfizer Inc. (NYSE: PFE ) and Johnson & Johnson (NYSE: JNJ ). So if I end up owning the shares at 18 price-earnings ratio it wouldn't be the end of the world as U would own a reasonably priced asset.
My thesis here is that technically ABBV looks like it wants to set new highs soon. I want to sell puts below support so I can generate income as the rally continues. Central to my execution is the fact that I am willing and able to own ABBV stock 10% lower in case I am wrong.
ABBV Stock Options
The Trade: Sell ABBV stock Nov $65 put naked and collect 90 cents to open. Here I have a 90% theoretical odds of retaining my premium for maximum gains. Otherwise and if price falls below my strike then I then own the shares and accrue losses below $64.10.
For those who don't want to own the shares, I could use the $65/$62.50 credit put spread where the risk is limited thereby making it easier to manage. The spread would still yield 11% on risk. In either case I need AbbVie stock to stay above my strike to win.
I waited until now to commit because I wanted to see which way will the breakout go. The chart clearly shows that the bulls are in still charge. So I will watch for the next decision point around $73.7. If the bulls break through a neckline resistance point after a long struggle they often overshoot higher. In this case it would mean an additional 9% from there. So I could then chase it with a debit call spread.
Advanced Micro Devices, Inc. (AMD) Reveals Threadripper Price, Availability
The Juice (Optional Upon Trigger): Buy ABBV stock Aug $75/$77.50 debit call spread which could cost 40 cents to open and deliver $2 in profits. I have to note that earnings are coming soon and management usually beats estimates. So I may want to set this before the event, as it could serve as the catalyst. Analyst expectations are humble, so that helps too.
Remember: Investing is risky, otherwise there would be no reward, so never risk more than you are willing to lose.
Learn how to generate income from options here . Nicolas Chahine is the managing director of SellSpreads.com . As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernic and stocktwits at @racernic .
More From InvestorPlace
7 Blue-Chip Stocks at High Risk for Earnings Crashes
Bank of America Corp (BAC) Stock May Face a Trifecta of Pain
5 Stocks the Top-Performing Fund Managers Love
The post AbbVie Inc (ABBV) Stock Isn't Done Charting New Highs Yet appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Advanced Micro Devices, Inc. (AMD) Reveals Threadripper Price, Availability The Juice (Optional Upon Trigger): Buy ABBV stock Aug $75/$77.50 debit call spread which could cost 40 cents to open and deliver $2 in profits. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. Case in point, ABBV stock is now 30% higher than last November and 60% since a year prior to that. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. ABBV Stock Options The Trade: Sell ABBV stock Nov $65 put naked and collect 90 cents to open. Advanced Micro Devices, Inc. (AMD) Reveals Threadripper Price, Availability The Juice (Optional Upon Trigger): Buy ABBV stock Aug $75/$77.50 debit call spread which could cost 40 cents to open and deliver $2 in profits. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. ABBV Stock Options The Trade: Sell ABBV stock Nov $65 put naked and collect 90 cents to open. More From InvestorPlace 7 Blue-Chip Stocks at High Risk for Earnings Crashes Bank of America Corp (BAC) Stock May Face a Trifecta of Pain 5 Stocks the Top-Performing Fund Managers Love The post AbbVie Inc (ABBV) Stock Isn't Done Charting New Highs Yet appeared first on InvestorPlace . | Case in point, ABBV stock is now 30% higher than last November and 60% since a year prior to that. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. ABBV is a fundamentally sound company and from a PE perspective it's half as cheap as Merck & Co., Inc. (NYSE: MRK ). |
26098.0 | 2017-07-13 00:00:00 UTC | Franklin Street Advisors Inc Buys Coca-Cola Co, JPMorgan Chase, Cisco Systems Inc, Sells ... | ABBV | https://www.nasdaq.com/articles/franklin-street-advisors-inc-buys-coca-cola-co-jpmorgan-chase-cisco-systems-inc-sells-2017 | nan | nan | Franklin Street Advisors Inc
New Purchases: SPGI , UNH , ABC , VEU, VFC,
Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK,
Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD,
Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC,
For the details of FRANKLIN STREET ADVISORS INC 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FRANKLIN+STREET+ADVISORS+INC+
These are the top 5 holdings of FRANKLIN STREET ADVISORS INC
Apple Inc ( AAPL ) - 195,038 shares, 4.84% of the total portfolio. Shares reduced by 3.04%
CME Group Inc ( CME ) - 184,112 shares, 3.98% of the total portfolio. Shares added by 5.76%
Microsoft Corp ( MSFT ) - 272,537 shares, 3.24% of the total portfolio. Shares added by 3.43%
Alphabet Inc ( GOOG ) - 17,770 shares, 2.78% of the total portfolio. Shares reduced by 0.42%
AbbVie Inc ( ABBV ) - 215,187 shares, 2.69% of the total portfolio. Shares added by 12.50%
New Purchase: UnitedHealth Group Inc (UNH)
Franklin Street Advisors Inc initiated holdings in UnitedHealth Group Inc. The purchase prices were between $164.01 and $186.5, with an estimated average price of $175.01. The stock is now traded at around $185.71. The impact to the portfolio due to this purchase was 0.04%. The holdings were 1,175 shares as of 2017-06-30.
New Purchase: S&P Global Inc (SPGI)
Franklin Street Advisors Inc initiated holdings in S&P Global Inc. The purchase prices were between $128.28 and $149.4, with an estimated average price of $138.61. The stock is now traded at around $149.91. The impact to the portfolio due to this purchase was 0.04%. The holdings were 1,466 shares as of 2017-06-30.
New Purchase: Vanguard FTSE All World Ex US (VEU)
Franklin Street Advisors Inc initiated holdings in Vanguard FTSE All World Ex US. The purchase prices were between $47.21 and $51.09, with an estimated average price of $49.44. The stock is now traded at around $50.86. The impact to the portfolio due to this purchase was 0.03%. The holdings were 4,000 shares as of 2017-06-30.
New Purchase: VF Corp (VFC)
Franklin Street Advisors Inc initiated holdings in VF Corp. The purchase prices were between $51.62 and $57.85, with an estimated average price of $54.76. The stock is now traded at around $56.07. The impact to the portfolio due to this purchase was 0.03%. The holdings were 3,500 shares as of 2017-06-30.
New Purchase: AmerisourceBergen Corp (ABC)
Franklin Street Advisors Inc initiated holdings in AmerisourceBergen Corp. The purchase prices were between $80.94 and $96.38, with an estimated average price of $88.96. The stock is now traded at around $92.85. The impact to the portfolio due to this purchase was 0.03%. The holdings were 2,145 shares as of 2017-06-30.
Added: Coca-Cola Co (KO)
Franklin Street Advisors Inc added to the holdings in Coca-Cola Co by 410.32%. The purchase prices were between $42.41 and $45.99, with an estimated average price of $44.15. The stock is now traded at around $44.45. The impact to the portfolio due to this purchase was 1.24%. The holdings were 199,097 shares as of 2017-06-30.
Added: JPMorgan Chase & Co (JPM)
Franklin Street Advisors Inc added to the holdings in JPMorgan Chase & Co by 41.85%. The purchase prices were between $82.15 and $91.15, with an estimated average price of $86.23. The stock is now traded at around $93.27. The impact to the portfolio due to this purchase was 0.69%. The holdings were 149,101 shares as of 2017-06-30.
Added: Cisco Systems Inc (CSCO)
Franklin Street Advisors Inc added to the holdings in Cisco Systems Inc by 29.36%. The purchase prices were between $31.21 and $34.39, with an estimated average price of $32.62. The stock is now traded at around $31.24. The impact to the portfolio due to this purchase was 0.61%. The holdings were 495,498 shares as of 2017-06-30.
Added: Starbucks Corp (SBUX)
Franklin Street Advisors Inc added to the holdings in Starbucks Corp by 32.34%. The purchase prices were between $57.51 and $64.57, with an estimated average price of $60.47. The stock is now traded at around $58.40. The impact to the portfolio due to this purchase was 0.33%. The holdings were 133,864 shares as of 2017-06-30.
Added: Mattel Inc (MAT)
Franklin Street Advisors Inc added to the holdings in Mattel Inc by 32.52%. The purchase prices were between $19.99 and $25.73, with an estimated average price of $22.66. The stock is now traded at around $20.74. The impact to the portfolio due to this purchase was 0.26%. The holdings were 288,126 shares as of 2017-06-30.
Added: Alliance Data Systems Corp (ADS)
Franklin Street Advisors Inc added to the holdings in Alliance Data Systems Corp by 32.15%. The purchase prices were between $234.66 and $263.01, with an estimated average price of $248.87. The stock is now traded at around $264.42. The impact to the portfolio due to this purchase was 0.24%. The holdings were 22,689 shares as of 2017-06-30.
Sold Out: Kohl's Corp (KSS)
Franklin Street Advisors Inc sold out the holdings in Kohl's Corp. The sale prices were between $35.32 and $40.76, with an estimated average price of $38.35.
Sold Out: Akamai Technologies Inc (AKAM)
Franklin Street Advisors Inc sold out the holdings in Akamai Technologies Inc. The sale prices were between $47 and $62.5, with an estimated average price of $52.93.
Sold Out: Harley-Davidson Inc (HOG)
Franklin Street Advisors Inc sold out the holdings in Harley-Davidson Inc. The sale prices were between $51.86 and $62.05, with an estimated average price of $55.75.
Sold Out: Atara Biotherapeutics Inc (ATRA)
Franklin Street Advisors Inc sold out the holdings in Atara Biotherapeutics Inc. The sale prices were between $12.3 and $20.55, with an estimated average price of $15.52.
Sold Out: Sun Life Financial Inc (SLF)
Franklin Street Advisors Inc sold out the holdings in Sun Life Financial Inc. The sale prices were between $32.61 and $36.55, with an estimated average price of $34.5.
Sold Out: Eli Lilly and Co (LLY)
Franklin Street Advisors Inc sold out the holdings in Eli Lilly and Co. The sale prices were between $76.98 and $86.25, with an estimated average price of $81.61.
Reduced: General Electric Co (GE)
Franklin Street Advisors Inc reduced to the holdings in General Electric Co by 71.03%. The sale prices were between $27.02 and $30.27, with an estimated average price of $28.65. The stock is now traded at around $26.81. The impact to the portfolio due to this sale was -1.02%. Franklin Street Advisors Inc still held 78,227 shares as of 2017-06-30.
Reduced: Bristol-Myers Squibb Company (BMY)
Franklin Street Advisors Inc reduced to the holdings in Bristol-Myers Squibb Company by 26.45%. The sale prices were between $51.66 and $57.33, with an estimated average price of $54.39. The stock is now traded at around $54.82. The impact to the portfolio due to this sale was -0.26%. Franklin Street Advisors Inc still held 74,623 shares as of 2017-06-30.
Reduced: Calithera Biosciences Inc (CALA)
Franklin Street Advisors Inc reduced to the holdings in Calithera Biosciences Inc by 53.63%. The sale prices were between $10.8 and $16.65, with an estimated average price of $13.32. The stock is now traded at around $19.00. The impact to the portfolio due to this sale was -0.08%. Franklin Street Advisors Inc still held 34,580 shares as of 2017-06-30.
Reduced: Puma Biotechnology Inc (PBYI)
Franklin Street Advisors Inc reduced to the holdings in Puma Biotechnology Inc by 23.33%. The sale prices were between $29 and $88.85, with an estimated average price of $55.14. The stock is now traded at around $91.90. The impact to the portfolio due to this sale was -0.05%. Franklin Street Advisors Inc still held 23,000 shares as of 2017-06-30.
Warning! GuruFocus has detected 8 Warning Signs with KO. Click here to check it out.
KO 15-Year Financial Data
The intrinsic value of KO
Peter Lynch Chart of KO
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FRANKLIN+STREET+ADVISORS+INC+ These are the top 5 holdings of FRANKLIN STREET ADVISORS INC Apple Inc ( AAPL ) - 195,038 shares, 4.84% of the total portfolio. Shares reduced by 0.42% AbbVie Inc ( ABBV ) - 215,187 shares, 2.69% of the total portfolio. Sold Out: Sun Life Financial Inc (SLF) Franklin Street Advisors Inc sold out the holdings in Sun Life Financial Inc. | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FRANKLIN+STREET+ADVISORS+INC+ These are the top 5 holdings of FRANKLIN STREET ADVISORS INC Apple Inc ( AAPL ) - 195,038 shares, 4.84% of the total portfolio. Shares reduced by 0.42% AbbVie Inc ( ABBV ) - 215,187 shares, 2.69% of the total portfolio. Added: Alliance Data Systems Corp (ADS) Franklin Street Advisors Inc added to the holdings in Alliance Data Systems Corp by 32.15%. | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FRANKLIN+STREET+ADVISORS+INC+ These are the top 5 holdings of FRANKLIN STREET ADVISORS INC Apple Inc ( AAPL ) - 195,038 shares, 4.84% of the total portfolio. Shares reduced by 0.42% AbbVie Inc ( ABBV ) - 215,187 shares, 2.69% of the total portfolio. Shares added by 12.50% New Purchase: UnitedHealth Group Inc (UNH) Franklin Street Advisors Inc initiated holdings in UnitedHealth Group Inc. | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FRANKLIN+STREET+ADVISORS+INC+ These are the top 5 holdings of FRANKLIN STREET ADVISORS INC Apple Inc ( AAPL ) - 195,038 shares, 4.84% of the total portfolio. Shares reduced by 0.42% AbbVie Inc ( ABBV ) - 215,187 shares, 2.69% of the total portfolio. Franklin Street Advisors Inc still held 78,227 shares as of 2017-06-30. |
26099.0 | 2017-07-12 00:00:00 UTC | Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label | ABBV | https://www.nasdaq.com/articles/amgen-gets-fda-nod-to-broaden-leukemia-drug-blincytos-label-2017-07-12 | nan | nan | Amgen Inc.AMGN announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been accepted by the FDA.
So far this year, Amgen's shares are up 18.5%, outperforming the 7.1% increase registered by the Zacks classified Biomed/Genetics industry.
The regular approval is based on data from the confirmatory phase III TOWER study evaluating the efficacy of Blincyto versus standard of care (SOC) chemotherapy for the treatment of Ph- relapsed or refractory B-cell precursor ALL in adults.
In the study, it was seen that Blincyto, a single-agent T cell engager immunotherapy, led to a nearly twofold improvement in median overall survival (OS), demonstrating its superiority over chemotherapy. The median OS for Blincyto was 7.7 months compared with 4.4 months for SOC. The OS data from the TOWER study will be included in the label of Blincyto.
The sBLA also includes new data from a phase II ALCANTARAstudy to broaden the indication of Blincyto for the treatment of patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor ALL.
The ALCANTARA study evaluated the efficacy of Blincyto in adult patients with Ph+ relapsed or refractory B-cell precursor ALL. The data from the study showed comparable results to that of phase II study in Ph- relapsed or refractory B-cell precursor ALL. .
In the press release, the company mentioned that in May this year, the FDA approved another sBLA for Blincyto. With the recent sBLA, Amgen was looking for approval to add an administration option to infuse Blincyto over seven days with preservative. This expands the previously approved administration options of infusion over 24 and 48 hours preservative-free.
Blincyto has the potential to be developed for other hematologic malignancies as well. Phase II/III studies in patients with diffuse large B-cell lymphoma, which is currently enrolling patients.
In the first quarter of 2017, Blincyto sales surged almost 26% from the year-ago period to $44 million, reflecting higher demand.
The market is becoming competitive with many companies developing treatment for ALL. Pfizer Inc.'s PFE Besponsa is under review in the U.S. for Ph+ or Ph- relapsed or refractory B-cell precursor ALL with a decision expected in Aug 2017. It was approved by the European Commission for the same indication earlier this month. Meanwhile, Kite Pharma, Inc. KITE is also developing its lead candidate, axicabtagene ciloleucel for the treatment of ALL patients.
Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest label expansion of Blincyto.
We note that investors will remain focused on the company's pipeline data expected in the second half of 2017 including a decision on label expansion of Xgeva and Mimpara.
Amgen Inc. Price and Consensus
Amgen Inc. Price and Consensus | Amgen Inc. Quote
Zacks Rank
Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest label expansion of Blincyto. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. The regular approval is based on data from the confirmatory phase III TOWER study evaluating the efficacy of Blincyto versus standard of care (SOC) chemotherapy for the treatment of Ph- relapsed or refractory B-cell precursor ALL in adults. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest label expansion of Blincyto. The ALCANTARA study evaluated the efficacy of Blincyto in adult patients with Ph+ relapsed or refractory B-cell precursor ALL. | Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest label expansion of Blincyto. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. The regular approval is based on data from the confirmatory phase III TOWER study evaluating the efficacy of Blincyto versus standard of care (SOC) chemotherapy for the treatment of Ph- relapsed or refractory B-cell precursor ALL in adults. | Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest label expansion of Blincyto. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. The OS data from the TOWER study will be included in the label of Blincyto. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.